US	US	PRP	0
20070005094	20070005094	CD	0
A1	A1	CD	0
20070104	20070104	CD	0
US	US	NNP	0
11398342	11398342	CD	0
20060404	20060404	CD	0
11	11	CD	0
20060101	20060101	CD	0
A	A	DT	0
A	A	NNP	0
61	61	CD	0
B	B	NNP	0
17	17	CD	0
24	24	CD	0
F	F	NN	0
I	I	PRP	0
20070104	20070104	CD	0
US	US	NNP	0
B	B	NNP	B-NP
H	H	NNP	I-NP
20060101	20060101	CD	0
A	A	DT	0
A	A	NNP	0
61	61	CD	0
F	F	NN	0
2	2	CD	0
18	18	CD	0
L	L	NNP	0
I	I	NNP	0
20070104	20070104	CD	0
US	US	NNP	0
B	B	NNP	B-NP
H	H	NNP	I-NP
US	US	NNP	0
606199000	606199000	CD	0
623023700	623023700	CD	0
Device	Device	NN	0
and	and	CC	0
methods	methods	NNS	0
for	for	IN	0
treating	treating	VBG	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
US	US	NNP	0
60668569	60668569	CD	0
20050404	20050404	CD	0
Eaton	Eaton	NNP	B-NP
Donald	Donald	NNP	I-NP
J	J	NNP	I-NP
.	.	.	I-NP
Woodside	Woodside	NNP	B-NP
CA	CA	NNP	I-NP
US	US	NNP	0
Indian	Indian	NNP	0
Springs	Springs	NNP	0
AL	AL	NNP	0
US	US	NNP	0
Cupertino	Cupertino	NNP	B-NP
CA	CA	NNP	I-NP
US	US	NNP	0
Palo	Palo	NNP	B-NP
Alto	Alto	NNP	I-NP
CA	CA	NNP	I-NP
US	US	NNP	0
San	San	NNP	B-NP
Juan	Juan	NNP	I-NP
Capistrano	Capistrano	NNP	I-NP
CA	CA	NNP	I-NP
US	US	NNP	0
Hoover	Hoover	NNP	0
AL	AL	NNP	0
US	US	NNP	0
755	755	CD	0
PAGE	PAGE	NNP	B-NP
MILL	MILL	NNP	I-NP
RD	RD	NNP	I-NP
PALO	PALO	NNP	I-NP
ALTO	ALTO	NNP	I-NP
CA	CA	NNP	I-NP
94304-1018	94304-1018	NNP	0
US	US	NNP	0
Described	Described	VBN	0
here	here	RB	0
are	are	VBP	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
for	for	IN	0
treating	treating	VBG	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
include	include	VBP	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
One	One	CD	0
or	or	CC	0
more	more	JJR	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
may	may	MD	0
deliver	deliver	VB	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
for	for	IN	0
sustained	sustained	JJ	0
release	release	NN	0
to	to	TO	0
treat	treat	VB	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
.	.	.	0
exemplary	exemplary	JJ	B-NP
paranasal	paranasal	JJ	I-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
are	are	VBP	0
sinus	sinus	JJ	B-NP
inflammation	inflammation	JJ	I-NP
due	due	JJ	0
to	to	TO	0
functional	functional	VB	B-NP
endoscopic	endoscopic	JJ	I-NP
sinus	sinus	JJ	I-NP
surgery	surgery	NN	I-NP
(	(	-LRB-	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
)	)	-RRB-	0
and	and	CC	0
rhinosinusiti	rhinosinusiti	NN	B-NP
.	.	.	0
This	This	DT	0
application	application	NN	0
claims	claims	NNS	0
priority	priority	NN	0
to	to	TO	0
U.S.	U.S.	NNP	0
Provisional	Provisional	NNP	0
Application	Application	NNP	0
Ser	Ser	NNP	0
.	.	.	0
No.	No.	NNP	0
60	60	CD	0
/	/	CD	0
668,569	668,569	CD	0
,	,	,	0
filed	filed	VBD	0
Apr.	Apr.	CD	0
4	4	CD	0
,	,	,	0
2005	2005	CD	0
,	,	,	0
which	which	WDT	0
is	is	VBZ	0
hereby	hereby	VBN	0
incorporated	incorporated	VBN	0
by	by	IN	0
reference	reference	NN	0
in	in	IN	0
its	its	PRP$	0
entirety	entirety	NN	0
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
,	,	,	0
systems	systems	NNS	0
,	,	,	0
and	and	CC	0
methods	methods	NNS	0
described	described	VBD	0
here	here	RB	0
are	are	VBP	0
in	in	IN	0
the	the	DT	0
field	field	NN	0
of	of	IN	0
local	local	JJ	0
drug	drug	NN	B-NP
delivery	delivery	NN	I-NP
to	to	TO	0
treat	treat	VB	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
.	.	.	0
More	More	RBR	0
specifically	specifically	RB	0
,	,	,	0
the	the	DT	0
treatment	treatment	NN	0
of	of	IN	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
inflammation	inflammation	NN	I-NP
and	and	CC	0
rhinosinusiti	rhinosinusiti	NN	B-NP
is	is	VBZ	0
described	described	VBN	0
.	.	.	0
rhinosinusiti	rhinosinusiti	NN	B-NP
is	is	VBZ	0
a	a	DT	0
common	common	JJ	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
that	that	WDT	0
is	is	VBZ	0
generally	generally	RB	0
understood	understood	VBN	0
as	as	IN	0
encompassing	encompassing	JJ	0
sinusitis	sinusitis	NN	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
rhiniti	rhiniti	NN	B-NP
.	.	.	0
Typically	Typically	RB	0
,	,	,	0
rhinosinusiti	rhinosinusiti	NN	B-NP
is	is	VBZ	0
characterized	characterized	VBN	0
by	by	IN	0
such	such	JJ	0
major	major	JJ	0
symptom	symptom	NN	B-NP
such	such	JJ	0
as	as	IN	0
nasal	nasal	JJ	B-NP
discharge	discharge	NN	I-NP
,	,	,	0
nasal	nasal	JJ	B-NP
obstruction	obstruction	NN	I-NP
,	,	,	0
facial	facial	JJ	B-NP
congestion	congestion	NN	I-NP
,	,	,	0
facial	facial	JJ	B-NP
pain	pain	NN	I-NP
/	/	CD	I-NP
pressure	pressure	NN	I-NP
,	,	,	0
loss	loss	NN	0
of	of	IN	0
smell	smell	NN	0
,	,	,	0
and	and	CC	0
fever	fever	NN	0
,	,	,	0
and	and	CC	0
such	such	JJ	0
minor	minor	JJ	0
symptom	symptom	NN	B-NP
as	as	IN	0
headache	headache	NN	0
,	,	,	0
ear	ear	JJ	B-NP
pain	pain	NN	I-NP
/	/	CD	I-NP
pressure	pressure	NN	I-NP
,	,	,	0
halitosis	halitosis	NN	0
,	,	,	0
dental	dental	JJ	B-NP
pain	pain	NN	I-NP
,	,	,	0
cough	cough	NN	0
,	,	,	0
and	and	CC	0
fatigue	fatigue	NN	0
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
are	are	VBP	0
air-filled	air-filled	JJ	0
cavities	cavities	NN	0
within	within	IN	0
the	the	DT	0
facial	facial	JJ	B-NP
skeleton	skeleton	NN	I-NP
.	.	.	0
Each	Each	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
is	is	VBZ	0
contiguous	contiguous	VBN	0
with	with	IN	0
a	a	DT	0
nasal	nasal	JJ	B-NP
cavity	cavity	NN	I-NP
and	and	CC	0
opens	opens	VBZ	0
into	into	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
cavity	cavity	NN	I-NP
through	through	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
The	The	DT	0
key	key	JJ	0
to	to	TO	0
normal	normal	JJ	B-NP
sinus	sinus	JJ	I-NP
function	function	NN	I-NP
is	is	VBZ	0
its	its	PRP$	0
mucociliary	mucociliary	JJ	B-NP
transport	transport	NN	I-NP
system	system	NN	I-NP
which	which	WDT	0
is	is	VBZ	0
comprised	comprised	VBN	0
of	of	IN	0
epithelial	epithelial	JJ	B-NP
goblet	goblet	JJ	I-NP
cell	cell	NN	I-NP
and	and	CC	0
submucosal	submucosal	JJ	B-NP
seromucous	seromucous	JJ	I-NP
gland	gland	NN	I-NP
that	that	WDT	0
produce	produce	VBP	0
nearly	nearly	RB	0
a	a	DT	0
quart	quart	NN	0
of	of	IN	0
mucus	mucus	NN	0
in	in	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
a	a	DT	0
day	day	NN	0
,	,	,	0
and	and	CC	0
a	a	DT	0
ciliated	ciliated	NN	0
,	,	,	0
pseudostratified	pseudostratified	NN	B-NP
,	,	,	0
columnar	columnar	JJ	B-NP
epithelium	epithelium	NN	I-NP
that	that	IN	0
lines	lines	NNS	0
the	the	DT	0
sinuses	sinuses	NN	0
and	and	CC	0
which	which	WDT	0
moves	moves	VBZ	0
the	the	DT	0
mucous	mucous	NN	0
toward	toward	IN	0
the	the	DT	0
natural	natural	JJ	0
sinus	sinus	JJ	B-NP
ostia	ostia	NN	I-NP
.	.	.	0
Any	Any	DT	0
alteration	alteration	NN	0
in	in	IN	0
ostia	ostia	JJ	B-NP
patency	patency	NN	I-NP
sinus	sinus	JJ	I-NP
,	,	,	0
ciliary	ciliary	JJ	B-NP
function	function	NN	I-NP
,	,	,	0
or	or	CC	0
the	the	DT	0
quality	quality	NN	0
of	of	IN	0
mucous	mucous	NNS	0
may	may	MD	0
disrupt	disrupt	VB	0
the	the	DT	0
system	system	NN	0
and	and	CC	0
lead	lead	VB	0
to	to	TO	0
rhinosinusitis	rhinosinusitis	VB	0
.	.	.	0
One	One	CD	0
important	important	JJ	0
factor	factor	NN	B-NP
in	in	IN	0
the	the	DT	0
rhinosinusiti	rhinosinusiti	NN	B-NP
pathogenesi	pathogenesi	NN	I-NP
is	is	VBZ	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostia	ostia	NN	I-NP
patency	patency	NN	I-NP
.	.	.	0
sinus	sinus	JJ	B-NP
ostia	ostia	NNS	I-NP
partial	partial	JJ	I-NP
obstruction	obstruction	NN	I-NP
often	often	RB	0
results	results	NNS	0
in	in	IN	0
stagnation	stagnation	NN	0
of	of	IN	0
mucous	mucous	JJ	B-NP
secretion	secretion	NN	I-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
decrease	decrease	NN	0
in	in	IN	0
pH	pH	JJ	0
and	and	CC	0
oxygen	oxygen	JJ	B-NP
tension	tension	NN	I-NP
within	within	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
These	These	DT	0
physiologic	physiologic	JJ	B-NP
change	change	NN	I-NP
are	are	VBP	0
thought	thought	VBN	0
to	to	TO	0
create	create	VB	0
a	a	DT	0
favorable	favorable	JJ	0
environment	environment	NN	0
for	for	IN	0
microbial	microbial	JJ	B-NP
infection	infection	NN	I-NP
.	.	.	0
The	The	DT	0
microbial	microbial	JJ	B-NP
infection	infection	NN	I-NP
subsequently	subsequently	NN	0
causes	causes	NNS	0
or	or	CC	0
enhances	enhances	VBZ	0
mucosal	mucosal	JJ	B-NP
inflammation	inflammation	NN	I-NP
that	that	WDT	0
may	may	MD	0
further	further	RB	0
reduce	reduce	VB	0
ostial	ostial	JJ	B-NP
patency	patency	NN	I-NP
or	or	CC	0
completely	completely	RB	0
obstruct	obstruct	VBP	0
the	the	DT	0
ostia	ostia	NN	B-NP
.	.	.	0
The	The	DT	0
medical	medical	JJ	B-NP
treatment	treatment	NN	I-NP
for	for	IN	0
rhinosinusitis	rhinosinusitis	VBG	0
typically	typically	RB	0
includes	includes	VBZ	0
a	a	DT	0
combination	combination	NN	0
of	of	IN	0
oral	oral	JJ	B-NP
antibiotic	antibiotic	JJ	I-NP
,	,	,	0
topical	topical	NN	0
or	or	CC	0
oral	oral	JJ	B-NP
decongestant	decongestant	NN	I-NP
,	,	,	0
nasal	nasal	JJ	B-NP
spray	spray	NN	I-NP
steroid	steroid	JJ	I-NP
,	,	,	0
or	or	CC	0
oral	oral	JJ	B-NP
steroid	steroid	NN	I-NP
such	such	JJ	0
as	as	IN	0
prednisone	prednisone	NN	B-NP
.	.	.	0
When	When	WRB	0
medical	medical	JJ	B-NP
therapy	therapy	NN	I-NP
fails	fails	VBZ	0
,	,	,	0
which	which	WDT	0
is	is	VBZ	0
often	often	RB	0
the	the	DT	0
case	case	NN	0
with	with	IN	0
rhinosinusiti	rhinosinusiti	NN	B-NP
,	,	,	0
sinus	sinus	JJ	B-NP
surgery	surgery	NN	I-NP
is	is	VBZ	0
an	an	DT	0
alternative	alternative	NN	0
.	.	.	0
The	The	DT	0
most	most	RBS	0
common	common	JJ	0
surgery	surgery	NN	0
performed	performed	VBN	0
today	today	NN	0
is	is	VBZ	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	JJ	I-NP
sinus	sinus	JJ	I-NP
surgery	surgery	NN	I-NP
(	(	-LRB-	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
goal	goal	NN	0
of	of	IN	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
is	is	VBZ	0
to	to	TO	0
improve	improve	VB	0
the	the	DT	0
drainage	drainage	NN	0
of	of	IN	0
the	the	DT	0
sinuses	sinuses	NN	0
by	by	IN	0
enlarging	enlarging	VBG	0
the	the	DT	0
maxillary	maxillary	NN	B-NP
ostia	ostia	NN	I-NP
and	and	CC	0
frontal	frontal	JJ	B-NP
sinus	sinus	NN	I-NP
,	,	,	0
and	and	CC	0
opening	opening	VBG	0
the	the	DT	0
ethmoid	ethmoid	JJ	B-NP
sinus	sinus	JJ	I-NP
area	area	NN	I-NP
by	by	IN	0
removing	removing	VBG	0
the	the	DT	0
ethmoid	ethmoid	JJ	B-NP
air	air	NN	I-NP
cell	cell	NN	I-NP
under	under	IN	0
direct	direct	JJ	0
visualization	visualization	NN	B-NP
.	.	.	0
However	However	RB	0
,	,	,	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
itself	itself	PRP	0
creates	creates	VBZ	0
inflammation	inflammation	VBN	B-NP
,	,	,	0
which	which	WDT	0
can	can	MD	0
lead	lead	VB	0
to	to	TO	0
post-operative	post-operative	JJ	B-NP
fibrosis	fibrosis	NN	I-NP
,	,	,	0
stenosi	stenosi	NN	B-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
polyposi	polyposi	NN	B-NP
that	that	WDT	0
frequently	frequently	RB	0
obstructs	obstructs	VB	0
the	the	DT	0
newly	newly	RB	0
opened	opened	VBN	0
sinuses	sinuses	NN	0
,	,	,	0
requiring	requiring	VBG	0
the	the	DT	0
surgeon	surgeon	NN	0
to	to	TO	0
reoperate	reoperate	VB	0
to	to	TO	0
revise	revise	VB	0
the	the	DT	0
ostia	ostia	NN	B-NP
and	and	CC	0
insert	insert	JJ	0
stenting	stenting	JJ	B-NP
device	device	NN	I-NP
to	to	TO	0
keep	keep	VB	0
sinus	sinus	JJ	B-NP
ostia	ostia	JJ	0
patent	patent	NN	0
.	.	.	0
U.S.	U.S.	NNP	0
Pat	Pat	NNP	0
.	.	.	0
No.	No.	NNP	0
5,246,455	5,246,455	NNP	0
(	(	-LRB-	0
Shikani	Shikani	NNP	B-NP
)	)	-RRB-	0
and	and	CC	0
U.S.	U.S.	NNP	0
Pat	Pat	NNP	0
.	.	.	0
No.	No.	NNP	0
5,693,065	5,693,065	NNP	0
(	(	-LRB-	0
Rains	Rains	NNP	0
)	)	-RRB-	0
describe	describe	VBP	0
stents	stents	VBN	0
for	for	IN	0
insertion	insertion	NN	0
into	into	IN	0
sinus	sinus	JJ	B-NP
ostia	ostia	NN	I-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
sinus	sinus	JJ	B-NP
antrostomy	antrostomy	NN	I-NP
or	or	CC	0
fenestrations	fenestrations	JJ	0
to	to	TO	0
improve	improve	VB	0
sinus	sinus	JJ	B-NP
drainage	drainage	NN	I-NP
,	,	,	0
reduce	reduce	VB	0
the	the	DT	0
degree	degree	NN	0
of	of	IN	0
adhesion	adhesion	JJ	B-NP
formation	formation	NN	I-NP
,	,	,	0
and	and	CC	0
prevent	prevent	VB	0
ostial	ostial	JJ	B-NP
stenosi	stenosi	NN	I-NP
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
stents	stents	JJ	0
such	such	JJ	0
as	as	IN	0
the	the	DT	0
Parrell	Parrell	NNP	B-NP
Frontal	Frontal	NNP	I-NP
Sinus	Sinus	NNP	I-NP
T-Stent	T-Stent	NNP	I-NP
(	(	-LRB-	0
Medtronic	Medtronic	NNP	B-NP
Xomed	Xomed	NNP	I-NP
,	,	,	0
Inc.	Inc.	NNP	0
,	,	,	0
Jacksonville	Jacksonville	NNP	B-NP
,	,	,	0
Fla.	Fla.	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
the	the	DT	0
Jasin	Jasin	NNP	0
Frontal	Frontal	NNP	0
Sinus	Sinus	NNP	0
Ostent	Ostent	NNP	0
Stent	Stent	NNP	0
(	(	-LRB-	0
Medtronic	Medtronic	NNP	B-NP
Xomed	Xomed	NNP	I-NP
,	,	,	0
Inc.	Inc.	NNP	0
,	,	,	0
Jacksonville	Jacksonville	NNP	B-NP
,	,	,	0
Fla.	Fla.	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
the	the	DT	0
salman	salman	NNP	B-NP
fe	fe	NNP	I-NP
Stent	Stent	NNP	0
(	(	-LRB-	0
boston	boston	NNP	B-NP
medical	medical	JJ	I-NP
product	product	NN	I-NP
,	,	,	0
Westborough	Westborough	NNP	B-NP
,	,	,	0
Mass.	Mass.	NNP	0
)	)	-RRB-	0
are	are	VBP	0
currently	currently	RB	0
used	used	VBN	0
after	after	IN	0
endoscopic	endoscopic	JJ	B-NP
sinus	sinus	JJ	I-NP
surgery	surgery	NN	I-NP
for	for	IN	0
the	the	DT	0
same	same	JJ	0
purpose	purpose	NN	0
.	.	.	0
However	However	RB	0
,	,	,	0
these	these	DT	0
stent	stent	NNP	B-NP
are	are	VBP	0
nonbiodegradable	nonbiodegradable	VBN	0
and	and	CC	0
thus	thus	RB	0
require	require	VB	0
a	a	DT	0
follow-up	follow-up	JJ	B-NP
procedure	procedure	NN	I-NP
for	for	IN	0
removal	removal	NN	0
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
because	because	IN	0
these	these	DT	0
stent	stent	NNP	B-NP
do	do	VBP	0
not	not	RB	0
deliver	deliver	VB	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
active	active	JJ	0
agent	agent	NN	B-NP
to	to	TO	0
the	the	DT	0
sinuses	sinuses	NN	0
,	,	,	0
they	they	PRP	0
often	often	RB	0
only	only	RB	0
delay	delay	VB	0
stenosis	stenosis	JJ	0
due	due	JJ	0
to	to	TO	0
postoperative	postoperative	VB	0
inflammation	inflammation	NN	B-NP
and	and	CC	0
the	the	DT	0
normal	normal	JJ	B-NP
wound	wound	NN	I-NP
healing	healing	NN	I-NP
process	process	NN	I-NP
.	.	.	0
Thus	Thus	RB	0
,	,	,	0
they	they	PRP	0
are	are	VBP	0
typically	typically	RB	0
used	used	VBN	0
in	in	IN	0
combination	combination	NN	0
with	with	IN	0
systemic	systemic	JJ	B-NP
oral	oral	JJ	I-NP
corticosteroid	corticosteroid	NN	I-NP
,	,	,	0
which	which	WDT	0
may	may	MD	0
result	result	VB	0
in	in	IN	0
undesirable	undesirable	JJ	0
side-effect	side-effect	NN	B-NP
the	the	DT	0
longer	longer	RBR	0
they	they	PRP	0
are	are	VBP	0
administered	administered	VBN	0
.	.	.	0
sinus	sinus	NN	B-NP
stent	stent	NNP	I-NP
that	that	IN	0
elute	elute	JJ	B-NP
drug	drug	NN	I-NP
have	have	VBP	0
been	been	VBN	0
proposed	proposed	VBN	0
by	by	IN	0
others	others	NNS	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
a	a	DT	0
nonbiodegradable	nonbiodegradable	NN	B-NP
or	or	CC	0
biodegradable	biodegradable	JJ	0
polymeric	polymeric	JJ	B-NP
spacer	spacer	JJ	I-NP
device	device	NN	I-NP
for	for	IN	0
placement	placement	NN	0
into	into	IN	0
surgically	surgically	FW	0
created	created	FW	0
frontal	frontal	JJ	B-NP
sinus	sinus	NNS	I-NP
fenestration	fenestration	NN	I-NP
is	is	VBZ	0
described	described	VBN	0
in	in	IN	0
U.S.	U.S.	NNP	0
Published	Published	NNP	B-NP
Application	Application	NNP	I-NP
No	No	NNP	0
.	.	.	0
U.S.	U.S.	NNP	0
2004	2004	CD	0
/	/	CD	0
0116958	0116958	CD	0
to	to	TO	0
Goferich	Goferich	NNP	B-NP
et	et	FW	0
al	al	FW	0
.	.	.	0
The	The	DT	0
spacer	spacer	NN	B-NP
is	is	VBZ	0
tubular	tubular	JJ	0
or	or	CC	0
shaped	shaped	VBN	0
like	like	IN	0
an	an	DT	0
hour-glass	hour-glass	JJ	B-NP
,	,	,	0
and	and	CC	0
capable	capable	JJ	0
of	of	IN	0
releasing	releasing	VBG	0
medicinal	medicinal	JJ	B-NP
substance	substance	NN	I-NP
such	such	JJ	0
as	as	IN	0
glucocorticosteroid	glucocorticosteroid	NN	B-NP
,	,	,	0
tyrosine	tyrosine	NN	B-NP
kinase	kinase	NN	I-NP
inhibitor	inhibitor	NN	I-NP
,	,	,	0
and	and	CC	0
mitosis	mitosis	JJ	B-NP
inhibitor	inhibitor	NN	I-NP
around	around	IN	0
newly	newly	RB	0
created	created	VBN	B-NP
fenestration	fenestration	NN	I-NP
.	.	.	0
An	An	DT	0
hour-glass	hour-glass	JJ	B-NP
or	or	CC	0
tubular	tubular	JJ	B-NP
shape	shape	NN	I-NP
is	is	VBZ	0
described	described	VBN	0
as	as	RB	0
preferred	preferred	VBN	0
because	because	IN	0
it	it	PRP	0
allows	allows	VBZ	0
secretions	secretions	VBN	0
to	to	TO	0
drain	drain	VB	0
from	from	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
The	The	DT	0
spacer	spacer	NN	B-NP
is	is	VBZ	0
placed	placed	VBN	0
solely	solely	RB	0
at	at	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
and	and	CC	0
does	does	VBZ	0
not	not	RB	0
undergo	undergo	VB	0
a	a	DT	0
structural	structural	JJ	B-NP
change	change	NN	I-NP
,	,	,	0
for	for	IN	0
example	example	NN	0
,	,	,	0
to	to	TO	0
transition	transition	NN	0
between	between	IN	0
a	a	DT	0
collapsed	collapsed	JJ	0
and	and	CC	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
,	,	,	0
upon	upon	IN	0
delivery	delivery	NN	0
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
the	the	DT	0
spacer	spacer	NN	B-NP
primarily	primarily	RB	0
lies	lies	VBZ	0
within	within	IN	0
the	the	DT	0
natural	natural	JJ	0
ostium	ostium	NN	B-NP
or	or	CC	0
surgically	surgically	RB	0
created	created	VBN	B-NP
fenestration	fenestration	NN	I-NP
.	.	.	0
It	It	PRP	0
does	does	VBZ	0
not	not	RB	0
have	have	VB	0
a	a	DT	0
portion	portion	NN	0
that	that	WDT	0
extends	extends	VBZ	0
into	into	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
to	to	TO	0
contact	contact	VB	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
.	.	.	0
Another	Another	DT	0
treating	treating	VBG	B-NP
sinusitis	sinusitis	NN	I-NP
implantable	implantable	JJ	I-NP
device	device	NN	I-NP
is	is	VBZ	0
described	described	VBN	0
in	in	IN	0
U.S.	U.S.	NNP	0
Publication	Publication	NNP	0
No.	No.	NNP	0
2005	2005	CD	0
/	/	CD	0
0245906	0245906	CD	0
to	to	TO	0
Makower	Makower	NNP	B-NP
et	et	FW	0
al	al	FW	0
.	.	.	0
This	This	DT	0
application	application	NN	0
describes	describes	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymeric	polymeric	JJ	B-NP
device	device	NN	I-NP
having	having	VBG	0
a	a	DT	0
spacer	spacer	NN	B-NP
for	for	IN	0
positioning	positioning	NN	0
within	within	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
body	body	NN	0
comprised	comprised	NN	0
of	of	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
substance-eluting	substance-eluting	JJ	B-NP
strut	strut	NN	I-NP
.	.	.	0
The	The	DT	0
struts	struts	NNS	0
are	are	VBP	0
configured	configured	VBN	0
to	to	TO	0
lie	lie	VB	0
substantially	substantially	RB	0
parallel	parallel	VB	0
to	to	TO	0
the	the	DT	0
flow	flow	NN	0
of	of	IN	0
mucus	mucus	NN	0
along	along	IN	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
walls	walls	NNS	0
without	without	IN	0
substantially	substantially	RB	0
touching	touching	VBG	0
the	the	DT	0
walls	walls	NNS	0
so	so	RB	0
that	that	IN	0
mucociliary	mucociliary	JJ	B-NP
transport	transport	NN	I-NP
is	is	VBZ	0
not	not	RB	0
interrupted	interrupted	VBN	0
.	.	.	0
It	It	PRP	0
is	is	VBZ	0
uncertain	uncertain	JJ	0
how	how	WRB	0
a	a	DT	0
device	device	NN	0
of	of	IN	0
this	this	DT	0
design	design	NN	0
would	would	MD	0
be	be	VB	0
constructed	constructed	VBN	0
or	or	CC	0
deployed	deployed	VBN	0
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
given	given	VBN	0
that	that	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
is	is	VBZ	0
a	a	DT	0
source	source	NN	0
of	of	IN	0
water	water	NN	0
needed	needed	VBN	0
for	for	IN	0
device	device	NN	B-NP
degradation	degradation	NN	I-NP
and	and	CC	0
drug	drug	NN	B-NP
release	release	NN	I-NP
,	,	,	0
it	it	PRP	0
is	is	VBZ	0
questionable	questionable	JJ	0
whether	whether	IN	0
this	this	DT	0
device	device	NN	0
is	is	VBZ	0
capable	capable	JJ	0
of	of	IN	0
providing	providing	VBG	0
a	a	DT	0
dosing	dosing	JJ	0
regimen	regimen	JJ	0
effective	effective	JJ	0
for	for	IN	0
treating	treating	VBG	B-NP
rhinosinusiti	rhinosinusiti	NN	I-NP
because	because	IN	0
it	it	PRP	0
does	does	VBZ	0
not	not	RB	0
substantially	substantially	RB	0
contact	contact	VB	0
the	the	DT	0
walls	walls	NNS	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
Other	Other	JJ	0
compositions	compositions	NNS	0
for	for	IN	0
the	the	DT	0
treatment	treatment	NN	0
of	of	IN	0
rhinosinusiti	rhinosinusiti	NN	B-NP
,	,	,	0
such	such	JJ	0
as	as	IN	0
aqueous	aqueous	JJ	B-NP
solution	solution	NN	I-NP
,	,	,	0
creams	creams	NNS	0
,	,	,	0
or	or	CC	0
gels	gels	NN	0
,	,	,	0
for	for	IN	0
topical	topical	JJ	B-NP
application	application	NN	I-NP
in	in	IN	0
the	the	DT	0
nose	nose	NN	0
have	have	VBP	0
also	also	RB	0
been	been	VBN	0
formulated	formulated	VBN	0
,	,	,	0
but	but	CC	0
usually	usually	RB	0
never	never	RB	0
travel	travel	VB	0
far	far	RB	0
enough	enough	RB	0
into	into	IN	0
the	the	DT	0
nose	nose	NN	0
to	to	TO	0
reach	reach	VB	0
the	the	DT	0
sinuses	sinuses	NN	0
,	,	,	0
are	are	VBP	0
blocked	blocked	VBN	0
from	from	IN	0
entering	entering	VBG	0
the	the	DT	0
sinuses	sinuses	JJ	0
due	due	JJ	0
to	to	TO	0
obstructed	obstructed	VB	B-NP
oston	oston	NN	I-NP
,	,	,	0
or	or	CC	0
have	have	VBP	0
such	such	JJ	0
short	short	JJ	0
contact	contact	NN	0
with	with	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
that	that	IN	0
absorption	absorption	NN	0
of	of	IN	0
the	the	DT	0
agent	agent	NN	B-NP
is	is	VBZ	0
low	low	JJ	0
.	.	.	0
For	For	IN	0
similar	similar	JJ	0
reasons	reasons	NNS	0
,	,	,	0
nasally	nasally	FW	0
inhaled	inhaled	VBN	B-NP
steroid	steroid	NN	I-NP
and	and	CC	0
anti-infective	anti-infective	JJ	B-NP
aerosol	aerosol	NN	I-NP
that	that	WDT	0
have	have	VBP	0
been	been	VBN	0
developed	developed	VBN	0
to	to	TO	0
treat	treat	VB	0
sinusitis	sinusitis	NNS	0
are	are	VBP	0
equally	equally	RB	0
ineffective	ineffective	JJ	0
.	.	.	0
Another	Another	DT	0
method	method	NN	0
that	that	WDT	0
has	has	VBZ	0
been	been	VBN	0
described	described	VBN	0
for	for	IN	0
locally	locally	RB	0
treating	treating	VBG	B-NP
sinusitis	sinusitis	NN	I-NP
is	is	VBZ	0
to	to	TO	0
place	place	VB	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
implant	implant	NN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
delivery	delivery	NN	0
of	of	IN	0
ampicillin	ampicillin	NN	B-NP
from	from	IN	0
a	a	DT	0
rolled-up	rolled-up	JJ	0
1.5	1.5	CD	0
cm	cm	CD	0
1.5	1.5	CD	0
cm	cm	CD	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic-co-glycolic	lactic-co-glycolic	NNP	I-NP
)	)	-RRB-	I-NP
acid	acid	NN	I-NP
(	(	-LRB-	0
PLGA	PLGA	NNP	B-NP
)	)	-RRB-	0
film	film	NN	0
to	to	TO	0
increase	increase	VB	0
residence	residence	NN	B-NP
time	time	NN	I-NP
of	of	IN	0
the	the	DT	0
antibiotic	antibiotic	NN	0
in	in	IN	0
rabbit	rabbit	JJ	0
sinuses	sinuses	NN	0
has	has	VBZ	0
been	been	VBN	0
investigated	investigated	VBN	0
for	for	IN	0
the	the	DT	0
treatment	treatment	NN	0
of	of	IN	0
sinusitis	sinusitis	NNS	0
(	(	-LRB-	0
Min	Min	FW	0
et	et	FW	0
al	al	FW	0
.	.	.	0
Mucociliary	Mucociliary	JJ	B-NP
Activity	Activity	NN	I-NP
and	and	CC	0
sinus	sinus	NN	B-NP
mucosa	mucosa	NN	I-NP
histopathology	histopathology	NN	I-NP
in	in	IN	0
Experimental	Experimental	NNP	B-NP
Maxillary	Maxillary	NNP	I-NP
Sinusitis	Sinusitis	NNP	I-NP
:	:	:	0
A	A	DT	0
Comparison	Comparison	NNP	0
of	of	IN	0
Systemic	Systemic	NNP	B-NP
Administration	Administration	NNP	I-NP
of	of	IN	0
Antibiotic	Antibiotic	NNP	0
and	and	CC	0
Antibiotic	Antibiotic	NNP	B-NP
Delivery	Delivery	NN	I-NP
by	by	IN	0
Polylactic	Polylactic	NNP	B-NP
Acid	Acid	NNP	I-NP
Polymer	Polymer	NNP	I-NP
.	.	.	0
Laryngoscope	Laryngoscope	NNP	B-NP
105	105	CD	0
:	:	:	0
835-342	835-342	CD	0
(	(	-LRB-	0
1995	1995	CD	0
)	)	-RRB-	0
and	and	CC	0
Min	Min	NNP	0
et	et	FW	0
al	al	FW	0
.	.	.	0
Application	Application	NN	0
of	of	IN	0
Polylactic	Polylactic	NNP	B-NP
Acid	Acid	NNP	I-NP
Polymer	Polymer	NNP	I-NP
in	in	IN	0
the	the	DT	0
Treatment	Treatment	NNP	0
of	of	IN	0
Acute	Acute	NNP	B-NP
Maxillary	Maxillary	NNP	I-NP
Sinusitis	Sinusitis	NNP	I-NP
in	in	IN	0
Rabbits	Rabbits	NNP	0
.	.	.	0
Acta	Acta	NNP	B-NP
Otolaryngol	Otolaryngol	NNP	I-NP
115	115	CD	0
:	:	:	0
548-552	548-552	CD	0
(	(	-LRB-	0
1995	1995	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
Although	Although	IN	0
clinical	clinical	JJ	B-NP
sign	sign	NN	I-NP
of	of	IN	0
sinusitis	sinusitis	VBG	0
improved	improved	VBN	0
over	over	IN	0
28	28	CD	0
days	days	NNS	0
,	,	,	0
the	the	DT	0
procedure	procedure	NN	0
for	for	IN	0
placing	placing	VBG	0
the	the	DT	0
film	film	NN	0
was	was	VBD	0
quite	quite	RB	0
invasive	invasive	JJ	0
,	,	,	0
requiring	requiring	VBG	0
that	that	IN	0
a	a	DT	0
hole	hole	NN	0
be	be	VB	0
drilled	drilled	VBN	0
through	through	IN	0
the	the	DT	0
anterior	anterior	JJ	0
wall	wall	NN	0
of	of	IN	0
the	the	DT	0
maxillary	maxillary	JJ	B-NP
sinus	sinus	NN	I-NP
.	.	.	0
A	A	DT	0
less	less	RBR	0
invasive	invasive	JJ	B-NP
method	method	NN	I-NP
of	of	IN	0
placing	placing	VBG	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
implant	implant	NN	0
into	into	IN	0
a	a	DT	0
sinus	sinus	NN	B-NP
for	for	IN	0
the	the	DT	0
local	local	JJ	0
treatment	treatment	NN	0
of	of	IN	0
sinusitis	sinusitis	NN	0
is	is	VBZ	0
described	described	VBN	0
in	in	IN	0
commonly	commonly	RB	0
owned	owned	VBN	0
U.S.	U.S.	NNP	0
Publication	Publication	NNP	0
No.	No.	NNP	0
2005	2005	CD	0
/	/	CD	0
0043706	0043706	CD	0
.	.	.	0
In	In	IN	0
this	this	DT	0
application	application	NN	0
,	,	,	0
the	the	DT	0
implant	implant	NN	0
is	is	VBZ	0
generally	generally	RB	0
delivered	delivered	VBN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
through	through	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
,	,	,	0
and	and	CC	0
has	has	VBZ	0
at	at	IN	0
least	least	JJS	0
one	one	CD	0
characteristic	characteristic	NN	0
that	that	WDT	0
substantially	substantially	RB	0
prevents	prevents	VBZ	0
its	its	PRP$	0
clearance	clearance	NN	0
by	by	IN	0
the	the	DT	0
mucociliary	mucociliary	JJ	B-NP
transport	transport	NN	I-NP
system	system	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
implant	implant	NN	0
is	is	VBZ	0
typically	typically	RB	0
formed	formed	VBN	0
to	to	TO	0
possess	possess	VB	0
a	a	DT	0
mucoadhesivene	mucoadhesivene	NN	B-NP
that	that	WDT	0
substantially	substantially	RB	0
prevents	prevents	VBZ	0
implant	implant	JJ	0
clearance	clearance	NN	0
from	from	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
A	A	DT	0
mucoadhesive	mucoadhesive	JJ	B-NP
polymer	polymer	NN	I-NP
is	is	VBZ	0
incorporated	incorporated	VBN	0
into	into	IN	0
the	the	DT	0
implant	implant	NN	0
to	to	TO	0
make	make	VB	0
it	it	PRP	0
mucoadhesive	mucoadhesive	VBD	0
.	.	.	0
mucoadhesive	mucoadhesive	NN	B-NP
polymer	polymer	NN	I-NP
are	are	VBP	0
usually	usually	RB	0
hydrophilic	hydrophilic	JJ	B-NP
,	,	,	0
and	and	CC	0
upon	upon	IN	0
moistening	moistening	NN	0
,	,	,	0
absorb	absorb	JJ	0
water	water	NN	0
to	to	TO	0
swell	swell	VB	0
and	and	CC	0
become	become	VB	0
adhesive	adhesive	NN	B-NP
.	.	.	0
This	This	DT	0
implant	implant	NN	0
lacks	lacks	VBZ	0
a	a	DT	0
structural	structural	JJ	B-NP
component	component	NN	I-NP
that	that	WDT	0
physically	physically	RB	0
maintains	maintains	VBZ	0
patency	patency	VBN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
Consequently	Consequently	RB	0
,	,	,	0
new	new	JJ	0
devices	devices	NNS	0
for	for	IN	0
locally	locally	RB	0
administering	administering	JJ	0
active	active	JJ	0
agents	agents	NNS	0
to	to	TO	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
for	for	IN	0
treating	treating	VBG	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
sinus	sinus	NN	B-NP
inflammation	inflammation	NN	I-NP
(	(	-LRB-	0
including	including	VBG	0
,	,	,	0
but	but	CC	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
rhinosinusiti	rhinosinusiti	NN	B-NP
and	and	CC	0
sinus	sinus	JJ	B-NP
procedure	procedure	NN	I-NP
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
for	for	IN	0
sinus	sinus	JJ	B-NP
ostia	ostia	NN	I-NP
maintaining	maintaining	VBG	I-NP
patency	patency	NN	I-NP
,	,	,	0
as	as	RB	0
well	well	RB	0
as	as	IN	0
methods	methods	NNS	0
for	for	IN	0
delivering	delivering	VBG	0
the	the	DT	0
devices	devices	NNS	0
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
are	are	VBP	0
desirable	desirable	JJ	0
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
,	,	,	0
systems	systems	NNS	0
,	,	,	0
and	and	CC	0
methods	methods	NNS	0
of	of	IN	0
this	this	DT	0
invention	invention	NNS	0
are	are	VBP	0
generally	generally	RB	0
used	used	VBN	0
to	to	TO	0
treat	treat	VB	0
patients	patients	NNS	0
having	having	VBG	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
to	to	TO	0
be	be	VB	0
treated	treated	VBN	0
is	is	VBZ	0
typically	typically	RB	0
postoperative	postoperative	NN	B-NP
paranasal	paranasal	NN	I-NP
sinus	sinus	NN	I-NP
inflammation	inflammation	NN	I-NP
due	due	JJ	0
to	to	TO	0
functional	functional	VB	B-NP
endoscopic	endoscopic	JJ	I-NP
sinus	sinus	JJ	I-NP
surgery	surgery	NN	I-NP
(	(	-LRB-	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
)	)	-RRB-	0
for	for	IN	0
sinusitis	sinusitis	NN	0
,	,	,	0
but	but	CC	0
also	also	RB	0
includes	includes	VBZ	0
conditions	conditions	NNS	0
such	such	JJ	0
as	as	RB	0
,	,	,	0
but	but	CC	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
acute	acute	JJ	0
sinusitis	sinusitis	NN	0
,	,	,	0
chronic	chronic	JJ	B-NP
sinusitis	sinusitis	NN	I-NP
,	,	,	0
allergic	allergic	JJ	B-NP
rhiniti	rhiniti	NN	I-NP
,	,	,	0
rhinosinusiti	rhinosinusiti	NN	B-NP
,	,	,	0
sinusitis	sinusitis	VBG	0
that	that	DT	0
recurs	recurs	NN	0
after	after	IN	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
,	,	,	0
upper	upper	JJ	0
respiratory	respiratory	JJ	B-NP
tract	tract	NN	I-NP
infection	infection	NN	I-NP
,	,	,	0
otitis	otitis	JJ	B-NP
medium	medium	JJ	I-NP
,	,	,	0
bronchitis	bronchitis	NN	0
,	,	,	0
bronchioliti	bronchioliti	NN	B-NP
,	,	,	0
asthma	asthma	NN	B-NP
,	,	,	0
tonsillitis	tonsillitis	NN	0
and	and	CC	0
other	other	JJ	0
chronic	chronic	JJ	B-NP
disease	disease	NN	I-NP
of	of	IN	0
the	the	DT	0
tonsils	tonsils	NN	0
and	and	CC	0
adenoid	adenoid	NN	B-NP
,	,	,	0
laryngitis	laryngitis	NN	0
,	,	,	0
tracheiti	tracheiti	NN	B-NP
,	,	,	0
nasal	nasal	NN	B-NP
and	and	CC	0
sinus	sinus	JJ	B-NP
polyposi	polyposi	NN	I-NP
,	,	,	0
neoplasms	neoplasms	VBG	0
of	of	IN	0
the	the	DT	0
large	large	JJ	0
and	and	CC	0
small	small	JJ	0
airway	airway	NN	B-NP
,	,	,	0
and	and	CC	0
nasal	nasal	NN	B-NP
,	,	,	0
sinus	sinus	NN	B-NP
,	,	,	0
or	or	CC	0
nasopharynx	nasopharynx	JJ	B-NP
tumor	tumor	NN	I-NP
such	such	JJ	0
as	as	IN	0
nasopharyngeal	nasopharyngeal	JJ	B-NP
carcinoma	carcinoma	NN	I-NP
,	,	,	0
plasmacytoma	plasmacytoma	NN	B-NP
,	,	,	0
inverted	inverted	JJ	0
papilloma	papilloma	NN	B-NP
,	,	,	0
rhabdomyosarcoma	rhabdomyosarcoma	NN	B-NP
,	,	,	0
squamous	squamous	JJ	B-NP
cell	cell	NN	I-NP
carcinoma	carcinoma	NN	I-NP
,	,	,	0
and	and	CC	0
lymphoma	lymphoma	NN	B-NP
,	,	,	0
when	when	WRB	0
they	they	PRP	0
involve	involve	VBP	0
the	the	DT	0
sinuses	sinuses	NN	0
or	or	CC	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
.	.	.	0
As	As	RB	0
used	used	VBN	0
herein	herein	NN	0
,	,	,	0
the	the	DT	0
terms	terms	NNS	0
paranasal	paranasal	VBP	0
sinus	sinus	JJ	B-NP
inflammation	inflammation	NN	I-NP
or	or	CC	0
sinus	sinus	JJ	B-NP
inflammation	inflammation	NN	I-NP
refer	refer	VBP	0
to	to	TO	0
any	any	DT	0
reaction	reaction	NN	0
of	of	IN	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
tissue	tissue	NN	I-NP
sinus	sinus	JJ	I-NP
,	,	,	0
or	or	CC	0
tissue	tissue	NN	0
in	in	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
proximate	proximate	VBD	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostia	ostia	NN	I-NP
that	that	WDT	0
involves	involves	VBZ	0
the	the	DT	0
inflammatory	inflammatory	JJ	B-NP
response	response	NN	I-NP
.	.	.	0
The	The	DT	0
inflammation	inflammation	NN	B-NP
may	may	MD	0
be	be	VB	0
caused	caused	VBN	0
by	by	IN	0
processes	processes	NNS	0
such	such	JJ	0
as	as	IN	0
allergy	allergy	NN	B-NP
(	(	-LRB-	0
hypersensitivity	hypersensitivity	LS	B-NP
)	)	-RRB-	0
,	,	,	0
injury	injury	NN	B-NP
to	to	TO	0
sinus	sinus	VB	B-NP
mucosa	mucosa	JJ	0
due	due	JJ	0
to	to	TO	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
trauma	trauma	NN	0
;	;	:	0
surgery	surgery	NN	0
;	;	:	0
infection	infection	NN	B-NP
by	by	IN	0
bacteria	bacteria	NNS	0
,	,	,	0
viruses	viruses	NN	0
,	,	,	0
fus	fus	NN	B-NP
,	,	,	0
chemicals	chemicals	NNS	0
,	,	,	0
or	or	CC	0
drugs	drugs	NNS	0
;	;	:	0
and	and	CC	0
benign	benign	JJ	0
or	or	CC	0
malignant	malignant	JJ	0
tumors	tumors	NNS	0
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
are	are	VBP	0
formed	formed	VBN	0
in	in	IN	0
such	such	PDT	0
a	a	DT	0
way	way	NN	0
to	to	TO	0
locally	locally	RB	0
deliver	deliver	VB	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
into	into	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
,	,	,	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
for	for	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
one	one	CD	0
week	week	NN	B-NP
to	to	TO	0
treat	treat	VB	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
.	.	.	0
The	The	DT	0
described	described	JJ	0
devices	devices	NNS	0
are	are	VBP	0
useful	useful	JJ	0
in	in	IN	0
surgical	surgical	JJ	0
,	,	,	0
non-surgical	non-surgical	NNP	B-NP
,	,	,	0
and	and	CC	0
other	other	JJ	0
therapeutic	therapeutic	JJ	B-NP
intervention	intervention	NN	I-NP
related	related	VBN	0
to	to	TO	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
and	and	CC	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
to	to	TO	0
restore	restore	VB	0
anatomical	anatomical	JJ	B-NP
function	function	NN	I-NP
and	and	CC	0
treat	treat	VB	0
any	any	DT	0
of	of	IN	0
the	the	DT	0
aforementioned	aforementioned	JJ	B-NP
condition	condition	NN	I-NP
.	.	.	0
Accordingly	Accordingly	RB	0
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
support	support	VB	0
sinus	sinus	NN	B-NP
and	and	CC	0
nasal	nasal	JJ	B-NP
surgery	surgery	NN	I-NP
,	,	,	0
reduce	reduce	VB	0
the	the	DT	0
need	need	NN	0
for	for	IN	0
surgical	surgical	JJ	B-NP
revision	revision	NN	I-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
prevent	prevent	VB	0
,	,	,	0
delay	delay	NN	0
,	,	,	0
or	or	CC	0
reduce	reduce	VB	0
recurrence	recurrence	VBN	0
of	of	IN	0
rhinosinusiti	rhinosinusiti	NN	B-NP
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
for	for	IN	0
treating	treating	VBG	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
may	may	MD	0
include	include	VB	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
that	that	WDT	0
has	has	VBZ	0
a	a	DT	0
first	first	JJ	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
that	that	WDT	0
permits	permits	VBZ	0
the	the	DT	0
device	device	NN	0
to	to	TO	0
pass	pass	VB	0
through	through	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
and	and	CC	0
a	a	DT	0
second	second	JJ	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
after	after	IN	0
placement	placement	NN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
As	As	RB	0
used	used	VBN	0
herein	herein	NN	0
,	,	,	0
the	the	DT	0
terms	terms	NNS	0
expand	expand	VBP	0
,	,	,	0
expansion	expansion	NN	0
,	,	,	0
or	or	CC	0
expanding	expanding	VBG	0
,	,	,	0
refer	refer	VBP	0
to	to	TO	0
a	a	DT	0
device	device	NN	0
that	that	IN	0
undergoes	undergoes	JJ	B-NP
physical	physical	JJ	I-NP
expansion	expansion	NN	I-NP
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
from	from	IN	0
a	a	DT	0
compressed	compressed	NN	0
to	to	TO	0
an	an	DT	0
expanded	expanded	JJ	0
state	state	NN	0
,	,	,	0
not	not	RB	0
expansion	expansion	JJ	0
due	due	JJ	0
to	to	TO	0
the	the	DT	0
absorption	absorption	NN	0
of	of	IN	0
water	water	NN	0
.	.	.	0
In	In	IN	0
their	their	PRP$	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
in	in	IN	0
some	some	DT	0
variations	variations	NNS	0
have	have	VBP	0
a	a	DT	0
surface	surface	NN	0
area	area	NN	0
to	to	TO	0
volume	volume	NN	B-NP
ratio	ratio	NN	I-NP
that	that	WDT	0
is	is	VBZ	0
substantially	substantially	RB	0
unchanged	unchanged	JJ	0
from	from	IN	0
that	that	DT	0
of	of	IN	0
the	the	DT	0
devices	devices	NNS	0
in	in	IN	0
their	their	PRP$	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
.	.	.	0
In	In	IN	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
upon	upon	IN	0
expansion	expansion	NN	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
also	also	RB	0
at	at	IN	0
least	least	JJS	0
partially	partially	RB	0
conforms	conforms	VBZ	0
to	to	TO	0
the	the	DT	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
and	and	CC	0
substantially	substantially	RB	0
contacts	contacts	VB	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
mucosa	mucosa	NN	I-NP
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
may	may	MD	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
any	any	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
they	they	PRP	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
from	from	IN	0
various	various	JJ	0
metals	metals	NNS	0
and	and	CC	0
their	their	PRP$	0
alloys	alloys	NNS	0
,	,	,	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
In	In	IN	0
addition	addition	NN	0
to	to	TO	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
may	may	MD	0
include	include	VB	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
and	and	CC	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
that	that	WDT	0
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
reside	reside	VB	0
within	within	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
member	member	NN	0
is	is	VBZ	0
attached	attached	VBN	0
to	to	TO	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
distal	distal	JJ	I-NP
end	end	NN	I-NP
.	.	.	0
The	The	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
is	is	VBZ	0
attached	attached	VBN	0
to	to	TO	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
proximal	proximal	JJ	I-NP
end	end	NN	I-NP
and	and	CC	0
lies	lies	VBZ	0
within	within	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
.	.	.	0
The	The	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
incorporated	incorporated	VBN	0
into	into	IN	0
all	all	DT	0
portions	portions	NNS	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
or	or	CC	0
only	only	RB	0
included	included	VBN	0
in	in	IN	0
the	the	DT	0
expandable	expandable	JJ	B-NP
cavity	cavity	JJ	I-NP
member	member	NN	I-NP
,	,	,	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
or	or	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
In	In	IN	0
one	one	CD	0
aspect	aspect	NN	B-NP
,	,	,	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
and	and	CC	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
.	.	.	0
In	In	IN	0
another	another	DT	0
aspect	aspect	NN	B-NP
,	,	,	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
and	and	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
In	In	IN	0
yet	yet	RB	0
a	a	DT	0
further	further	JJ	0
aspect	aspect	NN	B-NP
,	,	,	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
and	and	CC	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
may	may	MD	0
contain	contain	VB	0
and	and	CC	0
deliver	deliver	VB	0
the	the	DT	0
same	same	JJ	0
or	or	CC	0
different	different	JJ	0
active	active	JJ	0
agents	agents	NNS	0
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
may	may	MD	0
deliver	deliver	VB	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
over	over	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
one	one	CD	0
week	week	NN	B-NP
,	,	,	0
over	over	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
two	two	CD	0
weeks	weeks	NNS	0
,	,	,	0
over	over	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
three	three	CD	0
weeks	weeks	NNS	0
,	,	,	0
over	over	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
one	one	CD	0
month	month	NN	0
,	,	,	0
over	over	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
two	two	CD	0
months	months	NNS	0
,	,	,	0
over	over	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
three	three	CD	0
months	months	NNS	0
,	,	,	0
over	over	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
four	four	CD	0
months	months	NNS	0
,	,	,	0
over	over	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
five	five	CD	0
months	months	NNS	0
,	,	,	0
or	or	CC	0
over	over	RB	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
six	six	CD	0
months	months	NNS	0
or	or	CC	0
more	more	JJR	0
.	.	.	0
Typically	Typically	RB	0
,	,	,	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
delivered	delivered	VBN	0
over	over	RP	0
about	about	IN	0
four	four	CD	0
weeks	weeks	NNS	0
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
from	from	IN	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
polymeric	polymeric	JJ	B-NP
pliable	pliable	JJ	I-NP
filament	filament	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
cavity	cavity	JJ	0
members	members	NNS	0
that	that	WDT	0
resemble	resemble	VBP	0
a	a	DT	0
fringed	fringed	JJ	0
structure	structure	NN	0
,	,	,	0
a	a	DT	0
flexible	flexible	JJ	0
mesh	mesh	NN	0
,	,	,	0
a	a	DT	0
whisk-like	whisk-like	JJ	B-NP
structure	structure	NN	I-NP
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
expandabla	expandabla	NN	B-NP
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
self-expand	self-expand	JJ	0
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
expand	expand	VBP	0
after	after	IN	0
application	application	NN	0
of	of	IN	0
an	an	DT	0
expansive	expansive	JJ	0
or	or	CC	0
mechanical	mechanical	JJ	B-NP
force	force	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
may	may	MD	0
expand	expand	VB	0
after	after	IN	0
balloon	balloon	NN	B-NP
inflation	inflation	NN	I-NP
.	.	.	0
In	In	IN	0
some	some	DT	0
instances	instances	NNS	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
expand	expand	VBP	0
to	to	TO	0
substantially	substantially	RB	0
contact	contact	VB	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
after	after	IN	0
deployment	deployment	NN	0
within	within	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
Contact	Contact	NN	0
with	with	IN	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
may	may	MD	0
be	be	VB	0
verified	verified	VBN	0
by	by	IN	0
radiopaque	radiopaque	JJ	B-NP
marker	marker	NN	I-NP
incorporation	incorporation	NN	I-NP
on	on	IN	0
or	or	CC	0
within	within	IN	0
the	the	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
,	,	,	0
or	or	CC	0
visualization	visualization	VBP	B-NP
using	using	VBG	0
endoscopy	endoscopy	NN	B-NP
or	or	CC	0
other	other	JJ	0
imaging	imaging	NN	0
modalities	modalities	NN	0
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
pliable	pliable	JJ	0
filament	filament	NNS	B-NP
may	may	MD	0
contain	contain	VB	0
a	a	DT	0
plasticizer	plasticizer	NN	B-NP
or	or	CC	0
a	a	DT	0
solvent	solvent	NN	B-NP
which	which	WDT	0
softens	softens	VBZ	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
.	.	.	0
Balloon	Balloon	NN	B-NP
inflation	inflation	NN	I-NP
or	or	CC	0
other	other	JJ	0
mechanical	mechanical	JJ	B-NP
type	type	NN	I-NP
of	of	IN	0
expansion	expansion	NN	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
expand	expand	VB	0
variations	variations	NNS	0
of	of	IN	0
the	the	DT	0
plasticized	plasticized	JJ	B-NP
cavity	cavity	JJ	I-NP
member	member	NN	I-NP
that	that	WDT	0
are	are	VBP	0
not	not	RB	0
configured	configured	VBN	0
to	to	TO	0
self-expand	self-expand	JJ	0
.	.	.	0
Upon	Upon	IN	0
contact	contact	NN	0
of	of	IN	0
the	the	DT	0
plasticized	plasticized	JJ	B-NP
cavity	cavity	JJ	I-NP
member	member	NN	I-NP
to	to	TO	0
the	the	DT	0
mucosal	mucosal	JJ	B-NP
tissue	tissue	NN	I-NP
,	,	,	0
the	the	DT	0
plasticizer	plasticizer	NN	B-NP
diffuses	diffuses	VBD	0
out	out	RP	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
.	.	.	0
The	The	DT	0
plasticizer	plasticizer	JJ	B-NP
diffusion	diffusion	NN	I-NP
hardens	hardens	VBP	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
in	in	IN	0
such	such	PDT	0
a	a	DT	0
way	way	NN	0
that	that	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
substantially	substantially	RB	0
conforms	conforms	VBZ	0
to	to	TO	0
the	the	DT	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
As	As	IN	0
an	an	DT	0
example	example	NN	0
,	,	,	0
a	a	DT	0
filament	filament	NN	B-NP
made	made	VBN	0
from	from	IN	0
lactide	lactide	NN	B-NP
/	/	NN	I-NP
glycolide	glycolide	NN	I-NP
polymer	polymer	NN	I-NP
may	may	MD	0
be	be	VB	0
plasticized	plasticized	VBN	0
with	with	IN	0
materials	materials	NNS	0
such	such	JJ	0
as	as	IN	0
triethyl	triethyl	JJ	B-NP
citrate	citrate	NN	I-NP
,	,	,	0
acetone	acetone	NN	B-NP
and	and	CC	0
other	other	JJ	0
ketone	ketone	NN	B-NP
,	,	,	0
ethanol	ethanol	NN	B-NP
and	and	CC	0
other	other	JJ	0
alcohols	alcohols	NN	0
,	,	,	0
N-methylpyrrolidone	N-methylpyrrolidone	NNP	B-NP
,	,	,	0
ethyl	ethyl	JJ	B-NP
acetate	acetate	NN	I-NP
and	and	CC	0
mixtures	mixtures	JJ	0
thereof	thereof	NN	0
.	.	.	0
Upon	Upon	IN	0
placement	placement	NN	0
of	of	IN	0
the	the	DT	0
filament	filament	NN	B-NP
into	into	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
,	,	,	0
the	the	DT	0
plasticizer	plasticizer	NN	B-NP
,	,	,	0
triethyl	triethyl	JJ	B-NP
citrate	citrate	NN	I-NP
,	,	,	0
for	for	IN	0
example	example	NN	0
,	,	,	0
diffuses	diffuses	VBG	0
out	out	RP	0
of	of	IN	0
the	the	DT	0
filament	filament	JJ	B-NP
polymer	polymer	NN	I-NP
to	to	TO	0
result	result	VB	0
in	in	IN	0
a	a	DT	0
hardened	hardened	JJ	0
filament	filament	NN	B-NP
that	that	WDT	0
substantially	substantially	RB	0
conforms	conforms	VBZ	0
to	to	TO	0
the	the	DT	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
described	described	VBD	0
here	here	RB	0
for	for	IN	0
treating	treating	VBG	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
may	may	MD	0
include	include	VB	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
dispersed	dispersed	NN	I-NP
within	within	IN	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	JJ	B-NP
matrix	matrix	NN	I-NP
,	,	,	0
in	in	IN	0
which	which	WDT	0
the	the	DT	0
device	device	NN	0
comprises	comprises	VBZ	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
optionally	optionally	VBG	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
and	and	CC	0
exhibits	exhibits	VBZ	0
an	an	DT	0
in	in	IN	0
vivo	vivo	JJ	B-NP
cumulative	cumulative	JJ	I-NP
release	release	NN	I-NP
profile	profile	NN	I-NP
in	in	IN	0
which	which	WDT	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
amount	amount	NN	0
of	of	IN	0
said	said	VBD	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
maintained	maintained	VBN	0
in	in	IN	0
a	a	DT	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
for	for	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
4	4	CD	0
days	days	NNS	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
14	14	CD	0
days	days	NNS	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
25	25	CD	0
days	days	NNS	0
,	,	,	0
or	or	CC	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
35	35	CD	0
days	days	NNS	0
after	after	IN	0
implantation	implantation	NN	B-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
may	may	MD	0
be	be	VB	0
delivered	delivered	VBN	0
into	into	IN	0
a	a	DT	0
sinus	sinus	NN	B-NP
using	using	VBG	0
inserter	inserter	NN	B-NP
of	of	IN	0
various	various	JJ	0
designs	designs	NNS	0
.	.	.	0
typical	typical	JJ	B-NP
inserter	inserter	NN	I-NP
include	include	VBP	0
a	a	DT	0
conduit	conduit	NN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
a	a	DT	0
catheter	catheter	NN	B-NP
,	,	,	0
needle	needle	NN	0
,	,	,	0
or	or	CC	0
angiocatheter	angiocatheter	NN	B-NP
,	,	,	0
having	having	VBG	0
a	a	DT	0
lumen	lumen	NN	B-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
conduit	conduit	NN	0
may	may	MD	0
be	be	VB	0
made	made	VBN	0
such	such	JJ	0
that	that	IN	0
it	it	PRP	0
has	has	VBZ	0
variable	variable	JJ	0
stiffness	stiffness	NN	0
along	along	IN	0
its	its	PRP$	0
length	length	NN	0
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
the	the	DT	0
distal	distal	JJ	B-NP
portion	portion	NN	I-NP
of	of	IN	0
the	the	DT	0
conduit	conduit	NN	0
may	may	MD	0
be	be	VB	0
pre-angulated	pre-angulated	JJ	B-NP
to	to	TO	0
facilitate	facilitate	VB	0
access	access	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
,	,	,	0
or	or	CC	0
made	made	VBD	0
such	such	JJ	0
that	that	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
portion	portion	NN	I-NP
is	is	VBZ	0
malleable	malleable	JJ	0
such	such	JJ	0
that	that	IN	0
the	the	DT	0
physician	physician	NN	0
may	may	MD	0
angulate	angulate	VB	0
the	the	DT	0
conduit	conduit	NN	0
prior	prior	RB	0
to	to	TO	0
accessing	accessing	VB	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
and	and	CC	0
inserter	inserter	NN	B-NP
for	for	IN	0
their	their	PRP$	0
deployment	deployment	NN	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
in	in	IN	0
a	a	DT	0
system	system	NN	0
for	for	IN	0
treating	treating	VBG	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
.	.	.	0
In	In	IN	0
general	general	JJ	0
,	,	,	0
the	the	DT	0
system	system	NN	B-NP
work	work	NN	I-NP
by	by	IN	0
first	first	JJ	0
placing	placing	VBG	0
the	the	DT	0
inserter	inserter	NN	B-NP
having	having	VBG	0
one	one	CD	0
or	or	CC	0
more	more	JJR	0
devices	devices	NNS	0
in	in	IN	0
a	a	DT	0
collapsed	collapsed	JJ	0
,	,	,	0
folded	folded	VBD	0
,	,	,	0
or	or	CC	0
constrained	constrained	JJ	0
configuration	configuration	NN	B-NP
within	within	IN	0
or	or	CC	0
carried	carried	VBN	0
on	on	IN	0
its	its	PRP$	0
distal	distal	JJ	B-NP
end	end	NN	I-NP
through	through	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
Once	Once	RB	0
within	within	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	B-NP
transition	transition	NN	I-NP
from	from	IN	0
the	the	DT	0
first	first	JJ	0
collapsed	collapsed	NN	0
,	,	,	0
folded	folded	VBD	0
,	,	,	0
or	or	CC	0
constrained	constrained	JJ	0
configuration	configuration	NN	B-NP
to	to	TO	0
a	a	DT	0
second	second	JJ	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
a	a	DT	0
sheath	sheath	NN	0
may	may	MD	0
be	be	VB	0
retracted	retracted	VBN	0
to	to	TO	0
slidably	slidably	VB	0
deploy	deploy	VBN	0
a	a	DT	0
self-expanding	self-expanding	JJ	0
cavity	cavity	JJ	0
member	member	NN	0
that	that	IN	0
contacts	contacts	NNS	0
a	a	DT	0
substantial	substantial	JJ	0
portion	portion	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
.	.	.	0
Balloon	Balloon	NN	B-NP
inflation	inflation	NN	I-NP
or	or	CC	0
other	other	JJ	0
mechanical	mechanical	JJ	B-NP
type	type	NN	I-NP
of	of	IN	0
expansion	expansion	NN	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
expand	expand	VB	0
variations	variations	NNS	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
that	that	WDT	0
are	are	VBP	0
not	not	RB	0
configured	configured	VBN	0
to	to	TO	0
self-expand	self-expand	JJ	0
.	.	.	0
FIG.	FIG.	CD	0
1	1	CD	0
is	is	VBZ	0
a	a	DT	0
maxillary	maxillary	NN	B-NP
cross-sectional	cross-sectional	JJ	I-NP
view	view	NN	I-NP
and	and	CC	0
frontal	frontal	JJ	B-NP
sinus	sinus	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
2A-2M	2A-2M	NNP	0
are	are	VBP	0
transverse	transverse	JJ	B-NP
cross-sectional	cross-sectional	JJ	I-NP
view	view	NN	I-NP
of	of	IN	0
various	various	JJ	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
.	.	.	0
FIG.	FIG.	NNP	0
3A	3A	NNP	0
is	is	VBZ	0
a	a	DT	0
maxillary	maxillary	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
cross-sectional	cross-sectional	JJ	I-NP
view	view	NN	I-NP
having	having	VBG	0
a	a	DT	0
fringed	fringed	JJ	0
structure	structure	NN	0
according	according	VBG	0
to	to	TO	0
one	one	CD	0
variation	variation	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
.	.	.	0
FIG.	FIG.	NNP	0
3B	3B	NNP	0
is	is	VBZ	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
cross-sectional	cross-sectional	JJ	I-NP
view	view	NN	I-NP
of	of	IN	0
FIG.	FIG.	CD	0
3A	3A	CD	0
in	in	IN	0
a	a	DT	0
maxillary	maxillary	JJ	B-NP
sinus	sinus	NN	I-NP
.	.	.	0
FIG.	FIG.	NNP	0
4A	4A	NNP	0
is	is	VBZ	0
a	a	DT	0
frontal	frontal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
cross-sectional	cross-sectional	JJ	I-NP
view	view	NN	I-NP
having	having	VBG	0
a	a	DT	0
fringed	fringed	JJ	0
structure	structure	NN	0
according	according	VBG	0
to	to	TO	0
another	another	DT	0
variation	variation	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
.	.	.	0
FIG.	FIG.	NNP	0
4B	4B	NNP	0
is	is	VBZ	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
cross-sectional	cross-sectional	JJ	I-NP
view	view	NN	I-NP
of	of	IN	0
FIG.	FIG.	CD	0
4A	4A	CD	0
in	in	IN	0
a	a	DT	0
frontal	frontal	JJ	B-NP
sinus	sinus	NN	I-NP
.	.	.	0
FIG.	FIG.	NNP	0
5A	5A	NNP	0
is	is	VBZ	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
side	side	NN	I-NP
view	view	NN	I-NP
including	including	VBG	0
an	an	DT	0
expandable	expandable	JJ	B-NP
mesh	mesh	NN	I-NP
according	according	VBG	0
to	to	TO	0
another	another	DT	0
variation	variation	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
.	.	.	0
FIG.	FIG.	NNP	0
5B	5B	NNP	0
is	is	VBZ	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
side	side	NN	I-NP
view	view	NN	I-NP
of	of	IN	0
FIG.	FIG.	CD	0
5A	5A	CD	0
prior	prior	JJ	0
to	to	TO	0
expansion	expansion	NN	0
.	.	.	0
FIGS.	FIGS.	NNP	0
6A-6F	6A-6F	NNP	0
are	are	VBP	0
side	side	JJ	0
cross-sectional	cross-sectional	JJ	B-NP
view	view	NN	I-NP
of	of	IN	0
various	various	JJ	0
filament	filament	JJ	B-NP
anchoring	anchoring	JJ	0
mechanisms	mechanisms	NNS	0
.	.	.	0
FIGS.	FIGS.	NNP	0
7A-7R	7A-7R	NNP	0
are	are	VBP	0
perspective	perspective	JJ	B-NP
view	view	NN	I-NP
of	of	IN	0
various	various	JJ	0
cavity	cavity	JJ	B-NP
member	member	NN	I-NP
configuration	configuration	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
8A-8C	8A-8C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
coil-like	coil-like	JJ	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
9A-9C	9A-9C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
accordion-like	accordion-like	JJ	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
10A-10C	10A-10C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
mesh-like	mesh-like	JJ	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
11A-11C	11A-11C	NNP	0
depict	depict	JJ	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
star-like	star-like	JJ	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
12A-12C	12A-12C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
hexagonal	hexagonal	JJ	B-NP
shaped	shaped	JJ	I-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
13A-13C	13A-13C	NNP	0
depict	depict	JJ	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
end	end	NN	B-NP
view	view	NN	I-NP
of	of	IN	0
a	a	DT	0
furled	furled	JJ	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
sheet-like	sheet-like	JJ	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
14A-14C	14A-14C	NNP	0
depict	depict	JJ	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
15A-15C	15A-15C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
end	end	NN	B-NP
view	view	NN	I-NP
of	of	IN	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
.	.	.	0
FIGS.	FIGS.	NNP	0
16A-16C	16A-16C	NNP	0
depict	depict	JJ	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
end	end	NN	B-NP
view	view	NN	I-NP
of	of	IN	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
pliable	pliable	JJ	0
ribbon-like	ribbon-like	JJ	B-NP
or	or	CC	0
strip-like	strip-like	JJ	B-NP
filament	filament	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
17A-17C	17A-17C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
end	end	NN	B-NP
view	view	NN	I-NP
of	of	IN	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
configured	configured	NN	I-NP
as	as	IN	0
an	an	DT	0
expandable	expandable	JJ	B-NP
pleated	pleated	JJ	I-NP
tube	tube	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
18A-18C	18A-18C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
end	end	NN	B-NP
view	view	NN	I-NP
of	of	IN	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
made	made	VBN	0
from	from	IN	0
gel	gel	JJ	B-NP
foam	foam	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
19A-19C	19A-19C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
ostial	ostial	NN	B-NP
,	,	,	0
and	and	CC	0
cylindrical	cylindrical	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
having	having	VBG	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
lumen	lumen	NN	B-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
20A-20F	20A-20F	NNP	0
illustrate	illustrate	VBP	0
various	various	JJ	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
configuration	configuration	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
21	21	CD	0
depicts	depicts	VBZ	0
a	a	DT	0
perspective	perspective	NN	B-NP
view	view	NN	I-NP
of	of	IN	0
an	an	DT	0
exemplary	exemplary	JJ	B-NP
paranasal	paranasal	JJ	I-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
22A-22C	22A-22C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
side	side	NN	0
cross-sectional	cross-sectional	NN	0
,	,	,	0
and	and	CC	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
having	having	VBG	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
and	and	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
formed	formed	VBN	0
from	from	IN	0
multiple	multiple	JJ	0
loops	loops	NNS	0
of	of	IN	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
.	.	.	0
FIGS.	FIGS.	NNP	0
23A-23C	23A-23C	NNP	0
show	show	NN	0
perspective	perspective	NN	0
,	,	,	0
side	side	NN	0
cross-sectional	cross-sectional	NN	0
,	,	,	0
and	and	CC	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
having	having	VBG	0
a	a	DT	0
looped	looped	JJ	0
cavity	cavity	JJ	0
member	member	NN	0
and	and	CC	0
a	a	DT	0
nasal	nasal	JJ	B-NP
plate	plate	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
24A-24F	24A-24F	NNP	0
show	show	VBP	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
exemplary	exemplary	JJ	I-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
curve	curve	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
25	25	CD	0
is	is	VBZ	0
a	a	DT	0
graph	graph	NN	0
showing	showing	VBG	0
cumulative	cumulative	JJ	0
in	in	IN	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
vitro	vitro	JJ	I-NP
release	release	NN	I-NP
from	from	IN	0
various	various	JJ	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
over	over	IN	0
a	a	DT	0
30-day	30-day	JJ	0
time	time	NN	B-NP
period	period	NN	I-NP
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
of	of	IN	0
this	this	DT	0
invention	invention	NN	0
may	may	MD	0
take	take	VB	0
various	various	JJ	0
forms	forms	NNS	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
some	some	DT	0
are	are	VBP	0
designed	designed	VBN	0
to	to	TO	0
include	include	VB	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
and	and	CC	0
deliver	deliver	VB	0
active	active	JJ	0
agents	agents	NNS	0
for	for	IN	0
the	the	DT	0
treatment	treatment	NN	0
of	of	IN	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
sinus	sinus	JJ	B-NP
inflammation	inflammation	NN	I-NP
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
member	member	NN	0
may	may	MD	0
have	have	VB	0
a	a	DT	0
first	first	JJ	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
that	that	WDT	0
permits	permits	VBZ	0
it	it	PRP	0
to	to	TO	0
be	be	VB	0
inserted	inserted	VBN	0
through	through	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
or	or	CC	0
surgically	surgically	RB	0
created	created	VBN	B-NP
fenestration	fenestration	NN	I-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
second	second	JJ	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
upon	upon	IN	0
placement	placement	NN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
In	In	IN	0
this	this	DT	0
variation	variation	NN	0
,	,	,	0
once	once	RB	0
expanded	expanded	VBN	0
,	,	,	0
the	the	DT	0
structure	structure	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
generally	generally	RB	0
has	has	VBZ	0
a	a	DT	0
surface	surface	NN	0
area	area	NN	0
to	to	TO	0
volume	volume	NN	B-NP
ratio	ratio	NN	I-NP
that	that	WDT	0
is	is	VBZ	0
not	not	RB	0
substantially	substantially	RB	0
different	different	JJ	0
from	from	IN	0
the	the	DT	0
surface	surface	NN	0
area	area	NN	0
to	to	TO	0
volume	volume	NN	B-NP
ratio	ratio	NN	I-NP
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
in	in	IN	0
its	its	PRP$	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
.	.	.	0
This	This	DT	0
may	may	MD	0
be	be	VB	0
important	important	JJ	0
because	because	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
is	is	VBZ	0
a	a	DT	0
source	source	NN	0
of	of	IN	0
water	water	NN	0
needed	needed	VBN	0
for	for	IN	0
the	the	DT	0
release	release	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
from	from	IN	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
.	.	.	0
Thus	Thus	RB	0
,	,	,	0
if	if	IN	0
the	the	DT	0
surface	surface	NN	0
area	area	NN	0
of	of	IN	0
a	a	DT	0
device	device	NN	0
available	available	JJ	0
for	for	IN	0
contacting	contacting	VBG	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
is	is	VBZ	0
decreased	decreased	VBN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
in	in	IN	0
relation	relation	NN	0
to	to	TO	0
its	its	PRP$	0
volume	volume	NN	0
,	,	,	0
dissolution	dissolution	NN	0
(	(	-LRB-	0
and	and	CC	0
subsequent	subsequent	JJ	0
absorption	absorption	NN	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
should	should	MD	0
also	also	RB	0
be	be	VB	0
decreased	decreased	VBN	0
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
once	once	RB	0
expanded	expanded	VBN	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
may	may	MD	0
also	also	RB	0
substantially	substantially	RB	0
contact	contact	VB	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
.	.	.	0
The	The	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
generally	generally	RB	0
functions	functions	VBN	0
to	to	TO	0
position	position	NN	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
anchor	anchor	VB	0
the	the	DT	0
device	device	NN	0
at	at	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
,	,	,	0
middle	middle	JJ	B-NP
turbinate	turbinate	NN	I-NP
preventing	preventing	VBG	I-NP
lateralization	lateralization	NN	I-NP
,	,	,	0
occlusion	occlusion	VBG	0
of	of	IN	0
the	the	DT	0
middle	middle	JJ	B-NP
meatus	meatus	NN	I-NP
,	,	,	0
and	and	CC	0
formation	formation	NN	0
of	of	IN	0
tissue	tissue	NN	0
adhesions	adhesions	NN	0
.	.	.	0
The	The	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
located	located	VBN	0
at	at	IN	0
the	the	DT	0
proximal	proximal	JJ	B-NP
end	end	NN	I-NP
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
typically	typically	RB	0
functions	functions	VBN	0
to	to	TO	0
maintain	maintain	VB	0
patency	patency	VBN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
However	However	RB	0
,	,	,	0
as	as	RB	0
further	further	RB	0
described	described	VBN	0
below	below	RB	0
,	,	,	0
each	each	DT	0
component	component	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
may	may	MD	0
have	have	VB	0
various	various	JJ	0
functions	functions	NNS	0
,	,	,	0
depending	depending	VBG	0
on	on	IN	0
factors	factors	NNS	0
such	such	JJ	0
as	as	IN	0
the	the	DT	0
particular	particular	JJ	0
structure	structure	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
or	or	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
and	and	CC	0
whether	whether	IN	0
the	the	DT	0
component	component	NN	0
is	is	VBZ	0
capable	capable	JJ	0
of	of	IN	0
releasing	releasing	VBG	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
.	.	.	0
As	As	RB	0
used	used	VBN	0
herein	herein	NN	0
,	,	,	0
the	the	DT	0
terms	terms	NNS	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
and	and	CC	0
sinus	sinus	NN	B-NP
are	are	VBP	0
used	used	VBN	0
interchangeably	interchangeably	NN	0
,	,	,	0
and	and	CC	0
refer	refer	VBP	0
to	to	TO	0
all	all	DT	0
sinuses	sinuses	NN	0
,	,	,	0
i.e.	i.e.	FW	0
,	,	,	0
the	the	DT	0
maxillary	maxillary	NN	B-NP
,	,	,	0
frontal	frontal	NN	0
,	,	,	0
ethmoid	ethmoid	NN	B-NP
,	,	,	0
and	and	CC	0
sphenoidal	sphenoidal	JJ	B-NP
sinus	sinus	NN	I-NP
.	.	.	0
Each	Each	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
opens	opens	VBZ	0
into	into	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
cavity	cavity	NN	I-NP
through	through	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
As	As	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
1	1	CD	0
,	,	,	0
the	the	DT	0
maxillary	maxillary	JJ	B-NP
sinus	sinus	NN	I-NP
10	10	CD	0
opens	opens	NN	0
into	into	IN	0
nasal	nasal	CD	B-NP
cavity	cavity	CD	I-NP
12	12	CD	0
at	at	IN	0
maxillary	maxillary	CD	B-NP
sinus	sinus	CD	I-NP
ostium	ostium	CD	I-NP
14	14	CD	0
,	,	,	0
and	and	CC	0
the	the	DT	0
frontal	frontal	JJ	B-NP
sinus	sinus	NN	I-NP
16	16	CD	0
opens	opens	NN	0
into	into	IN	0
nasal	nasal	CD	B-NP
cavity	cavity	CD	I-NP
12	12	CD	0
at	at	IN	0
frontal	frontal	CD	B-NP
sinus	sinus	CD	I-NP
ostium	ostium	CD	I-NP
18	18	CD	0
.	.	.	0
As	As	RB	0
used	used	VBN	0
herein	herein	NN	0
,	,	,	0
the	the	DT	0
terms	terms	NNS	0
treat	treat	VBP	0
,	,	,	0
treating	treating	VBG	0
,	,	,	0
or	or	CC	0
treatment	treatment	NN	0
refer	refer	VBP	0
to	to	TO	0
the	the	DT	0
resolution	resolution	NN	0
,	,	,	0
reduction	reduction	NN	0
,	,	,	0
or	or	CC	0
prevention	prevention	NN	0
of	of	IN	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
or	or	CC	0
its	its	PRP$	0
symptom	symptom	NN	B-NP
,	,	,	0
prevention	prevention	NN	0
of	of	IN	0
complication	complication	NN	B-NP
attributable	attributable	JJ	0
to	to	TO	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
,	,	,	0
or	or	CC	0
provision	provision	NN	0
of	of	IN	0
a	a	DT	0
beneficial	beneficial	JJ	0
substance	substance	NN	0
,	,	,	0
to	to	TO	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
beneficial	beneficial	JJ	0
substance	substance	NN	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
promote	promote	VB	0
general	general	JJ	0
health	health	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
Once	Once	RB	0
expanded	expanded	VBN	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
may	may	MD	0
be	be	VB	0
configured	configured	VBN	0
to	to	TO	0
conform	conform	VB	0
at	at	IN	0
least	least	JJS	0
partly	partly	RB	0
to	to	TO	0
the	the	DT	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
and	and	CC	0
substantially	substantially	RB	0
contact	contact	VB	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
.	.	.	0
By	By	IN	0
substantially	substantially	RB	0
contact	contact	VB	0
it	it	PRP	0
is	is	VBZ	0
meant	meant	VBN	0
the	the	DT	0
percentage	percentage	NN	0
of	of	IN	0
surface	surface	NN	0
area	area	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
generally	generally	RB	0
required	required	VBN	0
to	to	TO	0
contact	contact	VB	0
a	a	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
(	(	-LRB-	0
sinus	sinus	NN	B-NP
mucosa	mucosa	NN	I-NP
)	)	-RRB-	0
that	that	WDT	0
provides	provides	VBZ	0
the	the	DT	0
appropriate	appropriate	JJ	0
release	release	NN	B-NP
kinetics	kinetics	NN	I-NP
for	for	IN	0
the	the	DT	0
active	active	JJ	0
agents	agents	NNS	0
throughout	throughout	IN	0
a	a	DT	0
treatment	treatment	NN	B-NP
period	period	NN	I-NP
,	,	,	0
for	for	IN	0
example	example	NN	0
,	,	,	0
for	for	IN	0
at	at	IN	0
least	least	JJS	0
one	one	CD	0
week	week	NN	B-NP
,	,	,	0
for	for	IN	0
at	at	IN	0
least	least	JJS	0
two	two	CD	0
weeks	weeks	NNS	0
,	,	,	0
for	for	IN	0
at	at	IN	0
least	least	JJS	0
three	three	CD	0
weeks	weeks	NNS	0
,	,	,	0
or	or	CC	0
for	for	IN	0
at	at	IN	0
least	least	JJS	0
four	four	CD	0
weeks	weeks	NNS	0
or	or	CC	0
more	more	JJR	0
.	.	.	0
Accordingly	Accordingly	RB	0
,	,	,	0
depending	depending	VBG	0
on	on	IN	0
the	the	DT	0
amount	amount	NN	0
of	of	IN	0
surface	surface	NN	0
area	area	NN	0
needed	needed	VBN	0
for	for	IN	0
contact	contact	NN	0
,	,	,	0
substantial	substantial	JJ	0
contact	contact	NN	0
may	may	MD	0
refer	refer	VB	0
to	to	TO	0
contact	contact	VB	0
of	of	IN	0
about	about	IN	0
10	10	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
%	%	NN	0
,	,	,	0
about	about	IN	0
20	20	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
%	%	NN	0
,	,	,	0
about	about	IN	0
30	30	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
%	%	NN	0
,	,	,	0
about	about	IN	0
40	40	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
%	%	NN	0
,	,	,	0
about	about	IN	0
50	50	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
%	%	NN	0
,	,	,	0
about	about	IN	0
60	60	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
%	%	NN	0
,	,	,	0
about	about	IN	0
70	70	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
%	%	NN	0
,	,	,	0
about	about	IN	0
80	80	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
%	%	NN	0
,	,	,	0
or	or	CC	0
about	about	IN	0
90	90	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
%	%	NN	0
of	of	IN	0
the	the	DT	0
surface	surface	NN	0
area	area	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
.	.	.	0
Importantly	Importantly	RB	0
,	,	,	0
the	the	DT	0
pressure	pressure	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
on	on	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
is	is	VBZ	0
sufficient	sufficient	JJ	0
for	for	IN	0
maintaining	maintaining	VBG	B-NP
contact	contact	NN	I-NP
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
against	against	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
but	but	CC	0
does	does	VBZ	0
not	not	RB	0
cause	cause	VB	0
significant	significant	JJ	0
damage	damage	NN	0
or	or	CC	0
necrosis	necrosis	JJ	0
to	to	TO	0
the	the	DT	0
mucosa	mucosa	NN	B-NP
.	.	.	0
As	As	RB	0
used	used	VBN	0
herein	herein	NN	0
,	,	,	0
the	the	DT	0
terms	terms	NNS	0
active	active	JJ	0
agent	agent	NN	B-NP
,	,	,	0
therapeutic	therapeutic	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
and	and	CC	0
drug	drug	NN	0
are	are	VBP	0
used	used	VBN	0
interchangeably	interchangeably	NNS	0
and	and	CC	0
refer	refer	VBP	0
to	to	TO	0
any	any	DT	0
substance	substance	NN	0
used	used	VBN	0
to	to	TO	0
treat	treat	VB	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
as	as	RB	0
used	used	VBN	0
herein	herein	NN	0
,	,	,	0
the	the	DT	0
term	term	NN	0
therapeutic	therapeutic	JJ	B-NP
amount	amount	NN	I-NP
refers	refers	VBZ	0
to	to	TO	0
a	a	DT	0
concentration	concentration	NN	B-NP
of	of	IN	0
active	active	JJ	0
agent	agent	NN	B-NP
that	that	WDT	0
has	has	VBZ	0
been	been	VBN	0
locally	locally	RB	0
delivered	delivered	VBN	0
to	to	TO	0
a	a	DT	0
sinus	sinus	NN	B-NP
or	or	CC	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
that	that	WDT	0
is	is	VBZ	0
appropriate	appropriate	JJ	0
to	to	TO	0
safely	safely	RB	0
treat	treat	VB	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
.	.	.	0
general	general	JJ	B-NP
element	element	NN	I-NP
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
described	described	VBD	0
here	here	RB	0
may	may	MD	0
be	be	VB	0
configured	configured	VBN	0
in	in	IN	0
a	a	DT	0
variety	variety	NN	0
of	of	IN	0
ways	ways	NNS	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
they	they	PRP	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
from	from	IN	0
one	one	CD	0
or	or	CC	0
more	more	JJR	0
filaments	filaments	NN	0
,	,	,	0
which	which	WDT	0
include	include	VBP	0
any	any	DT	0
linear	linear	JJ	0
structure	structure	NN	0
such	such	JJ	0
as	as	IN	0
strands	strands	NN	0
,	,	,	0
capillary	capillary	NN	B-NP
and	and	CC	0
tubular	tubular	JJ	0
and	and	CC	0
non-tubular	non-tubular	JJ	B-NP
structure	structure	NN	I-NP
,	,	,	0
but	but	CC	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
film	film	NN	0
or	or	CC	0
starting	starting	VBG	B-NP
material	material	NN	I-NP
sheet-like	sheet-like	JJ	I-NP
.	.	.	0
The	The	DT	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
of	of	IN	0
variable	variable	JJ	0
stiffness	stiffness	NN	0
and	and	CC	0
take	take	VB	0
a	a	DT	0
variety	variety	NN	0
of	of	IN	0
suitable	suitable	JJ	0
forms	forms	NNS	0
,	,	,	0
such	such	JJ	0
as	as	IN	0
threads	threads	NNS	0
,	,	,	0
ribbons	ribbons	NNS	0
,	,	,	0
strips	strips	NNS	0
,	,	,	0
beaded	beaded	JJ	B-NP
structure	structure	NN	I-NP
,	,	,	0
tubes	tubes	NNS	0
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
,	,	,	0
so	so	RB	0
long	long	RB	0
as	as	IN	0
they	they	PRP	0
are	are	VBP	0
flexible	flexible	JJ	0
enough	enough	JJ	0
to	to	TO	0
substantially	substantially	RB	0
contact	contact	VB	0
a	a	DT	0
portion	portion	NN	0
of	of	IN	0
a	a	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
after	after	IN	0
deployment	deployment	NN	0
,	,	,	0
exhibit	exhibit	VBG	0
the	the	DT	0
desired	desired	JJ	0
release	release	NN	B-NP
kinetics	kinetics	NN	I-NP
,	,	,	0
and	and	CC	0
deliver	deliver	VB	0
an	an	DT	0
amount	amount	NN	0
of	of	IN	0
drug	drug	NN	0
therapeutic	therapeutic	NN	0
for	for	IN	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
.	.	.	0
The	The	DT	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
of	of	IN	0
different	different	JJ	0
shapes	shapes	NNS	0
generally	generally	RB	0
,	,	,	0
and	and	CC	0
have	have	VB	0
a	a	DT	0
variety	variety	NN	0
of	of	IN	0
cross-sectional	cross-sectional	JJ	B-NP
shape	shape	NN	I-NP
,	,	,	0
as	as	RB	0
desired	desired	VBN	0
or	or	CC	0
as	as	IN	0
useful	useful	JJ	0
to	to	TO	0
maintain	maintain	VB	0
mucosal	mucosal	JJ	B-NP
contact	contact	NN	I-NP
and	and	CC	0
consistent	consistent	JJ	0
deployment	deployment	NN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIGS.	FIGS.	CD	0
2A-2M	2A-2M	CD	0
,	,	,	0
they	they	PRP	0
may	may	MD	0
be	be	VB	0
shaped	shaped	VBN	0
to	to	TO	0
be	be	VB	0
circular	circular	NNS	0
(	(	-LRB-	0
2A	2A	NNP	0
)	)	-RRB-	0
,	,	,	0
square	square	JJ	0
(	(	-LRB-	0
2B	2B	NNP	0
)	)	-RRB-	0
,	,	,	0
elliptical	elliptical	NNS	0
(	(	-LRB-	0
2C	2C	NNP	0
)	)	-RRB-	0
,	,	,	0
winged	winged	NNS	0
(	(	-LRB-	0
2D	2D	NNP	0
)	)	-RRB-	0
,	,	,	0
diamond-like	diamond-like	NNP	B-NP
(	(	-LRB-	0
2E	2E	NNP	0
)	)	-RRB-	0
,	,	,	0
rectangular	rectangular	NNS	0
(	(	-LRB-	0
2F	2F	NNP	0
)	)	-RRB-	0
,	,	,	0
wedged	wedged	NNS	0
(	(	-LRB-	0
2G	2G	NNP	0
)	)	-RRB-	0
,	,	,	0
ramped	ramped	NNS	0
(	(	-LRB-	0
2H	2H	NNP	0
)	)	-RRB-	0
,	,	,	0
tubular	tubular	JJ	0
(	(	-LRB-	0
2I	2I	NNP	0
)	)	-RRB-	0
,	,	,	0
parallelogram-like	parallelogram-like	NNP	B-NP
(	(	-LRB-	0
2J	2J	NNP	0
)	)	-RRB-	0
,	,	,	0
arc-like	arc-like	NNP	B-NP
(	(	-LRB-	0
2K	2K	NNP	0
)	)	-RRB-	0
,	,	,	0
dog	dog	NN	B-NP
bone	bone	NN	I-NP
/	/	NN	I-NP
dumbbell	dumbbell	NN	I-NP
shaped	shaped	FW	0
(	(	-LRB-	0
2L	2L	NNP	0
)	)	-RRB-	0
,	,	,	0
slightly	slightly	RB	0
concave	concave	JJ	0
(	(	-LRB-	0
2M	2M	NNP	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
on	on	IN	0
transverse	transverse	JJ	B-NP
cross-section	cross-section	NN	I-NP
.	.	.	0
If	If	IN	0
desired	desired	NN	0
,	,	,	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
combined	combined	VBN	0
to	to	TO	0
form	form	VB	0
woven	woven	JJ	0
structures	structures	NNS	0
such	such	JJ	0
as	as	IN	0
cords	cords	NN	0
,	,	,	0
ropes	ropes	NNS	0
,	,	,	0
braids	braids	NNS	0
,	,	,	0
mesh	mesh	NN	0
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
.	.	.	0
tubular	tubular	JJ	B-NP
filament	filament	NN	I-NP
may	may	MD	0
be	be	VB	0
combined	combined	VBN	0
into	into	IN	0
structures	structures	NNS	0
with	with	IN	0
multiple	multiple	JJ	0
lumen	lumen	NN	B-NP
,	,	,	0
in	in	IN	0
either	either	DT	0
concentric	concentric	NN	0
or	or	CC	0
adjacent	adjacent	JJ	0
configuration	configuration	NN	B-NP
,	,	,	0
or	or	CC	0
directly	directly	RB	0
formed	formed	VBN	0
as	as	IN	0
filaments	filaments	NN	0
with	with	IN	0
multiple	multiple	JJ	0
lumen	lumen	NN	B-NP
.	.	.	0
Films	Films	NNS	0
and	and	CC	0
sheets	sheets	NNS	0
may	may	MD	0
also	also	RB	0
include	include	VB	0
non-woven	non-woven	JJ	B-NP
mesh	mesh	NN	I-NP
and	and	CC	0
largely	largely	RB	0
two	two	CD	0
dimensional	dimensional	CD	B-NP
material	material	JJ	I-NP
,	,	,	0
where	where	WRB	0
dimensional	dimensional	JJ	B-NP
thickness	thickness	NN	I-NP
is	is	VBZ	0
much	much	RB	0
less	less	JJR	0
than	than	IN	0
dimensional	dimensional	JJ	B-NP
length	length	NN	I-NP
or	or	CC	0
width	width	NN	B-NP
.	.	.	0
Other	Other	JJ	0
materials	materials	NNS	0
such	such	JJ	0
as	as	IN	0
gelfoam	gelfoam	NN	B-NP
may	may	MD	0
form	form	VB	0
such	such	JJ	0
filaments	filaments	NN	0
upon	upon	IN	0
their	their	PRP$	0
application	application	NN	0
.	.	.	0
In	In	IN	0
some	some	DT	0
variations	variations	NNS	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
configured	configured	VBN	0
to	to	TO	0
include	include	VB	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
anchoring	anchoring	JJ	0
elements	elements	NNS	0
to	to	TO	0
help	help	VB	0
affix	affix	VBN	0
the	the	DT	0
filaments	filaments	NN	0
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
or	or	CC	0
otherwise	otherwise	RB	0
enhance	enhance	VB	0
contact	contact	NN	0
of	of	IN	0
the	the	DT	0
filaments	filaments	NN	0
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIGS.	FIGS.	CD	0
6A-6F	6A-6F	CD	0
,	,	,	0
the	the	DT	0
anchoring	anchoring	JJ	0
element	element	NN	0
may	may	MD	0
be	be	VB	0
one	one	CD	0
or	or	CC	0
more	more	JJR	0
hooks	hooks	NNS	0
(	(	-LRB-	0
6A	6A	NNP	0
)	)	-RRB-	0
,	,	,	0
spikes	spikes	NNS	0
(	(	-LRB-	0
6B	6B	NNP	0
)	)	-RRB-	0
,	,	,	0
opposed	opposed	VBN	0
spikes	spikes	NNS	0
(	(	-LRB-	0
6C	6C	NNP	0
)	)	-RRB-	0
,	,	,	0
arrows	arrows	NNS	0
(	(	-LRB-	0
6D	6D	NNP	0
)	)	-RRB-	0
,	,	,	0
ridges	ridges	NNS	0
(	(	-LRB-	0
6E	6E	NNP	0
)	)	-RRB-	0
,	,	,	0
barbs	barbs	NNS	0
(	(	-LRB-	0
6F	6F	NNP	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
6E	6E	CD	0
,	,	,	0
ridges	ridges	NNS	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
triangular	triangular	NNS	0
,	,	,	0
square	square	JJ	0
,	,	,	0
round	round	NN	0
,	,	,	0
semicircular	semicircular	NN	0
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
.	.	.	0
Cavity	Cavity	JJ	0
member	member	NN	0
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
are	are	VBP	0
generally	generally	RB	0
biodegradable	biodegradable	JJ	0
,	,	,	0
but	but	CC	0
they	they	PRP	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
made	made	VBN	0
to	to	TO	0
be	be	VB	0
nonbiodegradabla	nonbiodegradabla	NN	B-NP
.	.	.	0
Additionally	Additionally	RB	0
,	,	,	0
whether	whether	IN	0
formed	formed	VBN	0
as	as	IN	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	NN	B-NP
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
may	may	MD	0
be	be	VB	0
attached	attached	VBN	0
to	to	TO	0
a	a	DT	0
component	component	NN	0
,	,	,	0
for	for	IN	0
example	example	NN	0
,	,	,	0
a	a	DT	0
wire	wire	NN	0
or	or	CC	0
suture	suture	NN	B-NP
,	,	,	0
that	that	WDT	0
extends	extends	VBZ	0
from	from	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
and	and	CC	0
out	out	RB	0
through	through	IN	0
the	the	DT	0
ostium	ostium	NN	B-NP
,	,	,	0
which	which	WDT	0
could	could	MD	0
be	be	VB	0
grasped	grasped	VBN	0
by	by	IN	0
an	an	DT	0
instrument	instrument	NN	0
to	to	TO	0
remove	remove	VB	0
it	it	PRP	0
from	from	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NNS	0
are	are	VBP	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
a	a	DT	0
fringed	fringed	JJ	0
structure	structure	NN	0
.	.	.	0
As	As	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
3A	3A	CD	0
,	,	,	0
a	a	DT	0
cross-section	cross-section	JJ	0
of	of	IN	0
fringed	fringed	JJ	0
structure	structure	NN	0
20	20	CD	0
includes	includes	VBZ	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
or	or	CC	0
prongs	prongs	CD	0
22	22	CD	0
(	(	-LRB-	0
expanded	expanded	VBN	B-NP
configuration	configuration	NN	I-NP
)	)	-RRB-	0
.	.	.	0
Pliable	Pliable	NNP	0
filaments	filaments	VBD	0
22	22	CD	0
are	are	VBP	0
secured	secured	VBN	0
at	at	IN	0
their	their	PRP$	0
proximal	proximal	NN	B-NP
ends	ends	VBZ	0
24	24	CD	0
to	to	TO	0
a	a	DT	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
26	26	CD	0
.	.	.	0
Once	Once	RB	0
deployed	deployed	VBN	0
in	in	IN	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
such	such	JJ	0
as	as	IN	0
maxillary	maxillary	CD	B-NP
sinus	sinus	CD	I-NP
21	21	CD	0
in	in	IN	0
FIG.	FIG.	CD	0
3B	3B	CD	0
,	,	,	0
pliable	pliable	CD	0
filaments	filaments	CD	0
22	22	CD	0
radially	radially	NNS	0
expand	expand	VBP	0
,	,	,	0
unfurl	unfurl	NN	0
,	,	,	0
or	or	CC	0
otherwise	otherwise	RB	0
are	are	VBP	0
adapted	adapted	VBN	0
to	to	TO	0
undergo	undergo	VB	0
a	a	DT	0
change	change	NN	0
in	in	IN	0
configuration	configuration	NN	B-NP
after	after	IN	0
insertion	insertion	NN	0
into	into	IN	0
a	a	DT	0
sinus	sinus	NN	B-NP
,	,	,	0
to	to	TO	0
substantially	substantially	RB	0
contact	contact	VB	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
23	23	CD	0
and	and	CC	0
to	to	TO	0
deliver	deliver	VB	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
into	into	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
21	21	CD	0
.	.	.	0
The	The	DT	0
length	length	NN	0
of	of	IN	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
22	22	CD	0
is	is	VBZ	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
1	1	CD	0
cm	cm	NNS	0
and	and	CC	0
about	about	IN	0
6	6	CD	0
cm	cm	NN	0
,	,	,	0
more	more	RBR	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
2	2	CD	0
cm	cm	NN	0
to	to	TO	0
about	about	RB	0
6	6	CD	0
cm	cm	NN	0
,	,	,	0
and	and	CC	0
more	more	RBR	0
usually	usually	RB	0
still	still	RB	0
between	between	IN	0
about	about	IN	0
3	3	CD	0
cm	cm	NNS	0
and	and	CC	0
6	6	CD	0
cm	cm	NNS	0
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
26	26	CD	0
is	is	VBZ	0
placed	placed	VBN	0
at	at	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
25	25	CD	0
to	to	TO	0
maintain	maintain	VB	0
ostium	ostium	JJ	B-NP
patency	patency	NN	I-NP
so	so	IN	0
that	that	DT	0
drainage	drainage	NN	0
from	from	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
21	21	CD	0
to	to	TO	0
the	the	DT	0
nasal	nasal	JJ	B-NP
cavity	cavity	NN	I-NP
is	is	VBZ	0
uninterrupted	uninterrupted	VBN	0
.	.	.	0
Nasal	Nasal	JJ	B-NP
portion	portion	NN	I-NP
28	28	CD	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
provided	provided	VBN	0
on	on	IN	0
the	the	DT	0
proximal	proximal	JJ	B-NP
end	end	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
Nasal	Nasal	JJ	B-NP
portion	portion	NN	I-NP
28	28	CD	0
extends	extends	NN	0
into	into	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
cavity	cavity	NN	I-NP
and	and	CC	0
may	may	MD	0
minimize	minimize	VB	0
lateralization	lateralization	VBN	0
of	of	IN	0
the	the	DT	0
middle	middle	JJ	B-NP
turbinate	turbinate	NN	I-NP
to	to	TO	0
the	the	DT	0
lateral	lateral	JJ	B-NP
nasal	nasal	JJ	I-NP
wall	wall	NN	I-NP
and	and	CC	0
ostia	ostia	JJ	B-NP
opening	opening	NN	I-NP
,	,	,	0
further	further	RB	0
reducing	reducing	VBG	0
the	the	DT	0
possible	possible	JJ	0
risk	risk	NN	0
of	of	IN	0
occlusion	occlusion	NN	B-NP
and	and	CC	0
adhesion	adhesion	JJ	B-NP
formation	formation	NN	I-NP
in	in	IN	0
the	the	DT	0
middle	middle	JJ	B-NP
meatus	meatus	NN	I-NP
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
shown	shown	VBN	0
in	in	IN	0
FIGS.	FIGS.	NNP	0
4A	4A	NNP	0
and	and	CC	0
4B	4B	NNP	0
,	,	,	0
pliable	pliable	CD	0
filaments	filaments	CD	0
32	32	CD	0
are	are	VBP	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
a	a	DT	0
fringed	fringed	JJ	0
structure	structure	NN	0
30	30	CD	0
in	in	IN	0
a	a	DT	0
frontal	frontal	JJ	B-NP
sinus	sinus	NN	I-NP
31	31	CD	0
.	.	.	0
Like	Like	IN	0
in	in	IN	0
FIGS.	FIGS.	NNP	0
3A	3A	NNP	0
and	and	CC	0
3B	3B	NNP	0
,	,	,	0
pliable	pliable	CD	0
filaments	filaments	CD	0
32	32	CD	0
are	are	VBP	0
secured	secured	VBN	0
to	to	TO	0
ostial	ostial	VB	0
member	member	NN	0
36	36	CD	0
at	at	IN	0
their	their	PRP$	0
proximal	proximal	NN	B-NP
ends	ends	VBZ	0
34	34	CD	0
,	,	,	0
and	and	CC	0
once	once	RB	0
deployed	deployed	VBN	0
,	,	,	0
substantially	substantially	RB	0
contact	contact	VB	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
38	38	CD	0
to	to	TO	0
deliver	deliver	VB	0
drug	drug	NN	0
into	into	IN	0
frontal	frontal	CD	B-NP
sinus	sinus	CD	I-NP
31	31	CD	0
.	.	.	0
The	The	DT	0
length	length	NN	0
of	of	IN	0
pliable	pliable	CD	0
filaments	filaments	CD	0
32	32	CD	0
are	are	VBP	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
1	1	CD	0
cm	cm	NNS	0
and	and	CC	0
about	about	IN	0
5	5	CD	0
cm	cm	NN	0
,	,	,	0
and	and	CC	0
more	more	RBR	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
2	2	CD	0
cm	cm	NNS	0
and	and	CC	0
about	about	IN	0
5	5	CD	0
cm	cm	NNS	0
.	.	.	0
However	However	RB	0
,	,	,	0
because	because	IN	0
of	of	IN	0
the	the	DT	0
longer	longer	JJR	0
passageway	passageway	NN	0
from	from	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
cavity	cavity	NN	I-NP
to	to	TO	0
the	the	DT	0
frontal	frontal	JJ	B-NP
sinus	sinus	NN	I-NP
ostium	ostium	VBD	0
33	33	CD	0
than	than	IN	0
to	to	TO	0
the	the	DT	0
maxillary	maxillary	JJ	B-NP
ostium	ostium	NN	I-NP
,	,	,	0
and	and	CC	0
because	because	IN	0
the	the	DT	0
frontal	frontal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
30	30	CD	0
is	is	VBZ	0
subject	subject	JJ	0
to	to	TO	0
gravitational	gravitational	VB	0
pull	pull	VB	0
,	,	,	0
as	as	RB	0
well	well	RB	0
as	as	IN	0
encompasses	encompasses	VBG	0
a	a	DT	0
longer	longer	RB	0
narrower	narrower	JJR	0
cavity	cavity	JJ	B-NP
prone	prone	JJ	0
to	to	TO	0
stenosis	stenosis	VB	0
,	,	,	0
adhesions	adhesions	NN	0
and	and	CC	0
scarring	scarring	NN	0
,	,	,	0
the	the	DT	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
36	36	CD	0
is	is	VBZ	0
generally	generally	RB	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
longer	longer	JJR	0
in	in	IN	0
a	a	DT	0
frontal	frontal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
.	.	.	0
However	However	RB	0
,	,	,	0
the	the	DT	0
length	length	NN	0
of	of	IN	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
36	36	CD	0
may	may	MD	0
be	be	VB	0
shortened	shortened	VBN	0
if	if	IN	0
the	the	DT	0
fringed	fringed	JJ	0
structure	structure	NN	0
30	30	CD	0
(	(	-LRB-	0
or	or	CC	0
other	other	JJ	0
cavity	cavity	JJ	0
member	member	NN	0
)	)	-RRB-	0
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
anchor	anchor	VB	0
the	the	DT	0
device	device	NN	0
within	within	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
,	,	,	0
or	or	CC	0
if	if	IN	0
the	the	DT	0
risk	risk	NN	0
of	of	IN	0
such	such	JJ	0
aforementioned	aforementioned	JJ	B-NP
complication	complication	NN	I-NP
has	has	VBZ	0
been	been	VBN	0
reduced	reduced	VBN	0
through	through	IN	0
varying	varying	VBG	0
surgical	surgical	JJ	B-NP
technique	technique	NN	I-NP
(	(	-LRB-	0
more	more	JJR	0
or	or	CC	0
less	less	RBR	0
extensive	extensive	JJ	0
)	)	-RRB-	0
or	or	CC	0
anatomical	anatomical	JJ	B-NP
variation	variation	NN	I-NP
.	.	.	0
Turning	Turning	VBG	0
to	to	TO	0
the	the	DT	0
variation	variation	NN	0
shown	shown	VBN	0
in	in	IN	0
FIGS.	FIGS.	NNP	0
5A	5A	NNP	0
and	and	CC	0
5B	5B	NNP	0
,	,	,	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NNS	0
are	are	VBP	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
a	a	DT	0
flexible	flexible	JJ	0
mesh	mesh	NN	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	NNP	0
5B	5B	NNP	0
(	(	-LRB-	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
)	)	-RRB-	0
,	,	,	0
flexible	flexible	JJ	0
mesh	mesh	NN	0
40	40	CD	0
is	is	VBZ	0
secured	secured	VBN	0
to	to	TO	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
42	42	CD	0
(	(	-LRB-	0
and	and	CC	0
in	in	IN	0
some	some	DT	0
instances	instances	NNS	0
,	,	,	0
also	also	RB	0
to	to	TO	0
nasal	nasal	VB	B-NP
portion	portion	NN	I-NP
46	46	CD	0
)	)	-RRB-	0
by	by	IN	0
methods	methods	NNS	0
well	well	RB	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
by	by	IN	0
welding	welding	NN	0
,	,	,	0
annealing	annealing	NN	0
,	,	,	0
heat	heat	NN	B-NP
bonding	bonding	NN	I-NP
,	,	,	0
attachment	attachment	JJ	B-NP
band	band	NN	I-NP
or	or	CC	0
adhesives	adhesives	JJ	0
such	such	JJ	0
as	as	IN	0
thermoplastic	thermoplastic	JJ	B-NP
adhesive	adhesive	JJ	I-NP
,	,	,	0
thermosetting	thermosetting	JJ	0
adhesives	adhesives	NNS	0
,	,	,	0
rubber-resin	rubber-resin	JJ	B-NP
blend	blend	JJ	I-NP
adhesive	adhesive	JJ	I-NP
,	,	,	0
and	and	CC	0
other	other	JJ	0
adhesives	adhesives	NNS	0
well	well	RB	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
.	.	.	0
Upon	Upon	IN	0
expansion	expansion	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
5A	5A	CD	0
,	,	,	0
flexible	flexible	JJ	0
mesh	mesh	NN	0
40	40	CD	0
forms	forms	NNS	0
a	a	DT	0
spherical	spherical	JJ	B-NP
structure	structure	NN	I-NP
capable	capable	NN	0
of	of	IN	0
at	at	IN	0
least	least	JJS	0
partially	partially	RB	0
conforming	conforming	VBG	0
to	to	TO	0
the	the	DT	0
shape	shape	NN	0
of	of	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
The	The	DT	0
weave	weave	NN	0
of	of	IN	0
the	the	DT	0
mesh	mesh	NN	0
may	may	MD	0
be	be	VB	0
adjusted	adjusted	VBN	0
to	to	TO	0
be	be	VB	0
looser	looser	JJR	0
or	or	CC	0
tighter	tighter	JJR	0
,	,	,	0
or	or	CC	0
the	the	DT	0
width	width	NN	B-NP
of	of	IN	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
adjusted	adjusted	VBN	0
to	to	TO	0
correspondingly	correspondingly	VB	0
adjust	adjust	VB	0
the	the	DT	0
flexibility	flexibility	NN	0
of	of	IN	0
the	the	DT	0
mesh	mesh	NN	0
.	.	.	0
The	The	DT	0
flexible	flexible	JJ	0
mesh	mesh	NN	0
may	may	MD	0
be	be	VB	0
expanded	expanded	VBN	0
to	to	TO	0
a	a	DT	0
diameter	diameter	NN	0
between	between	IN	0
about	about	IN	0
1	1	CD	0
cm	cm	NN	0
to	to	TO	0
about	about	RB	0
5	5	CD	0
cm	cm	NN	0
,	,	,	0
and	and	CC	0
more	more	RBR	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
2	2	CD	0
cm	cm	NN	0
to	to	TO	0
about	about	RB	0
5	5	CD	0
cm	cm	NN	0
,	,	,	0
and	and	CC	0
as	as	RB	0
further	further	RB	0
described	described	VBN	0
below	below	RB	0
,	,	,	0
may	may	MD	0
form	form	VB	0
a	a	DT	0
self-expanding	self-expanding	JJ	0
,	,	,	0
controllably	controllably	JJ	B-NP
expandable	expandable	NN	I-NP
,	,	,	0
or	or	CC	0
balloon	balloon	NN	0
expandable	expandable	VBZ	0
cavity	cavity	JJ	0
member	member	NN	0
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
member	member	NN	0
may	may	MD	0
be	be	VB	0
of	of	IN	0
various	various	JJ	0
other	other	JJ	0
designs	designs	NNS	0
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
70	70	CD	0
is	is	VBZ	0
configured	configured	VBN	0
as	as	IN	0
a	a	DT	0
single	single	JJ	0
pliable	pliable	NN	0
filament	filament	VBD	B-NP
72	72	CD	0
(	(	-LRB-	0
FIG.	FIG.	NNP	0
7A	7A	NNP	0
)	)	-RRB-	0
.	.	.	0
Single	Single	JJ	B-NP
pliable	pliable	NN	I-NP
filament	filament	VBD	I-NP
72	72	CD	0
may	may	MD	0
curve	curve	VB	0
in	in	IN	0
such	such	PDT	0
a	a	DT	0
way	way	NN	0
to	to	TO	0
at	at	IN	0
least	least	JJS	0
partially	partially	RB	0
conform	conform	VB	0
to	to	TO	0
the	the	DT	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
implantation	implantation	NN	B-NP
sinus	sinus	NN	I-NP
and	and	CC	0
substantially	substantially	RB	0
contact	contact	VB	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
7B	7B	NN	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
74	74	CD	0
comprises	comprises	VBZ	0
a	a	DT	0
single	single	JJ	0
pliable	pliable	JJ	0
filament	filament	JJ	0
configured	configured	NN	0
as	as	IN	0
a	a	DT	0
coil	coil	JJ	0
76	76	CD	0
.	.	.	0
The	The	DT	0
number	number	NN	0
of	of	IN	0
turns	turns	NNS	0
of	of	IN	0
the	the	DT	0
coil	coil	NN	0
will	will	MD	0
vary	vary	VB	0
depending	depending	VBG	0
on	on	IN	0
such	such	JJ	0
factors	factors	NNS	0
as	as	IN	0
the	the	DT	0
implantation	implantation	NN	B-NP
sinus	sinus	NN	I-NP
,	,	,	0
placement	placement	NN	0
and	and	CC	0
deployment	deployment	JJ	B-NP
technique	technique	NN	I-NP
used	used	VBN	0
,	,	,	0
and	and	CC	0
whether	whether	IN	0
or	or	CC	0
not	not	RB	0
the	the	DT	0
coil	coil	NN	0
is	is	VBZ	0
to	to	TO	0
be	be	VB	0
used	used	VBN	0
as	as	IN	0
an	an	DT	0
anchor	anchor	NN	0
or	or	CC	0
for	for	IN	0
drug	drug	NN	B-NP
delivery	delivery	NN	I-NP
,	,	,	0
and	and	CC	0
flexibility	flexibility	NN	0
of	of	IN	0
the	the	DT	0
filament	filament	NN	B-NP
.	.	.	0
Similarly	Similarly	RB	0
,	,	,	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
78	78	CD	0
may	may	MD	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
a	a	DT	0
single	single	JJ	0
pliable	pliable	JJ	0
filament	filament	JJ	0
configured	configured	NN	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
inserted	inserted	VBN	0
as	as	IN	0
a	a	DT	0
random	random	JJ	0
coil	coil	NN	0
80	80	CD	0
(	(	-LRB-	0
FIG.	FIG.	NNP	0
7C	7C	NNP	0
)	)	-RRB-	0
.	.	.	0
In	In	IN	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
one	one	CD	0
or	or	CC	0
more	more	JJR	0
arced	arced	NN	B-NP
or	or	CC	0
looped	looped	JJ	0
filaments	filaments	NN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
in	in	IN	0
FIG.	FIG.	CD	0
7D	7D	CD	0
,	,	,	0
the	the	DT	0
expanded	expanded	JJ	0
cavity	cavity	JJ	0
member	member	NN	0
82	82	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
two	two	CD	0
pliable	pliable	CD	0
filaments	filaments	CD	0
84	84	CD	0
.	.	.	0
Pliable	Pliable	NNP	0
filaments	filaments	VBD	0
84	84	CD	0
are	are	VBP	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
concentric	concentric	JJ	B-NP
loop	loop	NN	I-NP
crossing	crossing	VBG	0
each	each	DT	0
other	other	JJ	0
.	.	.	0
The	The	DT	0
loops	loops	NNS	0
are	are	VBP	0
usually	usually	RB	0
affixed	affixed	VBN	0
to	to	TO	0
each	each	DT	0
other	other	JJ	0
by	by	IN	0
methods	methods	NNS	0
described	described	VBD	0
above	above	RB	0
to	to	TO	0
form	form	VB	0
a	a	DT	0
distal	distal	JJ	B-NP
apex	apex	NN	I-NP
86	86	CD	0
.	.	.	0
The	The	DT	0
proximal	proximal	NN	B-NP
ends	ends	VBZ	0
88	88	CD	0
of	of	IN	0
pliable	pliable	CD	0
filaments	filaments	CD	0
84	84	CD	0
may	may	MD	0
be	be	VB	0
joined	joined	VBN	0
and	and	CC	0
otherwise	otherwise	RB	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
230	230	CD	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
232	232	CD	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
21	21	CD	0
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
expanded	expanded	VBN	0
cavity	cavity	JJ	0
member	member	NN	0
90	90	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
pliable	pliable	CD	0
filaments	filaments	CD	0
92	92	CD	0
configured	configured	NN	0
to	to	TO	0
form	form	VB	0
multiple	multiple	JJ	0
free	free	JJ	0
loops	loops	NNS	0
(	(	-LRB-	0
FIG.	FIG.	NNP	0
7E	7E	NNP	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
proximal	proximal	NN	B-NP
ends	ends	VBZ	0
94	94	CD	0
of	of	IN	0
pliable	pliable	CD	0
filaments	filaments	CD	0
92	92	CD	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
joined	joined	VBN	0
or	or	CC	0
otherwise	otherwise	RB	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
In	In	IN	0
yet	yet	RB	0
a	a	DT	0
further	further	JJ	0
variation	variation	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
7F	7F	CD	0
,	,	,	0
the	the	DT	0
expanded	expanded	JJ	0
cavity	cavity	JJ	0
member	member	NN	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
pliable	pliable	CD	0
filaments	filaments	CD	0
98	98	CD	0
configured	configured	NN	0
as	as	IN	0
a	a	DT	0
whisk-like	whisk-like	JJ	B-NP
structure	structure	NN	I-NP
.	.	.	0
The	The	DT	0
spacing	spacing	JJ	0
100	100	CD	0
between	between	IN	0
the	the	DT	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
varied	varied	VBN	0
depending	depending	VBG	0
on	on	IN	0
the	the	DT	0
particular	particular	JJ	0
desired	desired	JJ	0
cavity	cavity	JJ	B-NP
member	member	NN	I-NP
configuration	configuration	NN	I-NP
.	.	.	0
The	The	DT	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
shaped	shaped	VBN	0
by	by	IN	0
adjusting	adjusting	VBG	0
their	their	PRP$	0
degree	degree	NN	0
of	of	IN	0
flexibility	flexibility	NN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
by	by	IN	0
plasticizer	plasticizer	NN	B-NP
addition	addition	NN	I-NP
,	,	,	0
use	use	NN	0
of	of	IN	0
various	various	JJ	0
molding	molding	NN	0
,	,	,	0
casting	casting	VBG	0
,	,	,	0
bonding	bonding	NN	0
,	,	,	0
and	and	CC	0
extrusion	extrusion	JJ	B-NP
technique	technique	NN	I-NP
,	,	,	0
and	and	CC	0
by	by	IN	0
other	other	JJ	0
methods	methods	NNS	0
well	well	RB	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
.	.	.	0
The	The	DT	0
angle	angle	NN	0
between	between	IN	0
each	each	DT	0
looped	looped	JJ	0
filament	filament	NN	B-NP
may	may	MD	0
also	also	RB	0
be	be	VB	0
varied	varied	VBN	0
depending	depending	VBG	0
on	on	IN	0
the	the	DT	0
particular	particular	JJ	0
desired	desired	JJ	0
cavity	cavity	JJ	B-NP
member	member	NN	I-NP
configuration	configuration	NN	I-NP
.	.	.	0
Any	Any	DT	0
number	number	NN	0
of	of	IN	0
filaments	filaments	NNS	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
employed	employed	VBN	0
to	to	TO	0
fabricate	fabricate	VB	0
devices	devices	NNS	0
with	with	IN	0
any	any	DT	0
number	number	NN	0
of	of	IN	0
arced	arced	NN	B-NP
or	or	CC	0
looped	looped	JJ	0
cavity	cavity	JJ	0
members	members	NNS	0
.	.	.	0
In	In	IN	0
yet	yet	RB	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
from	from	IN	0
ribbon	ribbon	NN	0
or	or	CC	0
strip-like	strip-like	JJ	B-NP
filament	filament	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
7G	7G	CD	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
100	100	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
strip-like	strip-like	JJ	B-NP
sub-filament	sub-filament	NN	I-NP
102	102	CD	0
resulting	resulting	VBG	0
from	from	IN	0
slitting	slitting	VBG	0
a	a	DT	0
single	single	JJ	0
tubular	tubular	JJ	B-NP
filament	filament	JJ	I-NP
structure	structure	NN	I-NP
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
7H	7H	CD	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
104	104	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
strip-like	strip-like	JJ	B-NP
filament	filament	NN	I-NP
106	106	CD	0
configured	configured	NN	0
as	as	IN	0
a	a	DT	0
pronged	pronged	JJ	B-NP
structure	structure	NN	I-NP
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
71	71	CD	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
108	108	CD	0
is	is	VBZ	0
made	made	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
strip-like	strip-like	JJ	B-NP
filament	filament	NN	I-NP
110	110	CD	0
resulting	resulting	VBG	0
from	from	IN	0
slitting	slitting	NN	0
and	and	CC	0
deformation	deformation	NN	B-NP
of	of	IN	0
children	children	NNS	0
filaments	filaments	VBN	0
from	from	IN	0
the	the	DT	0
end	end	NN	0
of	of	IN	0
a	a	DT	0
single	single	JJ	0
parent	parent	NN	0
tubular	tubular	JJ	B-NP
filament	filament	JJ	I-NP
structure	structure	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
7J-7O	7J-7O	NNP	0
show	show	VBP	0
yet	yet	RB	0
further	further	RBR	0
cavity	cavity	JJ	0
member	member	NN	0
design	design	NN	0
variations	variations	NNS	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
7J	7J	CD	0
,	,	,	0
cavity	cavity	JJ	0
member	member	NN	0
112	112	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
corrugated	corrugated	JJ	0
ribbon-like	ribbon-like	JJ	B-NP
filament	filament	NN	I-NP
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
7K	7K	CD	0
,	,	,	0
cavity	cavity	JJ	0
member	member	NN	0
116	116	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
filaments	filaments	JJ	0
configured	configured	NN	0
like	like	IN	0
springs	springs	CD	0
118	118	CD	0
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
member	member	NN	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
filaments	filaments	JJ	0
122	122	CD	0
comprising	comprising	CD	B-NP
gelfoam	gelfoam	NN	I-NP
.	.	.	0
FIGS.	FIGS.	NNP	0
7M-7O	7M-7O	NNP	0
also	also	RB	0
include	include	VB	0
features	features	NNS	0
allowing	allowing	VBG	0
the	the	DT	0
irreversible	irreversible	JJ	0
deployment	deployment	NN	0
of	of	IN	0
one	one	CD	0
or	or	CC	0
more	more	JJR	0
filaments	filaments	NN	0
in	in	IN	0
an	an	DT	0
open	open	JJ	0
or	or	CC	0
tensed	tensed	JJ	0
configuration	configuration	NN	B-NP
using	using	VBG	0
ridges	ridges	NNS	0
(	(	-LRB-	0
for	for	IN	0
example	example	NN	0
134	134	CD	0
,	,	,	0
136	136	CD	0
)	)	-RRB-	0
on	on	IN	0
the	the	DT	0
filaments	filaments	NN	0
and	and	CC	0
opposing	opposing	VBG	B-NP
ridge	ridge	NN	I-NP
upon	upon	IN	0
the	the	DT	0
adjacent	adjacent	JJ	0
lumen	lumen	NN	B-NP
or	or	CC	0
other	other	JJ	0
structures	structures	NNS	0
at	at	IN	0
their	their	PRP$	0
insertion	insertion	JJ	B-NP
site	site	NN	I-NP
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
7M	7M	CD	0
,	,	,	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
124	124	CD	0
consisting	consisting	NN	0
of	of	IN	0
a	a	DT	0
single	single	JJ	0
ridged	ridged	JJ	0
loop	loop	NN	0
is	is	VBZ	0
inserted	inserted	VBN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
and	and	CC	0
against	against	IN	0
the	the	DT	0
sinus	sinus	JJ	0
wall	wall	NN	0
(	(	-LRB-	0
arrows	arrows	LS	0
)	)	-RRB-	0
through	through	IN	0
a	a	DT	0
lumen	lumen	NN	B-NP
with	with	IN	0
an	an	DT	0
opposing	opposing	VBG	B-NP
ridge	ridge	CD	I-NP
125	125	CD	0
on	on	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
126	126	CD	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
7N	7N	CD	0
,	,	,	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
128	128	CD	0
consisting	consisting	NN	0
of	of	IN	0
two	two	CD	0
opposed	opposed	VBD	0
loops	loops	CD	0
129	129	CD	0
is	is	VBZ	0
similarly	similarly	RB	0
inserted	inserted	VBN	0
.	.	.	0
These	These	DT	0
ridges	ridges	JJ	0
130	130	CD	0
may	may	MD	0
alternatively	alternatively	RB	0
deform	deform	VB	0
the	the	DT	0
structure	structure	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
member	member	NN	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
7O	7O	CD	0
,	,	,	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
131	131	CD	0
of	of	IN	0
the	the	DT	0
type	type	NN	0
described	described	VBD	0
in	in	IN	0
above	above	JJ	0
in	in	IN	0
FIG.	FIG.	NNP	0
7I	7I	NNP	0
is	is	VBZ	0
modified	modified	VBN	0
by	by	IN	0
the	the	DT	0
addition	addition	NN	B-NP
of	of	IN	0
ridges	ridges	CD	0
133	133	CD	0
on	on	IN	0
the	the	DT	0
interior	interior	NN	0
of	of	IN	0
strip-like	strip-like	JJ	B-NP
filament	filament	NN	I-NP
135	135	CD	0
,	,	,	0
and	and	CC	0
an	an	DT	0
additional	additional	JJ	0
interior	interior	JJ	0
tubular	tubular	JJ	B-NP
member	member	NN	I-NP
with	with	IN	0
opposing	opposing	VBG	B-NP
ridge	ridge	NN	I-NP
137	137	CD	0
positioned	positioned	JJ	0
concentrically	concentrically	NN	0
within	within	IN	0
the	the	DT	0
parent	parent	NN	0
slit	slit	NN	0
tube	tube	NN	0
.	.	.	0
The	The	DT	0
device	device	NN	0
's	's	POS	0
cavity	cavity	JJ	B-NP
member	member	NN	I-NP
strip-like	strip-like	JJ	I-NP
filament	filament	NN	I-NP
135	135	CD	0
are	are	VBP	0
deployed	deployed	VBN	0
through	through	IN	0
their	their	PRP$	0
deformation	deformation	NN	B-NP
along	along	IN	0
the	the	DT	0
intersection	intersection	NN	B-NP
of	of	IN	0
the	the	DT	0
strip	strip	NN	0
ridges	ridges	NNS	0
and	and	CC	0
those	those	DT	0
of	of	IN	0
the	the	DT	0
opposing	opposing	VBG	0
interior	interior	JJ	0
ridges	ridges	NNS	0
as	as	IN	0
the	the	DT	0
concentric	concentric	JJ	B-NP
member	member	NN	I-NP
137	137	CD	0
is	is	VBZ	0
independently	independently	RB	0
pulled	pulled	VBN	0
back	back	RP	0
(	(	-LRB-	0
towards	towards	IN	0
the	the	DT	0
proximal	proximal	JJ	B-NP
direction	direction	NN	I-NP
)	)	-RRB-	0
while	while	IN	0
maintaining	maintaining	VBG	0
constant	constant	JJ	0
the	the	DT	0
position	position	NN	0
of	of	IN	0
the	the	DT	0
external	external	JJ	B-NP
sinus	sinus	JJ	I-NP
cavity	cavity	JJ	I-NP
parent	parent	NN	I-NP
slit	slit	NN	I-NP
tube	tube	NN	I-NP
.	.	.	0
The	The	DT	0
result	result	NN	0
is	is	VBZ	0
a	a	DT	0
splayed	splayed	NN	0
and	and	CC	0
deformed	deformed	JJ	0
open	open	JJ	0
pattern	pattern	NN	0
of	of	IN	0
slit	slit	JJ	0
children	children	NNS	0
filaments	filaments	VBN	0
along	along	IN	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
7R	7R	CD	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
132	132	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
filaments	filaments	CD	0
134	134	CD	0
woven	woven	NN	0
as	as	IN	0
a	a	DT	0
mesh	mesh	NN	0
and	and	CC	0
configured	configured	NN	0
as	as	IN	0
a	a	DT	0
funnel-type	funnel-type	JJ	B-NP
structure	structure	NN	I-NP
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
film	film	NN	0
,	,	,	0
non-woven	non-woven	NNP	B-NP
,	,	,	0
or	or	CC	0
sheet-like	sheet-like	JJ	B-NP
material	material	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
film	film	NN	0
or	or	CC	0
sheet	sheet	NN	0
may	may	MD	0
be	be	VB	0
pleated	pleated	NNS	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIGS.	FIGS.	NNP	0
7P	7P	NNP	0
and	and	CC	0
7Q	7Q	NNP	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
7P	7P	CD	0
the	the	DT	0
sheet	sheet	NN	0
140	140	CD	0
has	has	VBZ	0
pleats	pleats	CD	0
138	138	CD	0
that	that	WDT	0
allow	allow	VBP	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
136	136	CD	0
to	to	TO	0
be	be	VB	0
configured	configured	VBN	0
as	as	IN	0
a	a	DT	0
pleated	pleated	JJ	0
cone	cone	NN	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
7Q	7Q	CD	0
,	,	,	0
the	the	DT	0
sheet	sheet	NN	0
142	142	CD	0
has	has	VBZ	0
pleats	pleats	CD	0
144	144	CD	0
that	that	WDT	0
allow	allow	VBP	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
146	146	CD	0
to	to	TO	0
be	be	VB	0
configured	configured	VBN	0
as	as	IN	0
a	a	DT	0
pleated	pleated	JJ	0
fan	fan	NN	0
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
may	may	MD	0
be	be	VB	0
adapted	adapted	VBN	0
to	to	TO	0
self-expand	self-expand	JJ	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
if	if	IN	0
they	they	PRP	0
are	are	VBP	0
made	made	VBN	0
from	from	IN	0
a	a	DT	0
shape	shape	NN	B-NP
memory	memory	NN	I-NP
polymer	polymer	NN	I-NP
or	or	CC	0
if	if	IN	0
they	they	PRP	0
are	are	VBP	0
constrained	constrained	VBN	0
by	by	IN	0
a	a	DT	0
sheath	sheath	JJ	0
prior	prior	JJ	0
to	to	TO	0
sinus	sinus	VB	B-NP
insertion	insertion	NN	I-NP
and	and	CC	0
deployed	deployed	VBN	0
in	in	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
after	after	IN	0
retraction	retraction	NN	0
of	of	IN	0
the	the	DT	0
sheath	sheath	NN	0
.	.	.	0
They	They	PRP	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
expanded	expanded	VBN	0
via	via	IN	0
methods	methods	NNS	0
involving	involving	VBG	0
mechanical	mechanical	JJ	B-NP
expansion	expansion	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
they	they	PRP	0
may	may	MD	0
be	be	VB	0
expanded	expanded	VBN	0
by	by	IN	0
inflating	inflating	VBG	0
a	a	DT	0
balloon	balloon	NN	0
or	or	CC	0
pulling	pulling	VBG	0
a	a	DT	0
cord	cord	NN	0
or	or	CC	0
wire	wire	NN	0
attached	attached	VBN	0
to	to	TO	0
the	the	DT	0
distal	distal	JJ	B-NP
end	end	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
,	,	,	0
or	or	CC	0
by	by	IN	0
the	the	DT	0
application	application	NN	0
of	of	IN	0
expansive	expansive	JJ	B-NP
force	force	NN	I-NP
at	at	IN	0
the	the	DT	0
proximal	proximal	JJ	B-NP
end	end	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
,	,	,	0
or	or	CC	0
by	by	IN	0
deflecting	deflecting	NN	0
or	or	CC	0
deforming	deforming	VBG	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
along	along	IN	0
the	the	DT	0
sinus	sinus	JJ	0
walls	walls	NNS	0
.	.	.	0
However	However	RB	0
,	,	,	0
in	in	IN	0
addition	addition	NN	0
to	to	TO	0
the	the	DT	0
methods	methods	NNS	0
previously	previously	RB	0
described	described	VBN	0
,	,	,	0
the	the	DT	0
invention	invention	NN	0
also	also	RB	0
contemplates	contemplates	VBZ	0
mechanical	mechanical	JJ	B-NP
expansion	expansion	NN	I-NP
of	of	IN	0
cavity	cavity	JJ	0
members	members	NNS	0
made	made	VBN	0
from	from	IN	0
less	less	RBR	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
that	that	WDT	0
are	are	VBP	0
equipped	equipped	VBN	0
with	with	IN	0
one	one	CD	0
or	or	CC	0
more	more	JJR	0
joints	joints	NNS	0
or	or	CC	0
hinges	hinges	NNS	0
and	and	CC	0
which	which	WDT	0
expand	expand	VBP	0
by	by	IN	0
movement	movement	NN	0
of	of	IN	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
at	at	IN	0
the	the	DT	0
joints	joints	NNS	0
or	or	CC	0
hinges	hinges	NN	0
.	.	.	0
The	The	DT	0
joint	joint	JJ	0
or	or	CC	0
hinge	hinge	NNS	0
may	may	MD	0
be	be	VB	0
an	an	DT	0
area	area	NN	0
of	of	IN	0
greater	greater	JJR	0
flexibility	flexibility	NN	0
along	along	IN	0
the	the	DT	0
filament	filament	JJ	B-NP
due	due	JJ	0
to	to	TO	0
use	use	VB	0
of	of	IN	0
a	a	DT	0
polymer	polymer	NN	B-NP
in	in	IN	0
that	that	DT	0
area	area	NN	0
having	having	VBG	0
a	a	DT	0
lower	lower	JJR	0
durometer	durometer	NN	B-NP
,	,	,	0
decreasing	decreasing	VBG	0
the	the	DT	0
filament	filament	NN	B-NP
width	width	NN	I-NP
,	,	,	0
or	or	CC	0
by	by	IN	0
adjusting	adjusting	VBG	0
other	other	JJ	0
surface	surface	NN	0
features	features	NNS	0
or	or	CC	0
filament	filament	NN	B-NP
mass	mass	JJ	I-NP
density	density	NN	I-NP
in	in	IN	0
that	that	DT	0
area	area	NN	0
.	.	.	0
The	The	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
included	included	VBN	0
in	in	IN	0
any	any	DT	0
portion	portion	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
When	When	WRB	0
filaments	filaments	NNS	0
are	are	VBP	0
used	used	VBN	0
,	,	,	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
incorporated	incorporated	VBN	0
in	in	IN	0
the	the	DT	0
filaments	filaments	NN	0
as	as	IN	0
drug	drug	NN	0
dispersed	dispersed	NNS	0
or	or	CC	0
dissolved	dissolved	VBN	0
within	within	IN	0
a	a	DT	0
polymeric	polymeric	JJ	B-NP
matrix	matrix	NN	I-NP
,	,	,	0
or	or	CC	0
coated	coated	VBN	0
on	on	IN	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
,	,	,	0
or	or	CC	0
first	first	JJ	0
encapsulated	encapsulated	NN	0
,	,	,	0
such	such	JJ	0
as	as	IN	0
microencapsulated	microencapsulated	NN	0
,	,	,	0
and	and	CC	0
then	then	RB	0
incorporated	incorporated	VBN	0
within	within	IN	0
or	or	CC	0
coated	coated	VBN	0
onto	onto	IN	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
.	.	.	0
In	In	IN	0
some	some	DT	0
instances	instances	NNS	0
,	,	,	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
constructed	constructed	VBN	0
to	to	TO	0
have	have	VB	0
one	one	CD	0
or	or	CC	0
more	more	JJR	0
pouches	pouches	NNS	0
or	or	CC	0
pockets	pockets	NNS	0
for	for	IN	0
holding	holding	VBG	B-NP
pellet	pellet	NN	I-NP
of	of	IN	0
drug	drug	NN	0
.	.	.	0
The	The	DT	0
dosage	dosage	NN	0
of	of	IN	0
active	active	JJ	0
agent	agent	NN	B-NP
delivered	delivered	VBN	0
by	by	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
may	may	MD	0
be	be	VB	0
adjusted	adjusted	VBN	0
by	by	IN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
increasing	increasing	VBG	0
or	or	CC	0
decreasing	decreasing	VBG	0
the	the	DT	0
number	number	NN	0
of	of	IN	0
drug-containing	drug-containing	JJ	0
filaments	filaments	NN	0
in	in	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
increasing	increasing	VBG	0
or	or	CC	0
decreasing	decreasing	VBG	0
the	the	DT	0
amount	amount	NN	0
of	of	IN	0
drug	drug	NN	0
contained	contained	VBN	0
within	within	IN	0
or	or	CC	0
coated	coated	VBN	0
on	on	IN	0
the	the	DT	0
filaments	filaments	NN	0
,	,	,	0
or	or	CC	0
by	by	IN	0
forming	forming	VBG	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	JJ	0
such	such	JJ	0
that	that	IN	0
they	they	PRP	0
can	can	MD	0
be	be	VB	0
broken	broken	VBN	0
or	or	CC	0
cut	cut	NN	0
into	into	IN	0
smaller	smaller	JJR	0
filaments	filaments	NNS	0
either	either	CC	0
before	before	RB	0
or	or	CC	0
after	after	IN	0
insertion	insertion	NN	0
into	into	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
may	may	MD	0
include	include	VB	0
predetermined	predetermined	VBN	B-NP
fracture	fracture	JJ	I-NP
line	line	NN	I-NP
or	or	CC	0
markings	markings	NN	0
that	that	IN	0
a	a	DT	0
physician	physician	NN	0
can	can	MD	0
use	use	VB	0
as	as	IN	0
a	a	DT	0
guide	guide	NN	0
to	to	TO	0
adjust	adjust	VB	0
filament	filament	JJ	B-NP
length	length	NN	I-NP
prior	prior	RB	I-NP
to	to	TO	0
insertion	insertion	VB	0
,	,	,	0
or	or	CC	0
after	after	IN	0
insertion	insertion	NN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
,	,	,	0
the	the	DT	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
adapted	adapted	VBN	0
to	to	TO	0
preferentially	preferentially	VB	0
degrade	degrade	VBN	0
at	at	IN	0
the	the	DT	0
fracture	fracture	JJ	B-NP
line	line	NN	I-NP
into	into	IN	0
smaller	smaller	JJR	0
filaments	filaments	NN	0
.	.	.	0
In	In	IN	0
some	some	DT	0
instances	instances	NNS	0
,	,	,	0
it	it	PRP	0
may	may	MD	0
be	be	VB	0
desirable	desirable	JJ	0
to	to	TO	0
include	include	VB	0
filaments	filaments	VBN	0
having	having	VBG	0
different	different	JJ	0
active	active	JJ	0
agents	agents	NNS	0
in	in	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
.	.	.	0
Cavity	Cavity	JJ	0
members	members	NNS	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
a	a	DT	0
combination	combination	NN	0
of	of	IN	0
pliable	pliable	JJ	0
filament	filament	JJ	B-NP
configuration	configuration	NN	I-NP
or	or	CC	0
from	from	IN	0
combination	combination	NN	B-NP
of	of	IN	0
filaments	filaments	NN	0
and	and	CC	0
other	other	JJ	0
described	described	VBN	0
cavity	cavity	JJ	B-NP
member	member	NN	I-NP
configuration	configuration	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
structures	structures	NNS	0
of	of	IN	0
FIGS.	FIGS.	NNP	0
3A-3B	3A-3B	NNP	0
and	and	CC	0
FIGS.	FIGS.	NNP	0
4A-4B	4A-4B	NNP	0
could	could	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
support	support	VB	0
the	the	DT	0
flexible	flexible	JJ	0
mesh	mesh	NN	0
of	of	IN	0
FIG.	FIG.	CD	0
5A	5A	CD	0
.	.	.	0
If	If	IN	0
desired	desired	NN	0
,	,	,	0
a	a	DT	0
radiopaque	radiopaque	JJ	B-NP
marker	marker	NN	I-NP
may	may	MD	0
also	also	RB	0
be	be	VB	0
included	included	VBN	0
on	on	IN	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
to	to	TO	0
indicate	indicate	VB	0
the	the	DT	0
degree	degree	NN	0
of	of	IN	0
expansion	expansion	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
upon	upon	IN	0
radiographic	radiographic	JJ	B-NP
imaging	imaging	NN	I-NP
.	.	.	0
Usually	Usually	RB	0
,	,	,	0
the	the	DT	0
marker	marker	NN	0
will	will	MD	0
be	be	VB	0
detected	detected	VBN	0
by	by	IN	0
fluoroscopy	fluoroscopy	NN	B-NP
,	,	,	0
and	and	CC	0
if	if	IN	0
nonbiodegradable	nonbiodegradable	NN	B-NP
,	,	,	0
will	will	MD	0
exit	exit	VB	0
the	the	DT	0
sinus	sinus	NN	B-NP
with	with	IN	0
the	the	DT	0
normal	normal	JJ	B-NP
mucus	mucus	JJ	I-NP
flow	flow	NN	I-NP
if	if	IN	0
and	and	CC	0
after	after	IN	0
the	the	DT	0
expandable	expandable	JJ	B-NP
cavity	cavity	JJ	I-NP
member	member	NN	I-NP
has	has	VBZ	0
degraded	degraded	VBN	0
.	.	.	0
biodegradable	biodegradable	JJ	B-NP
radiopacifier	radiopacifier	NN	I-NP
such	such	JJ	0
as	as	IN	0
particles	particles	NN	0
of	of	IN	0
an	an	DT	0
iodinated	iodinated	JJ	B-NP
contrast	contrast	NN	I-NP
agent	agent	NN	I-NP
or	or	CC	0
bismuth	bismuth	JJ	0
salts	salts	NN	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
used	used	VBN	0
.	.	.	0
Contact	Contact	NN	0
with	with	IN	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
may	may	MD	0
be	be	VB	0
verified	verified	VBN	0
by	by	IN	0
radiopaque	radiopaque	JJ	B-NP
marker	marker	NN	I-NP
incorporation	incorporation	NN	I-NP
on	on	IN	0
or	or	CC	0
within	within	IN	0
the	the	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
,	,	,	0
or	or	CC	0
visualization	visualization	VBP	B-NP
using	using	VBG	0
endoscopy	endoscopy	NN	B-NP
or	or	CC	0
other	other	JJ	0
imaging	imaging	NN	0
modalities	modalities	NN	0
.	.	.	0
Contact	Contact	NN	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
anchoring	anchoring	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
may	may	MD	0
be	be	VB	0
enhanced	enhanced	VBN	0
by	by	IN	0
the	the	DT	0
mucoadhesive	mucoadhesive	JJ	B-NP
material	material	JJ	I-NP
addition	addition	NN	I-NP
,	,	,	0
that	that	WDT	0
may	may	MD	0
or	or	CC	0
may	may	MD	0
not	not	RB	0
be	be	VB	0
polymeric	polymeric	NN	B-NP
,	,	,	0
to	to	TO	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
,	,	,	0
as	as	RB	0
further	further	RB	0
described	described	VBN	0
below	below	RB	0
,	,	,	0
by	by	IN	0
adjusting	adjusting	VBG	B-NP
filament	filament	JJ	I-NP
dimension	dimension	NN	I-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
decreasing	decreasing	VBG	B-NP
filament	filament	JJ	I-NP
diameter	diameter	NN	I-NP
or	or	CC	0
otherwise	otherwise	RB	0
decreasing	decreasing	VBG	B-NP
aspect	aspect	NN	I-NP
ratio	ratio	NN	I-NP
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
by	by	IN	0
forming	forming	VBG	0
the	the	DT	0
filaments	filaments	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIGS.	FIGS.	CD	0
6A-6F	6A-6F	CD	0
,	,	,	0
such	such	JJ	0
that	that	IN	0
they	they	PRP	0
include	include	VBP	0
hooked	hooked	VBN	0
(	(	-LRB-	0
7A	7A	NNP	0
)	)	-RRB-	0
,	,	,	0
spiked	spiked	JJ	0
(	(	-LRB-	0
7B	7B	NNP	0
)	)	-RRB-	0
,	,	,	0
double	double	JJ	0
spiked	spiked	NNS	0
(	(	-LRB-	0
7C	7C	NNP	0
)	)	-RRB-	0
,	,	,	0
arrow-like	arrow-like	NNP	B-NP
(	(	-LRB-	0
7D	7D	NNP	0
)	)	-RRB-	0
,	,	,	0
ridged	ridged	NNS	0
(	(	-LRB-	0
7E	7E	NNP	0
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
barb-like	barb-like	JJ	B-NP
structure	structure	NN	I-NP
(	(	-LRB-	0
7F	7F	NNP	0
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
other	other	JJ	0
anchoring	anchoring	NN	0
or	or	CC	0
texturizing	texturizing	JJ	B-NP
element	element	NN	I-NP
for	for	IN	0
grasping	grasping	VBG	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
.	.	.	0
In	In	IN	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
configured	configured	VBN	0
toward	toward	IN	0
their	their	PRP$	0
distal	distal	JJ	B-NP
end	end	NN	I-NP
as	as	IN	0
screws	screws	NNS	0
or	or	CC	0
springs	springs	NNS	0
which	which	WDT	0
are	are	VBP	0
capable	capable	JJ	0
of	of	IN	0
being	being	VBG	0
fixed	fixed	VBN	B-NP
in	in	IN	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
or	or	CC	0
other	other	JJ	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
by	by	IN	0
insertion	insertion	NN	0
or	or	CC	0
tension	tension	NN	0
.	.	.	0
In	In	IN	0
yet	yet	RB	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
fixed	fixed	VBN	B-NP
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
by	by	IN	0
stapling	stapling	NN	0
or	or	CC	0
suturing	suturing	NN	B-NP
.	.	.	0
The	The	DT	0
cavity	cavity	JJ	0
member	member	NN	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
anchored	anchored	VBN	0
in	in	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
by	by	IN	0
adjusting	adjusting	VBG	0
its	its	PRP$	0
size	size	NN	0
such	such	JJ	0
that	that	IN	0
it	it	PRP	0
is	is	VBZ	0
too	too	RB	0
large	large	JJ	0
to	to	TO	0
move	move	VB	0
out	out	RP	0
of	of	IN	0
the	the	DT	0
ostium	ostium	NN	B-NP
,	,	,	0
or	or	CC	0
configuring	configuring	VBG	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
such	such	JJ	0
that	that	IN	0
it	it	PRP	0
expands	expands	VBZ	0
to	to	TO	0
fill	fill	VB	0
the	the	DT	0
entire	entire	JJ	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
or	or	CC	0
expands	expands	VBZ	0
to	to	TO	0
exert	exert	VB	0
sufficient	sufficient	JJ	0
pressure	pressure	NN	0
to	to	TO	0
maintain	maintain	VB	0
it	it	PRP	0
within	within	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
may	may	MD	0
have	have	VB	0
pliable	pliable	JJ	0
filaments	filaments	JJ	0
configured	configured	NN	0
to	to	TO	0
have	have	VB	0
flexibility	flexibility	NN	0
such	such	JJ	0
that	that	IN	0
portions	portions	NNS	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
members	members	NNS	0
can	can	MD	0
differentially	differentially	VB	0
bow	bow	VBN	0
to	to	TO	0
conform	conform	VB	0
to	to	TO	0
the	the	DT	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
in	in	IN	0
which	which	WDT	0
it	it	PRP	0
is	is	VBZ	0
deployed	deployed	VBN	0
.	.	.	0
Ostial	Ostial	JJ	B-NP
member	member	NN	I-NP
.	.	.	0
The	The	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
may	may	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
keep	keep	VB	0
the	the	DT	0
ostia	ostia	JJ	0
patent	patent	NN	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
anchor	anchor	VB	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
or	or	CC	0
cavity	cavity	JJ	0
member	member	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
In	In	IN	0
some	some	DT	0
variations	variations	NNS	0
,	,	,	0
its	its	PRP$	0
inclusion	inclusion	NN	0
may	may	MD	0
be	be	VB	0
to	to	TO	0
simply	simply	RB	0
connect	connect	VB	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
to	to	TO	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
or	or	CC	0
other	other	JJ	0
extra-sinus	extra-sinus	JJ	B-NP
portion	portion	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
The	The	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
is	is	VBZ	0
mounted	mounted	VBN	0
to	to	TO	0
the	the	DT	0
proximal	proximal	JJ	B-NP
end	end	NN	I-NP
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
and	and	CC	0
is	is	VBZ	0
positioned	positioned	VBN	0
at	at	IN	0
or	or	CC	0
relatively	relatively	RB	0
near	near	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
Again	Again	RB	0
,	,	,	0
the	the	DT	0
pressure	pressure	NN	0
generated	generated	VBD	0
by	by	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
on	on	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
is	is	VBZ	0
sufficient	sufficient	JJ	0
to	to	TO	0
keep	keep	VB	0
the	the	DT	0
ostium	ostium	JJ	0
open	open	JJ	0
,	,	,	0
but	but	CC	0
not	not	RB	0
so	so	RB	0
great	great	JJ	0
that	that	IN	0
it	it	PRP	0
compromises	compromises	VBZ	0
blood	blood	NN	0
flow	flow	NN	0
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
.	.	.	0
The	The	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
may	may	MD	0
be	be	VB	0
of	of	IN	0
various	various	JJ	0
designs	designs	NNS	0
.	.	.	0
In	In	IN	0
some	some	DT	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
is	is	VBZ	0
formed	formed	VBN	B-NP
form	form	NN	I-NP
a	a	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
in	in	IN	0
FIG.	FIG.	CD	0
8A	8A	CD	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
148	148	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
single	single	JJ	0
pliable	pliable	NN	0
filament	filament	VBD	B-NP
150	150	CD	0
configured	configured	NN	0
as	as	IN	0
an	an	DT	0
expandable	expandable	JJ	B-NP
coiled	coiled	JJ	I-NP
filament	filament	NN	I-NP
or	or	CC	0
wire	wire	NN	0
which	which	WDT	0
may	may	MD	0
be	be	VB	0
varied	varied	VBN	0
in	in	IN	0
its	its	PRP$	0
pitch	pitch	NN	0
,	,	,	0
number	number	NN	0
and	and	CC	0
density	density	NN	0
of	of	IN	0
coils	coils	NN	0
,	,	,	0
coil	coil	JJ	0
linear	linear	NN	0
and	and	CC	0
non-linear	non-linear	JJ	B-NP
or	or	CC	0
patterned	patterned	JJ	0
architecture	architecture	NN	B-NP
and	and	CC	0
other	other	JJ	0
like	like	IN	0
features	features	NNS	0
.	.	.	0
FIG.	FIG.	NNP	0
8B	8B	NNP	0
shows	shows	VBZ	0
the	the	DT	0
corkscrew	corkscrew	JJ	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
148	148	CD	0
positioned	positioned	VBN	0
within	within	IN	0
an	an	DT	0
ostium	ostium	NN	B-NP
,	,	,	0
and	and	CC	0
FIG.	FIG.	NNP	0
8C	8C	NNP	0
shows	shows	VBZ	0
an	an	DT	0
end	end	NN	B-NP
view	view	NN	I-NP
ostial	ostial	NN	I-NP
member	member	NN	I-NP
148	148	CD	0
.	.	.	0
Lumen	Lumen	NNP	B-NP
151	151	CD	0
allows	allows	JJ	0
flow	flow	NN	0
of	of	IN	0
mucus	mucus	VBG	0
out	out	RP	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
Ostial	Ostial	JJ	B-NP
member	member	NN	I-NP
148	148	CD	0
is	is	VBZ	0
adapted	adapted	VBN	0
to	to	TO	0
be	be	VB	0
laterally	laterally	JJ	0
compressible	compressible	NN	B-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
bendable	bendable	VBP	0
as	as	RB	0
shown	shown	VBN	0
by	by	IN	0
the	the	DT	0
arrows	arrows	NN	0
in	in	IN	0
FIG.	FIG.	CD	0
8B	8B	CD	0
,	,	,	0
in	in	IN	0
which	which	WDT	0
case	case	NN	0
the	the	DT	0
coil	coil	JJ	B-NP
diameter	diameter	NN	I-NP
will	will	MD	0
increase	increase	VB	0
or	or	CC	0
decrease	decrease	NN	0
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
15A	15A	CD	0
,	,	,	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
filaments	filaments	CD	0
154	154	CD	0
,	,	,	0
which	which	WDT	0
may	may	MD	0
be	be	VB	0
tubular	tubular	JJ	B-NP
filament	filament	NN	I-NP
(	(	-LRB-	0
having	having	VBG	B-NP
lumen	lumen	NN	I-NP
)	)	-RRB-	0
,	,	,	0
are	are	VBP	0
attached	attached	VBN	0
to	to	TO	0
form	form	VB	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
152	152	CD	0
.	.	.	0
FIG.	FIG.	NNP	0
15B	15B	NNP	0
shows	shows	VBZ	0
the	the	DT	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
152	152	CD	0
within	within	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
and	and	CC	0
FIG.	FIG.	NNP	0
15C	15C	NNP	0
shows	shows	VBZ	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
152	152	CD	0
.	.	.	0
Lumen	Lumen	NNP	B-NP
156	156	CD	0
allows	allows	JJ	0
flow	flow	NN	0
of	of	IN	0
mucus	mucus	VBG	0
out	out	RP	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
,	,	,	0
as	as	RB	0
would	would	MD	0
the	the	DT	0
lumen	lumen	NN	B-NP
of	of	IN	0
any	any	DT	0
tubular	tubular	JJ	B-NP
filament	filament	NNS	I-NP
if	if	IN	0
used	used	VBN	0
in	in	IN	0
its	its	PRP$	0
construction	construction	NN	B-NP
.	.	.	0
The	The	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
158	158	CD	0
shown	shown	VBN	0
in	in	IN	0
FIGS.	FIGS.	NNP	0
16A-16C	16A-16C	NNP	0
is	is	VBZ	0
similar	similar	JJ	0
to	to	TO	0
that	that	DT	0
in	in	IN	0
FIGS.	FIGS.	CD	0
15A-15C	15A-15C	CD	0
except	except	IN	0
that	that	IN	0
the	the	DT	0
filaments	filaments	JJ	0
160	160	CD	0
are	are	VBP	0
formed	formed	VBN	0
as	as	IN	0
strips	strips	NNS	0
.	.	.	0
Ostial	Ostial	JJ	B-NP
member	member	NN	I-NP
158	158	CD	0
also	also	RB	0
has	has	VBZ	0
a	a	DT	0
lumen	lumen	JJ	0
162	162	CD	0
that	that	WDT	0
permits	permits	VBZ	0
mucus	mucus	VBN	0
to	to	TO	0
flow	flow	VB	0
from	from	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
to	to	TO	0
into	into	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
.	.	.	0
In	In	IN	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
film	film	NN	0
or	or	CC	0
sheet-like	sheet-like	JJ	B-NP
material	material	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
in	in	IN	0
FIG.	FIG.	CD	0
9A	9A	CD	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
164	164	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
pleated	pleated	JJ	0
sheet	sheet	NN	0
(	(	-LRB-	0
or	or	CC	0
alternatively	alternatively	RB	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
tubular	tubular	JJ	B-NP
ring	ring	NN	I-NP
structure	structure	NN	I-NP
linked	linked	VBN	0
together	together	RB	0
)	)	-RRB-	0
166	166	CD	0
configured	configured	NN	0
as	as	IN	0
a	a	DT	0
reversibly	reversibly	JJ	B-NP
compressible	compressible	NN	I-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
bendabla	bendabla	NN	B-NP
(	(	-LRB-	0
as	as	RB	0
indicated	indicated	VBN	0
by	by	IN	0
arrows	arrows	NNS	0
in	in	IN	0
FIG.	FIG.	CD	0
9B	9B	CD	0
)	)	-RRB-	0
tubular	tubular	JJ	B-NP
structure	structure	NN	I-NP
accordion-like	accordion-like	JJ	I-NP
.	.	.	0
FIG.	FIG.	NNP	0
9B	9B	NNP	0
depicts	depicts	VBZ	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
164	164	CD	0
within	within	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
,	,	,	0
and	and	CC	0
FIG.	FIG.	NNP	0
9C	9C	NNP	0
shows	shows	VBZ	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
164	164	CD	0
.	.	.	0
Lumen	Lumen	NNP	B-NP
168	168	CD	0
allows	allows	JJ	0
flow	flow	NN	0
of	of	IN	0
mucus	mucus	VBG	0
out	out	RP	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
.	.	.	0
Referring	Referring	VBG	0
now	now	RB	0
to	to	TO	0
FIG.	FIG.	CD	0
10A	10A	CD	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
170	170	CD	0
includes	includes	VBZ	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
shaped	shaped	CD	0
apertures	apertures	CD	0
172	172	CD	0
cut	cut	VBN	0
out	out	RP	0
or	or	CC	0
punched	punched	VBD	0
out	out	RP	0
from	from	IN	0
film	film	NN	0
or	or	CC	0
sheet	sheet	NN	0
material	material	NN	0
174	174	CD	0
,	,	,	0
creating	creating	VBG	0
a	a	DT	0
non-woven	non-woven	JJ	B-NP
mesh	mesh	NN	I-NP
Although	Although	IN	0
the	the	DT	0
apertures	apertures	NNS	0
are	are	VBP	0
shown	shown	VBN	0
as	as	IN	0
hexagonal	hexagonal	NN	0
in	in	IN	0
shape	shape	NN	0
,	,	,	0
it	it	PRP	0
is	is	VBZ	0
understood	understood	VBN	0
that	that	IN	0
various	various	JJ	0
other	other	JJ	0
aperture	aperture	JJ	B-NP
shape	shape	NN	I-NP
may	may	MD	0
be	be	VB	0
used	used	VBN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
apertures	apertures	JJ	0
172	172	CD	0
may	may	MD	0
be	be	VB	0
triangles	triangles	NNS	0
,	,	,	0
squares	squares	NNS	0
,	,	,	0
octagons	octagons	NN	0
,	,	,	0
diamonds	diamonds	NNS	0
,	,	,	0
etc	etc	FW	0
.	.	.	0
FIG.	FIG.	NNP	0
10B	10B	NNP	0
shows	shows	VBZ	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
170	170	CD	0
within	within	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
10C	10C	CD	0
,	,	,	0
it	it	PRP	0
is	is	VBZ	0
shown	shown	VBN	0
how	how	WRB	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
of	of	IN	0
this	this	DT	0
design	design	NN	0
allow	allow	VBP	0
mucus	mucus	VBN	0
to	to	TO	0
flow	flow	VB	0
out	out	RP	0
through	through	IN	0
lumen	lumen	CD	B-NP
176	176	CD	0
as	as	IN	0
well	well	RB	0
as	as	RB	0
through	through	IN	0
apertures	apertures	CD	0
172	172	CD	0
(	(	-LRB-	0
see	see	VB	0
direction	direction	NN	0
of	of	IN	0
arrows	arrows	CD	0
)	)	-RRB-	0
.	.	.	0
Ostial	Ostial	JJ	B-NP
member	member	NN	I-NP
170	170	CD	0
may	may	MD	0
be	be	VB	0
also	also	RB	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
compressibla	compressibla	NN	B-NP
,	,	,	0
expandable	expandable	NN	B-NP
,	,	,	0
bendable	bendable	NN	B-NP
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
.	.	.	0
Referring	Referring	VBG	0
to	to	TO	0
FIGS.	FIGS.	CD	0
12A-12C	12A-12C	CD	0
,	,	,	0
14A-14C	14A-14C	NNP	0
,	,	,	0
and	and	CC	0
13A-13C	13A-13C	NNP	0
,	,	,	0
the	the	DT	0
film	film	NN	0
or	or	CC	0
sheet-like	sheet-like	JJ	B-NP
material	material	NN	I-NP
176	176	CD	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
a	a	DT	0
simple	simple	JJ	0
tube	tube	NN	0
178	178	CD	0
,	,	,	0
a	a	DT	0
tubular	tubular	JJ	B-NP
hexagon	hexagon	NN	I-NP
180	180	CD	0
,	,	,	0
and	and	CC	0
a	a	DT	0
furled	furled	JJ	0
tube	tube	NN	0
182	182	CD	0
.	.	.	0
lumen	lumen	NN	B-NP
184	184	CD	0
,	,	,	0
186	186	CD	0
,	,	,	0
and	and	CC	0
188	188	CD	0
allow	allow	JJ	0
passage	passage	NN	0
of	of	IN	0
mucus	mucus	NN	0
from	from	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
to	to	TO	0
the	the	DT	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
.	.	.	0
Pressure	Pressure	NN	0
may	may	MD	0
be	be	VB	0
applied	applied	VBN	0
in	in	IN	0
the	the	DT	0
direction	direction	NN	0
of	of	IN	0
the	the	DT	0
arrows	arrows	NN	0
to	to	TO	0
the	the	DT	0
furled	furled	JJ	0
tube	tube	NN	0
182	182	CD	0
in	in	IN	0
FIG.	FIG.	CD	0
13C	13C	CD	0
to	to	TO	0
adjust	adjust	VB	0
the	the	DT	0
diameter	diameter	NN	0
of	of	IN	0
lumen	lumen	CD	B-NP
188	188	CD	0
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
164	164	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
sheets	sheets	NNS	0
or	or	CC	0
strip-like	strip-like	JJ	B-NP
filament	filament	NN	I-NP
166	166	CD	0
configured	configured	NN	0
as	as	IN	0
a	a	DT	0
star	star	NN	0
or	or	CC	0
asterisk-like	asterisk-like	JJ	B-NP
structure	structure	NN	I-NP
.	.	.	0
Spaces	Spaces	NNP	0
168	168	CD	0
between	between	IN	0
each	each	DT	0
strip	strip	NN	0
allow	allow	VBP	0
mucus	mucus	VBN	0
to	to	TO	0
flow	flow	VB	0
past	past	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
164	164	CD	0
and	and	CC	0
optionally	optionally	NN	0
through	through	IN	0
a	a	DT	0
central	central	JJ	0
lumen	lumen	NN	B-NP
165	165	CD	0
.	.	.	0
FIG.	FIG.	NNP	0
11B	11B	NNP	0
shows	shows	VBZ	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
164	164	CD	0
within	within	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
,	,	,	0
and	and	CC	0
FIG.	FIG.	NNP	0
11C	11C	NNP	0
depicts	depicts	VBZ	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
end	end	NN	I-NP
view	view	NN	I-NP
164	164	CD	0
.	.	.	0
further	further	JJ	B-NP
variation	variation	NN	I-NP
are	are	VBP	0
illustrated	illustrated	VBN	0
in	in	IN	0
FIGS.	FIGS.	CD	0
17-19	17-19	CD	0
.	.	.	0
Referring	Referring	VBG	0
to	to	TO	0
FIGS.	FIGS.	CD	0
17A-17C	17A-17C	CD	0
,	,	,	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
190	190	CD	0
(	(	-LRB-	0
top	top	JJ	0
)	)	-RRB-	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
corrugated	corrugated	NN	0
or	or	CC	0
pleated	pleated	JJ	0
film	film	NN	0
or	or	CC	0
sheet	sheet	NN	0
192	192	CD	0
.	.	.	0
The	The	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
190	190	CD	0
may	may	MD	0
be	be	VB	0
expanded	expanded	VBN	0
in	in	IN	0
the	the	DT	0
direction	direction	NN	0
of	of	IN	0
the	the	DT	0
arrows	arrows	NNS	0
(	(	-LRB-	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
17C	17C	CD	0
)	)	-RRB-	0
to	to	TO	0
form	form	VB	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
of	of	IN	0
larger	larger	JJR	0
diameter	diameter	NN	0
194	194	CD	0
.	.	.	0
In	In	IN	0
FIGS.	FIGS.	CD	0
18A-18C	18A-18C	CD	0
,	,	,	0
the	the	DT	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
196	196	CD	0
is	is	VBZ	0
made	made	VBN	0
from	from	IN	0
gelfoam	gelfoam	CD	B-NP
198	198	CD	0
,	,	,	0
with	with	IN	0
a	a	DT	0
pierced	pierced	JJ	0
lumen	lumen	NN	B-NP
199	199	CD	0
,	,	,	0
which	which	WDT	0
may	may	MD	0
or	or	CC	0
not	not	RB	0
be	be	VB	0
supported	supported	VBN	0
by	by	IN	0
the	the	DT	0
addition	addition	NN	B-NP
of	of	IN	0
a	a	DT	0
tube	tube	NN	0
.	.	.	0
The	The	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
200	200	CD	0
in	in	IN	0
FIGS.	FIGS.	NNP	0
19A-19C	19A-19C	NNP	0
is	is	VBZ	0
a	a	DT	0
solid	solid	JJ	0
but	but	CC	0
porous	porous	CD	B-NP
cylinder	cylinder	CD	I-NP
204	204	CD	0
having	having	VBG	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
lumen	lumen	NN	B-NP
202	202	CD	0
.	.	.	0
lumen	lumen	NN	B-NP
202	202	CD	0
extend	extend	NN	0
through	through	IN	0
the	the	DT	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
200	200	CD	0
,	,	,	0
either	either	CC	0
directly	directly	RB	0
(	(	-LRB-	0
as	as	RB	0
in	in	IN	0
a	a	DT	0
tube	tube	NN	0
)	)	-RRB-	0
or	or	CC	0
indirectly	indirectly	RB	0
by	by	IN	0
connection	connection	NN	0
through	through	IN	0
other	other	JJ	0
internal	internal	JJ	B-NP
cavity	cavity	NN	I-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
lumen	lumen	NN	B-NP
(	(	-LRB-	0
not	not	RB	0
shown	shown	VBN	0
)	)	-RRB-	0
such	such	JJ	0
that	that	IN	0
mucus	mucus	NNS	0
may	may	MD	0
pass	pass	VB	0
out	out	RP	0
the	the	DT	0
end	end	NN	B-NP
wall	wall	NN	I-NP
206	206	CD	0
and	and	CC	0
outer	outer	JJ	0
wall	wall	NN	0
208	208	CD	0
of	of	IN	0
cylinder	cylinder	CD	0
204	204	CD	0
.	.	.	0
The	The	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
rigid	rigid	JJ	0
or	or	CC	0
flexible	flexible	JJ	0
,	,	,	0
and	and	CC	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
coated	coated	VBN	0
with	with	IN	0
drug	drug	NN	0
,	,	,	0
coated	coated	VBN	0
with	with	IN	0
microencapsulated	microencapsulated	JJ	B-NP
drug	drug	NN	I-NP
,	,	,	0
or	or	CC	0
made	made	VBN	0
as	as	IN	0
a	a	DT	0
polymer	polymer	JJ	B-NP
matrix	matrix	NN	I-NP
with	with	IN	0
dispersed	dispersed	NN	0
or	or	CC	0
dissolved	dissolved	JJ	0
drug	drug	NN	0
.	.	.	0
The	The	DT	0
drug	drug	NN	0
included	included	VBD	0
with	with	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
may	may	MD	0
be	be	VB	0
the	the	DT	0
same	same	JJ	0
or	or	CC	0
different	different	JJ	0
from	from	IN	0
that	that	DT	0
delivered	delivered	VBN	0
by	by	IN	0
the	the	DT	0
expandable	expandable	JJ	B-NP
cavity	cavity	JJ	I-NP
member	member	NN	I-NP
.	.	.	0
The	The	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
may	may	MD	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
a	a	DT	0
metal	metal	NN	0
,	,	,	0
or	or	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
The	The	DT	0
dimensions	dimensions	NN	0
of	of	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
will	will	MD	0
generally	generally	RB	0
vary	vary	VBP	0
with	with	IN	0
the	the	DT	0
intended	intended	JJ	0
sinus	sinus	NN	B-NP
of	of	IN	0
deployment	deployment	NN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
for	for	IN	0
the	the	DT	0
maxillary	maxillary	JJ	B-NP
sinus	sinus	NN	I-NP
,	,	,	0
the	the	DT	0
length	length	NN	0
of	of	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
may	may	MD	0
be	be	VB	0
less	less	JJR	0
than	than	IN	0
2	2	CD	0
mm	mm	NN	0
,	,	,	0
but	but	CC	0
is	is	VBZ	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
2	2	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
6	6	CD	0
mm	mm	NN	0
,	,	,	0
more	more	RBR	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
2	2	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
5	5	CD	0
mm	mm	NN	0
,	,	,	0
and	and	CC	0
more	more	RBR	0
usually	usually	RB	0
still	still	RB	0
between	between	IN	0
about	about	IN	0
2	2	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
4	4	CD	0
mm	mm	NNS	0
.	.	.	0
The	The	DT	0
outer	outer	JJ	0
diameter	diameter	NN	0
of	of	IN	0
the	the	DT	0
maxillary	maxillary	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
is	is	VBZ	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
5	5	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
10	10	CD	0
mm	mm	NN	0
,	,	,	0
more	more	RBR	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
5	5	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
9	9	CD	0
mm	mm	NN	0
,	,	,	0
and	and	CC	0
more	more	RBR	0
usually	usually	RB	0
still	still	RB	0
between	between	IN	0
about	about	IN	0
8	8	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
10	10	CD	0
mm	mm	NNS	0
.	.	.	0
The	The	DT	0
maxillary	maxillary	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
internal	internal	JJ	I-NP
diameter	diameter	NN	I-NP
is	is	VBZ	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
3	3	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
9	9	CD	0
mm	mm	NN	0
,	,	,	0
more	more	RBR	0
usually	usually	RB	0
between	between	IN	0
about	about	IN	0
3	3	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
8	8	CD	0
mm	mm	NN	0
,	,	,	0
and	and	CC	0
more	more	RBR	0
usually	usually	RB	0
still	still	RB	0
between	between	IN	0
about	about	IN	0
3	3	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
7	7	CD	0
mm	mm	NNS	0
.	.	.	0
For	For	IN	0
the	the	DT	0
frontal	frontal	JJ	B-NP
sinus	sinus	NN	I-NP
,	,	,	0
the	the	DT	0
length	length	NN	0
of	of	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
may	may	MD	0
be	be	VB	0
between	between	IN	0
about	about	IN	0
0.5	0.5	CD	0
mm	mm	NN	0
to	to	TO	0
about	about	RB	0
5	5	CD	0
cm	cm	NN	0
,	,	,	0
between	between	IN	0
about	about	IN	0
0.5	0.5	CD	0
cm	cm	NN	0
to	to	TO	0
about	about	RB	0
4	4	CD	0
cm	cm	NN	0
,	,	,	0
between	between	IN	0
about	about	IN	0
0.5	0.5	CD	0
cm	cm	NN	0
to	to	TO	0
about	about	RB	0
3	3	CD	0
cm	cm	NN	0
,	,	,	0
between	between	IN	0
about	about	IN	0
0.5	0.5	CD	0
cm	cm	NN	0
to	to	TO	0
about	about	RB	0
2	2	CD	0
cm	cm	NN	0
,	,	,	0
or	or	CC	0
between	between	IN	0
about	about	IN	0
0.5	0.5	CD	0
cm	cm	NN	0
to	to	TO	0
about	about	RB	0
1	1	CD	0
cm	cm	NNS	0
.	.	.	0
The	The	DT	0
outer	outer	JJ	0
diameter	diameter	NN	0
of	of	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
is	is	VBZ	0
usually	usually	RB	0
about	about	IN	0
5	5	CD	0
mm	mm	NN	0
,	,	,	0
and	and	CC	0
the	the	DT	0
internal	internal	JJ	B-NP
diameter	diameter	NN	I-NP
about	about	IN	0
3	3	CD	0
mm	mm	NNS	0
.	.	.	0
However	However	RB	0
,	,	,	0
the	the	DT	0
inner	inner	JJ	0
and	and	CC	0
outer	outer	JJ	0
diameters	diameters	NN	0
may	may	MD	0
be	be	VB	0
smaller	smaller	JJR	0
,	,	,	0
especially	especially	RB	0
in	in	IN	0
the	the	DT	0
instance	instance	NN	0
where	where	WRB	0
anchoring	anchoring	NNS	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
is	is	VBZ	0
accomplished	accomplished	VBN	0
by	by	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
or	or	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
Nasal	Nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
may	may	MD	0
include	include	VB	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
a	a	DT	0
nasal	nasal	JJ	B-NP
plate	plate	NN	I-NP
210	210	CD	0
(	(	-LRB-	0
FIG.	FIG.	NNP	0
20D	20D	NNP	0
)	)	-RRB-	0
,	,	,	0
to	to	TO	0
aid	aid	VB	0
in	in	IN	0
maintaining	maintaining	VBG	0
the	the	DT	0
position	position	NN	0
of	of	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
at	at	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
,	,	,	0
or	or	CC	0
as	as	IN	0
an	an	DT	0
aid	aid	NN	0
in	in	IN	0
reducing	reducing	VBG	0
turbinate	turbinate	JJ	B-NP
lateralization	lateralization	NN	I-NP
,	,	,	0
possible	possible	JJ	0
middle	middle	JJ	B-NP
meatus	meatus	NN	I-NP
occlusion	occlusion	NN	I-NP
around	around	IN	0
the	the	DT	0
ostia	ostia	NN	B-NP
,	,	,	0
and	and	CC	0
tissue	tissue	NN	0
adhesions	adhesions	NN	0
.	.	.	0
If	If	IN	0
included	included	VBN	0
,	,	,	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
element	element	NN	0
46	46	CD	0
in	in	IN	0
FIGS.	FIGS.	NNP	0
5A-5B	5A-5B	NNP	0
and	and	CC	0
element	element	NN	0
232	232	CD	0
in	in	IN	0
FIG.	FIG.	CD	0
21	21	CD	0
)	)	-RRB-	0
is	is	VBZ	0
secured	secured	VBN	0
to	to	TO	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
proximal	proximal	JJ	I-NP
end	end	NN	I-NP
to	to	TO	0
extend	extend	VB	0
into	into	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
,	,	,	0
and	and	CC	0
may	may	MD	0
lie	lie	VB	0
against	against	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
mucosa	mucosa	NN	I-NP
.	.	.	0
The	The	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
have	have	VB	0
at	at	IN	0
least	least	JJS	0
one	one	CD	0
opening	opening	NN	0
through	through	IN	0
which	which	WDT	0
mucus	mucus	VBP	0
flowing	flowing	VBG	0
from	from	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
can	can	MD	0
drain	drain	VB	0
into	into	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
.	.	.	0
The	The	DT	0
opening	opening	NN	0
may	may	MD	0
be	be	VB	0
eccentrically	eccentrically	VBN	0
located	located	VBN	0
,	,	,	0
or	or	CC	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
in	in	IN	0
the	the	DT	0
center	center	NN	0
of	of	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
20D	20D	CD	0
,	,	,	0
opening	opening	VBG	0
212	212	CD	0
is	is	VBZ	0
in	in	IN	0
the	the	DT	0
center	center	NN	0
of	of	IN	0
nasal	nasal	JJ	B-NP
plate	plate	NN	I-NP
210	210	CD	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
20E	20E	CD	0
,	,	,	0
nasal	nasal	JJ	B-NP
plate	plate	NN	I-NP
214	214	CD	0
has	has	VBZ	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
openings	openings	CD	0
216	216	CD	0
that	that	WDT	0
allow	allow	VBP	0
drainage	drainage	VBN	0
of	of	IN	0
mucus	mucus	NN	0
from	from	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
into	into	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
.	.	.	0
In	In	IN	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
is	is	VBZ	0
configured	configured	VBN	0
from	from	IN	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
.	.	.	0
Referring	Referring	VBG	0
to	to	TO	0
FIG.	FIG.	CD	0
20A	20A	CD	0
,	,	,	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
218	218	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
filaments	filaments	CD	0
220	220	CD	0
configured	configured	NN	0
as	as	IN	0
radially	radially	NNS	0
extending	extending	VBG	0
spokes	spokes	NNS	0
,	,	,	0
which	which	WDT	0
may	may	MD	0
be	be	VB	0
inserted	inserted	VBN	0
as	as	IN	0
a	a	DT	0
more	more	RBR	0
compact	compact	JJ	0
bundle	bundle	NN	0
of	of	IN	0
aligned	aligned	JJ	0
parallel	parallel	JJ	0
spokes	spokes	NNS	0
,	,	,	0
then	then	RB	0
deployed	deployed	VBN	0
or	or	CC	0
unfurled	unfurled	VBP	0
so	so	RB	0
as	as	RB	0
to	to	TO	0
encircle	encircle	VB	0
the	the	DT	0
insertion	insertion	JJ	B-NP
point	point	NN	I-NP
(	(	-LRB-	0
see	see	VB	0
arrows	arrows	NNS	0
and	and	CC	0
insertion	insertion	JJ	B-NP
view	view	NN	I-NP
)	)	-RRB-	0
.	.	.	0
Similarly	Similarly	RB	0
,	,	,	0
in	in	IN	0
FIG.	FIG.	CD	0
20C	20C	CD	0
,	,	,	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
226	226	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
strip-like	strip-like	JJ	B-NP
filament	filament	NN	I-NP
228	228	CD	0
.	.	.	0
In	In	IN	0
FIG.	FIG.	CD	0
20B	20B	CD	0
,	,	,	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
222	222	CD	0
is	is	VBZ	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
single	single	JJ	0
pliable	pliable	NN	0
filament	filament	VBD	B-NP
224	224	CD	0
configured	configured	NN	0
as	as	IN	0
a	a	DT	0
spiral	spiral	NN	B-NP
/	/	CD	I-NP
helical	helical	JJ	I-NP
structure	structure	NN	I-NP
.	.	.	0
Another	Another	DT	0
exemplary	exemplary	JJ	B-NP
nasal	nasal	JJ	I-NP
portion	portion	NN	I-NP
is	is	VBZ	0
depicted	depicted	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
20F	20F	CD	0
,	,	,	0
which	which	WDT	0
comprises	comprises	VBZ	0
a	a	DT	0
compressible	compressible	JJ	0
woven	woven	NN	0
or	or	CC	0
nonwoven	nonwoven	JJ	0
fold	fold	NN	0
of	of	IN	0
sheeted	sheeted	JJ	B-NP
material	material	NN	I-NP
in	in	IN	0
the	the	DT	0
form	form	NN	0
of	of	IN	0
a	a	DT	0
wing-shaped	wing-shaped	JJ	0
tube	tube	NN	0
,	,	,	0
intended	intended	VBN	0
to	to	TO	0
adjustably	adjustably	VB	0
conform	conform	VBN	0
to	to	TO	0
and	and	CC	0
support	support	VB	0
the	the	DT	0
middle	middle	JJ	0
meatus	meatus	JJ	B-NP
space	space	NN	I-NP
and	and	CC	0
turbinate	turbinate	JJ	B-NP
anatomy	anatomy	NN	I-NP
directly	directly	RB	0
outside	outside	JJ	0
of	of	IN	0
an	an	DT	0
ostium	ostium	NN	B-NP
.	.	.	0
The	The	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
rigid	rigid	JJ	0
,	,	,	0
flexible	flexible	JJ	0
,	,	,	0
or	or	CC	0
self-expanding	self-expanding	JJ	0
,	,	,	0
and	and	CC	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
coated	coated	VBN	0
with	with	IN	0
drug	drug	NN	0
,	,	,	0
coated	coated	VBN	0
with	with	IN	0
microencapsulated	microencapsulated	JJ	B-NP
drug	drug	NN	I-NP
,	,	,	0
or	or	CC	0
made	made	VBN	0
as	as	IN	0
a	a	DT	0
polymer	polymer	JJ	B-NP
matrix	matrix	NN	I-NP
with	with	IN	0
dispersed	dispersed	NN	0
or	or	CC	0
dissolved	dissolved	JJ	0
drug	drug	NN	0
within	within	IN	0
the	the	DT	0
polymer	polymer	JJ	B-NP
matrix	matrix	NN	I-NP
.	.	.	0
The	The	DT	0
drug	drug	NN	0
included	included	VBD	0
with	with	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
may	may	MD	0
be	be	VB	0
the	the	DT	0
same	same	JJ	0
or	or	CC	0
different	different	JJ	0
from	from	IN	0
that	that	DT	0
delivered	delivered	VBN	0
by	by	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
.	.	.	0
The	The	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
may	may	MD	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
a	a	DT	0
metal	metal	NN	0
,	,	,	0
or	or	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
The	The	DT	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
may	may	MD	0
also	also	RB	0
vary	vary	VBP	0
depending	depending	VBG	0
on	on	IN	0
such	such	JJ	0
factors	factors	NNS	0
as	as	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
of	of	IN	0
deployment	deployment	NN	0
and	and	CC	0
whether	whether	IN	0
additional	additional	JJ	0
sinuses	sinuses	NN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
the	the	DT	0
ethmoid	ethmoid	JJ	B-NP
sinus	sinus	NN	I-NP
,	,	,	0
are	are	VBP	0
to	to	TO	0
be	be	VB	0
treated	treated	VBN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
in	in	IN	0
an	an	DT	0
individual	individual	JJ	B-NP
needing	needing	JJ	I-NP
treatment	treatment	NN	I-NP
for	for	IN	0
both	both	DT	0
maxillary	maxillary	NN	B-NP
and	and	CC	0
ethmoid	ethmoid	JJ	B-NP
sinus	sinus	JJ	I-NP
inflammation	inflammation	NN	I-NP
,	,	,	0
a	a	DT	0
maxillary	maxillary	JJ	B-NP
paranasal	paranasal	JJ	I-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
having	having	VBG	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
shaped	shaped	VBN	0
to	to	TO	0
contact	contact	VB	0
a	a	DT	0
portion	portion	NN	0
of	of	IN	0
the	the	DT	0
ethmoid	ethmoid	JJ	B-NP
air	air	NN	I-NP
cell	cell	NN	I-NP
is	is	VBZ	0
particularly	particularly	RB	0
desirable	desirable	JJ	0
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
may	may	MD	0
include	include	VB	0
any	any	DT	0
combination	combination	NN	0
of	of	IN	0
the	the	DT	0
aforementioned	aforementioned	JJ	B-NP
cavity	cavity	JJ	I-NP
member	member	NN	I-NP
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
21	21	CD	0
,	,	,	0
device	device	NN	0
may	may	MD	0
include	include	VB	0
a	a	DT	0
multiple	multiple	JJ	0
looped	looped	JJ	0
cavity	cavity	JJ	0
member	member	NN	0
228	228	CD	0
(	(	-LRB-	0
previously	previously	RB	0
described	described	VBN	0
for	for	IN	0
FIG.	FIG.	CD	0
7D	7D	CD	0
)	)	-RRB-	0
and	and	CC	0
a	a	DT	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
(	(	-LRB-	0
previously	previously	RB	0
described	described	VBN	0
for	for	IN	0
FIG.	FIG.	CD	0
15A	15A	CD	0
)	)	-RRB-	0
.	.	.	0
Nasal	Nasal	JJ	B-NP
portion	portion	NN	I-NP
232	232	CD	0
is	is	VBZ	0
also	also	RB	0
formed	formed	VBN	0
from	from	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
filaments	filaments	CD	0
234	234	CD	0
configured	configured	NN	0
as	as	IN	0
splayed	splayed	JJ	0
prongs	prongs	NNS	0
.	.	.	0
Each	Each	DT	0
component	component	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
,	,	,	0
i.e.	i.e.	FW	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
contiguously	contiguously	NNS	0
(	(	-LRB-	0
each	each	DT	0
filament	filament	NN	B-NP
,	,	,	0
tube	tube	NN	0
,	,	,	0
sheet	sheet	NN	0
,	,	,	0
or	or	CC	0
film	film	NN	0
forms	forms	VBZ	0
all	all	DT	0
components	components	NNS	0
)	)	-RRB-	0
or	or	CC	0
separately	separately	RB	0
,	,	,	0
and	and	CC	0
then	then	RB	0
attached	attached	VBN	0
by	by	IN	0
methods	methods	NNS	0
previously	previously	RB	0
described	described	VBN	0
.	.	.	0
Each	Each	DT	0
component	component	NN	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
perforated	perforated	NNS	0
,	,	,	0
contain	contain	VBP	0
pores	pores	VBN	0
,	,	,	0
or	or	CC	0
have	have	VBP	0
other	other	JJ	0
structural	structural	JJ	0
or	or	CC	0
surface	surface	NN	0
features	features	NNS	0
which	which	WDT	0
enhance	enhance	NNS	0
or	or	CC	0
alternatively	alternatively	RB	0
prevent	prevent	VB	0
impedence	impedence	VBN	0
of	of	IN	0
mucociliary	mucociliary	JJ	B-NP
clearance	clearance	NN	I-NP
,	,	,	0
and	and	CC	0
aid	aid	NN	0
in	in	IN	0
the	the	DT	0
placement	placement	NN	0
and	and	CC	0
deployment	deployment	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
236	236	CD	0
includes	includes	VBZ	0
a	a	DT	0
whisk-like	whisk-like	JJ	B-NP
cavity	cavity	JJ	I-NP
member	member	NN	I-NP
238	238	CD	0
(	(	-LRB-	0
previously	previously	RB	0
described	described	VBN	0
for	for	IN	0
FIG.	FIG.	CD	0
7F	7F	CD	0
)	)	-RRB-	0
,	,	,	0
a	a	DT	0
tubular	tubular	JJ	B-NP
ostial	ostial	JJ	I-NP
member	member	NN	I-NP
240	240	CD	0
(	(	-LRB-	0
previously	previously	RB	0
described	described	VBN	0
for	for	IN	0
FIG.	FIG.	CD	0
14A	14A	CD	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
another	another	DT	0
whisk-like	whisk-like	JJ	B-NP
component	component	NN	I-NP
242	242	CD	0
similar	similar	JJ	0
to	to	TO	0
cavity	cavity	VB	0
member	member	NN	0
238	238	CD	0
as	as	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
242	242	CD	0
.	.	.	0
FIG.	FIG.	NNP	0
22C	22C	NNP	0
shows	shows	VBZ	0
an	an	DT	0
end	end	NN	B-NP
view	view	NN	I-NP
from	from	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
In	In	IN	0
a	a	DT	0
further	further	JJ	0
variation	variation	NN	0
,	,	,	0
shown	shown	VBN	0
in	in	IN	0
FIGS.	FIGS.	CD	0
23A-23C	23A-23C	CD	0
,	,	,	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
244	244	CD	0
includes	includes	VBZ	0
a	a	DT	0
multiple	multiple	JJ	0
looped	looped	JJ	0
cavity	cavity	JJ	0
member	member	NN	0
246	246	CD	0
(	(	-LRB-	0
previously	previously	RB	0
described	described	VBN	0
for	for	IN	0
FIG.	FIG.	CD	0
7D	7D	CD	0
)	)	-RRB-	0
and	and	CC	0
a	a	DT	0
nasal	nasal	JJ	B-NP
plate	plate	NN	I-NP
248	248	CD	0
(	(	-LRB-	0
previously	previously	RB	0
described	described	VBN	0
for	for	IN	0
FIG.	FIG.	CD	0
20D	20D	CD	0
.	.	.	0
FIG.	FIG.	NNP	0
23B	23B	NNP	0
is	is	VBZ	0
a	a	DT	0
side	side	NN	0
cross-sectional	cross-sectional	JJ	B-NP
view	view	NN	I-NP
of	of	IN	0
device	device	NN	0
244	244	CD	0
and	and	CC	0
an	an	DT	0
cross-section	cross-section	JJ	B-NP
end	end	NN	I-NP
view	view	NN	I-NP
through	through	IN	0
line	line	NN	0
A-A	A-A	NN	0
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
23C	23C	CD	0
.	.	.	0
active	active	JJ	B-NP
agent	agent	NN	I-NP
.	.	.	0
Any	Any	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
included	included	VBN	0
in	in	IN	0
the	the	DT	0
devices	devices	NNS	0
described	described	VBD	0
herein	herein	VBN	0
so	so	RB	0
long	long	RB	0
as	as	IN	0
they	they	PRP	0
are	are	VBP	0
suitable	suitable	JJ	0
to	to	TO	0
treat	treat	VB	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
and	and	CC	0
are	are	VBP	0
capable	capable	JJ	0
of	of	IN	0
achieving	achieving	VBG	0
the	the	DT	0
desired	desired	JJ	0
release	release	NN	B-NP
kinetics	kinetics	NN	I-NP
.	.	.	0
The	The	DT	0
active	active	JJ	0
agents	agents	NNS	0
that	that	WDT	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
in	in	IN	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
to	to	TO	0
treat	treat	VB	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
anticholinergic	anticholinergic	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antihistamine	antihistamine	NN	B-NP
,	,	,	0
anti-infective	anti-infective	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antiscarring	antiscarring	NN	B-NP
or	or	CC	0
antiproliferative	antiproliferative	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
chemotherapeutic/antineoplastic	chemotherapeutic/antineoplastic	NN	B-NP
agent	agent	NN	I-NP
,	,	,	0
cytokines	cytokines	JJ	0
such	such	JJ	0
as	as	IN	0
interfereon	interfereon	NN	B-NP
and	and	CC	0
interleukin	interleukin	NN	B-NP
,	,	,	0
decongestant	decongestant	NN	B-NP
,	,	,	0
healing	healing	VBG	B-NP
promotion	promotion	NN	I-NP
agent	agent	NN	I-NP
and	and	CC	0
vitamins	vitamins	NNS	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
retinoic	retinoic	JJ	B-NP
acid	acid	NN	I-NP
,	,	,	0
vitamin	vitamin	VBG	0
A	A	DT	0
,	,	,	0
and	and	CC	0
their	their	PRP$	0
derivatives	derivatives	NNS	0
)	)	-RRB-	0
,	,	,	0
hyperosmolar	hyperosmolar	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
immunomodulator/immunosuppressive	immunomodulator/immunosuppressive	NN	B-NP
agent	agent	NN	I-NP
,	,	,	0
leukotriene	leukotriene	JJ	B-NP
modifier	modifier	NN	I-NP
,	,	,	0
mucolytic	mucolytic	NN	B-NP
,	,	,	0
narcotic	narcotic	JJ	B-NP
analgesic	analgesic	NN	I-NP
,	,	,	0
small	small	JJ	0
molecules	molecules	NNS	0
,	,	,	0
tyrosine	tyrosine	NN	B-NP
kinase	kinase	NN	I-NP
inhibitor	inhibitor	NN	I-NP
,	,	,	0
peptide	peptide	NN	B-NP
,	,	,	0
proteins	proteins	NNS	0
,	,	,	0
nucleic	nucleic	JJ	B-NP
acid	acid	JJ	I-NP
,	,	,	0
vasoconstrictor	vasoconstrictor	NN	B-NP
,	,	,	0
or	or	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
anti-sense	anti-sense	NN	B-NP
nucleic	nucleic	JJ	I-NP
acid	acid	NN	I-NP
oligomer	oligomer	NN	I-NP
or	or	CC	0
other	other	JJ	0
direct	direct	JJ	0
transactivation	transactivation	NN	B-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
mrna	mrna	NN	B-NP
expression	expression	NN	I-NP
transrepression	transrepression	JJ	I-NP
modifier	modifier	NN	I-NP
,	,	,	0
transcription	transcription	NN	B-NP
,	,	,	0
and	and	CC	0
protein	protein	NN	B-NP
production	production	NN	I-NP
may	may	MD	0
also	also	RB	0
be	be	VB	0
used	used	VBN	0
.	.	.	0
anti-infective	anti-infective	NN	B-NP
agent	agent	NN	I-NP
generally	generally	RB	0
include	include	VB	0
antibacterial	antibacterial	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antifungal	antifungal	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antiparasitic	antiparasitic	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antiviral	antiviral	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
and	and	CC	0
antiseptics	antiseptics	NN	0
.	.	.	0
anti-inflammatory	anti-inflammatory	NN	B-NP
agent	agent	NN	I-NP
generally	generally	RB	0
include	include	VB	0
steroidal	steroidal	NN	B-NP
and	and	CC	0
nonsteroidal	nonsteroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
.	.	.	0
Examples	Examples	NNS	0
of	of	IN	0
antibacterial	antibacterial	JJ	B-NP
agent	agent	NN	I-NP
that	that	WDT	0
may	may	MD	0
be	be	VB	0
suitable	suitable	JJ	0
for	for	IN	0
use	use	NN	0
with	with	IN	0
the	the	DT	0
described	described	JJ	0
methods	methods	NNS	0
and	and	CC	0
devices	devices	NNS	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
aminoglycoside	aminoglycoside	NN	B-NP
,	,	,	0
amphenicol	amphenicol	NN	B-NP
,	,	,	0
ansamycin	ansamycin	NN	B-NP
,	,	,	0
-lactams	-lactams	NNP	0
,	,	,	0
lincosamide	lincosamide	NN	B-NP
,	,	,	0
macrolide	macrolide	NN	B-NP
,	,	,	0
nitrofuran	nitrofuran	NN	B-NP
,	,	,	0
quinolone	quinolone	NN	B-NP
,	,	,	0
sulfonamide	sulfonamide	NN	B-NP
,	,	,	0
sulfone	sulfone	NN	B-NP
,	,	,	0
tetracycline	tetracycline	NN	B-NP
,	,	,	0
vancomycin	vancomycin	NN	B-NP
,	,	,	0
and	and	CC	0
any	any	DT	0
of	of	IN	0
their	their	PRP$	0
derivatives	derivatives	NNS	0
,	,	,	0
or	or	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
-lactams	-lactams	NNS	0
are	are	VBP	0
the	the	DT	0
preferred	preferred	JJ	0
antibacterial	antibacterial	JJ	B-NP
agent	agent	NN	I-NP
.	.	.	0
-lactams	-lactams	NNP	0
that	that	WDT	0
may	may	MD	0
be	be	VB	0
suitable	suitable	JJ	0
for	for	IN	0
use	use	NN	0
with	with	IN	0
the	the	DT	0
described	described	JJ	0
methods	methods	NNS	0
and	and	CC	0
devices	devices	NNS	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
carbacephem	carbacephem	NN	B-NP
,	,	,	0
carbapenem	carbapenem	NN	B-NP
,	,	,	0
cephalosporin	cephalosporin	NN	B-NP
,	,	,	0
cephamycin	cephamycin	NN	B-NP
,	,	,	0
monobactam	monobactam	NN	B-NP
,	,	,	0
oxacephem	oxacephem	NN	B-NP
,	,	,	0
penicillins	penicillins	NN	0
,	,	,	0
and	and	CC	0
any	any	DT	0
of	of	IN	0
their	their	PRP$	0
derivatives	derivatives	NNS	0
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
penicillins	penicillins	NNS	0
(	(	-LRB-	0
and	and	CC	0
their	their	PRP$	0
corresponding	corresponding	JJ	0
salts	salts	NN	0
)	)	-RRB-	0
are	are	VBP	0
the	the	DT	0
preferred	preferred	JJ	0
-lactams	-lactams	NN	0
.	.	.	0
The	The	DT	0
penicillins	penicillins	NN	0
that	that	WDT	0
may	may	MD	0
be	be	VB	0
suitable	suitable	JJ	0
for	for	IN	0
use	use	NN	0
with	with	IN	0
the	the	DT	0
described	described	JJ	0
methods	methods	NNS	0
and	and	CC	0
devices	devices	NNS	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
amdinocillin	amdinocillin	NN	B-NP
,	,	,	0
amdinocillin	amdinocillin	JJ	B-NP
pivoxil	pivoxil	NN	I-NP
,	,	,	0
amoxicillin	amoxicillin	NN	B-NP
,	,	,	0
ampicillin	ampicillin	NN	B-NP
,	,	,	0
apalcillin	apalcillin	NN	B-NP
,	,	,	0
aspoxicillin	aspoxicillin	NN	B-NP
,	,	,	0
azidocillin	azidocillin	NN	B-NP
,	,	,	0
azlocillin	azlocillin	NN	B-NP
,	,	,	0
bacampicillin	bacampicillin	NN	B-NP
,	,	,	0
benzylpenicillinic	benzylpenicillinic	JJ	B-NP
acid	acid	NN	I-NP
,	,	,	0
benzylpenicillin	benzylpenicillin	JJ	B-NP
sodium	sodium	NN	I-NP
,	,	,	0
carbenicillin	carbenicillin	NN	B-NP
,	,	,	0
carindacillin	carindacillin	NN	B-NP
,	,	,	0
clometocillin	clometocillin	NN	B-NP
,	,	,	0
cloxacillin	cloxacillin	NN	B-NP
,	,	,	0
cyclacillin	cyclacillin	NN	B-NP
,	,	,	0
dicloxacillin	dicloxacillin	NN	B-NP
,	,	,	0
epicillin	epicillin	NN	B-NP
,	,	,	0
fenbenicillin	fenbenicillin	NN	B-NP
,	,	,	0
floxacillin	floxacillin	NN	B-NP
,	,	,	0
hetacillin	hetacillin	NN	B-NP
,	,	,	0
lenampicillin	lenampicillin	NN	B-NP
,	,	,	0
metampicillin	metampicillin	NN	B-NP
,	,	,	0
methicillin	methicillin	JJ	B-NP
sodium	sodium	NN	I-NP
,	,	,	0
mezlocillin	mezlocillin	NN	B-NP
,	,	,	0
nafcillin	nafcillin	JJ	B-NP
sodium	sodium	NN	I-NP
,	,	,	0
oxacillin	oxacillin	NN	B-NP
,	,	,	0
penamecillin	penamecillin	NN	B-NP
,	,	,	0
penethamate	penethamate	JJ	B-NP
hydriodide	hydriodide	NN	I-NP
,	,	,	0
penicillin	penicillin	VBG	B-NP
G	G	NNP	I-NP
benethamine	benethamine	NN	I-NP
,	,	,	0
penicillin	penicillin	VBG	B-NP
G	G	NNP	I-NP
benzathine	benzathine	NN	I-NP
,	,	,	0
penicillin	penicillin	VBG	B-NP
G	G	NNP	I-NP
benzhydrylamine	benzhydrylamine	NN	I-NP
,	,	,	0
penicillin	penicillin	VBG	B-NP
G	G	NNP	I-NP
calcium	calcium	NN	I-NP
,	,	,	0
penicillin	penicillin	VBG	B-NP
G	G	NNP	I-NP
hydrabamine	hydrabamine	NN	I-NP
,	,	,	0
penicillin	penicillin	VBG	B-NP
G	G	NNP	I-NP
potassium	potassium	NN	I-NP
,	,	,	0
penicillin	penicillin	VBG	B-NP
G	G	NNP	I-NP
procaine	procaine	NN	I-NP
,	,	,	0
penicillin	penicillin	VBG	B-NP
N	N	NNP	I-NP
,	,	,	0
penicillin	penicillin	VBG	B-NP
O	O	NNP	I-NP
,	,	,	0
penicillin	penicillin	VBG	0
V	V	NNP	0
,	,	,	0
penicillin	penicillin	VBG	0
V	V	NNP	0
benzathine	benzathine	NN	B-NP
,	,	,	0
penicillin	penicillin	VBG	0
V	V	NNP	0
hydrabamine	hydrabamine	NN	B-NP
,	,	,	0
penimepicycline	penimepicycline	NN	B-NP
,	,	,	0
phenethicillin	phenethicillin	JJ	B-NP
potassium	potassium	NN	I-NP
,	,	,	0
piperacillin	piperacillin	NN	B-NP
,	,	,	0
pivampicillin	pivampicillin	NN	B-NP
,	,	,	0
propicillin	propicillin	NN	B-NP
,	,	,	0
quinacillin	quinacillin	NN	B-NP
,	,	,	0
sulbenicillin	sulbenicillin	NN	B-NP
,	,	,	0
sultamicillin	sultamicillin	NN	B-NP
,	,	,	0
talampicillin	talampicillin	NN	B-NP
,	,	,	0
temocillin	temocillin	NN	B-NP
,	,	,	0
and	and	CC	0
ticarcillin	ticarcillin	NN	B-NP
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
amoxicillin	amoxicillin	NN	B-NP
may	may	MD	0
be	be	VB	0
included	included	VBN	0
in	in	IN	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
device	device	NN	0
includes	includes	VBZ	0
ampicillin	ampicillin	VBN	0
.	.	.	0
Penicillins	Penicillins	RB	0
combined	combined	VBN	0
with	with	IN	0
clavulanic	clavulanic	JJ	B-NP
acid	acid	JJ	I-NP
such	such	JJ	0
as	as	IN	0
Augmentin	Augmentin	NNP	B-NP
(	(	-LRB-	0
amoxicillin	amoxicillin	NN	B-NP
and	and	CC	0
clavulanic	clavulanic	JJ	B-NP
acid	acid	NN	I-NP
)	)	-RRB-	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
used	used	VBN	0
.	.	.	0
Examples	Examples	NNS	0
of	of	IN	0
antifungal	antifungal	JJ	B-NP
agent	agent	NN	I-NP
suitable	suitable	JJ	0
for	for	IN	0
use	use	NN	0
with	with	IN	0
the	the	DT	0
described	described	JJ	0
methods	methods	NNS	0
and	and	CC	0
devices	devices	NNS	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
allylamine	allylamine	NN	B-NP
,	,	,	0
imidazole	imidazole	NN	B-NP
,	,	,	0
polyene	polyene	NN	B-NP
,	,	,	0
thiocarbamate	thiocarbamate	NN	B-NP
,	,	,	0
triazole	triazole	NN	B-NP
,	,	,	0
and	and	CC	0
any	any	DT	0
of	of	IN	0
their	their	PRP$	0
derivatives	derivatives	NNS	0
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
imidazole	imidazole	NN	B-NP
are	are	VBP	0
the	the	DT	0
preferred	preferred	JJ	0
antifungal	antifungal	JJ	B-NP
agent	agent	NN	I-NP
.	.	.	0
antiparasitic	antiparasitic	NN	B-NP
agent	agent	NN	I-NP
that	that	WDT	0
may	may	MD	0
be	be	VB	0
employed	employed	VBN	0
include	include	VBP	0
such	such	JJ	0
agents	agents	NNS	0
as	as	IN	0
atovaquone	atovaquone	NN	B-NP
,	,	,	0
clindamycin	clindamycin	NN	B-NP
,	,	,	0
dapsone	dapsone	NN	B-NP
,	,	,	0
iodoquinol	iodoquinol	NN	B-NP
,	,	,	0
metronidazole	metronidazole	NN	B-NP
,	,	,	0
pentamidine	pentamidine	NN	B-NP
,	,	,	0
primaquine	primaquine	NN	B-NP
,	,	,	0
pyrimethamine	pyrimethamine	NN	B-NP
,	,	,	0
sulfadiazine	sulfadiazine	NN	B-NP
,	,	,	0
trimethoprim	trimethoprim	NN	B-NP
/	/	NN	I-NP
sulfamethoxazole	sulfamethoxazole	NN	I-NP
,	,	,	0
trimetrexate	trimetrexate	NN	B-NP
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
Examples	Examples	NNS	0
of	of	IN	0
antiviral	antiviral	JJ	B-NP
agent	agent	NN	I-NP
suitable	suitable	JJ	0
for	for	IN	0
use	use	NN	0
with	with	IN	0
the	the	DT	0
described	described	JJ	0
methods	methods	NNS	0
and	and	CC	0
devices	devices	NNS	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
acyclovir	acyclovir	NN	B-NP
,	,	,	0
famciclovir	famciclovir	NN	B-NP
,	,	,	0
valacyclovir	valacyclovir	NN	B-NP
,	,	,	0
edoxudine	edoxudine	NN	B-NP
,	,	,	0
ganciclovir	ganciclovir	NN	B-NP
,	,	,	0
foscamet	foscamet	NN	B-NP
,	,	,	0
cidovir	cidovir	NN	B-NP
(	(	-LRB-	0
vistide	vistide	LS	B-NP
)	)	-RRB-	0
,	,	,	0
vitrasert	vitrasert	NN	B-NP
,	,	,	0
formivirsen	formivirsen	NN	B-NP
,	,	,	0
HPMPA	HPMPA	NNP	B-NP
(	(	-LRB-	I-NP
9-	9-	NNP	I-NP
(	(	-LRB-	I-NP
3-hydroxy-2-phosphonomethoxypropyl	3-hydroxy-2-phosphonomethoxypropyl	NNP	I-NP
)	)	-RRB-	I-NP
adenine	adenine	NN	I-NP
)	)	-RRB-	0
,	,	,	0
PMEA	PMEA	NNP	B-NP
(	(	-LRB-	I-NP
9-	9-	NNP	I-NP
(	(	-LRB-	I-NP
2-phosphonomethoxyethyl	2-phosphonomethoxyethyl	NNP	I-NP
)	)	-RRB-	I-NP
adenine	adenine	NN	I-NP
)	)	-RRB-	0
,	,	,	0
HPMPG	HPMPG	NNP	B-NP
(	(	-LRB-	I-NP
9-	9-	NNP	I-NP
(	(	-LRB-	I-NP
3-Hydroxy-2-	3-Hydroxy-2-	NNP	I-NP
(	(	-LRB-	I-NP
Phosphonomet-hoxy	Phosphonomet-hoxy	NNP	I-NP
)	)	-RRB-	I-NP
propyl	propyl	NN	I-NP
)	)	-RRB-	I-NP
guanine	guanine	NN	I-NP
)	)	-RRB-	0
,	,	,	0
PMEG	PMEG	NNP	B-NP
(	(	-LRB-	I-NP
9-	9-	NNP	I-NP
[	[	-LRB-	I-NP
2-	2-	NNP	I-NP
(	(	-LRB-	I-NP
phosphonomethoxy	phosphonomethoxy	LS	I-NP
)	)	-RRB-	I-NP
ethyl	ethyl	NN	I-NP
]	]	-RRB-	0
guanine	guanine	NN	B-NP
)	)	-RRB-	0
,	,	,	0
HPMPC	HPMPC	NNP	B-NP
(	(	-LRB-	I-NP
1-	1-	NNP	I-NP
(	(	-LRB-	I-NP
2-phosphonomethoxy-3-hydroxypropyl	2-phosphonomethoxy-3-hydroxypropyl	NNP	I-NP
)	)	-RRB-	I-NP
-cytosine	-cytosine	NNP	I-NP
)	)	-RRB-	0
,	,	,	0
ribavirin	ribavirin	NN	0
,	,	,	0
EICAR	EICAR	NNP	B-NP
(	(	-LRB-	0
5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamine	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamine	NNP	0
)	)	-RRB-	0
,	,	,	0
pyrazofurin	pyrazofurin	NN	B-NP
(	(	-LRB-	I-NP
3-	3-	NNP	I-NP
[	[	-LRB-	I-NP
beta-D-ribofuranosyl	beta-D-ribofuranosyl	NNP	I-NP
]	]	-RRB-	I-NP
-4-hydroxypyrazole-5-carboxamine	-4-hydroxypyrazole-5-carboxamine	CD	I-NP
)	)	-RRB-	0
,	,	,	0
3-Deazaguanine	3-Deazaguanine	NNP	0
,	,	,	0
GR-92938X	GR-92938X	NNP	B-NP
(	(	-LRB-	0
1-beta-D-ribofuranosylpyrazole-3,4-dicarboxami-de	1-beta-D-ribofuranosylpyrazole-3,4-dicarboxami-de	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
LY253963	LY253963	NNP	0
(	(	-LRB-	0
1,3,4-thiadiazol-2-yl-cyanamide	1,3,4-thiadiazol-2-yl-cyanamide	NNP	0
)	)	-RRB-	0
,	,	,	0
RD3-0028	RD3-0028	NNP	B-NP
(	(	-LRB-	0
1,4-dihydro-2,3-Benzodithiin	1,4-dihydro-2,3-Benzodithiin	NNP	0
)	)	-RRB-	0
,	,	,	0
CL387626	CL387626	NNP	0
(	(	-LRB-	0
4	4	CD	0
,	,	,	0
4	4	CD	0
-bis	-bis	NNS	0
[	[	-LRB-	0
4,6-d	4,6-d	NNP	0
]	]	-RRB-	0
-aminophenyl-N-	-aminophenyl-N-	NNP	0
,	,	,	0
N-bis	N-bis	NNP	0
(	(	-LRB-	0
2-carbamoylethyl	2-carbamoylethyl	NNP	0
)	)	-RRB-	0
-sulfonilimino	-sulfonilimino	NNP	0
]	]	-RRB-	0
-1,3,5-triazin-2-ylamino-biphenyl-2-	-1,3,5-triazin-2-ylamino-biphenyl-2-	NNP	0
,	,	,	0
2	2	CD	0
-disulfonic	-disulfonic	JJ	0
acid	acid	NN	0
disodium	disodium	NN	0
salt	salt	NN	0
)	)	-RRB-	0
,	,	,	0
BABIM	BABIM	NNP	B-NP
(	(	-LRB-	I-NP
Bis	Bis	NNP	I-NP
[	[	-LRB-	I-NP
5-Amidino-2-benzimidazoly-1	5-Amidino-2-benzimidazoly-1	NNP	I-NP
]	]	-RRB-	I-NP
-methane	-methane	NNP	I-NP
)	)	-RRB-	0
,	,	,	0
NIH351	NIH351	NNP	B-NP
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
Typically	Typically	RB	0
,	,	,	0
if	if	IN	0
inclusion	inclusion	NN	0
of	of	IN	0
an	an	DT	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
agent	agent	NN	I-NP
is	is	VBZ	0
desired	desired	VBN	0
,	,	,	0
a	a	DT	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
a	a	DT	0
corticosteroid	corticosteroid	NN	B-NP
,	,	,	0
is	is	VBZ	0
employed	employed	VBN	0
.	.	.	0
Examples	Examples	NNS	0
of	of	IN	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
that	that	WDT	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
in	in	IN	0
the	the	DT	0
devices	devices	NNS	0
include	include	VBP	0
21-acetoxypregnenolone	21-acetoxypregnenolone	RB	0
,	,	,	0
alclometasone	alclometasone	NN	B-NP
,	,	,	0
algestone	algestone	NN	B-NP
,	,	,	0
amcinonide	amcinonide	NN	B-NP
,	,	,	0
beclomethasone	beclomethasone	NN	B-NP
,	,	,	0
betamethasone	betamethasone	NN	B-NP
,	,	,	0
budesonide	budesonide	NN	B-NP
,	,	,	0
chloroprednisone	chloroprednisone	NN	B-NP
,	,	,	0
clobetasol	clobetasol	NN	B-NP
,	,	,	0
clobetasone	clobetasone	NN	B-NP
,	,	,	0
clocortolone	clocortolone	NN	B-NP
,	,	,	0
cloprednol	cloprednol	NN	B-NP
,	,	,	0
corticosterone	corticosterone	NN	B-NP
,	,	,	0
cortisone	cortisone	NN	B-NP
,	,	,	0
cortivazol	cortivazol	NN	B-NP
,	,	,	0
deflazacort	deflazacort	NN	B-NP
,	,	,	0
desonide	desonide	NN	B-NP
,	,	,	0
desoximetasone	desoximetasone	NN	B-NP
,	,	,	0
dexamethasone	dexamethasone	NN	B-NP
,	,	,	0
diflorasone	diflorasone	NN	B-NP
,	,	,	0
diflucortolone	diflucortolone	NN	B-NP
,	,	,	0
difluprednate	difluprednate	NN	B-NP
,	,	,	0
enoxolone	enoxolone	NN	B-NP
,	,	,	0
fluazacort	fluazacort	NN	B-NP
,	,	,	0
flucloronide	flucloronide	NN	B-NP
,	,	,	0
flumethasone	flumethasone	NN	B-NP
,	,	,	0
flunisolide	flunisolide	NN	B-NP
,	,	,	0
fluocinolone	fluocinolone	JJ	B-NP
acetonide	acetonide	NN	I-NP
,	,	,	0
fluocinonide	fluocinonide	NN	B-NP
,	,	,	0
fluocortin	fluocortin	JJ	B-NP
butyl	butyl	NN	I-NP
,	,	,	0
fluocortolone	fluocortolone	NN	B-NP
,	,	,	0
fluorometholone	fluorometholone	NN	B-NP
,	,	,	0
fluperolone	fluperolone	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
fluprednidene	fluprednidene	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
fluprednisolone	fluprednisolone	NN	B-NP
,	,	,	0
flurandrenolide	flurandrenolide	NN	B-NP
,	,	,	0
fluticasone	fluticasone	JJ	B-NP
propionate	propionate	NN	I-NP
,	,	,	0
formocortal	formocortal	NN	B-NP
,	,	,	0
halcinonide	halcinonide	NN	B-NP
,	,	,	0
halobetasol	halobetasol	JJ	B-NP
propionate	propionate	NN	I-NP
,	,	,	0
halometasone	halometasone	NN	B-NP
,	,	,	0
halopredone	halopredone	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
hydrocortamate	hydrocortamate	NN	B-NP
,	,	,	0
hydrocortisone	hydrocortisone	NN	B-NP
,	,	,	0
loteprednol	loteprednol	JJ	B-NP
etabonate	etabonate	NN	I-NP
,	,	,	0
mazipredone	mazipredone	NN	B-NP
,	,	,	0
medrysone	medrysone	NN	B-NP
,	,	,	0
meprednisone	meprednisone	NN	B-NP
,	,	,	0
methylprednisolone	methylprednisolone	NN	B-NP
,	,	,	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
,	,	,	0
paramethasone	paramethasone	NN	B-NP
,	,	,	0
prednicarbate	prednicarbate	NN	B-NP
,	,	,	0
prednisolone	prednisolone	NN	B-NP
,	,	,	0
prednisolone	prednisolone	CD	0
25-diethylamino-acetate	25-diethylamino-acetate	CD	0
,	,	,	0
prednisolone	prednisolone	NN	B-NP
sodium	sodium	NN	I-NP
phosphate	phosphate	NN	I-NP
,	,	,	0
prednisone	prednisone	NN	B-NP
,	,	,	0
prednival	prednival	NN	B-NP
,	,	,	0
prednylidene	prednylidene	NN	B-NP
,	,	,	0
rimexolone	rimexolone	NN	B-NP
,	,	,	0
tixocortol	tixocortol	NN	B-NP
,	,	,	0
triamcinolone	triamcinolone	NN	B-NP
,	,	,	0
triamcinolone	triamcinolone	JJ	B-NP
acetonide	acetonide	NN	I-NP
,	,	,	0
triamcinolone	triamcinolone	JJ	B-NP
benetonide	benetonide	NN	I-NP
,	,	,	0
triamcinolone	triamcinolone	JJ	B-NP
hexacetonide	hexacetonide	NN	I-NP
,	,	,	0
any	any	DT	0
of	of	IN	0
their	their	PRP$	0
derivatives	derivatives	NNS	0
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
budesonide	budesonide	NN	B-NP
is	is	VBZ	0
included	included	VBN	0
in	in	IN	0
the	the	DT	0
device	device	NN	0
as	as	IN	0
the	the	DT	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
may	may	MD	0
be	be	VB	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
.	.	.	0
In	In	IN	0
yet	yet	RB	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
may	may	MD	0
be	be	VB	0
beclomethasona	beclomethasona	NN	B-NP
.	.	.	0
In	In	IN	0
yet	yet	RB	0
a	a	DT	0
further	further	JJ	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
may	may	MD	0
be	be	VB	0
fluticasone	fluticasone	JJ	B-NP
propionate	propionate	NN	I-NP
.	.	.	0
If	If	IN	0
a	a	DT	0
nonsteroidal	nonsteroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
is	is	VBZ	0
used	used	VBN	0
,	,	,	0
suitable	suitable	JJ	0
agents	agents	NNS	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
cox	cox	NN	B-NP
inhibitor	inhibitor	NN	I-NP
(	(	-LRB-	0
COX-1	COX-1	NNP	B-NP
or	or	CC	0
cox	cox	NN	B-NP
nonspecific	nonspecific	NN	I-NP
inhibitor	inhibitor	NN	I-NP
)	)	-RRB-	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
salicylic	salicylic	JJ	B-NP
acid	acid	NN	I-NP
derivative	derivative	JJ	I-NP
,	,	,	0
aspirin	aspirin	NN	0
,	,	,	0
sodium	sodium	JJ	B-NP
salicylate	salicylate	NN	I-NP
,	,	,	0
choline	choline	NN	B-NP
magnesium	magnesium	NN	I-NP
trisalicylate	trisalicylate	NN	I-NP
,	,	,	0
salsalate	salsalate	NN	B-NP
,	,	,	0
diflunisal	diflunisal	NN	B-NP
,	,	,	0
sulfasalazine	sulfasalazine	NN	B-NP
and	and	CC	0
olsalazina	olsalazina	NN	B-NP
;	;	:	0
para-aminophenol	para-aminophenol	JJ	B-NP
derivative	derivative	JJ	I-NP
such	such	JJ	0
as	as	IN	0
acetaminophan	acetaminophan	NN	B-NP
;	;	:	0
indola	indola	NN	B-NP
and	and	CC	0
indene	indene	JJ	B-NP
acetic	acetic	NNS	I-NP
acid	acid	JJ	I-NP
such	such	JJ	0
as	as	IN	0
indomethacin	indomethacin	NN	B-NP
and	and	CC	0
sulindac	sulindac	NN	B-NP
;	;	:	0
heteroaryl	heteroaryl	NN	B-NP
acetic	acetic	JJ	I-NP
acid	acid	JJ	I-NP
such	such	JJ	0
as	as	IN	0
tolmetin	tolmetin	NN	B-NP
,	,	,	0
dicofenac	dicofenac	NN	B-NP
and	and	CC	0
ketorolac	ketorolac	NN	B-NP
;	;	:	0
arylpropionic	arylpropionic	JJ	B-NP
acid	acid	JJ	I-NP
such	such	JJ	0
as	as	IN	0
ibuprofen	ibuprofen	NN	0
,	,	,	0
naproxen	naproxen	NN	B-NP
,	,	,	0
flurbiprofen	flurbiprofen	NN	B-NP
,	,	,	0
ketoprofen	ketoprofen	NN	B-NP
,	,	,	0
fenoprofen	fenoprofen	NN	B-NP
and	and	CC	0
oxaprozin	oxaprozin	NN	B-NP
;	;	:	0
anthranilic	anthranilic	JJ	B-NP
acid	acid	JJ	I-NP
(	(	-LRB-	0
fenamate	fenamate	NN	B-NP
)	)	-RRB-	0
such	such	JJ	0
as	as	IN	0
mefenamic	mefenamic	JJ	B-NP
acid	acid	NN	I-NP
and	and	CC	0
meloxicam	meloxicam	NN	B-NP
;	;	:	0
enolic	enolic	JJ	B-NP
acid	acid	JJ	I-NP
such	such	JJ	0
as	as	IN	0
the	the	DT	0
oxicam	oxicam	NN	B-NP
(	(	-LRB-	0
piroxicam	piroxicam	UH	B-NP
,	,	,	0
meloxicam	meloxicam	CD	B-NP
)	)	-RRB-	0
and	and	CC	0
alkanones	alkanones	JJ	0
such	such	JJ	0
as	as	IN	0
nabumetone	nabumetone	CD	B-NP
)	)	-RRB-	0
and	and	CC	0
selective	selective	JJ	B-NP
cox-2	cox-2	NN	I-NP
inhibitor	inhibitor	NN	I-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
diaryl-substituted	diaryl-substituted	JJ	B-NP
furanone	furanone	NN	I-NP
such	such	JJ	0
as	as	IN	0
rofecoxib	rofecoxib	NN	B-NP
;	;	:	0
diaryl-substituted	diaryl-substituted	JJ	B-NP
pyrazole	pyrazole	NN	I-NP
such	such	JJ	0
as	as	IN	0
celecoxib	celecoxib	NN	B-NP
;	;	:	0
indole	indole	NN	B-NP
acetic	acetic	JJ	I-NP
acid	acid	JJ	I-NP
such	such	JJ	0
as	as	IN	0
etodolac	etodolac	NN	B-NP
and	and	CC	0
sulfonanilides	sulfonanilides	JJ	0
such	such	JJ	0
as	as	IN	0
nimesulide	nimesulide	CD	B-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
chemotherapeutic/antineoplastic	chemotherapeutic/antineoplastic	NN	B-NP
agent	agent	NN	I-NP
that	that	WDT	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
in	in	IN	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
antitumor	antitumor	VB	0
agents	agents	NNS	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
cancer	cancer	NN	B-NP
chemotherapeutic	chemotherapeutic	NN	I-NP
agent	agent	NN	I-NP
,	,	,	0
biological	biological	JJ	B-NP
response	response	NN	I-NP
modifier	modifier	NN	I-NP
,	,	,	0
vascularization	vascularization	JJ	B-NP
inhibitor	inhibitor	NN	I-NP
,	,	,	0
hormone	hormone	JJ	B-NP
receptor	receptor	NN	I-NP
blocker	blocker	NNP	I-NP
,	,	,	0
cryotherapeutic	cryotherapeutic	JJ	B-NP
agent	agent	NN	I-NP
or	or	CC	0
other	other	JJ	0
agents	agents	NNS	0
that	that	IN	0
destroy	destroy	NN	0
or	or	CC	0
inhibit	inhibit	JJ	0
neoplasia	neoplasia	NN	B-NP
or	or	CC	0
tumorigenesi	tumorigenesi	NN	B-NP
)	)	-RRB-	0
such	such	JJ	0
as	as	IN	0
alkylating	alkylating	JJ	0
agents	agents	NNS	0
or	or	CC	0
other	other	JJ	0
agents	agents	NNS	0
which	which	WDT	0
directly	directly	RB	0
kill	kill	VB	0
cancer	cancer	NN	B-NP
cell	cell	NN	I-NP
by	by	IN	0
attacking	attacking	VBG	0
their	their	PRP$	0
DNA	DNA	NN	B-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
cyclophosphamide	cyclophosphamide	NN	B-NP
,	,	,	0
isophosphamide	isophosphamide	CD	B-NP
)	)	-RRB-	0
,	,	,	0
nitrosourea	nitrosourea	NN	B-NP
or	or	CC	0
other	other	JJ	0
agents	agents	NNS	0
which	which	WDT	0
kill	kill	VBP	0
cancer	cancer	NN	B-NP
cell	cell	NN	I-NP
by	by	IN	0
inhibiting	inhibiting	JJ	0
changes	changes	NNS	0
necessary	necessary	JJ	0
for	for	IN	0
cellular	cellular	JJ	B-NP
DNA	DNA	NN	I-NP
repair	repair	NN	I-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
carmustina	carmustina	NN	B-NP
(	(	-LRB-	0
BCNU	BCNU	NNP	B-NP
)	)	-RRB-	0
and	and	CC	0
lomustina	lomustina	NN	B-NP
(	(	-LRB-	0
CCNU	CCNU	NNP	B-NP
)	)	-RRB-	0
)	)	-RRB-	0
,	,	,	0
antimetabolite	antimetabolite	NN	B-NP
and	and	CC	0
other	other	JJ	0
agents	agents	NNS	0
that	that	IN	0
block	block	NN	B-NP
cancer	cancer	NN	I-NP
cell	cell	NN	I-NP
growth	growth	NN	I-NP
by	by	IN	0
interfering	interfering	VBG	0
with	with	IN	0
certain	certain	JJ	0
cell	cell	NN	0
functions	functions	NNS	0
,	,	,	0
usually	usually	RB	0
DNA	DNA	NN	B-NP
synthesis	synthesis	NN	I-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
6	6	CD	0
mercaptopurina	mercaptopurina	NN	B-NP
and	and	CC	0
5-fluorouracil	5-fluorouracil	NN	0
(	(	-LRB-	0
5FU	5FU	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
antitumor	antitumor	JJ	B-NP
antibiotic	antibiotic	JJ	I-NP
and	and	CC	0
other	other	JJ	0
compounds	compounds	NN	0
that	that	IN	0
act	act	NN	0
by	by	IN	0
binding	binding	JJ	0
or	or	CC	0
intercalating	intercalating	JJ	B-NP
DNA	DNA	NN	I-NP
and	and	CC	0
preventing	preventing	VBG	B-NP
RNA	RNA	NNP	I-NP
synthesis	synthesis	NN	I-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
doxorubicin	doxorubicin	NN	B-NP
,	,	,	0
daunorubicin	daunorubicin	NN	B-NP
,	,	,	0
epirubicin	epirubicin	NN	B-NP
,	,	,	0
idarubicin	idarubicin	NN	B-NP
,	,	,	0
mitomycin-C	mitomycin-C	JJ	B-NP
and	and	CC	0
bleomycin	bleomycin	CD	B-NP
)	)	-RRB-	0
plant	plant	NN	0
(	(	-LRB-	0
vinca	vinca	LS	B-NP
)	)	-RRB-	0
alkaloid	alkaloid	NN	B-NP
and	and	CC	0
other	other	JJ	0
anti-tumor	anti-tumor	JJ	B-NP
agent	agent	NN	I-NP
derived	derived	VBN	0
from	from	IN	0
plants	plants	NNS	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
vincristine	vincristine	NN	B-NP
and	and	CC	0
vinblastine	vinblastine	CD	B-NP
)	)	-RRB-	0
,	,	,	0
steroid	steroid	JJ	B-NP
hormone	hormone	NN	I-NP
,	,	,	0
hormone	hormone	JJ	B-NP
inhibitor	inhibitor	NN	I-NP
,	,	,	0
hormone	hormone	JJ	B-NP
receptor	receptor	NN	I-NP
antagonist	antagonist	NN	I-NP
and	and	CC	0
other	other	JJ	0
agents	agents	NNS	0
which	which	WDT	0
affect	affect	VBP	0
the	the	DT	0
hormone-responsive	hormone-responsive	JJ	B-NP
cancer	cancer	NN	I-NP
growth	growth	NN	I-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
tamoxifen	tamoxifen	NN	B-NP
,	,	,	0
herceptin	herceptin	NN	B-NP
,	,	,	0
aromatase	aromatase	JJ	B-NP
ingibitor	ingibitor	NN	I-NP
such	such	JJ	0
as	as	IN	0
aminoglutethamide	aminoglutethamide	NN	B-NP
and	and	CC	0
formestane	formestane	NN	B-NP
,	,	,	0
trriazole	trriazole	JJ	B-NP
inhibitor	inhibitor	NN	I-NP
such	such	JJ	0
as	as	IN	0
letrozole	letrozole	NN	B-NP
and	and	CC	0
anastrazole	anastrazole	NN	B-NP
,	,	,	0
steroidal	steroidal	JJ	B-NP
inhibitor	inhibitor	NN	I-NP
such	such	JJ	0
as	as	IN	0
exemestane	exemestane	CD	B-NP
)	)	-RRB-	0
,	,	,	0
antiangiogenic	antiangiogenic	JJ	B-NP
protein	protein	NN	I-NP
,	,	,	0
small	small	JJ	0
molecules	molecules	NNS	0
,	,	,	0
gene	gene	NN	B-NP
therapy	therapy	NN	I-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
other	other	JJ	0
agents	agents	NNS	0
that	that	WDT	0
inhibit	inhibit	VBP	0
angiogenesis	angiogenesis	VBN	0
or	or	CC	0
vascularization	vascularization	NN	B-NP
of	of	IN	0
tumors	tumors	NNS	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
meth-1	meth-1	NNP	B-NP
,	,	,	0
meth-2	meth-2	NNP	B-NP
,	,	,	0
thalidomide	thalidomide	CD	0
)	)	-RRB-	0
,	,	,	0
bevacizumab	bevacizumab	NN	B-NP
(	(	-LRB-	0
Avastin	Avastin	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
squalamine	squalamine	NN	B-NP
,	,	,	0
endostatin	endostatin	NN	B-NP
,	,	,	0
angiostatin	angiostatin	NN	B-NP
,	,	,	0
Angiozyme	Angiozyme	NNP	B-NP
,	,	,	0
AE-941	AE-941	NNP	B-NP
(	(	-LRB-	0
Neovastat	Neovastat	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
CC-5013	CC-5013	NNP	B-NP
(	(	-LRB-	0
Revimid	Revimid	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
medi-522	medi-522	NNP	B-NP
(	(	-LRB-	0
Vitaxin	Vitaxin	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
2-methoxyestradiol	2-methoxyestradiol	NNP	0
(	(	-LRB-	0
2ME2	2ME2	NNP	B-NP
,	,	,	0
Panzem	Panzem	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
carboxyamidotriazola	carboxyamidotriazola	NN	B-NP
(	(	-LRB-	0
carboxyamidotriazole	carboxyamidotriazole	NN	B-NP
)	)	-RRB-	0
,	,	,	0
combretastatin	combretastatin	NN	B-NP
A4	A4	NN	I-NP
prodrug	prodrug	NN	I-NP
(	(	-LRB-	0
CA4P	CA4P	NNP	0
)	)	-RRB-	0
,	,	,	0
SU6668	SU6668	NNP	0
,	,	,	0
SU11248	SU11248	NNP	0
,	,	,	0
BMS-275291	BMS-275291	NNP	B-NP
,	,	,	0
COL-3	COL-3	NNP	B-NP
,	,	,	0
EMD	EMD	NNP	B-NP
121974	121974	CD	0
,	,	,	0
IMC-1C11	IMC-1C11	NNP	B-NP
,	,	,	0
IM862	IM862	NNP	B-NP
,	,	,	0
TNP-470	TNP-470	NNP	B-NP
,	,	,	0
celecoxib	celecoxib	NN	B-NP
(	(	-LRB-	0
Celebrex	Celebrex	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
rofecoxib	rofecoxib	NN	B-NP
(	(	-LRB-	0
Vioxx	Vioxx	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
interferon	interferon	JJ	0
alpha	alpha	NN	0
,	,	,	0
interleukin-12	interleukin-12	NNP	B-NP
(	(	-LRB-	0
IL-12	IL-12	NNP	B-NP
)	)	-RRB-	0
or	or	CC	0
any	any	DT	0
of	of	IN	0
the	the	DT	0
compounds	compounds	NN	0
identified	identified	VBN	0
in	in	IN	0
Science	Science	NNP	B-NP
Vol.	Vol.	CD	I-NP
289	289	CD	0
,	,	,	0
Pages	Pages	NNP	0
1197-1201	1197-1201	NNP	0
(	(	-LRB-	0
Aug.	Aug.	NNP	0
17	17	CD	0
,	,	,	0
2000	2000	CD	0
)	)	-RRB-	0
,	,	,	0
which	which	WDT	0
is	is	VBZ	0
expressly	expressly	RB	0
incorporated	incorporated	VBN	0
herein	herein	VBN	0
by	by	IN	0
reference	reference	NN	0
,	,	,	0
biological	biological	JJ	B-NP
response	response	NN	I-NP
modifier	modifier	NN	I-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
interferon	interferon	NN	0
,	,	,	0
bacillus	bacillus	JJ	B-NP
calmette-guerin	calmette-guerin	NN	I-NP
(	(	-LRB-	0
bacillus	bacillus	NN	B-NP
calmette	calmette	NN	I-NP
guerin	guerin	NNP	I-NP
)	)	-RRB-	0
,	,	,	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
,	,	,	0
interluken	interluken	CD	B-NP
2	2	CD	0
,	,	,	0
stimulating	stimulating	VBG	B-NP
factor	factor	NN	I-NP
granulocyte	granulocyte	JJ	I-NP
colony	colony	NN	I-NP
(	(	-LRB-	0
granulocyte	granulocyte	NN	B-NP
colony	colony	NN	I-NP
stimulating	stimulating	JJ	I-NP
factor	factor	NN	I-NP
)	)	-RRB-	0
,	,	,	0
etc.	etc.	FW	0
)	)	-RRB-	0
,	,	,	0
pgdf	pgdf	NN	B-NP
receptor	receptor	NN	I-NP
antagonist	antagonist	NN	I-NP
,	,	,	0
herceptin	herceptin	NN	B-NP
,	,	,	0
asparaginase	asparaginase	NN	B-NP
,	,	,	0
busulphan	busulphan	NN	B-NP
,	,	,	0
carboplatin	carboplatin	NN	B-NP
,	,	,	0
cisplatin	cisplatin	NN	B-NP
,	,	,	0
carmustine	carmustine	NN	B-NP
,	,	,	0
cchlorambucil	cchlorambucil	NN	B-NP
,	,	,	0
cytarabine	cytarabine	NN	B-NP
,	,	,	0
dacarbazine	dacarbazine	NN	B-NP
,	,	,	0
etoposide	etoposide	NN	B-NP
,	,	,	0
flucarbazine	flucarbazine	NN	B-NP
,	,	,	0
flurouracil	flurouracil	NN	B-NP
,	,	,	0
gemcitabine	gemcitabine	NN	B-NP
,	,	,	0
hydroxyurea	hydroxyurea	NN	B-NP
,	,	,	0
ifosphamide	ifosphamide	NN	B-NP
,	,	,	0
irinotecan	irinotecan	NN	B-NP
,	,	,	0
lomustine	lomustine	NN	B-NP
,	,	,	0
melphalan	melphalan	NN	B-NP
,	,	,	0
mercaptopurine	mercaptopurine	NN	B-NP
,	,	,	0
methotrexate	methotrexate	NN	B-NP
,	,	,	0
thioguanine	thioguanine	NN	B-NP
,	,	,	0
thiotepa	thiotepa	NN	B-NP
,	,	,	0
tomudex	tomudex	NN	B-NP
,	,	,	0
topotecan	topotecan	NN	B-NP
,	,	,	0
treosulfan	treosulfan	NN	B-NP
,	,	,	0
vinblastine	vinblastine	NN	B-NP
,	,	,	0
vincristine	vincristine	NN	B-NP
,	,	,	0
mitoazitrone	mitoazitrone	NN	B-NP
,	,	,	0
oxaliplatin	oxaliplatin	NN	B-NP
,	,	,	0
procarbazine	procarbazine	NN	B-NP
,	,	,	0
streptocin	streptocin	NN	B-NP
,	,	,	0
taxol	taxol	NN	B-NP
or	or	CC	0
paclitaxel	paclitaxel	NN	B-NP
,	,	,	0
taxotere	taxotere	NN	B-NP
,	,	,	0
analogs/congener	analogs/congener	NN	B-NP
,	,	,	0
derivatives	derivatives	NNS	0
of	of	IN	0
such	such	JJ	0
compounds	compounds	NN	0
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
exemplary	exemplary	JJ	B-NP
decongestant	decongestant	NN	I-NP
that	that	WDT	0
may	may	MD	0
be	be	VB	0
incorporated	incorporated	VBN	0
in	in	IN	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
,	,	,	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
epinephrine	epinephrine	NN	B-NP
,	,	,	0
pseudoephedrine	pseudoephedrine	NN	B-NP
,	,	,	0
oxymetazoline	oxymetazoline	NN	B-NP
,	,	,	0
phenylephrine	phenylephrine	NN	B-NP
,	,	,	0
tetrahydrozolidine	tetrahydrozolidine	NN	B-NP
,	,	,	0
and	and	CC	0
xylometazoline	xylometazoline	NN	B-NP
.	.	.	0
mucolytic	mucolytic	NN	B-NP
that	that	WDT	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limted	limted	VBN	0
to	to	TO	0
,	,	,	0
acetylcysteine	acetylcysteine	NN	B-NP
,	,	,	0
domase	domase	JJ	B-NP
alpha	alpha	NN	I-NP
,	,	,	0
and	and	CC	0
guaifenesin	guaifenesin	NN	B-NP
.	.	.	0
anti-histamine	anti-histamine	NN	B-NP
such	such	JJ	0
as	as	IN	0
azelastine	azelastine	NN	B-NP
,	,	,	0
diphenhydramine	diphenhydramine	NN	B-NP
,	,	,	0
and	and	CC	0
loratidina	loratidina	NN	B-NP
may	may	MD	0
also	also	RB	0
be	be	VB	0
used	used	VBN	0
.	.	.	0
In	In	IN	0
those	those	DT	0
instances	instances	NNS	0
where	where	WRB	0
it	it	PRP	0
is	is	VBZ	0
desirable	desirable	JJ	0
to	to	TO	0
remove	remove	VB	0
water	water	NN	0
from	from	IN	0
tissue	tissue	NN	0
,	,	,	0
e.g	e.g	NNP	0
,	,	,	0
to	to	TO	0
remove	remove	VB	0
fluid	fluid	VBN	B-NP
from	from	IN	0
polyps	polyps	NNS	0
or	or	CC	0
edematous	edematous	JJ	B-NP
tissue	tissue	NN	I-NP
,	,	,	0
a	a	DT	0
hyperosmolar	hyperosmolar	JJ	B-NP
agent	agent	NN	I-NP
may	may	MD	0
be	be	VB	0
employed	employed	VBN	0
.	.	.	0
suitable	suitable	JJ	B-NP
hyperosmolar	hyperosmolar	JJ	I-NP
agent	agent	NN	I-NP
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
furosemide	furosemide	NN	B-NP
,	,	,	0
sodium	sodium	JJ	B-NP
chloride	chloride	NN	I-NP
gel	gel	NN	I-NP
,	,	,	0
or	or	CC	0
other	other	JJ	0
salt	salt	NN	B-NP
preparation	preparation	NN	I-NP
that	that	IN	0
draw	draw	JJ	0
water	water	NN	0
from	from	IN	0
tissue	tissue	NN	0
or	or	CC	0
substances	substances	NNS	0
that	that	WDT	0
directly	directly	RB	0
or	or	CC	0
indirectly	indirectly	RB	0
change	change	VB	0
the	the	DT	0
mucous	mucous	JJ	B-NP
layer	layer	NN	I-NP
osmolar	osmolar	JJ	I-NP
content	content	NN	I-NP
.	.	.	0
The	The	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
constitute	constitute	VB	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
95	95	CD	0
%	%	NN	0
,	,	,	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
95	95	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
90	90	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
80	80	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
70	70	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
60	60	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
50	50	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
40	40	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
30	30	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
20	20	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
10	10	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
5	5	CD	0
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
1	1	CD	0
%	%	NN	0
,	,	,	0
or	or	CC	0
from	from	IN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
0.25	0.25	CD	0
%	%	NN	0
by	by	IN	0
weight	weight	NN	0
of	of	IN	0
the	the	DT	0
releasing	releasing	JJ	0
portion	portion	NN	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
)	)	-RRB-	0
or	or	CC	0
releasing	releasing	JJ	0
material	material	NN	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
layer	layer	NN	0
or	or	CC	0
layers	layers	NNS	0
having	having	VBG	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
The	The	DT	0
amount	amount	NN	0
of	of	IN	0
active	active	JJ	0
agent	agent	NN	B-NP
used	used	VBN	0
will	will	MD	0
usually	usually	RB	0
depend	depend	VB	0
on	on	IN	0
factors	factors	NNS	0
such	such	JJ	0
as	as	IN	0
the	the	DT	0
particular	particular	JJ	0
agent	agent	NN	B-NP
incorporated	incorporated	VBN	0
,	,	,	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
being	being	VBG	0
treated	treated	VBN	0
,	,	,	0
and	and	CC	0
the	the	DT	0
severity	severity	NN	0
of	of	IN	0
clinical	clinical	JJ	B-NP
symptom	symptom	NN	I-NP
,	,	,	0
but	but	CC	0
in	in	IN	0
all	all	DT	0
instances	instances	NNS	0
will	will	MD	0
usually	usually	RB	0
be	be	VB	0
an	an	DT	0
amount	amount	NN	0
that	that	WDT	0
is	is	VBZ	0
effective	effective	JJ	0
for	for	IN	0
treating	treating	VBG	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
upon	upon	IN	0
delivery	delivery	NN	0
into	into	IN	0
a	a	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
when	when	WRB	0
treating	treating	VBG	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
inflammation	inflammation	NN	I-NP
,	,	,	0
the	the	DT	0
device	device	NN	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
deliver	deliver	VB	0
per	per	IN	0
day	day	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
1	1	CD	0
g	g	NN	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
10	10	CD	0
g	g	NN	0
to	to	TO	0
about	about	RB	0
50	50	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
10	10	CD	0
g	g	NN	0
to	to	TO	0
about	about	RB	0
40	40	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
10	10	CD	0
g	g	NN	0
to	to	TO	0
about	about	RB	0
30	30	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
10	10	CD	0
g	g	NN	0
to	to	TO	0
about	about	RB	0
25	25	CD	0
g	g	NN	0
,	,	,	0
or	or	CC	0
from	from	IN	0
about	about	IN	0
10	10	CD	0
g	g	NN	0
to	to	TO	0
about	about	RB	0
20	20	CD	0
g	g	NN	0
of	of	IN	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
into	into	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
device	device	NN	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
deliver	deliver	VB	0
per	per	IN	0
day	day	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
10	10	CD	0
g	g	NN	0
to	to	TO	0
about	about	RB	0
700	700	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
25	25	CD	0
g	g	NN	0
to	to	TO	0
about	about	RB	0
400	400	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
75	75	CD	0
g	g	NN	0
to	to	TO	0
about	about	RB	0
300	300	CD	0
g	g	NN	0
,	,	,	0
or	or	CC	0
about	about	IN	0
100	100	CD	0
to	to	TO	0
about	about	RB	0
200	200	CD	0
g	g	NN	0
of	of	IN	0
fluticasone	fluticasone	JJ	B-NP
propionate	propionate	NN	I-NP
into	into	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
.	.	.	0
In	In	IN	0
some	some	DT	0
instances	instances	NNS	0
,	,	,	0
crystal	crystal	NN	0
forms	forms	NNS	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
hydrous	hydrous	NN	B-NP
and	and	CC	0
anhydrous	anhydrous	JJ	B-NP
crystal	crystal	NN	I-NP
form	form	NN	I-NP
,	,	,	0
of	of	IN	0
drugs	drugs	NNS	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
in	in	IN	0
the	the	DT	0
methods	methods	NNS	0
and	and	CC	0
devices	devices	NNS	0
described	described	VBD	0
here	here	RB	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
mometasone	mometasone	NN	B-NP
furoate	furoate	NN	I-NP
monohydrate	monohydrate	NN	I-NP
may	may	MD	0
be	be	VB	0
used	used	VBN	0
.	.	.	0
The	The	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
incorporated	incorporated	VBN	0
and	and	CC	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
coated	coated	VBN	0
onto	onto	IN	0
the	the	DT	0
surface	surface	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
An	An	DT	0
exemplary	exemplary	JJ	B-NP
way	way	NN	I-NP
the	the	DT	0
coating	coating	NN	0
may	may	MD	0
be	be	VB	0
achieved	achieved	VBN	0
is	is	VBZ	0
by	by	IN	0
dissolving	dissolving	NN	0
or	or	CC	0
suspending	suspending	VBG	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
in	in	IN	0
a	a	DT	0
solution	solution	NN	B-NP
or	or	CC	0
melt	melt	VB	0
of	of	IN	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
.	.	.	0
In	In	IN	0
another	another	DT	0
exemplary	exemplary	JJ	B-NP
way	way	NN	I-NP
,	,	,	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
powder	powder	VBN	0
coated	coated	VBN	0
onto	onto	IN	0
the	the	DT	0
surface	surface	NN	0
of	of	IN	0
the	the	DT	0
filament	filament	NN	B-NP
that	that	WDT	0
has	has	VBZ	0
been	been	VBN	0
made	made	VBN	0
adhesive	adhesive	NN	B-NP
by	by	IN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
heating	heating	VBG	0
or	or	CC	0
softening	softening	NN	0
with	with	IN	0
a	a	DT	0
solvent	solvent	JJ	0
or	or	CC	0
plasticizer	plasticizer	NN	B-NP
.	.	.	0
In	In	IN	0
yet	yet	RB	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
microencapsulated	microencapsulated	JJ	B-NP
drug	drug	NN	I-NP
may	may	MD	0
be	be	VB	0
attached	attached	VBN	0
to	to	TO	0
the	the	DT	0
surface	surface	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
As	As	RB	0
previously	previously	RB	0
mentioned	mentioned	VBN	0
,	,	,	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
incorporated	incorporated	VBN	0
throughout	throughout	IN	0
all	all	DT	0
portions	portions	NNS	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
or	or	CC	0
in	in	IN	0
particular	particular	JJ	0
portions	portions	NNS	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
and	and	CC	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
and	and	CC	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
etc.	etc.	FW	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
included	included	VBN	0
in	in	IN	0
the	the	DT	0
device	device	NN	0
such	such	JJ	0
that	that	IN	0
differential	differential	JJ	B-NP
release	release	NN	I-NP
result	result	NN	I-NP
.	.	.	0
The	The	DT	0
differential	differential	JJ	B-NP
release	release	NN	I-NP
may	may	MD	0
be	be	VB	0
of	of	IN	0
the	the	DT	0
same	same	JJ	0
active	active	JJ	0
agent	agent	NN	B-NP
or	or	CC	0
for	for	IN	0
different	different	JJ	0
active	active	JJ	0
agents	agents	NNS	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
variable	variable	JJ	0
release	release	NN	0
of	of	IN	0
a	a	DT	0
single	single	JJ	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
achieved	achieved	VBN	0
using	using	VBG	0
methods	methods	NNS	0
such	such	JJ	0
as	as	IN	0
bulk	bulk	JJ	B-NP
loading	loading	NN	I-NP
,	,	,	0
surface	surface	NN	0
coating	coating	NN	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
by	by	IN	0
having	having	VBG	0
a	a	DT	0
higher	higher	JJR	0
load	load	NN	0
layer	layer	NN	0
)	)	-RRB-	0
,	,	,	0
surface	surface	NN	0
loading	loading	NN	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
by	by	IN	0
embedding	embedding	NN	0
,	,	,	0
spraying	spraying	VBG	0
,	,	,	0
or	or	CC	0
absorbing	absorbing	JJ	0
drug	drug	NN	0
onto	onto	IN	0
the	the	DT	0
device	device	NN	B-NP
surface	surface	NN	I-NP
,	,	,	0
etc.	etc.	FW	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
other	other	JJ	0
techniques	techniques	NNS	0
well	well	RB	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
.	.	.	0
Variable	Variable	JJ	B-NP
release	release	NN	I-NP
of	of	IN	0
different	different	JJ	0
active	active	JJ	0
agents	agents	NNS	0
may	may	MD	0
be	be	VB	0
achieved	achieved	VBN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
by	by	IN	0
segmenting	segmenting	VBG	0
the	the	DT	0
drugs	drugs	NNS	0
into	into	IN	0
different	different	JJ	0
layers	layers	NNS	0
,	,	,	0
reservoirs	reservoirs	NNS	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
microsphere	microsphere	NN	B-NP
,	,	,	0
which	which	WDT	0
themselves	themselves	PRP	0
may	may	MD	0
have	have	VB	0
differing	differing	VBG	B-NP
permeability	permeability	NN	I-NP
or	or	CC	0
biodegradation	biodegradation	JJ	B-NP
profile	profile	NN	I-NP
,	,	,	0
as	as	RB	0
well	well	RB	0
as	as	RB	0
by	by	IN	0
other	other	JJ	0
techniques	techniques	NNS	0
well	well	RB	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
.	.	.	0
Polymers	Polymers	NNS	0
.	.	.	0
When	When	WRB	0
the	the	DT	0
devices	devices	NNS	0
are	are	VBP	0
made	made	VBN	0
with	with	IN	0
polymers	polymers	NNS	0
,	,	,	0
selection	selection	NN	0
of	of	IN	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
to	to	TO	0
be	be	VB	0
employed	employed	VBN	0
will	will	MD	0
vary	vary	VB	0
depending	depending	VBG	0
on	on	IN	0
the	the	DT	0
residence	residence	NN	B-NP
time	time	NN	I-NP
and	and	CC	0
release	release	NN	B-NP
kinetics	kinetics	VBZ	I-NP
desired	desired	VBN	0
,	,	,	0
method	method	NN	0
of	of	IN	0
device	device	NN	B-NP
delivery	delivery	NN	I-NP
,	,	,	0
particular	particular	JJ	0
therapeutic	therapeutic	JJ	B-NP
agent	agent	NN	I-NP
used	used	VBN	0
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
.	.	.	0
In	In	IN	0
all	all	DT	0
instances	instances	NNS	0
,	,	,	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
when	when	WRB	0
degraded	degraded	JJ	0
results	results	NNS	0
in	in	IN	0
physiologically	physiologically	JJ	B-NP
acceptable	acceptable	JJ	I-NP
degradation	degradation	NN	I-NP
product	product	NN	I-NP
.	.	.	0
The	The	DT	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
may	may	MD	0
constitute	constitute	VB	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
5	5	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
10	10	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
20	20	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
30	30	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
40	40	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
50	50	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
60	60	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
70	70	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
80	80	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
90	90	CD	0
%	%	NN	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
95	95	CD	0
%	%	NN	0
,	,	,	0
or	or	CC	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
100	100	CD	0
%	%	NN	0
by	by	IN	0
weight	weight	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
or	or	CC	0
component	component	NN	0
that	that	IN	0
it	it	PRP	0
makes	makes	VBZ	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
or	or	CC	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
)	)	-RRB-	0
.	.	.	0
Suitable	Suitable	JJ	0
biodegradable	biodegradable	NN	0
and	and	CC	0
biocompatible	biocompatible	JJ	B-NP
polymer	polymer	NN	I-NP
for	for	IN	0
use	use	NN	0
in	in	IN	0
making	making	VBG	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
polymers	polymers	JJ	0
such	such	JJ	0
as	as	IN	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolide	glycolide	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolic	glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid-co-glycolic	acid-co-glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolide	glycolide	LS	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolic	glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid-co-glycolic	acid-co-glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
caprolactone	caprolactone	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
caprolactone	caprolactone	LS	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
a	a	FW	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
orthoester	orthoester	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
phosphazene	phosphazene	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
hydroxybutyrate	hydroxybutyrate	LS	I-NP
)	)	-RRB-	I-NP
or	or	CC	0
a	a	DT	0
copolymer	copolymer	NN	B-NP
including	including	VBG	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
hydroxybutyrate	hydroxybutyrate	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-caprolactone	lactide-co-caprolactone	NNP	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
polycarbonate	polycarbonate	NN	0
;	;	:	0
a	a	DT	0
polyesteramide	polyesteramide	NN	B-NP
;	;	:	0
a	a	DT	0
polyanhidride	polyanhidride	NN	B-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
dioxanone	dioxanone	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
alkylene	alkylene	NN	I-NP
alkylate	alkylate	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
copolymer	copolymer	NN	B-NP
of	of	IN	0
polyethylene	polyethylene	NN	0
glycol	glycol	NNS	0
and	and	CC	0
a	a	DT	0
polyorthoester	polyorthoester	NN	B-NP
;	;	:	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polyurethane	polyurethane	NN	B-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
amino	amino	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
polyetherester	polyetherester	NN	B-NP
;	;	:	0
a	a	DT	0
polyacetal	polyacetal	NN	0
;	;	:	0
a	a	DT	0
polycyanoacrylate	polycyanoacrylate	NN	B-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
oxyethylene	oxyethylene	LS	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
oxypropylene	oxypropylene	LS	I-NP
)	)	-RRB-	I-NP
copolymer	copolymer	NN	I-NP
,	,	,	0
or	or	CC	0
a	a	DT	0
blend	blend	NN	0
or	or	CC	0
copolymer	copolymer	JJ	B-NP
thereof	thereof	NN	0
.	.	.	0
biodegradable	biodegradable	JJ	B-NP
shape	shape	NN	I-NP
memory	memory	NN	I-NP
polymer	polymer	NN	I-NP
,	,	,	0
such	such	JJ	0
as	as	IN	0
those	those	DT	0
commercialized	commercialized	NN	0
by	by	IN	0
nmemoScience	nmemoScience	JJ	0
in	in	IN	0
Aachen	Aachen	NNP	B-NP
,	,	,	0
Germany	Germany	NNP	0
,	,	,	0
or	or	CC	0
those	those	DT	0
described	described	VBN	0
in	in	IN	0
U.S.	U.S.	NNP	0
Pat	Pat	NNP	0
.	.	.	0
No.	No.	NNP	0
5,189,110	5,189,110	NNP	0
or	or	CC	0
U.S.	U.S.	NNP	0
Pat	Pat	NNP	0
.	.	.	0
No.	No.	NNP	0
5,139,832	5,139,832	NNP	0
,	,	,	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
employed	employed	VBN	0
.	.	.	0
As	As	RB	0
used	used	VBN	0
herein	herein	NN	0
,	,	,	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolide	glycolide	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolic	glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid-co-glycolic	acid-co-glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
will	will	MD	0
all	all	RB	0
be	be	VB	0
referred	referred	VBN	0
to	to	TO	0
as	as	IN	0
PLG	PLG	NNP	B-NP
,	,	,	0
plg	plg	NN	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
or	or	CC	0
lactide/glycolide	lactide/glycolide	NN	B-NP
polymer	polymer	NN	I-NP
.	.	.	0
drug	drug	NN	B-NP
delivery	delivery	NN	I-NP
device	device	NN	I-NP
lactide/glycolide	lactide/glycolide	NN	I-NP
polymer	polymer	NN	I-NP
and	and	CC	0
composition	composition	NN	B-NP
of	of	IN	0
this	this	DT	0
invention	invention	NNS	0
are	are	VBP	0
typically	typically	RB	0
made	made	VBN	0
by	by	IN	0
melt	melt	JJ	0
polymerization	polymerization	NN	B-NP
through	through	IN	0
the	the	DT	0
lactide	lactide	NN	B-NP
ring	ring	NN	I-NP
opening	opening	NN	I-NP
and	and	CC	0
glycolide	glycolide	JJ	B-NP
monomer	monomer	NN	I-NP
.	.	.	0
Some	Some	DT	0
polymers	polymers	NNS	0
are	are	VBP	0
available	available	JJ	0
with	with	IN	0
or	or	CC	0
without	without	IN	0
carboxylic	carboxylic	JJ	B-NP
acid	acid	NN	I-NP
end	end	NN	I-NP
group	group	NN	I-NP
.	.	.	0
When	When	WRB	0
the	the	DT	0
poly(lactide-co-glycolide)	poly(lactide-co-glycolide)	NN	B-NP
end	end	NN	I-NP
group	group	NN	I-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
,	,	,	0
or	or	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolide	glycolide	LS	I-NP
)	)	-RRB-	I-NP
is	is	VBZ	0
not	not	RB	0
a	a	DT	0
carboxylic	carboxylic	JJ	B-NP
acid	acid	NN	I-NP
,	,	,	0
for	for	IN	0
example	example	NN	0
,	,	,	0
an	an	DT	0
ester	ester	NN	B-NP
,	,	,	0
then	then	RB	0
the	the	DT	0
resultant	resultant	JJ	0
polymer	polymer	NN	B-NP
is	is	VBZ	0
referred	referred	VBN	0
to	to	TO	0
herein	herein	VB	0
as	as	RB	0
blocked	blocked	VBN	0
or	or	CC	0
capped	capped	VBD	0
.	.	.	0
The	The	DT	0
unblocked	unblocked	JJ	0
polymer	polymer	NN	B-NP
,	,	,	0
conversely	conversely	NN	0
,	,	,	0
has	has	VBZ	0
a	a	DT	0
terminal	terminal	NN	B-NP
carboxylic	carboxylic	NN	I-NP
group	group	NN	I-NP
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
linear	linear	FW	0
lactide/glycolide	lactide/glycolide	NN	B-NP
polymer	polymer	NN	I-NP
are	are	VBP	0
used	used	VBN	0
;	;	:	0
however	however	RB	0
,	,	,	0
star	star	NN	B-NP
polymer	polymer	NN	I-NP
may	may	MD	0
be	be	VB	0
used	used	VBN	0
as	as	IN	0
well	well	RB	0
.	.	.	0
In	In	IN	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
high	high	JJ	0
molecular	molecular	JJ	B-NP
weight	weight	NN	I-NP
polymer	polymer	NN	I-NP
may	may	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
form	form	VB	0
the	the	DT	0
devices	devices	NNS	0
of	of	IN	0
this	this	DT	0
invention	invention	NN	0
,	,	,	0
for	for	IN	0
example	example	NN	0
,	,	,	0
to	to	TO	0
meet	meet	VB	0
strength	strength	NN	B-NP
requirement	requirement	NN	I-NP
and	and	CC	0
extend	extend	VB	0
bioabsorption	bioabsorption	JJ	B-NP
time	time	NN	I-NP
.	.	.	0
In	In	IN	0
other	other	JJ	0
instances	instances	NNS	0
,	,	,	0
low	low	JJ	0
molecular	molecular	JJ	B-NP
weight	weight	NN	I-NP
polymer	polymer	NN	I-NP
may	may	MD	0
be	be	VB	0
used	used	VBN	0
when	when	WRB	0
resorption	resorption	JJ	B-NP
time	time	NN	I-NP
and	and	CC	0
not	not	RB	0
material	material	JJ	B-NP
strength	strength	NN	I-NP
is	is	VBZ	0
important	important	JJ	0
.	.	.	0
The	The	DT	0
polymer	polymer	NN	B-NP
lactide	lactide	JJ	I-NP
portion	portion	NN	I-NP
has	has	VBZ	0
an	an	DT	0
asymmetric	asymmetric	JJ	B-NP
carbon	carbon	NN	I-NP
.	.	.	0
Racemic	Racemic	NNP	B-NP
DL-	DL-	NNP	I-NP
,	,	,	0
L-	L-	NNP	0
,	,	,	0
and	and	CC	0
d-polymer	d-polymer	NN	B-NP
are	are	VBP	0
commercially	commercially	RB	0
available	available	JJ	0
to	to	TO	0
include	include	VB	0
in	in	IN	0
the	the	DT	0
devices	devices	NNS	0
of	of	IN	0
this	this	DT	0
invention	invention	NN	0
.	.	.	0
The	The	DT	0
l-polymer	l-polymer	NN	B-NP
are	are	VBP	0
more	more	RBR	0
crystalline	crystalline	JJ	0
and	and	CC	0
resorb	resorb	VBG	0
slower	slower	JJR	0
than	than	IN	0
dl-polymer	dl-polymer	NN	B-NP
.	.	.	0
In	In	IN	0
addition	addition	NN	0
to	to	TO	0
copolymers	copolymers	VB	0
comprising	comprising	VBG	B-NP
glycolida	glycolida	NN	I-NP
and	and	CC	0
DL-lactide	DL-lactide	JJ	B-NP
or	or	CC	0
L-lactide	L-lactide	JJ	B-NP
,	,	,	0
copolymers	copolymers	VBG	0
of	of	IN	0
L-lactide	L-lactide	JJ	B-NP
and	and	CC	0
DL-lactide	DL-lactide	NN	B-NP
are	are	VBP	0
also	also	RB	0
commercially	commercially	RB	0
available	available	JJ	0
.	.	.	0
Additionally	Additionally	RB	0
,	,	,	0
homopolymers	homopolymers	VBG	0
of	of	IN	0
lactide	lactide	NN	B-NP
or	or	CC	0
glycolida	glycolida	NN	B-NP
are	are	VBP	0
commercially	commercially	RB	0
available	available	JJ	0
.	.	.	0
lactide	lactide	NN	B-NP
star	star	NN	I-NP
polymer	polymer	NN	I-NP
or	or	CC	0
glycolida	glycolida	NN	B-NP
or	or	CC	0
lactide/glycolide	lactide/glycolide	NN	B-NP
copolymer	copolymer	NN	I-NP
are	are	VBP	0
also	also	RB	0
commercially	commercially	RB	0
available	available	JJ	0
.	.	.	0
In	In	IN	0
the	the	DT	0
case	case	NN	0
when	when	WRB	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
is	is	VBZ	0
poly	poly	JJ	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
,	,	,	0
or	or	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolide	glycolide	LS	I-NP
)	)	-RRB-	I-NP
,	,	,	0
the	the	DT	0
amount	amount	NN	0
of	of	IN	0
lactide	lactide	NN	B-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
glycolide	glycolide	NN	B-NP
in	in	IN	0
the	the	DT	0
polymer	polymer	NN	B-NP
may	may	MD	0
vary	vary	VB	0
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
contains	contains	VBZ	0
from	from	IN	0
about	about	IN	0
0	0	CD	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
40	40	CD	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
50	50	CD	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
60	60	CD	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
70	70	CD	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
,	,	,	0
or	or	CC	0
from	from	IN	0
about	about	IN	0
80	80	CD	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
lactide	lactide	NN	B-NP
,	,	,	0
and	and	CC	0
from	from	IN	0
about	about	IN	0
0	0	CD	0
to	to	TO	0
about	about	RB	0
100	100	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0	0	CD	0
to	to	TO	0
about	about	RB	0
60	60	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
10	10	CD	0
to	to	TO	0
about	about	RB	0
40	40	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
20	20	CD	0
to	to	TO	0
about	about	RB	0
40	40	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
,	,	,	0
or	or	CC	0
from	from	IN	0
about	about	IN	0
30	30	CD	0
to	to	TO	0
about	about	RB	0
40	40	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
glycolide	glycolide	NN	B-NP
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
amount	amount	NN	0
of	of	IN	0
lactide	lactide	NN	B-NP
and	and	CC	0
glycolide	glycolide	NN	B-NP
is	is	VBZ	0
100	100	CD	0
mole	mole	JJ	B-NP
%	%	NN	0
.	.	.	0
In	In	IN	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
may	may	MD	0
be	be	VB	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
,	,	,	0
about	about	IN	0
85	85	CD	0
:	:	:	0
15	15	CD	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
,	,	,	0
about	about	IN	0
75	75	CD	0
:	:	:	0
25	25	CD	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
,	,	,	0
about	about	IN	0
65	65	CD	0
:	:	:	0
35	35	CD	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
,	,	,	0
or	or	CC	0
about	about	IN	0
50	50	CD	0
:	:	:	0
50	50	CD	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
,	,	,	0
where	where	WRB	0
the	the	DT	0
ratios	ratios	NNS	0
are	are	VBP	0
mole	mole	JJ	B-NP
ratio	ratio	NN	I-NP
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
when	when	WRB	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
is	is	VBZ	0
poly	poly	JJ	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
,	,	,	0
or	or	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolide	glycolide	LS	I-NP
)	)	-RRB-	I-NP
,	,	,	0
the	the	DT	0
polymer	polymer	NN	B-NP
has	has	VBZ	0
an	an	DT	0
intrinsic	intrinsic	JJ	B-NP
viscosity	viscosity	NN	I-NP
of	of	IN	0
from	from	IN	0
about	about	IN	0
0.15	0.15	CD	0
to	to	TO	0
about	about	RB	0
1.5	1.5	CD	0
dL	dL	JJ	0
/	/	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.25	0.25	CD	0
to	to	TO	0
about	about	RB	0
1.5	1.5	CD	0
dL	dL	JJ	0
/	/	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.25	0.25	CD	0
to	to	TO	0
about	about	RB	0
1.0	1.0	CD	0
dL	dL	JJ	0
/	/	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.25	0.25	CD	0
to	to	TO	0
about	about	RB	0
0.8	0.8	CD	0
dL	dL	JJ	0
/	/	CD	0
g	g	NN	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0.25	0.25	CD	0
to	to	TO	0
about	about	RB	0
0.6	0.6	CD	0
dL	dL	JJ	0
/	/	CD	0
g	g	NN	0
,	,	,	0
or	or	CC	0
from	from	IN	0
about	about	IN	0
0.25	0.25	CD	0
to	to	TO	0
about	about	RB	0
0.4	0.4	CD	0
dL	dL	JJ	0
/	/	NN	0
g	g	VBZ	0
as	as	RB	0
measured	measured	VBN	0
in	in	IN	0
chloroform	chloroform	NN	B-NP
at	at	IN	0
a	a	DT	0
concentration	concentration	NN	B-NP
of	of	IN	0
0.5	0.5	CD	0
g	g	CD	B-NP
/	/	CD	I-NP
dL	dL	NN	I-NP
at	at	IN	0
30	30	CD	0
C	C	NNP	0
.	.	.	0
If	If	IN	0
a	a	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
is	is	VBZ	0
used	used	VBN	0
to	to	TO	0
make	make	VB	0
or	or	CC	0
incorporate	incorporate	VB	0
into	into	IN	0
the	the	DT	0
device	device	NN	0
or	or	CC	0
composition	composition	NN	0
,	,	,	0
suitable	suitable	JJ	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
ethylene	ethylene	NN	I-NP
vinyl	vinyl	NN	I-NP
acetate	acetate	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
vinyl	vinyl	NN	I-NP
acetate	acetate	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
silicone	silicone	JJ	0
polymers	polymers	NNS	0
,	,	,	0
polyurethanes	polyurethanes	NN	0
,	,	,	0
polysaccharides	polysaccharides	JJ	0
such	such	JJ	0
as	as	IN	0
a	a	DT	0
cellulosic	cellulosic	JJ	B-NP
polymer	polymer	NN	I-NP
and	and	CC	0
cellulose	cellulose	JJ	B-NP
derivative	derivative	JJ	I-NP
,	,	,	0
acyl	acyl	NN	B-NP
substituted	substituted	FW	0
cellulose	cellulose	FW	0
acetates	acetates	FW	0
and	and	CC	0
derivatives	derivatives	NNS	0
thereof	thereof	RB	0
,	,	,	0
copolymers	copolymers	VBG	0
of	of	IN	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
ethylene	ethylene	NN	I-NP
glycol	glycol	NN	I-NP
)	)	-RRB-	I-NP
and	and	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
butylene	butylene	NN	I-NP
terephthalate	terephthalate	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
polystyrenes	polystyrenes	NN	0
,	,	,	0
polyvinyl	polyvinyl	JJ	B-NP
chloride	chloride	NN	I-NP
,	,	,	0
polyvinyl	polyvinyl	JJ	B-NP
fluoride	fluoride	NN	I-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
vinyl	vinyl	NN	I-NP
imidazole	imidazole	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
chorosulphonated	chorosulphonated	JJ	B-NP
polyolefin	polyolefin	NN	I-NP
,	,	,	0
polyethylene	polyethylene	NN	B-NP
oxide	oxide	NN	I-NP
,	,	,	0
and	and	CC	0
copolymers	copolymers	NNS	0
and	and	CC	0
blends	blends	JJ	0
thereof	thereof	NN	0
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
may	may	MD	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
any	any	DT	0
biocompatible	biocompatible	NN	B-NP
,	,	,	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
that	that	WDT	0
is	is	VBZ	0
mucoadhesive	mucoadhesive	VBN	0
.	.	.	0
In	In	IN	0
some	some	DT	0
instances	instances	NNS	0
,	,	,	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
nasal	nasal	JJ	B-NP
plate	plate	NN	I-NP
may	may	MD	0
be	be	VB	0
coated	coated	VBN	0
with	with	IN	0
a	a	DT	0
mucoadhesive	mucoadhesive	NN	B-NP
,	,	,	0
which	which	WDT	0
may	may	MD	0
or	or	CC	0
may	may	MD	0
not	not	RB	0
be	be	VB	0
a	a	DT	0
polymer	polymer	NN	B-NP
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
a	a	DT	0
polymer	polymer	NN	B-NP
that	that	WDT	0
carries	carries	VBZ	0
a	a	DT	0
charge	charge	NN	0
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
natural	natural	JJ	0
polymers	polymers	NNS	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
.	.	.	0
Representative	Representative	JJ	B-NP
natural	natural	JJ	0
polymers	polymers	NNS	0
that	that	WDT	0
may	may	MD	0
be	be	VB	0
included	included	VBN	0
in	in	IN	0
the	the	DT	0
devices	devices	NNS	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
proteins	proteins	NNS	0
,	,	,	0
such	such	JJ	0
as	as	IN	0
zein	zein	NN	B-NP
,	,	,	0
modified	modified	VBN	B-NP
zein	zein	NN	I-NP
,	,	,	0
casein	casein	NN	B-NP
,	,	,	0
chitin	chitin	NN	B-NP
,	,	,	0
gelatin	gelatin	NN	B-NP
,	,	,	0
gluten	gluten	NN	B-NP
,	,	,	0
serum	serum	JJ	B-NP
albumin	albumin	NN	I-NP
,	,	,	0
or	or	CC	0
collagen	collagen	NN	B-NP
,	,	,	0
and	and	CC	0
polysaccharide	polysaccharide	NN	B-NP
,	,	,	0
such	such	JJ	0
as	as	IN	0
cellulose	cellulose	NN	B-NP
,	,	,	0
dextran	dextran	NN	B-NP
,	,	,	0
and	and	CC	0
polyhyaluronic	polyhyaluronic	JJ	B-NP
acid	acid	NN	I-NP
.	.	.	0
Hydrogel	Hydrogel	NNP	B-NP
or	or	CC	0
polysaccharide	polysaccharide	NN	B-NP
sol-gel	sol-gel	JJ	I-NP
mixture	mixture	NN	I-NP
are	are	VBP	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
employed	employed	VBN	0
.	.	.	0
Other	Other	JJ	0
materials	materials	NNS	0
.	.	.	0
In	In	IN	0
some	some	DT	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
may	may	MD	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
a	a	DT	0
metal	metal	NN	0
.	.	.	0
Examples	Examples	NNS	0
of	of	IN	0
suitable	suitable	JJ	0
metals	metals	NNS	0
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
cobalt	cobalt	NN	0
,	,	,	0
chromium	chromium	NN	0
,	,	,	0
nickel	nickel	NN	0
,	,	,	0
platinum	platinum	NN	0
,	,	,	0
stainless	stainless	JJ	0
steel	steel	NN	0
,	,	,	0
titanium	titanium	NN	B-NP
,	,	,	0
tantalum	tantalum	NN	0
,	,	,	0
and	and	CC	0
any	any	DT	0
of	of	IN	0
their	their	PRP$	0
alloys	alloys	NNS	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
nickel-titanium	nickel-titanium	JJ	B-NP
alloy	alloy	NN	I-NP
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
.	.	.	0
additional	additional	JJ	B-NP
agent	agent	NN	I-NP
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
and	and	CC	0
composition	composition	NN	B-NP
of	of	IN	0
this	this	DT	0
invention	invention	NN	0
may	may	MD	0
further	further	RB	0
include	include	VB	0
components	components	NNS	0
such	such	JJ	0
as	as	IN	0
preservatives	preservatives	NN	0
,	,	,	0
buffers	buffers	NN	0
,	,	,	0
binders	binders	NNS	0
,	,	,	0
disintegrant	disintegrant	NN	B-NP
,	,	,	0
lubricants	lubricants	NNS	0
,	,	,	0
and	and	CC	0
any	any	DT	0
other	other	JJ	0
excipients	excipients	JJ	0
necessary	necessary	JJ	0
to	to	TO	0
maintain	maintain	VB	0
the	the	DT	0
structure	structure	NN	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
function	function	NN	0
of	of	IN	0
the	the	DT	0
devices	devices	NNS	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
contain	contain	VB	0
a	a	DT	0
plasticizer	plasticizer	NN	B-NP
or	or	CC	0
solvent	solvent	JJ	0
such	such	JJ	0
as	as	IN	0
acetone	acetone	NN	B-NP
,	,	,	0
methyl	methyl	NN	B-NP
ethyl	ethyl	NN	I-NP
ketone	ketone	NN	I-NP
,	,	,	0
ethyl	ethyl	JJ	B-NP
lactate	lactate	NN	I-NP
,	,	,	0
ethyl	ethyl	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
dichloromethane	dichloromethane	NN	B-NP
,	,	,	0
or	or	CC	0
ethyl	ethyl	CD	B-NP
acetate/alcohol	acetate/alcohol	NN	I-NP
blend	blend	NN	I-NP
that	that	WDT	0
would	would	MD	0
soften	soften	VB	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
or	or	CC	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
The	The	DT	0
plasticizer	plasticizer	NN	B-NP
or	or	CC	0
solvent	solvent	NN	B-NP
would	would	MD	0
diffuse	diffuse	VB	0
or	or	CC	0
otherwise	otherwise	RB	0
be	be	VB	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
device	device	NN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
after	after	IN	0
deployment	deployment	NN	0
and	and	CC	0
expansion	expansion	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
to	to	TO	0
harden	harden	VB	0
the	the	DT	0
polymeric	polymeric	JJ	B-NP
filament	filament	NN	I-NP
(	(	-LRB-	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
)	)	-RRB-	0
such	such	JJ	0
that	that	IN	0
the	the	DT	0
device	device	NN	0
substantially	substantially	RB	0
conforms	conforms	VBZ	0
to	to	TO	0
the	the	DT	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
,	,	,	0
and	and	CC	0
to	to	TO	0
the	the	DT	0
extent	extent	NN	0
that	that	IN	0
a	a	DT	0
better	better	JJR	0
friction	friction	NN	B-NP
fit	fit	NN	I-NP
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
against	against	IN	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
is	is	VBZ	0
provided	provided	VBN	0
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
as	as	RB	0
previously	previously	RB	0
described	described	VBN	0
,	,	,	0
the	the	DT	0
pliable	pliable	JJ	0
filaments	filaments	NN	0
may	may	MD	0
also	also	RB	0
include	include	VB	0
a	a	DT	0
mucoadhesive	mucoadhesive	JJ	B-NP
polymer	polymer	NN	I-NP
to	to	TO	0
enhance	enhance	VB	0
contact	contact	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	B-NP
mucosa	mucosa	NN	I-NP
.	.	.	0
Examples	Examples	NNS	0
of	of	IN	0
mucoadhesive	mucoadhesive	JJ	B-NP
polymer	polymer	NN	I-NP
that	that	WDT	0
may	may	MD	0
be	be	VB	0
employed	employed	VBN	0
include	include	VBP	0
homopolymers	homopolymers	VBN	0
of	of	IN	0
acrylic	acrylic	JJ	0
acid	acid	NN	0
monomers	monomers	VBZ	0
such	such	JJ	0
as	as	IN	0
polyacrylic	polyacrylic	JJ	B-NP
acid	acid	NN	I-NP
and	and	CC	0
any	any	DT	0
of	of	IN	0
its	its	PRP$	0
pharmaceutically	pharmaceutically	JJ	B-NP
acceptable	acceptable	JJ	I-NP
salt	salt	JJ	I-NP
;	;	:	0
copolymers	copolymers	NN	0
of	of	IN	0
acrylic	acrylic	JJ	B-NP
acid	acid	NN	I-NP
and	and	CC	0
methacrylic	methacrylic	JJ	B-NP
acid	acid	NN	I-NP
,	,	,	0
styrene	styrene	NN	B-NP
,	,	,	0
or	or	CC	0
vinyl	vinyl	JJ	0
ethers	ethers	NN	0
;	;	:	0
vinyl	vinyl	JJ	0
polymers	polymers	NNS	0
such	such	JJ	0
as	as	IN	0
polyhydroxyethyl	polyhydroxyethyl	JJ	B-NP
acrylate	acrylate	NN	I-NP
,	,	,	0
polyhydroxyethyl	polyhydroxyethyl	JJ	B-NP
methacrylate	methacrylate	NN	I-NP
,	,	,	0
polyvinyl	polyvinyl	JJ	B-NP
alcohol	alcohol	NN	I-NP
,	,	,	0
and	and	CC	0
polyvinyl	polyvinyl	JJ	B-NP
pyrrolidone	pyrrolidone	NN	I-NP
;	;	:	0
cellulosic	cellulosic	JJ	B-NP
derivative	derivative	JJ	I-NP
such	such	JJ	0
as	as	IN	0
methyl	methyl	JJ	B-NP
cellulose	cellulose	NN	I-NP
,	,	,	0
ethyl	ethyl	JJ	B-NP
cellulose	cellulose	NN	I-NP
,	,	,	0
hydroxyethyl	hydroxyethyl	JJ	B-NP
cellulose	cellulose	NN	I-NP
,	,	,	0
hydroxypropyl	hydroxypropyl	JJ	B-NP
cellulose	cellulose	NN	I-NP
,	,	,	0
hydroxypropylmethyl	hydroxypropylmethyl	JJ	B-NP
cellulose	cellulose	NN	I-NP
,	,	,	0
and	and	CC	0
carboxymethyl	carboxymethyl	JJ	B-NP
cellulose	cellulose	NN	I-NP
;	;	:	0
polysaccharides	polysaccharides	JJ	0
such	such	JJ	0
as	as	IN	0
alginic	alginic	JJ	B-NP
acid	acid	NN	I-NP
,	,	,	0
sodium	sodium	JJ	B-NP
alginate	alginate	NN	I-NP
,	,	,	0
and	and	CC	0
tragacanth	tragacanth	JJ	B-NP
gum	gum	NN	I-NP
;	;	:	0
collagen	collagen	NN	B-NP
;	;	:	0
gelatin	gelatin	CD	B-NP
;	;	:	0
and	and	CC	0
any	any	DT	0
combination	combination	NN	0
thereof	thereof	NN	0
.	.	.	0
Release	Release	NN	B-NP
kinetics	kinetics	NN	I-NP
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
described	described	VBD	0
here	here	RB	0
may	may	MD	0
be	be	VB	0
formulated	formulated	VBN	0
with	with	IN	0
particles	particles	NN	0
of	of	IN	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
dispersed	dispersed	NNS	0
or	or	CC	0
dissolved	dissolved	VBN	0
within	within	IN	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	JJ	B-NP
matrix	matrix	NN	I-NP
,	,	,	0
and	and	CC	0
formulated	formulated	VBN	0
to	to	TO	0
provide	provide	VB	0
sustained	sustained	VBN	B-NP
release	release	NN	I-NP
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
.	.	.	0
If	If	IN	0
made	made	VBN	0
from	from	IN	0
a	a	DT	0
non-swellable	non-swellable	JJ	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
lactide/glycolide	lactide/glycolide	NN	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
release	release	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
from	from	IN	0
the	the	DT	0
matrix	matrix	NN	B-NP
is	is	VBZ	0
most	most	RBS	0
likely	likely	RB	0
achieved	achieved	VBN	0
by	by	IN	0
erosion	erosion	NN	0
of	of	IN	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	JJ	B-NP
matrix	matrix	NN	I-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
by	by	IN	0
diffusion	diffusion	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
into	into	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
mucous	mucous	JJ	I-NP
layer	layer	NN	I-NP
.	.	.	0
Factors	Factors	NNS	0
that	that	WDT	0
may	may	MD	0
influence	influence	VB	0
the	the	DT	0
release	release	NN	B-NP
kinetics	kinetics	NN	I-NP
include	include	VBP	0
such	such	JJ	0
characteristics	characteristics	NNS	0
as	as	IN	0
the	the	DT	0
size	size	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
particle	particle	NN	I-NP
,	,	,	0
the	the	DT	0
solubility	solubility	NN	B-NP
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
,	,	,	0
the	the	DT	0
ratio	ratio	NN	0
of	of	IN	0
active	active	JJ	0
agent	agent	NN	B-NP
to	to	TO	0
polymer	polymer	VB	0
(	(	-LRB-	0
s	s	LS	0
)	)	-RRB-	0
,	,	,	0
the	the	DT	0
porosity	porosity	NN	0
of	of	IN	0
the	the	DT	0
polymer	polymer	NN	B-NP
,	,	,	0
the	the	DT	0
method	method	NN	0
of	of	IN	0
device	device	NN	B-NP
manufacture	manufacture	NN	I-NP
,	,	,	0
the	the	DT	0
exposed	exposed	JJ	0
surface	surface	NN	0
area	area	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
,	,	,	0
the	the	DT	0
surface	surface	NN	0
area	area	NN	0
to	to	TO	0
volume	volume	NN	B-NP
ratio	ratio	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
,	,	,	0
and	and	CC	0
the	the	DT	0
matrix	matrix	JJ	B-NP
polymer	polymer	NNS	I-NP
erosion	erosion	NN	I-NP
rate	rate	NN	I-NP
.	.	.	0
The	The	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
device	device	NN	0
over	over	IN	0
a	a	DT	0
prolonged	prolonged	JJ	0
time	time	NN	B-NP
period	period	NN	I-NP
including	including	VBG	0
,	,	,	0
but	but	CC	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
one	one	CD	0
week	week	NN	B-NP
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
two	two	CD	0
weeks	weeks	NNS	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
three	three	CD	0
weeks	weeks	NNS	0
,	,	,	0
or	or	CC	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
four	four	CD	0
weeks	weeks	NNS	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
two	two	CD	0
months	months	NNS	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
three	three	CD	0
months	months	NNS	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
four	four	CD	0
months	months	NNS	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
five	five	CD	0
months	months	NNS	0
,	,	,	0
or	or	CC	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
six	six	CD	0
months	months	NNS	0
or	or	CC	0
more	more	JJR	0
.	.	.	0
In	In	IN	0
one	one	CD	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
therapeutic	therapeutic	JJ	B-NP
agent	agent	NN	I-NP
is	is	VBZ	0
released	released	VBN	0
over	over	RP	0
about	about	IN	0
two	two	CD	0
weeks	weeks	NNS	0
to	to	TO	0
about	about	RB	0
four	four	CD	0
weeks	weeks	NNS	0
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
profile	profile	NN	I-NP
may	may	MD	0
be	be	VB	0
adjusted	adjusted	VBN	0
by	by	IN	0
various	various	JJ	0
techniques	techniques	NNS	0
,	,	,	0
such	such	JJ	0
as	as	IN	0
through	through	IN	0
use	use	NN	0
of	of	IN	0
different	different	JJ	0
drug	drug	NN	0
,	,	,	0
polymer	polymer	NN	B-NP
,	,	,	0
and	and	CC	0
excipient	excipient	JJ	B-NP
formulation	formulation	NN	I-NP
or	or	CC	0
adjustment	adjustment	NN	0
of	of	IN	0
their	their	PRP$	0
amounts	amounts	NNS	0
in	in	IN	0
the	the	DT	0
formulation	formulation	NN	B-NP
,	,	,	0
use	use	NN	0
of	of	IN	0
release	release	NN	0
and	and	CC	0
drug	drug	NN	B-NP
barrier	barrier	NN	I-NP
layer	layer	NN	I-NP
,	,	,	0
differential	differential	JJ	B-NP
bead	bead	NN	I-NP
,	,	,	0
microsphere	microsphere	NN	B-NP
,	,	,	0
or	or	CC	0
microcapsule	microcapsule	JJ	B-NP
construction	construction	NN	I-NP
(	(	-LRB-	0
with	with	IN	0
shells	shells	NNS	0
of	of	IN	0
varying	varying	VBG	0
molecular	molecular	JJ	B-NP
weight	weight	NN	I-NP
or	or	CC	0
thicknesses	thicknesses	CD	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
,	,	,	0
as	as	RB	0
is	is	VBZ	0
well	well	RB	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
.	.	.	0
The	The	DT	0
duration	duration	NN	0
of	of	IN	0
release	release	NN	0
can	can	MD	0
also	also	RB	0
be	be	VB	0
adjusted	adjusted	VBN	0
through	through	IN	0
polymer	polymer	JJ	B-NP
blending	blending	NN	I-NP
ratio	ratio	NN	I-NP
,	,	,	0
monomer	monomer	JJ	B-NP
average	average	JJ	0
molecular	molecular	JJ	B-NP
weight	weight	NN	I-NP
,	,	,	0
and	and	CC	0
coatings	coatings	NNS	0
.	.	.	0
As	As	RB	0
previously	previously	RB	0
mentioned	mentioned	VBN	0
,	,	,	0
drug	drug	NN	B-NP
differential	differential	JJ	I-NP
release	release	NN	I-NP
may	may	MD	0
also	also	RB	0
be	be	VB	0
effected	effected	NNS	0
.	.	.	0
The	The	DT	0
differential	differential	JJ	B-NP
release	release	NN	I-NP
may	may	MD	0
be	be	VB	0
of	of	IN	0
the	the	DT	0
same	same	JJ	0
active	active	JJ	0
agent	agent	NN	B-NP
or	or	CC	0
for	for	IN	0
different	different	JJ	0
active	active	JJ	0
agents	agents	NNS	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
variable	variable	JJ	0
release	release	NN	0
of	of	IN	0
a	a	DT	0
single	single	JJ	0
active	active	JJ	0
agent	agent	NN	B-NP
may	may	MD	0
be	be	VB	0
achieved	achieved	VBN	0
using	using	VBG	0
methods	methods	NNS	0
such	such	JJ	0
as	as	IN	0
bulk	bulk	JJ	B-NP
loading	loading	NN	I-NP
,	,	,	0
surface	surface	NN	0
coating	coating	NN	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
by	by	IN	0
having	having	VBG	0
a	a	DT	0
higher	higher	JJR	0
load	load	NN	0
layer	layer	NN	0
)	)	-RRB-	0
,	,	,	0
surface	surface	NN	0
loading	loading	NN	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
by	by	IN	0
embedding	embedding	NN	0
,	,	,	0
spraying	spraying	VBG	0
,	,	,	0
or	or	CC	0
absorbing	absorbing	JJ	0
drug	drug	NN	0
onto	onto	IN	0
the	the	DT	0
device	device	NN	B-NP
surface	surface	NN	I-NP
,	,	,	0
etc.	etc.	FW	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
other	other	JJ	0
techniques	techniques	NNS	0
well	well	RB	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
.	.	.	0
Variable	Variable	JJ	B-NP
release	release	NN	I-NP
of	of	IN	0
different	different	JJ	0
active	active	JJ	0
agents	agents	NNS	0
may	may	MD	0
be	be	VB	0
achieved	achieved	VBN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
by	by	IN	0
segmenting	segmenting	VBG	0
the	the	DT	0
drugs	drugs	NNS	0
into	into	IN	0
different	different	JJ	0
layers	layers	NNS	0
,	,	,	0
reservoirs	reservoirs	NNS	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
microsphere	microsphere	NN	B-NP
,	,	,	0
as	as	RB	0
well	well	RB	0
as	as	RB	0
by	by	IN	0
other	other	JJ	0
techniques	techniques	NNS	0
well	well	RB	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
.	.	.	0
Delayed	Delayed	JJ	B-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	NNP	0
24A	24A	NNP	0
is	is	VBZ	0
useful	useful	JJ	0
for	for	IN	0
adjunctive	adjunctive	JJ	B-NP
therapy	therapy	NN	I-NP
,	,	,	0
as	as	IN	0
when	when	WRB	0
tapering	tapering	VBG	0
off	off	RP	0
of	of	IN	0
intravenous	intravenous	NN	0
or	or	CC	0
oral	oral	JJ	B-NP
steroid	steroid	NN	I-NP
previously	previously	RB	0
given	given	VBN	0
to	to	TO	0
a	a	DT	0
patient	patient	NN	0
,	,	,	0
or	or	CC	0
when	when	WRB	0
releasing	releasing	VBG	B-NP
anti-scarring	anti-scarring	JJ	I-NP
and	and	CC	0
anti-restenosis	anti-restenosis	JJ	B-NP
agent	agent	NN	I-NP
later	later	RB	0
in	in	IN	0
the	the	DT	0
healing	healing	NN	B-NP
process	process	NN	I-NP
.	.	.	0
Substantially	Substantially	RB	0
zero	zero	CD	0
order	order	NN	B-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	NNP	0
24B	24B	NNP	0
is	is	VBZ	0
useful	useful	JJ	0
for	for	IN	0
chronic	chronic	JJ	B-NP
disease	disease	NN	I-NP
maintenance	maintenance	NN	I-NP
therapy	therapy	NN	I-NP
without	without	IN	0
trauma	trauma	NN	0
or	or	CC	0
scarring	scarring	NN	0
,	,	,	0
or	or	CC	0
for	for	IN	0
anti-infective	anti-infective	JJ	B-NP
agent	agent	NN	I-NP
course	course	NN	I-NP
of	of	IN	0
therapy	therapy	NN	0
,	,	,	0
providing	providing	VBG	0
a	a	DT	0
constant	constant	JJ	0
equilibrium	equilibrium	NN	B-NP
concentration	concentration	NN	I-NP
of	of	IN	0
drug	drug	NN	0
and	and	CC	0
maximizing	maximizing	JJ	0
receptor	receptor	NN	B-NP
target	target	NN	I-NP
occupation	occupation	NN	I-NP
level	level	JJ	I-NP
.	.	.	0
Upfront	Upfront	JJ	B-NP
bolus	bolus	JJ	I-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
24C	24C	CD	0
during	during	IN	0
the	the	DT	0
first	first	JJ	0
five	five	CD	0
to	to	TO	0
ten	ten	VB	0
days	days	NNS	0
is	is	VBZ	0
useful	useful	JJ	0
for	for	IN	0
treatment	treatment	NN	0
of	of	IN	0
post-surgical	post-surgical	JJ	0
or	or	CC	0
implant	implant	JJ	0
insertion	insertion	JJ	B-NP
trauma	trauma	NN	I-NP
and	and	CC	0
for	for	IN	0
creating	creating	VBG	0
maximum	maximum	JJ	0
diffusion	diffusion	NN	0
into	into	IN	0
the	the	DT	0
adjacent	adjacent	JJ	0
surgical	surgical	JJ	B-NP
anatomy	anatomy	NN	I-NP
.	.	.	0
Delayed	Delayed	VBN	B-NP
bolus	bolus	JJ	I-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	NNP	0
24D	24D	NNP	0
is	is	VBZ	0
useful	useful	JJ	0
in	in	IN	0
post-operative	post-operative	JJ	B-NP
treatment	treatment	NN	I-NP
,	,	,	0
particularly	particularly	RB	0
amelioration	amelioration	VBN	B-NP
of	of	IN	0
trauma	trauma	NN	0
in	in	IN	0
debridement	debridement	JJ	B-NP
therapy	therapy	NN	I-NP
post-operative	post-operative	JJ	I-NP
.	.	.	0
Degradation	Degradation	JJ	0
dependent	dependent	JJ	0
release	release	NN	0
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
24E	24E	CD	0
,	,	,	0
increasing	increasing	VBG	0
as	as	IN	0
the	the	DT	0
device	device	NN	0
is	is	VBZ	0
fully	fully	RB	0
bioabsorbed	bioabsorbed	JJ	0
,	,	,	0
is	is	VBZ	0
useful	useful	JJ	0
for	for	IN	0
prevention	prevention	NN	0
of	of	IN	0
any	any	DT	0
implant	implant	JJ	B-NP
/	/	CD	I-NP
device	device	NN	I-NP
elimination	elimination	NN	I-NP
trauma	trauma	NN	I-NP
or	or	CC	0
complication	complication	NN	B-NP
due	due	JJ	0
to	to	TO	0
bioabsorption	bioabsorption	VB	0
.	.	.	0
combination	combination	NN	B-NP
are	are	VBP	0
possible	possible	JJ	0
of	of	IN	0
any	any	DT	0
of	of	IN	0
the	the	DT	0
above	above	JJ	0
drug	drug	NN	B-NP
release	release	NN	I-NP
curve	curve	NN	I-NP
by	by	IN	0
integrating	integrating	VBG	0
various	various	JJ	0
drug	drug	NN	B-NP
release	release	NN	I-NP
method	method	NN	I-NP
(	(	-LRB-	0
for	for	IN	0
one	one	CD	0
or	or	CC	0
more	more	JJR	0
drugs	drugs	NNS	0
)	)	-RRB-	0
in	in	IN	0
a	a	DT	0
single	single	JJ	0
device	device	NN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
as	as	RB	0
illustrated	illustrated	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
24F	24F	CD	0
,	,	,	0
a	a	DT	0
combination	combination	NN	0
of	of	IN	0
an	an	DT	0
initial	initial	JJ	0
bolus	bolus	NN	B-NP
,	,	,	0
followed	followed	VBN	0
by	by	IN	0
substantially	substantially	RB	0
zero	zero	CD	0
order	order	NN	B-NP
release	release	NN	I-NP
,	,	,	0
followed	followed	VBN	0
by	by	IN	0
a	a	DT	0
final	final	JJ	B-NP
release	release	NN	I-NP
burst	burst	NN	I-NP
is	is	VBZ	0
particularly	particularly	RB	0
useful	useful	JJ	0
in	in	IN	0
post-surgical	post-surgical	JJ	B-NP
application	application	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
,	,	,	0
treating	treating	VBG	0
surgical	surgical	JJ	0
and	and	CC	0
implantation	implantation	JJ	B-NP
trauma	trauma	NN	I-NP
(	(	-LRB-	0
initial	initial	JJ	0
bolus	bolus	NN	B-NP
)	)	-RRB-	0
then	then	RB	0
surgical	surgical	JJ	B-NP
healing	healing	NN	I-NP
and	and	CC	0
disease	disease	NN	B-NP
recurrence	recurrence	NN	I-NP
(	(	-LRB-	0
substantially	substantially	RB	0
zero	zero	CD	0
order	order	NN	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
ultimately	ultimately	RB	0
any	any	DT	0
implant	implant	JJ	0
elimination	elimination	NN	B-NP
trauma	trauma	NN	I-NP
(	(	-LRB-	0
final	final	JJ	B-NP
release	release	NN	I-NP
burst	burst	NN	I-NP
)	)	-RRB-	0
.	.	.	0
application	application	NN	B-NP
.	.	.	0
Therapeutic	Therapeutic	JJ	B-NP
action	action	NN	I-NP
of	of	IN	0
device	device	NN	0
.	.	.	0
The	The	DT	0
structure	structure	NN	0
of	of	IN	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
itself	itself	PRP	0
may	may	MD	0
also	also	RB	0
have	have	VB	0
a	a	DT	0
therapeutic	therapeutic	JJ	B-NP
function	function	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
device	device	NN	0
may	may	MD	0
provide	provide	VB	0
such	such	JJ	0
functions	functions	NNS	0
as	as	IN	0
fixation	fixation	NN	0
or	or	CC	0
splinting	splinting	JJ	B-NP
tissue	tissue	NN	I-NP
via	via	IN	0
space	space	NN	B-NP
filling	filling	NN	I-NP
,	,	,	0
fastening	fastening	NN	0
,	,	,	0
deflection	deflection	NN	0
,	,	,	0
in	in	IN	0
order	order	NN	0
to	to	TO	0
provide	provide	VB	0
support	support	NN	0
and	and	CC	0
to	to	TO	0
keep	keep	VB	0
a	a	DT	0
body	body	NN	0
structure	structure	NN	0
open	open	JJ	0
,	,	,	0
as	as	RB	0
in	in	IN	0
stenting	stenting	NN	B-NP
or	or	CC	0
packing	packing	VBG	0
to	to	TO	0
prevent	prevent	VB	0
the	the	DT	0
middle	middle	JJ	B-NP
turbinate	turbinate	NN	I-NP
lateralization	lateralization	NN	I-NP
and	and	CC	0
middle	middle	JJ	B-NP
meatus	meatus	NN	I-NP
occlusion	occlusion	NN	I-NP
,	,	,	0
or	or	CC	0
by	by	IN	0
providing	providing	VBG	0
a	a	DT	0
physical	physical	JJ	B-NP
barrier	barrier	NN	I-NP
to	to	TO	0
adhesions	adhesions	VB	0
which	which	WDT	0
may	may	MD	0
form	form	VB	0
between	between	IN	0
various	various	JJ	0
post-surgical	post-surgical	JJ	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
inflamed	inflamed	JJ	0
tissue	tissue	NN	0
surfaces	surfaces	NN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
any	any	DT	0
device	device	NN	0
incorporating	incorporating	VBG	0
a	a	DT	0
solid	solid	JJ	0
,	,	,	0
semi-solid	semi-solid	NNP	B-NP
(	(	-LRB-	0
gel	gel	LS	B-NP
)	)	-RRB-	0
or	or	CC	0
woven	woven	NNS	0
or	or	CC	0
nonwoven	nonwoven	JJ	0
mesh	mesh	JJ	0
structure	structure	NN	0
could	could	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
practice	practice	VB	0
this	this	DT	0
method	method	NN	0
.	.	.	0
In	In	IN	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
device	device	NN	0
may	may	MD	0
non-occlusively	non-occlusively	RB	B-NP
maintain	maintain	VB	0
patency	patency	VBN	0
through	through	IN	0
the	the	DT	0
implant	implant	JJ	0
feature	feature	NN	B-NP
area	area	NN	I-NP
providing	providing	VBG	0
the	the	DT	0
device	device	NN	B-NP
action	action	NN	I-NP
by	by	IN	0
direct	direct	JJ	0
provision	provision	NN	0
and	and	CC	0
maintenance	maintenance	NN	0
of	of	IN	0
a	a	DT	0
channel	channel	NN	0
,	,	,	0
fenestration	fenestration	NN	B-NP
or	or	CC	0
port	port	NN	0
from	from	IN	0
the	the	DT	0
sinuses	sinuses	NN	0
to	to	TO	0
the	the	DT	0
infundibulum	infundibulum	NN	B-NP
,	,	,	0
osteomeatal	osteomeatal	JJ	B-NP
complex	complex	NN	I-NP
,	,	,	0
meatus	meatus	NN	B-NP
or	or	CC	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
by	by	IN	0
which	which	WDT	0
mucociliary	mucociliary	JJ	B-NP
flow	flow	NN	I-NP
may	may	MD	0
travel	travel	VB	0
.	.	.	0
Such	Such	PDT	0
a	a	DT	0
channel	channel	NN	0
may	may	MD	0
be	be	VB	0
within	within	IN	0
and	and	CC	0
support	support	VB	0
the	the	DT	0
structure	structure	NN	0
of	of	IN	0
natural	natural	JJ	0
ostia	ostia	NN	B-NP
or	or	CC	0
within	within	IN	0
and	and	CC	0
support	support	VB	0
a	a	DT	0
surgically	surgically	NN	0
created	created	VBN	0
or	or	CC	0
modified	modified	JJ	0
antrostomy	antrostomy	NN	B-NP
to	to	TO	0
the	the	DT	0
sinus	sinus	NN	B-NP
,	,	,	0
but	but	CC	0
may	may	MD	0
not	not	RB	0
totally	totally	RB	0
occlude	occlude	JJ	0
such	such	JJ	0
openings	openings	NNS	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
any	any	DT	0
device	device	NN	0
with	with	IN	0
a	a	DT	0
lumen	lumen	NN	B-NP
or	or	CC	0
pore	pore	JJ	0
such	such	JJ	0
as	as	IN	0
a	a	DT	0
tube	tube	NN	0
or	or	CC	0
cannula	cannula	NN	B-NP
,	,	,	0
or	or	CC	0
stent	stent	NN	B-NP
with	with	IN	0
a	a	DT	0
lumen	lumen	NN	B-NP
,	,	,	0
could	could	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
practice	practice	VB	0
this	this	DT	0
method	method	NN	0
,	,	,	0
as	as	RB	0
could	could	MD	0
a	a	DT	0
highly	highly	RB	0
porous	porous	JJ	B-NP
packing	packing	JJ	I-NP
material	material	NN	I-NP
,	,	,	0
three	three	CD	0
dimensional	dimensional	JJ	B-NP
mesh	mesh	NN	I-NP
,	,	,	0
or	or	CC	0
surface	surface	NN	0
or	or	CC	0
interior	interior	JJ	0
structured	structured	JJ	0
device	device	NN	0
through	through	IN	0
which	which	WDT	0
mucus	mucus	NNS	0
can	can	MD	0
flow	flow	VB	0
and	and	CC	0
which	which	WDT	0
does	does	VBZ	0
not	not	RB	0
become	become	VB	0
occlusive	occlusive	VBN	0
of	of	IN	0
the	the	DT	0
provided	provided	VBN	0
channel	channel	NN	0
through	through	IN	0
absorbancy	absorbancy	NN	B-NP
,	,	,	0
expansion	expansion	NN	0
,	,	,	0
or	or	CC	0
degradation	degradation	NN	0
.	.	.	0
Reduction	Reduction	NN	0
of	of	IN	0
complication	complication	NN	B-NP
upon	upon	IN	0
implantation	implantation	NN	B-NP
.	.	.	0
In	In	IN	0
yet	yet	RB	0
another	another	DT	0
variation	variation	NN	0
,	,	,	0
the	the	DT	0
device	device	NN	0
may	may	MD	0
possess	possess	VB	0
a	a	DT	0
structural	structural	JJ	B-NP
feature	feature	NN	I-NP
or	or	CC	0
active	active	JJ	0
agent	agent	NN	B-NP
that	that	WDT	0
helps	helps	VBZ	0
to	to	TO	0
reduce	reduce	VB	0
the	the	DT	0
device	device	NN	B-NP
implantation	implantation	NN	I-NP
complication	complication	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
device	device	NN	0
may	may	MD	0
:	:	:	0
1	1	LS	0
)	)	-RRB-	0
prevent	prevent	VB	0
trauma	trauma	JJ	0
due	due	JJ	0
to	to	TO	0
device	device	NN	B-NP
removal	removal	NN	I-NP
by	by	IN	0
use	use	NN	0
of	of	IN	0
bioabsorbable	bioabsorbable	JJ	B-NP
material	material	JJ	I-NP
;	;	:	0
2	2	LS	0
)	)	-RRB-	0
prevent	prevent	VB	0
biofilm	biofilm	JJ	B-NP
formation	formation	NN	I-NP
by	by	IN	0
use	use	NN	0
of	of	IN	0
coatings	coatings	NNS	0
,	,	,	0
physical	physical	JJ	B-NP
surface	surface	NN	I-NP
treatment	treatment	NN	I-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
incorporation	incorporation	NN	B-NP
or	or	CC	0
elution	elution	NN	B-NP
of	of	IN	0
an	an	DT	0
anti-infective	anti-infective	JJ	B-NP
or	or	CC	0
antiseptic	antiseptic	JJ	B-NP
substance	substance	NN	I-NP
;	;	:	0
3	3	LS	0
)	)	-RRB-	0
prevent	prevent	VB	0
foreign	foreign	JJ	0
body	body	NN	0
reactions	reactions	NNS	0
by	by	IN	0
including	including	VBG	B-NP
steroidal	steroidal	NNS	I-NP
incorporating	incorporating	VBG	I-NP
low-dose	low-dose	JJ	I-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
substance	substance	NN	I-NP
and	and	CC	0
non-steroidal	non-steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	NN	I-NP
(	(	-LRB-	0
for	for	IN	0
example	example	NN	0
,	,	,	0
including	including	VBG	0
the	the	DT	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
effect	effect	NN	I-NP
of	of	IN	0
low	low	JJ	0
dose	dose	NN	B-NP
macrolide	macrolide	NN	I-NP
antibiotic	antibiotic	JJ	I-NP
)	)	-RRB-	0
;	;	:	0
and	and	CC	0
4	4	LS	0
)	)	-RRB-	0
prevent	prevent	VB	0
device	device	NN	B-NP
migration	migration	NN	I-NP
by	by	IN	0
specific	specific	JJ	0
active	active	JJ	0
or	or	CC	0
passive	passive	JJ	B-NP
fixation	fixation	NN	I-NP
and	and	CC	0
anchoring	anchoring	JJ	0
features	features	NNS	0
incorporated	incorporated	VBN	0
in	in	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
Substances	Substances	NNS	0
that	that	WDT	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
prevent	prevent	VB	0
biofilm	biofilm	JJ	B-NP
formation	formation	NN	I-NP
include	include	VBP	0
,	,	,	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
alcohol	alcohol	NN	B-NP
,	,	,	0
chlorhexidine	chlorhexidine	NN	B-NP
,	,	,	0
iodine	iodine	NN	0
,	,	,	0
triclosan	triclosan	NN	B-NP
,	,	,	0
hexachlorophene	hexachlorophene	NN	B-NP
,	,	,	0
and	and	CC	0
silver-based	silver-based	JJ	0
agents	agents	NNS	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
silver	silver	JJ	B-NP
chloride	chloride	NN	I-NP
,	,	,	0
silver	silver	JJ	B-NP
oxide	oxide	NN	I-NP
,	,	,	0
silver	silver	JJ	B-NP
nanoparticle	nanoparticle	NN	I-NP
)	)	-RRB-	0
.	.	.	0
In	In	IN	0
other	other	JJ	0
variations	variations	NNS	0
,	,	,	0
the	the	DT	0
surface	surface	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
may	may	MD	0
treated	treated	VB	0
by	by	IN	0
a	a	DT	0
process	process	NN	0
(	(	-LRB-	0
e.g.	e.g.	FW	0
ion	ion	NN	B-NP
embedding	embedding	FW	0
,	,	,	0
plasma	plasma	JJ	0
etching	etching	NN	0
,	,	,	0
etc.	etc.	FW	0
)	)	-RRB-	0
altering	altering	VBG	0
the	the	DT	0
physical	physical	JJ	B-NP
property	property	NN	I-NP
of	of	IN	0
the	the	DT	0
surface	surface	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
in	in	IN	0
order	order	NN	0
to	to	TO	0
prevent	prevent	VB	0
biofilm	biofilm	JJ	B-NP
formation	formation	NN	I-NP
.	.	.	0
mucociliary	mucociliary	JJ	B-NP
clearance	clearance	NN	I-NP
exploitation	exploitation	NN	I-NP
.	.	.	0
Normal	Normal	JJ	B-NP
mucociliary	mucociliary	JJ	I-NP
clearance	clearance	NN	I-NP
may	may	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
extend	extend	VB	0
drug	drug	NN	B-NP
diffusion	diffusion	NN	I-NP
and	and	CC	0
effect	effect	NN	0
beyond	beyond	IN	0
the	the	DT	0
physical	physical	JJ	B-NP
location	location	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
This	This	DT	0
is	is	VBZ	0
useful	useful	JJ	0
in	in	IN	0
both	both	DT	0
normal	normal	JJ	0
and	and	CC	0
particularly	particularly	RB	0
diseased	diseased	JJ	0
mucociliary	mucociliary	JJ	B-NP
flow	flow	NN	I-NP
pattern	pattern	NN	I-NP
.	.	.	0
In	In	IN	0
the	the	DT	0
later	later	JJ	0
case	case	NN	0
,	,	,	0
the	the	DT	0
device	device	NN	0
is	is	VBZ	0
useful	useful	JJ	0
in	in	IN	0
effecting	effecting	VBG	0
the	the	DT	0
build	build	VB	0
up	up	RP	0
of	of	IN	0
released	released	VBN	B-NP
drug	drug	NN	I-NP
therapeutically	therapeutically	JJ	I-NP
desirable	desirable	JJ	I-NP
concentration	concentration	NN	I-NP
at	at	IN	0
blockages	blockages	NN	0
when	when	WRB	0
the	the	DT	0
normal	normal	JJ	B-NP
mucociliary	mucociliary	JJ	I-NP
flow	flow	NN	I-NP
is	is	VBZ	0
interrupted	interrupted	VBN	0
or	or	CC	0
impeded	impeded	VBN	0
by	by	IN	0
disease	disease	NN	0
,	,	,	0
and	and	CC	0
increasing	increasing	VBG	B-NP
drug	drug	NN	I-NP
concentration	concentration	NN	I-NP
gradient	gradient	NN	I-NP
where	where	WRB	0
mucociliary	mucociliary	JJ	B-NP
function	function	NN	I-NP
is	is	VBZ	0
most	most	RBS	0
impacted	impacted	JJ	0
by	by	IN	0
disease	disease	NN	0
.	.	.	0
anatomical	anatomical	JJ	B-NP
blockage	blockage	NN	I-NP
and	and	CC	0
areas	areas	NNS	0
of	of	IN	0
mucociliary	mucociliary	JJ	B-NP
dysfunction	dysfunction	NN	I-NP
or	or	CC	0
ciliary	ciliary	JJ	B-NP
dysmotility	dysmotility	NN	I-NP
may	may	MD	0
be	be	VB	0
particularly	particularly	RB	0
desirable	desirable	JJ	0
areas	areas	NNS	0
of	of	IN	0
such	such	JJ	0
drug	drug	NN	B-NP
treatment	treatment	NN	I-NP
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
anti-inflammatory	anti-inflammatory	NN	B-NP
and	and	CC	0
anti-infective	anti-infective	NN	B-NP
,	,	,	0
but	but	CC	0
also	also	RB	0
including	including	VBG	0
chemotherapeutic	chemotherapeutic	JJ	B-NP
agent	agent	NN	I-NP
)	)	-RRB-	0
,	,	,	0
so	so	RB	0
as	as	RB	0
to	to	TO	0
chemically	chemically	VB	0
open	open	RP	0
the	the	DT	0
blockage	blockage	NN	0
and	and	CC	0
to	to	TO	0
increase	increase	VB	0
treatment	treatment	NN	0
of	of	IN	0
the	the	DT	0
damaged	damaged	JJ	0
mucosa	mucosa	NN	B-NP
.	.	.	0
Thus	Thus	RB	0
,	,	,	0
the	the	DT	0
natural	natural	JJ	0
sinus	sinus	NN	B-NP
and	and	CC	0
upstream	upstream	JJ	0
locations	locations	NNS	0
along	along	IN	0
the	the	DT	0
mucociliary	mucociliary	JJ	B-NP
clearance	clearance	NN	I-NP
pathway	pathway	NN	I-NP
may	may	MD	0
serve	serve	VB	0
as	as	IN	0
drug	drug	NN	B-NP
depot	depot	NN	I-NP
,	,	,	0
with	with	IN	0
drug	drug	NN	0
traveling	traveling	VBG	0
to	to	TO	0
desired	desired	VB	0
sites	sites	NNS	0
downstream	downstream	VBN	0
in	in	IN	0
the	the	DT	0
pathway	pathway	NN	0
.	.	.	0
This	This	DT	0
contrasts	contrasts	NN	0
with	with	IN	0
previous	previous	JJ	0
and	and	CC	0
current	current	JJ	0
teachings	teachings	NN	0
in	in	IN	0
the	the	DT	0
field	field	NN	0
which	which	WDT	0
seek	seek	VBP	0
to	to	TO	0
impede	impede	VB	0
or	or	CC	0
reduce	reduce	VB	0
mucociliary	mucociliary	JJ	B-NP
clearance	clearance	NN	I-NP
of	of	IN	0
active	active	JJ	0
agents	agents	NNS	0
in	in	IN	0
order	order	NN	0
to	to	TO	0
maximize	maximize	VB	0
dose	dose	JJ	0
duration	duration	NN	0
.	.	.	0
In	In	IN	0
addition	addition	NN	0
to	to	TO	0
treating	treating	VBG	0
any	any	DT	0
one	one	NN	0
of	of	IN	0
the	the	DT	0
aforementioned	aforementioned	JJ	B-NP
paranasal	paranasal	JJ	I-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
described	described	VBD	0
herein	herein	NNS	0
may	may	MD	0
be	be	VB	0
placed	placed	VBN	0
during	during	IN	0
,	,	,	0
or	or	CC	0
as	as	IN	0
an	an	DT	0
adjunct	adjunct	NN	B-NP
to	to	TO	0
,	,	,	0
a	a	DT	0
surgical	surgical	JJ	0
,	,	,	0
non-surgical	non-surgical	NNP	B-NP
,	,	,	0
or	or	CC	0
other	other	JJ	0
therapeutic	therapeutic	JJ	B-NP
intervention	intervention	NN	I-NP
of	of	IN	0
the	the	DT	0
sinuses	sinuses	NN	0
or	or	CC	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
device	device	NN	0
may	may	MD	0
be	be	VB	0
used	used	VBN	0
during	during	IN	0
or	or	CC	0
as	as	IN	0
an	an	DT	0
adjunt	adjunt	NN	B-NP
to	to	TO	0
such	such	JJ	0
procedures	procedures	NNS	0
including	including	VBG	0
,	,	,	0
but	but	CC	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
septoplasty	septoplasty	NN	B-NP
(	(	-LRB-	0
surgical	surgical	JJ	B-NP
removal	removal	NN	I-NP
or	or	CC	0
adjustment	adjustment	NN	0
of	of	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
septum	septum	NN	I-NP
)	)	-RRB-	0
;	;	:	0
turbinoplasty	turbinoplasty	CD	B-NP
(	(	-LRB-	0
surgical	surgical	JJ	B-NP
removal	removal	NN	I-NP
or	or	CC	0
adjustment	adjustment	NN	0
of	of	IN	0
the	the	DT	0
turbinate	turbinate	JJ	B-NP
bone	bone	NN	I-NP
)	)	-RRB-	0
;	;	:	0
rhinoplasty	rhinoplasty	VBP	0
generally	generally	RB	0
;	;	:	0
sinus	sinus	JJ	B-NP
surgery	surgery	NN	I-NP
(	(	-LRB-	0
including	including	VBG	0
the	the	DT	0
exploration	exploration	NN	0
,	,	,	0
revision	revision	NN	0
,	,	,	0
repair	repair	NN	0
,	,	,	0
tissue	tissue	NN	0
dissection	dissection	NN	0
or	or	CC	0
removal	removal	NN	0
of	of	IN	0
some	some	DT	0
or	or	CC	0
part	part	NN	0
of	of	IN	0
any	any	DT	0
of	of	IN	0
the	the	DT	0
sinuses	sinuses	NN	0
,	,	,	0
including	including	VBG	0
the	the	DT	0
ethmoid	ethmoid	JJ	B-NP
sinus	sinus	NN	I-NP
(	(	-LRB-	0
as	as	RB	0
in	in	IN	0
ethmoidectomy	ethmoidectomy	CD	B-NP
)	)	-RRB-	0
,	,	,	0
maxillary	maxillary	JJ	B-NP
sinus	sinus	NN	I-NP
,	,	,	0
frontal	frontal	JJ	B-NP
sinus	sinus	NN	I-NP
,	,	,	0
or	or	CC	0
sphenoid	sphenoid	JJ	B-NP
sinus	sinus	NN	I-NP
)	)	-RRB-	0
;	;	:	0
polyp	polyp	JJ	B-NP
removal	removal	NN	I-NP
in	in	IN	0
any	any	DT	0
part	part	NN	0
of	of	IN	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
and	and	CC	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
;	;	:	0
cannulation	cannulation	CD	B-NP
,	,	,	0
irrigation	irrigation	NN	0
,	,	,	0
and	and	CC	0
therapy	therapy	NN	B-NP
instillation	instillation	NN	I-NP
or	or	CC	0
injection	injection	NN	B-NP
of	of	IN	0
any	any	DT	0
of	of	IN	0
the	the	DT	0
above	above	JJ	0
sinuses	sinuses	NN	0
or	or	CC	0
the	the	DT	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
,	,	,	0
including	including	VBG	0
through	through	IN	0
nasal	nasal	NN	B-NP
,	,	,	0
trans-ostial	trans-ostial	NNP	B-NP
,	,	,	0
and	and	CC	0
external	external	JJ	B-NP
puncture	puncture	JJ	I-NP
approach	approach	NN	I-NP
(	(	-LRB-	0
such	such	JJ	0
as	as	IN	0
through	through	IN	0
antral	antral	JJ	B-NP
puncture	puncture	NN	I-NP
,	,	,	0
trephination	trephination	NN	B-NP
or	or	CC	0
caldwell-luc	caldwell-luc	NN	B-NP
procedure	procedure	NN	I-NP
)	)	-RRB-	0
;	;	:	0
surgical	surgical	JJ	B-NP
revision	revision	NN	I-NP
,	,	,	0
dissection	dissection	NN	0
,	,	,	0
reconstruction	reconstruction	NN	B-NP
or	or	CC	0
repair	repair	NN	0
of	of	IN	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
anatomy	anatomy	NN	I-NP
and	and	CC	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
,	,	,	0
including	including	VBG	0
any	any	DT	0
removal	removal	NN	0
or	or	CC	0
adjustment	adjustment	NN	0
of	of	IN	0
neoplasms	neoplasms	NN	0
,	,	,	0
foreign	foreign	JJ	0
bodies	bodies	NNS	0
,	,	,	0
lesions	lesions	NNS	0
,	,	,	0
adhesions	adhesions	NN	0
,	,	,	0
defects	defects	NNS	0
,	,	,	0
stenosi	stenosi	NN	B-NP
,	,	,	0
and	and	CC	0
fistula	fistula	NN	B-NP
of	of	IN	0
the	the	DT	0
natural	natural	JJ	0
or	or	CC	0
post-surgical	post-surgical	JJ	B-NP
anatomy	anatomy	NN	I-NP
;	;	:	0
ligation	ligation	CD	B-NP
,	,	,	0
cauterization	cauterization	NN	B-NP
,	,	,	0
and	and	CC	0
ablation	ablation	JJ	B-NP
procedure	procedure	NN	I-NP
to	to	TO	0
control	control	VB	0
nasal	nasal	JJ	B-NP
bleeding	bleeding	NN	I-NP
and	and	CC	0
repair	repair	VB	0
vasculature	vasculature	VBN	0
in	in	IN	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
anatomy	anatomy	NN	I-NP
and	and	CC	0
nasal	nasal	JJ	B-NP
passage	passage	NN	I-NP
,	,	,	0
or	or	CC	0
as	as	IN	0
an	an	DT	0
adjunct	adjunct	NN	B-NP
or	or	CC	0
technique	technique	NN	0
to	to	TO	0
perform	perform	VB	0
any	any	DT	0
such	such	JJ	0
surgical	surgical	JJ	0
or	or	CC	0
non-surgical	non-surgical	JJ	B-NP
procedure	procedure	NN	I-NP
.	.	.	0
Thus	Thus	RB	0
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
described	described	VBD	0
here	here	RB	0
may	may	MD	0
have	have	VB	0
a	a	DT	0
variety	variety	NN	0
of	of	IN	0
functions	functions	NNS	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
they	they	PRP	0
may	may	MD	0
deliver	deliver	VB	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
to	to	TO	0
treat	treat	VB	0
rhinosinusiti	rhinosinusiti	NN	B-NP
,	,	,	0
have	have	VBP	0
a	a	DT	0
structure	structure	NN	0
that	that	WDT	0
prevents	prevents	VBZ	0
lateralization	lateralization	VBN	0
of	of	IN	0
the	the	DT	0
middle	middle	JJ	B-NP
turbinate	turbinate	NN	I-NP
and	and	CC	0
formation	formation	NN	0
of	of	IN	0
adhesions	adhesions	NN	0
,	,	,	0
have	have	VBP	0
a	a	DT	0
structure	structure	NN	0
which	which	WDT	0
directly	directly	RB	0
or	or	CC	0
indirectly	indirectly	RB	0
preserves	preserves	VBZ	0
ostial	ostial	JJ	B-NP
patency	patency	NN	I-NP
,	,	,	0
as	as	RB	0
well	well	RB	0
as	as	RB	0
have	have	VB	0
a	a	DT	0
coating	coating	NN	0
that	that	WDT	0
prevents	prevents	VBZ	0
biofilm	biofilm	JJ	B-NP
formation	formation	NN	I-NP
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
may	may	MD	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
include	include	VB	0
any	any	DT	0
number	number	NN	0
and	and	CC	0
combination	combination	NN	0
of	of	IN	0
functions	functions	NNS	0
listed	listed	VBN	0
above	above	IN	0
.	.	.	0
delivery	delivery	NN	B-NP
device	device	NN	I-NP
and	and	CC	0
methods	methods	NNS	0
of	of	IN	0
use	use	NN	0
.	.	.	0
The	The	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
may	may	MD	0
be	be	VB	0
placed	placed	VBN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	NN	B-NP
using	using	VBG	0
various	various	JJ	0
types	types	NNS	0
of	of	IN	0
sinus	sinus	JJ	B-NP
inserter	inserter	NN	I-NP
.	.	.	0
The	The	DT	0
inserter	inserter	NN	B-NP
may	may	MD	0
include	include	VB	0
a	a	DT	0
conduit	conduit	NN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
a	a	DT	0
catheter	catheter	NN	B-NP
with	with	IN	0
a	a	DT	0
lumen	lumen	NN	B-NP
.	.	.	0
The	The	DT	0
conduit	conduit	NN	0
may	may	MD	0
be	be	VB	0
flexible	flexible	JJ	0
or	or	CC	0
rigid	rigid	JJ	0
,	,	,	0
or	or	CC	0
may	may	MD	0
be	be	VB	0
designed	designed	VBN	0
to	to	TO	0
have	have	VB	0
varying	varying	VBG	B-NP
degree	degree	NN	I-NP
of	of	IN	0
stiffness	stiffness	NN	0
along	along	IN	0
its	its	PRP$	0
length	length	NN	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
the	the	DT	0
distal	distal	JJ	B-NP
portion	portion	NN	I-NP
of	of	IN	0
the	the	DT	0
conduit	conduit	NN	0
may	may	MD	0
be	be	VB	0
stiffer	stiffer	JJR	0
than	than	IN	0
the	the	DT	0
proximal	proximal	JJ	B-NP
portion	portion	NN	I-NP
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
the	the	DT	0
distal	distal	JJ	B-NP
portion	portion	NN	I-NP
of	of	IN	0
the	the	DT	0
conduit	conduit	NN	0
may	may	MD	0
be	be	VB	0
variously	variously	JJ	0
angulated	angulated	NN	0
to	to	TO	0
facilitate	facilitate	VB	0
positioning	positioning	NN	0
and	and	CC	0
advancement	advancement	NN	0
of	of	IN	0
the	the	DT	0
conduit	conduit	NN	0
through	through	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
distal	distal	JJ	B-NP
portion	portion	NN	I-NP
may	may	MD	0
be	be	VB	0
angulated	angulated	VBN	0
from	from	IN	0
about	about	IN	0
0	0	CD	0
to	to	TO	0
about	about	RB	0
175	175	CD	0
,	,	,	0
from	from	IN	0
about	about	IN	0
0	0	CD	0
to	to	TO	0
about	about	RB	0
135	135	CD	0
,	,	,	0
or	or	CC	0
from	from	IN	0
about	about	IN	0
0	0	CD	0
to	to	TO	0
about	about	RB	0
90	90	CD	0
.	.	.	0
If	If	IN	0
desired	desired	NN	0
,	,	,	0
the	the	DT	0
distal	distal	JJ	B-NP
portion	portion	NN	I-NP
of	of	IN	0
the	the	DT	0
conduit	conduit	NN	0
may	may	MD	0
also	also	RB	0
be	be	VB	0
formed	formed	VBN	0
to	to	TO	0
be	be	VB	0
malleable	malleable	NNS	0
.	.	.	0
The	The	DT	0
conduit	conduit	NN	0
may	may	MD	0
be	be	VB	0
made	made	VBN	0
from	from	IN	0
any	any	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
including	including	VBG	0
,	,	,	0
but	but	CC	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
,	,	,	0
stainless	stainless	JJ	0
steel	steel	NN	0
and	and	CC	0
any	any	DT	0
of	of	IN	0
its	its	PRP$	0
alloys	alloys	NNS	0
;	;	:	0
titanium	titanium	JJ	0
alloys	alloys	NNS	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
nickel-titanium	nickel-titanium	JJ	B-NP
alloy	alloy	NN	I-NP
;	;	:	0
polymers	polymers	NNS	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
polyethylene	polyethylene	NN	B-NP
and	and	CC	0
copolymers	copolymers	JJ	0
thereof	thereof	NN	0
,	,	,	0
polyethylene	polyethylene	NN	0
terephthalate	terephthalate	NNS	0
or	or	CC	0
copolymers	copolymers	JJ	0
thereof	thereof	NN	0
,	,	,	0
nylon	nylon	NN	B-NP
,	,	,	0
silicone	silicone	NN	B-NP
,	,	,	0
polyurethanes	polyurethanes	NN	0
,	,	,	0
fluoropolymer	fluoropolymer	NN	B-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
vinylchloride	vinylchloride	LS	I-NP
)	)	-RRB-	I-NP
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof	thereof	NN	0
,	,	,	0
depending	depending	VBG	0
on	on	IN	0
the	the	DT	0
amount	amount	NN	0
of	of	IN	0
flexibility	flexibility	NN	0
or	or	CC	0
stiffness	stiffness	JJ	0
desired	desired	NN	0
.	.	.	0
The	The	DT	0
inserter	inserter	NN	B-NP
may	may	MD	0
be	be	VB	0
preloaded	preloaded	VBN	0
with	with	IN	0
a	a	DT	0
single	single	JJ	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
on	on	IN	0
or	or	CC	0
within	within	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
end	end	NN	I-NP
of	of	IN	0
the	the	DT	0
conduit	conduit	NN	0
,	,	,	0
but	but	CC	0
more	more	JJR	0
than	than	IN	0
one	one	CD	0
device	device	NN	0
may	may	MD	0
be	be	VB	0
preloaded	preloaded	VBN	0
if	if	IN	0
desired	desired	NN	0
.	.	.	0
It	It	PRP	0
may	may	MD	0
be	be	VB	0
preloaded	preloaded	VBN	0
on	on	IN	0
or	or	CC	0
within	within	IN	0
the	the	DT	0
inserter	inserter	NN	B-NP
by	by	IN	0
the	the	DT	0
physician	physician	NN	0
prior	prior	RB	0
to	to	TO	0
insertion	insertion	VB	0
or	or	CC	0
preloaded	preloaded	NN	0
on	on	IN	0
or	or	CC	0
within	within	IN	0
the	the	DT	0
inserter	inserter	NN	B-NP
during	during	IN	0
the	the	DT	0
manufacturing	manufacturing	NN	B-NP
process	process	NN	I-NP
.	.	.	0
Once	Once	IN	0
access	access	NN	0
through	through	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
or	or	CC	0
surgically	surgically	RB	0
created	created	VBN	B-NP
fenestration	fenestration	NN	I-NP
has	has	VBZ	0
been	been	VBN	0
obtained	obtained	VBN	0
with	with	IN	0
the	the	DT	0
conduit	conduit	NN	0
,	,	,	0
the	the	DT	0
sheath	sheath	NN	0
may	may	MD	0
be	be	VB	0
retracted	retracted	VBN	0
to	to	TO	0
slidably	slidably	VB	0
deploy	deploy	VBN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
If	If	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
is	is	VBZ	0
self-expanding	self-expanding	JJ	0
,	,	,	0
then	then	RB	0
retraction	retraction	VBN	0
of	of	IN	0
a	a	DT	0
sheath	sheath	NN	0
also	also	RB	0
causes	causes	VBZ	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
to	to	TO	0
be	be	VB	0
deployed	deployed	VBN	0
.	.	.	0
If	If	IN	0
expansion	expansion	NN	0
using	using	VBG	0
a	a	DT	0
balloon	balloon	NN	0
is	is	VBZ	0
required	required	VBN	0
,	,	,	0
any	any	DT	0
balloon	balloon	NN	B-NP
catheter	catheter	NN	I-NP
(	(	-LRB-	0
including	including	VBG	0
double	double	JJ	0
balloon	balloon	NN	B-NP
catheter	catheter	NN	I-NP
)	)	-RRB-	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
may	may	MD	0
be	be	VB	0
advanced	advanced	VBN	0
through	through	IN	0
the	the	DT	0
lumen	lumen	NN	B-NP
in	in	IN	0
the	the	DT	0
conduit	conduit	NN	0
until	until	IN	0
the	the	DT	0
balloon	balloon	NN	0
lies	lies	VBZ	0
within	within	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
.	.	.	0
Inflation	Inflation	NN	B-NP
of	of	IN	0
the	the	DT	0
balloon	balloon	NN	0
thereby	thereby	RB	0
causes	causes	VBZ	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
to	to	TO	0
change	change	VB	0
from	from	IN	0
a	a	DT	0
first	first	JJ	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
to	to	TO	0
a	a	DT	0
second	second	JJ	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
and	and	CC	0
contact	contact	VB	0
the	the	DT	0
sinus	sinus	JJ	0
cavity	cavity	JJ	0
wall	wall	NN	0
.	.	.	0
An	An	DT	0
endoscope	endoscope	NN	B-NP
may	may	MD	0
also	also	RB	0
be	be	VB	0
used	used	VBN	0
while	while	IN	0
positioning	positioning	VBG	0
the	the	DT	0
inserter	inserter	NN	B-NP
to	to	TO	0
aid	aid	VB	0
with	with	IN	0
ostium	ostium	NN	B-NP
visualization	visualization	NN	I-NP
.	.	.	0
irrigation	irrigation	NN	B-NP
tool	tool	NN	I-NP
and	and	CC	0
electrocautery	electrocautery	NN	B-NP
may	may	MD	0
also	also	RB	0
be	be	VB	0
employed	employed	VBN	0
if	if	IN	0
needed	needed	VBN	0
.	.	.	0
The	The	DT	0
following	following	JJ	0
description	description	NN	0
provides	provides	VBZ	0
an	an	DT	0
exemplary	exemplary	JJ	B-NP
way	way	NN	I-NP
of	of	IN	0
a	a	DT	0
how	how	WRB	0
a	a	DT	0
single	single	JJ	0
device	device	NN	0
might	might	MD	0
be	be	VB	0
deployed	deployed	VBN	0
into	into	IN	0
a	a	DT	0
sinus	sinus	NN	B-NP
using	using	VBG	0
a	a	DT	0
sinus	sinus	JJ	B-NP
inserter	inserter	NN	I-NP
.	.	.	0
The	The	DT	0
sinus	sinus	JJ	B-NP
inserter	inserter	NN	I-NP
typically	typically	RB	0
includes	includes	VBZ	0
a	a	DT	0
distal	distal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
a	a	DT	0
sinus	sinus	JJ	B-NP
device	device	NN	I-NP
in	in	IN	0
its	its	PRP$	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
on	on	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
a	a	DT	0
handle	handle	NN	0
,	,	,	0
a	a	DT	0
conduit	conduit	NN	0
having	having	VBG	0
a	a	DT	0
lumen	lumen	NN	B-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
sheath	sheath	NN	0
connected	connected	VBN	0
to	to	TO	0
a	a	DT	0
retractable	retractable	JJ	0
knob	knob	NN	B-NP
.	.	.	0
Upon	Upon	IN	0
pulling	pulling	VBG	0
the	the	DT	0
retractable	retractable	JJ	0
knob	knob	NN	B-NP
,	,	,	0
the	the	DT	0
knob	knob	JJ	B-NP
move	move	NN	I-NP
proximally	proximally	VBP	0
to	to	TO	0
abut	abut	VB	0
the	the	DT	0
handle	handle	NN	0
and	and	CC	0
slidably	slidably	NNS	0
deploy	deploy	VBP	0
the	the	DT	0
self-expanding	self-expanding	JJ	0
nasal	nasal	JJ	B-NP
plate	plate	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
.	.	.	0
A	A	DT	0
balloon	balloon	NN	B-NP
catheter	catheter	NN	I-NP
may	may	MD	0
then	then	RB	0
be	be	VB	0
advanced	advanced	VBN	0
through	through	IN	0
the	the	DT	0
lumen	lumen	NN	B-NP
of	of	IN	0
the	the	DT	0
conduit	conduit	NN	0
into	into	IN	0
the	the	DT	0
inserter	inserter	NN	B-NP
distal	distal	JJ	I-NP
portion	portion	NN	I-NP
and	and	CC	0
inflated	inflated	VBN	0
to	to	TO	0
expand	expand	VB	0
the	the	DT	0
sinus	sinus	JJ	B-NP
device	device	NN	I-NP
,	,	,	0
such	such	JJ	0
as	as	IN	0
the	the	DT	0
flexible	flexible	JJ	0
mesh	mesh	NN	0
40	40	CD	0
of	of	IN	0
FIGS.	FIGS.	CD	0
4A-4B	4A-4B	CD	0
.	.	.	0
Method	Method	NN	0
of	of	IN	0
manufacture	manufacture	NN	0
.	.	.	0
The	The	DT	0
method	method	NN	0
of	of	IN	0
preparing	preparing	VBG	0
the	the	DT	0
devices	devices	NNS	0
of	of	IN	0
this	this	DT	0
invention	invention	NN	0
will	will	MD	0
generally	generally	RB	0
depend	depend	VB	0
on	on	IN	0
the	the	DT	0
particular	particular	JJ	0
active	active	JJ	0
agent	agent	NN	B-NP
or	or	CC	0
polymer	polymer	VB	B-NP
used	used	VBN	0
,	,	,	0
form	form	NN	0
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
and	and	CC	0
the	the	DT	0
release	release	NN	B-NP
kinetics	kinetics	VBZ	I-NP
desired	desired	VBN	0
,	,	,	0
but	but	CC	0
may	may	MD	0
be	be	VB	0
made	made	VBN	0
by	by	IN	0
any	any	DT	0
one	one	NN	0
of	of	IN	0
the	the	DT	0
numerous	numerous	JJ	B-NP
method	method	NN	I-NP
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
the	the	DT	0
devices	devices	NNS	0
may	may	MD	0
be	be	VB	0
made	made	VBN	0
by	by	IN	0
such	such	JJ	0
processes	processes	NNS	0
as	as	IN	0
extrusion	extrusion	NN	0
;	;	:	0
injection	injection	NN	B-NP
or	or	CC	0
form	form	NN	B-NP
mold	mold	NN	I-NP
;	;	:	0
blow	blow	NN	0
,	,	,	0
film	film	NN	0
,	,	,	0
or	or	CC	0
melt	melt	JJ	0
casting	casting	NN	0
;	;	:	0
welding	welding	CD	0
;	;	:	0
and	and	CC	0
other	other	JJ	0
manufacturing	manufacturing	NN	B-NP
technique	technique	NN	I-NP
well	well	RB	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
cutting	cutting	VBG	0
and	and	CC	0
annealing	annealing	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
filaments	filaments	NN	0
may	may	MD	0
be	be	VB	0
wet	wet	JJ	0
or	or	CC	0
melt	melt	VB	0
spun	spun	VBN	0
,	,	,	0
formed	formed	VBN	0
by	by	IN	0
laser	laser	NN	0
or	or	CC	0
other	other	JJ	0
cutting	cutting	NN	0
,	,	,	0
formed	formed	VBN	0
by	by	IN	0
slitting	slitting	NN	0
,	,	,	0
formed	formed	VBN	0
by	by	IN	0
extrusion	extrusion	NN	0
,	,	,	0
injection	injection	NN	B-NP
or	or	CC	0
other	other	JJ	0
molding	molding	NN	0
,	,	,	0
or	or	CC	0
casting	casting	NN	0
.	.	.	0
The	The	DT	0
following	following	JJ	0
examples	examples	NNS	0
serve	serve	VBP	0
to	to	TO	0
more	more	RBR	0
fully	fully	RB	0
describe	describe	VB	0
the	the	DT	0
manner	manner	NN	0
of	of	IN	0
making	making	VBG	0
and	and	CC	0
using	using	VBG	0
the	the	DT	0
above-described	above-described	JJ	0
devices	devices	NNS	0
.	.	.	0
It	It	PRP	0
is	is	VBZ	0
understood	understood	VBN	0
that	that	IN	0
these	these	DT	0
examples	examples	NNS	0
in	in	IN	0
no	no	DT	0
way	way	NN	0
serve	serve	VBP	0
to	to	TO	0
limit	limit	VB	0
the	the	DT	0
scope	scope	NN	0
of	of	IN	0
this	this	DT	0
invention	invention	NN	0
,	,	,	0
but	but	CC	0
rather	rather	RB	0
are	are	VBP	0
presented	presented	VBN	0
for	for	IN	0
illustrative	illustrative	JJ	B-NP
purpose	purpose	NN	I-NP
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
the	the	DT	0
following	following	JJ	0
examples	examples	NNS	0
will	will	MD	0
employ	employ	VB	0
,	,	,	0
unless	unless	IN	0
otherwise	otherwise	RB	0
indicated	indicated	VBN	0
,	,	,	0
pharmaceutical	pharmaceutical	JJ	B-NP
formulation	formulation	NN	I-NP
conventional	conventional	JJ	I-NP
technique	technique	NN	I-NP
,	,	,	0
medicinal	medicinal	JJ	B-NP
chemistry	chemistry	NN	I-NP
,	,	,	0
and	and	CC	0
the	the	DT	0
like	like	JJ	0
,	,	,	0
which	which	WDT	0
are	are	VBP	0
within	within	IN	0
the	the	DT	0
skill	skill	NN	0
of	of	IN	0
the	the	DT	0
art	art	NN	0
.	.	.	0
Such	Such	JJ	0
techniques	techniques	NNS	0
are	are	VBP	0
explained	explained	VBN	0
fully	fully	RB	0
in	in	IN	0
the	the	DT	0
literature	literature	NN	0
.	.	.	0
Efforts	Efforts	NNS	0
have	have	VBP	0
been	been	VBN	0
made	made	VBN	0
to	to	TO	0
ensure	ensure	VB	0
accuracy	accuracy	NN	B-NP
with	with	IN	0
respect	respect	NN	0
to	to	TO	0
numbers	numbers	NNS	0
(	(	-LRB-	0
e.g.	e.g.	NNP	0
,	,	,	0
amounts	amounts	NNS	0
,	,	,	0
temperature	temperature	NN	0
,	,	,	0
etc.	etc.	FW	0
)	)	-RRB-	0
,	,	,	0
but	but	CC	0
some	some	DT	0
experimental	experimental	JJ	B-NP
error	error	NN	I-NP
and	and	CC	0
deviation	deviation	NN	0
should	should	MD	0
be	be	VB	0
accounted	accounted	VBN	0
for	for	IN	0
.	.	.	0
Unless	Unless	IN	0
indicated	indicated	VBN	0
otherwise	otherwise	RB	0
,	,	,	0
parts	parts	NNS	0
are	are	VBP	0
parts	parts	NNS	0
by	by	IN	0
weight	weight	NN	0
,	,	,	0
temperature	temperature	NN	0
is	is	VBZ	0
in	in	IN	0
degrees	degrees	JJ	0
Celsius	Celsius	NNP	B-NP
(	(	-LRB-	0
C.	C.	LS	0
)	)	-RRB-	0
and	and	CC	0
pressure	pressure	NN	0
is	is	VBZ	0
at	at	IN	0
or	or	CC	0
near	near	IN	0
atmospheric	atmospheric	JJ	B-NP
pressure	pressure	NN	I-NP
at	at	IN	0
sea	sea	NN	B-NP
level	level	NN	I-NP
.	.	.	0
All	All	DT	0
components	components	NNS	0
are	are	VBP	0
obtainable	obtainable	JJ	0
commercially	commercially	NN	0
unless	unless	IN	0
otherwise	otherwise	RB	0
indicated	indicated	VBN	0
.	.	.	0
Extruded	Extruded	JJ	B-NP
ribbon	ribbon	JJ	I-NP
fiber	fiber	NN	I-NP
was	was	VBD	0
made	made	VBN	0
with	with	IN	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
and	and	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
DL-lactide-co-glycolide	DL-lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
.	.	.	0
The	The	DT	0
desired	desired	JJ	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	JJ	I-NP
content	content	NN	I-NP
in	in	IN	0
the	the	DT	0
device	device	NN	0
was	was	VBD	0
5	5	CD	0
wt	wt	JJ	0
%	%	NN	0
mometasone	mometasone	NN	B-NP
furoate	furoate	NN	I-NP
.	.	.	0
The	The	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
DL-lactide-co-glycolide	DL-lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
was	was	VBD	0
ester	ester	VBN	B-NP
capped	capped	VBN	0
with	with	IN	0
a	a	DT	0
molar	molar	JJ	B-NP
ratio	ratio	NN	I-NP
of	of	IN	0
70	70	CD	0
/	/	CD	0
30	30	CD	0
DL-lactide	DL-lactide	JJ	B-NP
/	/	CD	I-NP
glycolida	glycolida	NN	I-NP
and	and	CC	0
had	had	VBD	0
an	an	DT	0
inherent	inherent	JJ	0
viscosity	viscosity	NN	0
of	of	IN	0
0.81	0.81	NNP	0
dL	dL	NNP	B-NP
/	/	NNP	I-NP
g	g	NN	I-NP
.	.	.	0
The	The	DT	0
inherent	inherent	JJ	0
viscosity	viscosity	NN	0
was	was	VBD	0
measured	measured	VBN	0
at	at	IN	0
30	30	CD	0
C.	C.	NNP	0
with	with	IN	0
0.5	0.5	CD	0
gm	gm	CD	B-NP
/	/	CD	I-NP
dL	dL	JJ	I-NP
polymer	polymer	JJ	I-NP
concentration	concentration	NN	I-NP
in	in	IN	0
chloroform	chloroform	NN	B-NP
.	.	.	0
First	First	JJ	B-NP
mometasone	mometasone	JJ	I-NP
furoata	furoata	NN	I-NP
(	(	-LRB-	0
0.5	0.5	CD	0
gm	gm	CD	B-NP
)	)	-RRB-	0
and	and	CC	0
the	the	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
DL-lactide-co-glycolide	DL-lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
(	(	-LRB-	0
9.5	9.5	CD	0
gm	gm	CD	B-NP
)	)	-RRB-	0
were	were	VBD	0
dissolved	dissolved	VBN	0
in	in	IN	0
methylene	methylene	JJ	B-NP
chloride	chloride	NN	I-NP
(	(	-LRB-	0
40	40	CD	0
gm	gm	CD	B-NP
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
thin	thin	JJ	0
film	film	NN	0
was	was	VBD	0
cast	cast	VBN	0
from	from	IN	0
the	the	DT	0
resulting	resulting	JJ	0
solution	solution	NN	B-NP
.	.	.	0
The	The	DT	0
cast	cast	NN	B-NP
film	film	NN	I-NP
was	was	VBD	0
dried	dried	VBN	0
in	in	IN	0
a	a	DT	0
vacuum	vacuum	NN	0
oven	oven	NN	0
for	for	IN	0
48-96	48-96	CD	0
hours	hours	NNS	0
to	to	TO	0
remove	remove	VB	0
residual	residual	JJ	B-NP
methylene	methylene	JJ	I-NP
chloride	chloride	NN	I-NP
.	.	.	0
The	The	DT	0
cast	cast	NN	B-NP
film	film	NN	I-NP
was	was	VBD	0
cut	cut	VBN	0
into	into	IN	0
thin	thin	JJ	0
strips	strips	NNS	0
approximately	approximately	RB	0
10-20	10-20	CD	0
mm	mm	CD	0
wide	wide	JJ	0
and	and	CC	0
100-150	100-150	NNP	0
mm	mm	VBD	0
long	long	RB	0
.	.	.	0
Next	Next	IN	0
a	a	DT	0
Tinius	Tinius	NNP	B-NP
Olsen	Olsen	NNP	I-NP
Model	Model	NNP	I-NP
UE-4-78	UE-4-78	NNP	I-NP
melt	melt	NN	0
plastometer	plastometer	NN	B-NP
was	was	VBD	0
used	used	VBN	0
to	to	TO	0
extrude	extrude	VB	0
the	the	DT	0
cast	cast	NN	B-NP
film	film	NN	I-NP
strip	strip	NN	I-NP
.	.	.	0
The	The	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
is	is	VBZ	0
a	a	DT	0
solid	solid	JJ	0
block	block	NN	0
of	of	IN	0
steel	steel	NN	0
about	about	IN	0
80	80	CD	0
mm	mm	NN	0
in	in	IN	0
diameter	diameter	NN	0
and	and	CC	0
about	about	IN	0
160	160	CD	0
mm	mm	CD	0
high	high	JJ	0
/	/	NN	0
long	long	RB	0
with	with	IN	0
a	a	DT	0
hollow	hollow	JJ	0
core	core	NN	0
about	about	IN	0
13	13	CD	0
mm	mm	NN	0
in	in	IN	0
diameter	diameter	NN	0
.	.	.	0
The	The	DT	0
discharge	discharge	NN	0
of	of	IN	0
the	the	DT	0
core	core	NN	0
has	has	VBZ	0
a	a	DT	0
shoulder	shoulder	NN	0
that	that	WDT	0
allows	allows	VBZ	0
different	different	JJ	0
size	size	NN	0
dies	dies	VBZ	0
to	to	TO	0
be	be	VB	0
used	used	VBN	0
based	based	VBN	0
on	on	IN	0
the	the	DT	0
desired	desired	JJ	0
diameter	diameter	NN	0
of	of	IN	0
extruded	extruded	JJ	0
rod	rod	NN	0
.	.	.	0
For	For	IN	0
this	this	DT	0
run	run	NN	0
,	,	,	0
a	a	DT	0
custom	custom	NN	0
machined	machined	NNS	0
die	die	VBP	0
was	was	VBD	0
used	used	VBN	0
with	with	IN	0
internal	internal	JJ	B-NP
core	core	NN	I-NP
dimension	dimension	NN	I-NP
of	of	IN	0
0.3556	0.3556	FW	0
mm	mm	FW	0
2.0015	2.0015	FW	0
mm	mm	FW	0
.	.	.	0
The	The	DT	0
main	main	JJ	0
block	block	NN	0
of	of	IN	0
the	the	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
has	has	VBZ	0
heater	heater	JJ	B-NP
band	band	NN	I-NP
encased	encased	NN	0
by	by	IN	0
insulation	insulation	NN	B-NP
and	and	CC	0
a	a	DT	0
shroud	shroud	NN	0
that	that	WDT	0
allow	allow	VBP	0
the	the	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
to	to	TO	0
be	be	VB	0
heated	heated	VBN	0
to	to	TO	0
a	a	DT	0
desired	desired	JJ	0
temperature	temperature	NN	0
.	.	.	0
A	A	DT	0
thermocouple	thermocouple	NN	B-NP
was	was	VBD	0
used	used	VBN	0
to	to	TO	0
measure	measure	VB	0
the	the	DT	0
temperature	temperature	NN	0
of	of	IN	0
the	the	DT	0
block	block	NN	0
.	.	.	0
The	The	DT	0
control	control	NN	B-NP
system	system	NN	I-NP
then	then	RB	0
uses	uses	VBZ	0
the	the	DT	0
thermocouple	thermocouple	JJ	B-NP
value	value	NN	I-NP
to	to	TO	0
either	either	RB	0
turn	turn	VB	0
the	the	DT	0
heater	heater	JJ	B-NP
band	band	NN	I-NP
on	on	IN	0
or	or	CC	0
off	off	RB	0
.	.	.	0
Throughout	Throughout	IN	0
the	the	DT	0
extrusion	extrusion	NN	B-NP
process	process	NN	I-NP
,	,	,	0
the	the	DT	0
heater	heater	JJ	B-NP
band	band	NN	I-NP
will	will	MD	0
switch	switch	VB	0
off	off	RP	0
and	and	CC	0
on	on	IN	0
to	to	TO	0
maintain	maintain	VB	0
the	the	DT	0
desired	desired	JJ	0
temperature	temperature	NN	0
.	.	.	0
The	The	DT	0
cast	cast	NN	B-NP
film	film	NN	I-NP
strip	strip	NN	I-NP
,	,	,	0
approximately	approximately	RB	0
4	4	CD	0
gm	gm	NN	B-NP
,	,	,	0
were	were	VBD	0
loaded	loaded	VBN	0
into	into	IN	0
the	the	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
which	which	WDT	0
had	had	VBD	0
been	been	VBN	0
equilibrated	equilibrated	VBN	0
to	to	TO	0
120	120	CD	0
C.	C.	NNP	0
A	A	NNP	0
charging	charging	VBG	0
rod	rod	NN	0
was	was	VBD	0
placed	placed	VBN	0
in	in	IN	0
the	the	DT	0
core	core	NN	0
of	of	IN	0
the	the	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
to	to	TO	0
compress	compress	VB	0
the	the	DT	0
blend	blend	NN	0
and	and	CC	0
a	a	DT	0
weight	weight	NN	0
of	of	IN	0
10	10	CD	0
kg	kg	NN	B-NP
was	was	VBD	0
placed	placed	VBN	B-NP
oh	oh	VBG	I-NP
the	the	DT	0
end	end	NN	0
of	of	IN	0
the	the	DT	0
charging	charging	VBG	0
rod	rod	NN	0
to	to	TO	0
aid	aid	VB	0
in	in	IN	0
the	the	DT	0
compaction	compaction	NN	B-NP
of	of	IN	0
the	the	DT	0
blend	blend	NN	0
.	.	.	0
The	The	DT	0
equilibration	equilibration	JJ	B-NP
time	time	NN	I-NP
for	for	IN	0
the	the	DT	0
blend	blend	NN	0
to	to	TO	0
melt	melt	VB	0
lasted	lasted	VBN	0
for	for	IN	0
about	about	IN	0
20	20	CD	0
minutes	minutes	NNS	0
.	.	.	0
After	After	IN	0
an	an	DT	0
extrusion	extrusion	NN	B-NP
load	load	NN	I-NP
of	of	IN	0
10,000	10,000	CD	0
gm	gm	NN	B-NP
was	was	VBD	0
placed	placed	VBN	0
on	on	IN	0
the	the	DT	0
charging	charging	VBG	0
rod	rod	NN	0
,	,	,	0
the	the	DT	0
plug	plug	NN	0
was	was	VBD	0
removed	removed	VBN	0
from	from	IN	0
the	the	DT	0
discharge	discharge	NN	B-NP
area	area	NN	I-NP
to	to	TO	0
begin	begin	VB	0
the	the	DT	0
extrusion	extrusion	NN	B-NP
run	run	NN	I-NP
.	.	.	0
As	As	IN	0
the	the	DT	0
ribbon	ribbon	JJ	B-NP
fiber	fiber	NN	I-NP
was	was	VBD	0
extruded	extruded	VBN	0
from	from	IN	0
the	the	DT	0
discharge	discharge	NN	0
,	,	,	0
it	it	PRP	0
was	was	VBD	0
pulled	pulled	VBN	0
using	using	VBG	0
a	a	DT	0
conveyor	conveyor	JJ	B-NP
belt	belt	NN	I-NP
to	to	TO	0
the	the	DT	0
desired	desired	JJ	0
dimensions	dimensions	NNS	0
(	(	-LRB-	0
0.3-0.4	0.3-0.4	FW	0
mm	mm	FW	0
1.0-1.2	1.0-1.2	FW	0
mm	mm	FW	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
4-gm	4-gm	JJ	0
charge	charge	NN	0
afforded	afforded	VBN	0
7-10	7-10	CD	0
segments	segments	NNS	0
of	of	IN	0
extruded	extruded	JJ	0
fiber	fiber	NN	B-NP
each	each	DT	0
having	having	VBG	0
a	a	DT	0
length	length	NN	0
of	of	IN	0
about	about	IN	0
100	100	CD	0
cm	cm	NNS	0
.	.	.	0
Extruded	Extruded	JJ	B-NP
ribbon	ribbon	JJ	I-NP
fiber	fiber	NN	I-NP
was	was	VBD	0
made	made	VBN	0
with	with	IN	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
,	,	,	0
triethyl	triethyl	NN	B-NP
citrate	citrate	NN	I-NP
(	(	-LRB-	0
plasticizer	plasticizer	LS	B-NP
)	)	-RRB-	0
and	and	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
DL-lactide-co-glycolide	DL-lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
.	.	.	0
The	The	DT	0
desired	desired	JJ	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	JJ	I-NP
content	content	NN	I-NP
in	in	IN	0
the	the	DT	0
device	device	NN	0
was	was	VBD	0
5	5	CD	0
wt	wt	JJ	0
%	%	NN	0
mometasone	mometasone	NN	B-NP
furoate	furoate	NN	I-NP
.	.	.	0
The	The	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
DL-lactide-co-glycolide	DL-lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
was	was	VBD	0
ester	ester	VBN	B-NP
capped	capped	VBN	0
with	with	IN	0
a	a	DT	0
molar	molar	JJ	B-NP
ratio	ratio	NN	I-NP
of	of	IN	0
70	70	CD	0
/	/	CD	0
30	30	CD	0
DL-lactide	DL-lactide	JJ	B-NP
/	/	CD	I-NP
glycolida	glycolida	NN	I-NP
and	and	CC	0
had	had	VBD	0
an	an	DT	0
inherent	inherent	JJ	0
viscosity	viscosity	NN	0
of	of	IN	0
0.81	0.81	NNP	0
dL	dL	NNP	B-NP
/	/	NNP	I-NP
g	g	NN	I-NP
.	.	.	0
The	The	DT	0
inherent	inherent	JJ	0
viscosity	viscosity	NN	0
was	was	VBD	0
measured	measured	VBN	0
at	at	IN	0
30	30	CD	0
C.	C.	NNP	0
with	with	IN	0
0.5	0.5	CD	0
gm	gm	CD	B-NP
/	/	CD	I-NP
dL	dL	JJ	I-NP
polymer	polymer	JJ	I-NP
concentration	concentration	NN	I-NP
in	in	IN	0
chloroform	chloroform	NN	B-NP
.	.	.	0
First	First	JJ	B-NP
mometasone	mometasone	JJ	I-NP
furoata	furoata	NN	I-NP
(	(	-LRB-	0
0.5	0.5	CD	0
gm	gm	CD	B-NP
)	)	-RRB-	0
,	,	,	0
triethyl	triethyl	NN	B-NP
citrate	citrate	NN	I-NP
(	(	-LRB-	0
0.2	0.2	CD	0
gm	gm	CD	B-NP
)	)	-RRB-	0
and	and	CC	0
the	the	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
DL-lactide-co-glycolide	DL-lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
(	(	-LRB-	0
9.3	9.3	CD	0
gm	gm	CD	B-NP
)	)	-RRB-	0
were	were	VBD	0
dissolved	dissolved	VBN	0
in	in	IN	0
ethyl	ethyl	JJ	B-NP
acetate	acetate	NN	I-NP
(	(	-LRB-	0
40	40	CD	0
gm	gm	CD	B-NP
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
thin	thin	JJ	0
film	film	NN	0
was	was	VBD	0
cast	cast	VBN	0
from	from	IN	0
the	the	DT	0
resulting	resulting	JJ	0
solution	solution	NN	B-NP
.	.	.	0
The	The	DT	0
cast	cast	NN	B-NP
film	film	NN	I-NP
was	was	VBD	0
dried	dried	VBN	0
in	in	IN	0
a	a	DT	0
vacuum	vacuum	NN	0
oven	oven	NN	0
for	for	IN	0
48-96	48-96	CD	0
hours	hours	NNS	0
to	to	TO	0
remove	remove	VB	0
residual	residual	JJ	B-NP
methylene	methylene	JJ	I-NP
chloride	chloride	NN	I-NP
.	.	.	0
The	The	DT	0
cast	cast	NN	B-NP
film	film	NN	I-NP
was	was	VBD	0
cut	cut	VBN	0
into	into	IN	0
thin	thin	JJ	0
strips	strips	NNS	0
approximately	approximately	RB	0
10-20	10-20	CD	0
mm	mm	CD	0
wide	wide	JJ	0
and	and	CC	0
100-150	100-150	NNP	0
mm	mm	VBD	0
long	long	RB	0
.	.	.	0
Next	Next	IN	0
a	a	DT	0
Tinius	Tinius	NNP	B-NP
Olsen	Olsen	NNP	I-NP
Model	Model	NNP	I-NP
UE-4-78	UE-4-78	NNP	I-NP
melt	melt	NN	0
plastometer	plastometer	NN	B-NP
was	was	VBD	0
used	used	VBN	0
to	to	TO	0
extrude	extrude	VB	0
the	the	DT	0
cast	cast	NN	B-NP
film	film	NN	I-NP
strip	strip	NN	I-NP
.	.	.	0
The	The	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
is	is	VBZ	0
a	a	DT	0
solid	solid	JJ	0
block	block	NN	0
of	of	IN	0
steel	steel	NN	0
about	about	IN	0
80	80	CD	0
mm	mm	NN	0
in	in	IN	0
diameter	diameter	NN	0
and	and	CC	0
about	about	IN	0
160	160	CD	0
mm	mm	CD	0
high	high	JJ	0
/	/	NN	0
long	long	RB	0
with	with	IN	0
a	a	DT	0
hollow	hollow	JJ	0
core	core	NN	0
about	about	IN	0
13	13	CD	0
mm	mm	NN	0
in	in	IN	0
diameter	diameter	NN	0
.	.	.	0
The	The	DT	0
discharge	discharge	NN	0
of	of	IN	0
the	the	DT	0
core	core	NN	0
has	has	VBZ	0
a	a	DT	0
shoulder	shoulder	NN	0
that	that	WDT	0
allows	allows	VBZ	0
different	different	JJ	0
size	size	NN	0
dies	dies	VBZ	0
to	to	TO	0
be	be	VB	0
used	used	VBN	0
based	based	VBN	0
on	on	IN	0
the	the	DT	0
desired	desired	JJ	0
diameter	diameter	NN	0
of	of	IN	0
extruded	extruded	JJ	0
rod	rod	NN	0
.	.	.	0
For	For	IN	0
this	this	DT	0
run	run	NN	0
,	,	,	0
a	a	DT	0
custom	custom	NN	0
machined	machined	NNS	0
die	die	VBP	0
was	was	VBD	0
used	used	VBN	0
with	with	IN	0
internal	internal	JJ	B-NP
core	core	NN	I-NP
dimension	dimension	NN	I-NP
of	of	IN	0
0.3556	0.3556	FW	0
mm	mm	FW	0
2.0015	2.0015	FW	0
mm	mm	FW	0
.	.	.	0
The	The	DT	0
main	main	JJ	0
block	block	NN	0
of	of	IN	0
the	the	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
has	has	VBZ	0
heater	heater	JJ	B-NP
band	band	NN	I-NP
encased	encased	NN	0
by	by	IN	0
insulation	insulation	NN	B-NP
and	and	CC	0
a	a	DT	0
shroud	shroud	NN	0
that	that	WDT	0
allow	allow	VBP	0
the	the	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
to	to	TO	0
be	be	VB	0
heated	heated	VBN	0
to	to	TO	0
a	a	DT	0
desired	desired	JJ	0
temperature	temperature	NN	0
.	.	.	0
A	A	DT	0
thermocouple	thermocouple	NN	B-NP
was	was	VBD	0
used	used	VBN	0
to	to	TO	0
measure	measure	VB	0
the	the	DT	0
temperature	temperature	NN	0
of	of	IN	0
the	the	DT	0
block	block	NN	0
.	.	.	0
The	The	DT	0
control	control	NN	B-NP
system	system	NN	I-NP
then	then	RB	0
used	used	VBN	0
the	the	DT	0
thermocouple	thermocouple	JJ	B-NP
value	value	NN	I-NP
to	to	TO	0
either	either	RB	0
turn	turn	VB	0
the	the	DT	0
heater	heater	JJ	B-NP
band	band	NN	I-NP
on	on	IN	0
or	or	CC	0
off	off	RB	0
.	.	.	0
Throughout	Throughout	IN	0
the	the	DT	0
extrusion	extrusion	NN	B-NP
process	process	NN	I-NP
,	,	,	0
the	the	DT	0
heater	heater	JJ	B-NP
band	band	NN	I-NP
switched	switched	VBD	0
off	off	RP	0
and	and	CC	0
on	on	IN	0
to	to	TO	0
maintain	maintain	VB	0
the	the	DT	0
desired	desired	JJ	0
temperature	temperature	NN	0
.	.	.	0
The	The	DT	0
cast	cast	NN	B-NP
film	film	NN	I-NP
strip	strip	NN	I-NP
,	,	,	0
approximately	approximately	RB	0
4	4	CD	0
gm	gm	NN	B-NP
,	,	,	0
were	were	VBD	0
loaded	loaded	VBN	0
into	into	IN	0
the	the	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
which	which	WDT	0
had	had	VBD	0
been	been	VBN	0
equilibrated	equilibrated	VBN	0
to	to	TO	0
120	120	CD	0
C.	C.	NNP	0
A	A	NNP	0
charging	charging	VBG	0
rod	rod	NN	0
was	was	VBD	0
placed	placed	VBN	0
in	in	IN	0
the	the	DT	0
core	core	NN	0
of	of	IN	0
the	the	DT	0
Tinius	Tinius	NNP	0
Olsen	Olsen	NNP	0
to	to	TO	0
compress	compress	VB	0
the	the	DT	0
blend	blend	NN	0
and	and	CC	0
a	a	DT	0
weight	weight	NN	0
of	of	IN	0
10	10	CD	0
kg	kg	NN	B-NP
was	was	VBD	0
placed	placed	VBN	0
on	on	IN	0
the	the	DT	0
end	end	NN	0
of	of	IN	0
the	the	DT	0
charging	charging	VBG	0
rod	rod	NN	0
to	to	TO	0
aid	aid	VB	0
in	in	IN	0
the	the	DT	0
compaction	compaction	NN	B-NP
of	of	IN	0
the	the	DT	0
blend	blend	NN	0
.	.	.	0
The	The	DT	0
equilibration	equilibration	JJ	B-NP
time	time	NN	I-NP
for	for	IN	0
the	the	DT	0
blend	blend	NN	0
to	to	TO	0
melt	melt	VB	0
lasted	lasted	VBN	0
for	for	IN	0
about	about	IN	0
20	20	CD	0
minutes	minutes	NNS	0
.	.	.	0
After	After	IN	0
an	an	DT	0
extrusion	extrusion	NN	B-NP
load	load	NN	I-NP
of	of	IN	0
10,000	10,000	CD	0
gm	gm	NN	B-NP
was	was	VBD	0
placed	placed	VBN	0
on	on	IN	0
the	the	DT	0
charging	charging	VBG	0
rod	rod	NN	0
,	,	,	0
the	the	DT	0
plug	plug	NN	0
was	was	VBD	0
removed	removed	VBN	0
from	from	IN	0
the	the	DT	0
discharge	discharge	NN	B-NP
area	area	NN	I-NP
to	to	TO	0
begin	begin	VB	0
the	the	DT	0
extrusion	extrusion	NN	B-NP
run	run	NN	I-NP
.	.	.	0
As	As	IN	0
the	the	DT	0
ribbon	ribbon	JJ	B-NP
fiber	fiber	NN	I-NP
was	was	VBD	0
extruded	extruded	VBN	0
from	from	IN	0
the	the	DT	0
discharge	discharge	NN	0
,	,	,	0
it	it	PRP	0
was	was	VBD	0
pulled	pulled	VBN	0
using	using	VBG	0
a	a	DT	0
conveyor	conveyor	JJ	B-NP
belt	belt	NN	I-NP
to	to	TO	0
the	the	DT	0
desired	desired	JJ	0
dimensions	dimensions	NNS	0
(	(	-LRB-	0
0.3-0.4	0.3-0.4	FW	0
mm	mm	FW	0
1.0-1.2	1.0-1.2	FW	0
mm	mm	FW	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
4-gm	4-gm	JJ	0
charge	charge	NN	0
afforded	afforded	VBN	0
7-10	7-10	CD	0
segments	segments	NNS	0
of	of	IN	0
extruded	extruded	JJ	0
fiber	fiber	NN	B-NP
each	each	DT	0
having	having	VBG	0
a	a	DT	0
length	length	NN	0
of	of	IN	0
about	about	IN	0
100	100	CD	0
cm	cm	NNS	0
.	.	.	0
ribbon	ribbon	JJ	B-NP
fiber	fiber	NN	I-NP
various	various	JJ	I-NP
composition	composition	NN	I-NP
were	were	VBD	0
made	made	VBN	0
following	following	VBG	0
fabrication	fabrication	NN	B-NP
technique	technique	NN	I-NP
similar	similar	JJ	0
to	to	TO	0
those	those	DT	0
described	described	VBN	0
in	in	IN	0
Examples	Examples	NNP	0
1	1	CD	0
and	and	CC	0
2	2	CD	0
.	.	.	0
Table	Table	NN	0
1	1	CD	0
below	below	IN	0
lists	lists	NNS	0
these	these	DT	0
formulation	formulation	JJ	B-NP
composition	composition	NN	I-NP
having	having	VBG	0
varying	varying	JJ	0
amounts	amounts	NNS	0
of	of	IN	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
,	,	,	0
plasticizer	plasticizer	NN	B-NP
,	,	,	0
and	and	CC	0
porosigen	porosigen	NN	B-NP
and	and	CC	0
showing	showing	VBG	0
the	the	DT	0
use	use	NN	0
of	of	IN	0
different	different	JJ	0
processing	processing	NN	B-NP
solvent	solvent	JJ	I-NP
(	(	-LRB-	0
ethyl	ethyl	JJ	B-NP
acetate	acetate	NN	I-NP
and	and	CC	0
methylene	methylene	JJ	B-NP
chloride	chloride	NN	I-NP
)	)	-RRB-	0
to	to	TO	0
prepare	prepare	VB	0
material	material	NN	0
to	to	TO	0
place	place	VB	0
into	into	IN	0
an	an	DT	0
extruder	extruder	NN	B-NP
.	.	.	0
TABLE	TABLE	NN	0
1	1	CD	0
composition	composition	NN	B-NP
of	of	IN	0
ribbon	ribbon	JJ	0
fibers	fibers	NNS	0
prepared	prepared	VBN	0
by	by	IN	0
melt	melt	JJ	0
batch	batch	NN	B-NP
size	size	NN	I-NP
polymer	polymer	NN	I-NP
mometasone	mometasone	NN	I-NP
content	content	JJ	I-NP
content	content	JJ	I-NP
thickness	thickness	NN	I-NP
width	width	NN	I-NP
extrusion	extrusion	NN	I-NP
batch	batch	NN	I-NP
plasticizer	plasticizer	NN	I-NP
porosigen	porosigen	NN	I-NP
fiber	fiber	NN	I-NP
dimension	dimension	NN	I-NP
Number	Number	NNP	0
(	(	-LRB-	0
g	g	LS	0
)	)	-RRB-	0
(	(	-LRB-	0
DL-PLG	DL-PLG	NNP	B-NP
)	)	-RRB-	0
Load	Load	NNP	0
(	(	-LRB-	0
wt	wt	JJ	0
%	%	NN	0
)	)	-RRB-	0
Processing	Processing	NNP	B-NP
Solvent	Solvent	NNP	I-NP
Plasticizer	Plasticizer	NNP	I-NP
(	(	-LRB-	0
wt	wt	JJ	0
%	%	NN	0
)	)	-RRB-	0
Porosigen	Porosigen	NNP	B-NP
(	(	-LRB-	0
wt	wt	JJ	0
%	%	NN	0
)	)	-RRB-	0
(	(	-LRB-	0
mm	mm	LS	0
)	)	-RRB-	0
(	(	-LRB-	0
mm	mm	LS	0
)	)	-RRB-	0
0015-50	0015-50	CD	0
5	5	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
2	2	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
2	2	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.4	0.4	CD	0
1.50	1.50	CD	0
0015-51	0015-51	CD	0
5	5	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
2	2	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
4	4	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.50	0.50	CD	0
1.45	1.45	CD	0
0015-52	0015-52	CD	0
5	5	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
5	5	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
0	0	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.36	0.36	CD	0
1.00	1.00	CD	0
0015-53	0015-53	CD	0
5	5	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
5	5	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
2	2	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.52	0.52	CD	0
1.45	1.45	CD	0
0015-54	0015-54	CD	0
5	5	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
5	5	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
4	4	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.56	0.56	CD	0
1.50	1.50	CD	0
0015-55	0015-55	CD	0
5	5	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
10	10	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
4	4	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.50	0.50	CD	0
1.30	1.30	CD	0
0015-56	0015-56	CD	0
5	5	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
10	10	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
2	2	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.50	0.50	CD	0
1.38	1.38	CD	0
0065-01	0065-01	CD	0
3.9	3.9	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
2	2	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
2	2	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.53	0.53	CD	0
1.33	1.33	CD	0
0065-02	0065-02	CD	0
3.8	3.8	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
5	5	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
0	0	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.38	0.38	CD	0
1.28	1.28	CD	0
0065-03	0065-03	CD	0
3.9	3.9	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
5	5	CD	0
Ethyl	Ethyl	NNP	0
Acetate	Acetate	NNP	0
TEC	TEC	NNP	0
2	2	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.42	0.42	CD	0
1.46	1.46	CD	0
0065-09	0065-09	CD	0
3.9	3.9	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
2	2	CD	0
Ethyl	Ethyl	NNP	B-NP
Acetate	Acetate	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.39	0.39	CD	0
1.25	1.25	CD	0
0065-10	0065-10	CD	0
1.9	1.9	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
2	2	CD	0
Ethyl	Ethyl	NNP	B-NP
Acetate	Acetate	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.35	0.35	CD	0
1.18	1.18	CD	0
0065-15	0065-15	CD	0
4.2	4.2	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
0.5	0.5	CD	0
Ethyl	Ethyl	NNP	B-NP
Acetate	Acetate	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.43	0.43	CD	0
1.37	1.37	CD	0
0065-16	0065-16	CD	0
4.1	4.1	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
0.5	0.5	CD	0
Methylene	Methylene	NNP	B-NP
Chloride	Chloride	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.35	0.35	CD	0
1.20	1.20	CD	0
0065-17	0065-17	CD	0
4.1	4.1	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
0.5	0.5	CD	0
Ethyl	Ethyl	NNP	B-NP
Acetate	Acetate	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
PEG	PEG	CD	0
1500	1500	CD	0
2	2	CD	0
0.42	0.42	CD	0
1.38	1.38	CD	0
0065-18	0065-18	CD	0
4.2	4.2	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
0.5	0.5	CD	0
Methylene	Methylene	NNP	B-NP
Chloride	Chloride	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
PEG	PEG	CD	0
1500	1500	CD	0
2	2	CD	0
0.38	0.38	CD	0
1.23	1.23	CD	0
0065-37	0065-37	CD	0
4	4	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
5.0	5.0	CD	0
Methylene	Methylene	NNP	B-NP
Chloride	Chloride	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.34	0.34	CD	0
1.19	1.19	CD	0
0065-38	0065-38	CD	0
3.9	3.9	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
2.0	2.0	CD	0
Methylene	Methylene	NNP	B-NP
Chloride	Chloride	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.30	0.30	CD	0
1.02	1.02	CD	0
0065-39	0065-39	CD	0
4.1	4.1	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
0.5	0.5	CD	0
Methylene	Methylene	NNP	B-NP
Chloride	Chloride	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
NA	NA	CD	B-NP
0	0	CD	0
0.32	0.32	CD	0
1.09	1.09	CD	0
0065-40	0065-40	CD	0
4	4	CD	0
69	69	CD	0
:	:	:	0
31	31	CD	0
0.25	0.25	CD	0
Methylene	Methylene	NNP	B-NP
Chloride	Chloride	NNP	I-NP
NA	NA	NNP	I-NP
0	0	CD	0
PEG	PEG	CD	0
1500	1500	CD	0
2	2	CD	0
0.39	0.39	CD	0
1.22	1.22	CD	0
A	A	DT	0
fiber	fiber	NN	B-NP
formulation	formulation	NN	I-NP
can	can	MD	0
be	be	VB	0
made	made	VBN	0
with	with	IN	0
fluticasone	fluticasone	JJ	B-NP
proprionate	proprionate	NN	I-NP
with	with	IN	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
DL-lactide	DL-lactide	NNP	I-NP
)	)	-RRB-	I-NP
or	or	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
.	.	.	0
The	The	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
or	or	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
can	can	MD	0
be	be	VB	0
capped	capped	VBN	0
or	or	CC	0
have	have	VBP	0
acid	acid	JJ	B-NP
end	end	NN	I-NP
group	group	NN	I-NP
.	.	.	0
The	The	DT	0
desired	desired	JJ	0
fluticasone	fluticasone	JJ	B-NP
proprionate	proprionate	JJ	I-NP
content	content	NN	I-NP
in	in	IN	0
the	the	DT	0
fiber	fiber	NN	B-NP
can	can	MD	0
range	range	VB	0
from	from	IN	0
0.1	0.1	CD	0
wt	wt	JJ	0
%	%	NN	0
to	to	TO	0
20	20	CD	0
wt	wt	JJ	0
%	%	NN	0
.	.	.	0
To	To	TO	0
prepare	prepare	VB	0
a	a	DT	0
fluticasone	fluticasone	JJ	B-NP
proprionate	proprionate	NN	I-NP
long-acting	long-acting	JJ	I-NP
formulation	formulation	NN	I-NP
,	,	,	0
particles	particles	VBG	0
of	of	IN	0
fluticasone	fluticasone	JJ	B-NP
proprionate	proprionate	NN	I-NP
and	and	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
DL-lactide-co-glycolide	DL-lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
or	or	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
can	can	MD	0
be	be	VB	0
dry	dry	JJ	0
blended	blended	NN	0
in	in	IN	0
a	a	DT	0
variety	variety	NN	0
of	of	IN	0
ways	ways	NNS	0
including	including	VBG	0
the	the	DT	0
use	use	NN	0
of	of	IN	0
a	a	DT	0
mortar	mortar	JJ	0
/	/	CD	0
pestle	pestle	NNS	0
or	or	CC	0
by	by	IN	0
mixing	mixing	VBG	0
preformed	preformed	JJ	B-NP
polymer	polymer	NN	I-NP
and	and	CC	0
peptide	peptide	JJ	B-NP
particle	particle	NN	I-NP
in	in	IN	0
a	a	DT	0
V-blender	V-blender	JJ	B-NP
to	to	TO	0
form	form	VB	0
a	a	DT	0
blended	blended	JJ	0
powder	powder	NN	0
.	.	.	0
Next	Next	IN	0
this	this	DT	0
blend	blend	NN	0
or	or	CC	0
admixture	admixture	NN	B-NP
can	can	MD	0
be	be	VB	0
added	added	VBN	0
to	to	TO	0
a	a	DT	0
twin-screw	twin-screw	JJ	B-NP
extruder	extruder	NN	I-NP
having	having	VBG	0
a	a	DT	0
machined	machined	JJ	0
die	die	NN	0
with	with	IN	0
a	a	DT	0
2-mm	2-mm	JJ	0
diameter	diameter	NN	0
.	.	.	0
The	The	DT	0
temperature	temperature	NN	0
of	of	IN	0
the	the	DT	0
extruder	extruder	NN	B-NP
should	should	MD	0
be	be	VB	0
about	about	IN	0
120	120	CD	0
C.	C.	NNP	0
As	As	IN	0
the	the	DT	0
fiber	fiber	NN	B-NP
is	is	VBZ	0
extruded	extruded	VBN	0
from	from	IN	0
the	the	DT	0
extruder	extruder	NN	B-NP
,	,	,	0
it	it	PRP	0
will	will	MD	0
be	be	VB	0
collected	collected	VBN	0
on	on	IN	0
a	a	DT	0
conveyor	conveyor	JJ	B-NP
belt	belt	NN	I-NP
.	.	.	0
Ribbon	Ribbon	JJ	B-NP
fiber	fiber	NN	I-NP
as	as	IN	0
prepared	prepared	VBN	0
by	by	IN	0
Example	Example	NNP	0
1	1	CD	0
,	,	,	0
was	was	VBD	0
fabricated	fabricated	VBN	0
into	into	IN	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
in	in	IN	0
the	the	DT	0
following	following	JJ	0
manner	manner	NN	0
.	.	.	0
Four	Four	CD	0
strands	strands	NN	0
of	of	IN	0
ribbon	ribbon	JJ	B-NP
fiber	fiber	NN	I-NP
were	were	VBD	0
cut	cut	VBN	0
to	to	TO	0
approximately	approximately	RB	0
35	35	CD	0
mm	mm	NNS	0
and	and	CC	0
then	then	RB	0
looped	looped	VBN	0
to	to	TO	0
form	form	VB	0
whisk-like	whisk-like	JJ	B-NP
structure	structure	NN	I-NP
as	as	IN	0
previously	previously	RB	0
described	described	VBN	0
.	.	.	0
paranasal	paranasal	NN	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
prepared	prepared	VBN	0
as	as	RB	0
described	described	VBN	0
in	in	IN	0
Example	Example	NNP	0
4	4	CD	0
were	were	VBD	0
sterilized	sterilized	VBN	0
with	with	IN	0
2.5	2.5	CD	0
gamma	gamma	JJ	B-NP
radiation	radiation	NN	I-NP
mrad	mrad	NN	I-NP
and	and	CC	0
placed	placed	VBN	0
in	in	IN	0
the	the	DT	0
maxillary	maxillary	JJ	B-NP
sinus	sinus	NN	I-NP
(	(	-LRB-	0
right	right	NN	0
and	and	CC	0
left	left	JJ	0
sides	sides	NNS	0
)	)	-RRB-	0
of	of	IN	0
5-kg	5-kg	CD	0
rabbits	rabbits	NN	0
through	through	IN	0
dorsal	dorsal	JJ	B-NP
nasal	nasal	JJ	I-NP
maxillary	maxillary	NN	I-NP
sinusotomy	sinusotomy	NN	I-NP
.	.	.	0
Three	Three	CD	0
formulation	formulation	NN	B-NP
were	were	VBD	0
tested	tested	VBN	0
.	.	.	0
These	These	DT	0
were	were	VBD	0
as	as	RB	0
follows	follows	VBZ	0
:	:	:	0
PLG	PLG	NNP	B-NP
69	69	CD	0
:	:	:	0
31	31	CD	0
with	with	IN	0
5	5	CD	0
%	%	NN	0
mometasona	mometasona	NN	B-NP
and	and	CC	0
0	0	CD	0
%	%	NN	0
triethylcitrata	triethylcitrata	NN	B-NP
(	(	-LRB-	0
TEC	TEC	NNP	0
)	)	-RRB-	0
PLG	PLG	NNP	B-NP
69	69	CD	0
:	:	:	0
31	31	CD	0
with	with	IN	0
5	5	CD	0
%	%	NN	0
mometasona	mometasona	NN	B-NP
and	and	CC	0
2	2	CD	0
%	%	NN	0
TEC	TEC	FW	0
PLG	PLG	NNP	B-NP
69	69	CD	0
:	:	:	0
31	31	CD	0
with	with	IN	0
10	10	CD	0
%	%	NN	0
mometasona	mometasona	NN	B-NP
and	and	CC	0
2	2	CD	0
%	%	NN	0
TEC	TEC	FW	0
The	The	DT	0
same	same	JJ	0
formulation	formulation	NN	B-NP
was	was	VBD	0
used	used	VBN	0
for	for	IN	0
both	both	DT	0
right	right	NN	0
and	and	CC	0
left	left	VBD	0
sinuses	sinuses	VBN	0
of	of	IN	0
a	a	DT	0
given	given	VBN	0
rabbit	rabbit	NN	0
.	.	.	0
Fifteen	Fifteen	JJ	0
rabbits	rabbits	NN	0
were	were	VBD	0
implanted	implanted	VBN	0
.	.	.	0
Five	Five	CD	0
rabbits	rabbits	NNS	0
were	were	VBD	0
implanted	implanted	VBN	0
with	with	IN	0
each	each	DT	0
device	device	NN	B-NP
formulation	formulation	NN	I-NP
.	.	.	0
The	The	DT	0
devices	devices	NNS	0
were	were	VBD	0
explanted	explanted	VBN	0
at	at	IN	0
approximately	approximately	RB	0
weekly	weekly	JJ	0
intervals	intervals	JJ	0
post	post	NN	B-NP
implantation	implantation	NN	I-NP
over	over	IN	0
a	a	DT	0
5-week	5-week	JJ	0
period	period	NN	0
.	.	.	0
The	The	DT	0
mucosa	mucosa	NN	B-NP
of	of	IN	0
both	both	DT	0
right	right	NN	0
and	and	CC	0
left	left	VBD	0
maxillary	maxillary	JJ	B-NP
sinus	sinus	NN	I-NP
was	was	VBD	0
removed	removed	VBN	0
completely	completely	RB	0
at	at	IN	0
the	the	DT	0
time	time	NN	0
of	of	IN	0
explanation	explanation	NN	0
.	.	.	0
The	The	DT	0
tissue	tissue	NN	0
was	was	VBD	0
rapidly	rapidly	RB	0
frozen	frozen	VBN	0
and	and	CC	0
the	the	DT	0
amount	amount	NN	0
of	of	IN	0
mometasone	mometasone	NN	B-NP
in	in	IN	0
the	the	DT	0
tissue	tissue	NN	0
was	was	VBD	0
quantitated	quantitated	VBN	0
by	by	IN	0
liquid	liquid	JJ	B-NP
chromatography	chromatography	NN	I-NP
/	/	NN	I-NP
mass	mass	NN	I-NP
spectroscopy	spectroscopy	NN	I-NP
(	(	-LRB-	0
liquid	liquid	JJ	B-NP
chromatography/mas	chromatography/mas	NN	I-NP
spectroscopy	spectroscopy	NN	I-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
amount	amount	NN	0
of	of	IN	0
mometasone	mometasone	VBG	0
maintained	maintained	VBN	0
in	in	IN	0
the	the	DT	0
tissue	tissue	NN	0
over	over	IN	0
a	a	DT	0
35-day	35-day	JJ	0
period	period	NN	0
is	is	VBZ	0
reported	reported	VBN	0
in	in	IN	0
the	the	DT	0
table	table	NN	0
below	below	RB	0
,	,	,	0
and	and	CC	0
is	is	VBZ	0
equivalent	equivalent	JJ	0
to	to	TO	0
10	10	CD	0
5	5	CD	0
M	M	NNP	0
to	to	TO	0
10	10	CD	0
7	7	CD	0
M	M	NNP	0
concentration	concentration	NN	B-NP
at	at	IN	0
the	the	DT	0
desired	desired	JJ	0
site	site	NN	0
of	of	IN	0
action	action	NN	0
,	,	,	0
at	at	IN	0
all	all	DT	0
time	time	NN	B-NP
point	point	NN	I-NP
demonstrating	demonstrating	VBG	0
a	a	DT	0
sustained	sustained	JJ	0
release	release	NN	0
and	and	CC	0
bioavailability	bioavailability	NN	B-NP
of	of	IN	0
drug	drug	NN	0
at	at	IN	0
levels	levels	NNS	0
of	of	IN	0
tissue	tissue	NN	0
concentration	concentration	NN	0
which	which	WDT	0
are	are	VBP	0
known	known	VBN	0
to	to	TO	0
have	have	VB	0
therapeutic	therapeutic	JJ	B-NP
efficacy	efficacy	NN	I-NP
(	(	-LRB-	0
see	see	VB	0
below	below	IN	0
)	)	-RRB-	0
.	.	.	0
mometasone	mometasone	NN	B-NP
level	level	JJ	I-NP
Measured	Measured	NNP	0
in	in	IN	0
Excised	Excised	NNP	B-NP
Sinus	Sinus	NNP	I-NP
Mucosa	Mucosa	NNP	I-NP
(	(	-LRB-	0
mometasone	mometasone	NN	B-NP
microgram	microgram	NN	I-NP
per	per	FW	0
gram	gram	FW	0
tissue	tissue	FW	0
)	)	-RRB-	0
4	4	CD	0
day	day	NN	0
14	14	CD	0
25	25	CD	0
30	30	CD	0
35	35	CD	0
pooled	pooled	JJ	0
day	day	NN	0
day	day	NN	0
day	day	NN	0
day	day	NN	0
10	10	CD	0
%	%	NN	0
Mometasone	Mometasone	NNP	B-NP
R	R	NNP	I-NP
0.915	0.915	CD	0
1.41	1.41	CD	0
183	183	CD	0
139	139	CD	0
97.6	97.6	CD	0
2	2	CD	0
%	%	NN	0
TEC	TEC	NNP	0
L	L	NNP	0
0.823	0.823	CD	0
5.95	5.95	CD	0
7.57	7.57	CD	0
152	152	CD	0
335	335	CD	0
5	5	CD	0
%	%	NN	0
Mometasone	Mometasone	NNP	B-NP
R	R	NNP	I-NP
1.17	1.17	CD	0
1.01	1.01	CD	0
1.44	1.44	CD	0
0.76	0.76	CD	0
81.7	81.7	CD	0
2	2	CD	0
%	%	NN	0
TEC	TEC	NNP	0
L	L	NNP	0
(	(	-LRB-	0
st	st	NN	B-NP
dev	dev	NN	I-NP
=	=	FW	0
No	No	DT	0
peak	peak	NN	0
44.3	44.3	CD	0
86.4	86.4	CD	0
153	153	CD	0
5	5	CD	0
%	%	NN	0
Mometasone	Mometasone	NNP	B-NP
R	R	NNP	I-NP
0.18	0.18	CD	0
)	)	-RRB-	0
246	246	CD	0
1.28	1.28	CD	0
2.11	2.11	CD	0
178	178	CD	0
0	0	CD	0
%	%	NN	0
TEC	TEC	NNP	0
L	L	NNP	0
2.57	2.57	CD	0
0.54	0.54	CD	0
158	158	CD	0
The	The	DT	0
in	in	IN	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
vitro	vitro	JJ	I-NP
release	release	NN	I-NP
from	from	IN	0
candidate	candidate	NN	B-NP
formulation	formulation	NN	I-NP
was	was	VBD	0
determined	determined	VBN	0
,	,	,	0
and	and	CC	0
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
25	25	CD	0
.	.	.	0
To	To	TO	0
carry	carry	VB	0
out	out	RP	0
this	this	DT	0
in	in	IN	0
vitro	vitro	JJ	B-NP
release	release	NN	I-NP
study	study	NN	I-NP
,	,	,	0
each	each	DT	0
device	device	NN	0
was	was	VBD	0
placed	placed	VBN	0
at	at	IN	0
37	37	CD	0
C.	C.	NNP	0
in	in	IN	0
1.0	1.0	CD	0
wt	wt	JJ	0
%	%	NN	0
sodium	sodium	NN	B-NP
dodectyl	dodectyl	NN	I-NP
sulfate	sulfate	NN	I-NP
(	(	-LRB-	0
sodium	sodium	NN	B-NP
dodectyl	dodectyl	NN	I-NP
sulfate	sulfate	NN	I-NP
)	)	-RRB-	0
in	in	IN	0
nanopure	nanopure	JJ	B-NP
water	water	NN	I-NP
,	,	,	0
the	the	DT	0
receiving	receiving	VBG	B-NP
fluid	fluid	NN	I-NP
.	.	.	0
At	At	IN	0
each	each	DT	0
time	time	NN	B-NP
point	point	NN	I-NP
,	,	,	0
the	the	DT	0
receiving	receiving	VBG	B-NP
fluid	fluid	NN	I-NP
was	was	VBD	0
removed	removed	VBN	0
completely	completely	RB	0
and	and	CC	0
fresh	fresh	JJ	0
receiving	receiving	VBG	B-NP
fluid	fluid	NN	I-NP
was	was	VBD	0
added	added	VBN	0
.	.	.	0
The	The	DT	0
amount	amount	NN	0
of	of	IN	0
mometasone	mometasone	VBG	0
released	released	VBN	0
into	into	IN	0
the	the	DT	0
receiving	receiving	VBG	0
at	at	IN	0
each	each	DT	0
time	time	NN	B-NP
point	point	NN	I-NP
was	was	VBD	0
quantified	quantified	VBN	0
by	by	IN	0
HPLC	HPLC	NNP	B-NP
.	.	.	0
In	In	IN	0
a	a	DT	0
first	first	JJ	0
in	in	IN	0
vitro	vitro	JJ	B-NP
cumulative	cumulative	JJ	I-NP
release	release	NN	I-NP
study	study	NN	I-NP
,	,	,	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
25	25	CD	0
,	,	,	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
cumulative	cumulative	JJ	I-NP
release	release	NN	I-NP
from	from	IN	0
a	a	DT	0
2	2	CD	0
%	%	NN	0
mometasone	mometasone	VBD	0
/	/	CD	0
4	4	CD	0
%	%	NN	0
TEC	TEC	NNP	B-NP
fiber	fiber	NN	I-NP
was	was	VBD	0
about	about	IN	0
6	6	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
7	7	CD	0
,	,	,	0
about	about	IN	0
11	11	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
14	14	CD	0
,	,	,	0
about	about	IN	0
14	14	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
21	21	CD	0
,	,	,	0
and	and	CC	0
about	about	IN	0
15	15	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
28	28	CD	0
.	.	.	0
For	For	IN	0
the	the	DT	0
5	5	CD	0
%	%	NN	0
mometasone	mometasone	VBD	0
/	/	CD	0
0	0	CD	0
%	%	NN	0
TEC	TEC	NNP	B-NP
fiber	fiber	NN	I-NP
,	,	,	0
cumulative	cumulative	JJ	B-NP
mometasone	mometasone	JJ	I-NP
release	release	NN	I-NP
was	was	VBD	0
about	about	IN	0
4	4	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
7	7	CD	0
,	,	,	0
about	about	IN	0
10	10	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
14	14	CD	0
,	,	,	0
about	about	IN	0
12	12	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
21	21	CD	0
,	,	,	0
and	and	CC	0
about	about	IN	0
12	12	CD	0
at	at	IN	0
day	day	NN	0
28	28	CD	0
.	.	.	0
The	The	DT	0
5	5	CD	0
%	%	NN	0
mometasone	mometasone	VBD	0
/	/	CD	0
2	2	CD	0
%	%	NN	0
cumulative	cumulative	JJ	B-NP
mometasone	mometasone	JJ	I-NP
release	release	NN	I-NP
tec	tec	NN	I-NP
fiber	fiber	NN	I-NP
was	was	VBD	0
about	about	IN	0
3	3	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
7	7	CD	0
,	,	,	0
about	about	IN	0
7	7	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
14	14	CD	0
,	,	,	0
about	about	IN	0
9	9	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
21	21	CD	0
,	,	,	0
and	and	CC	0
about	about	IN	0
9	9	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
28	28	CD	0
.	.	.	0
For	For	IN	0
the	the	DT	0
10	10	CD	0
%	%	NN	0
mometasone	mometasone	VBD	0
/	/	CD	0
2	2	CD	0
%	%	NN	0
TEC	TEC	NNP	B-NP
fiber	fiber	NN	I-NP
,	,	,	0
cumulative	cumulative	JJ	B-NP
mometasona	mometasona	NN	I-NP
release	release	VBP	0
measured	measured	VBN	0
to	to	TO	0
be	be	VB	0
about	about	IN	0
4	4	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
7	7	CD	0
,	,	,	0
9	9	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
14	14	CD	0
,	,	,	0
12	12	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
21	21	CD	0
,	,	,	0
and	and	CC	0
12	12	CD	0
%	%	NN	0
at	at	IN	0
day	day	NN	0
28	28	CD	0
.	.	.	0
Additional	Additional	JJ	B-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
due	due	JJ	0
to	to	TO	0
in	in	IN	0
vivo	vivo	JJ	B-NP
polymer	polymer	JJ	I-NP
biodegradation	biodegradation	NN	I-NP
and	and	CC	0
clearance	clearance	NN	0
was	was	VBD	0
demonstrated	demonstrated	VBN	0
and	and	CC	0
directly	directly	RB	0
observed	observed	VBD	0
as	as	RB	0
described	described	VBN	0
above	above	IN	0
in	in	IN	0
the	the	DT	0
tissue	tissue	NN	0
concentration	concentration	NN	0
data	data	NNS	0
.	.	.	0
Published	Published	VBN	0
in	in	IN	0
vitro	vitro	JJ	B-NP
cellular	cellular	JJ	I-NP
model	model	NN	I-NP
using	using	VBG	0
cultured	cultured	JJ	0
human	human	JJ	0
epithelial	epithelial	JJ	B-NP
cell	cell	NN	I-NP
airway	airway	JJ	I-NP
indicate	indicate	VBP	0
drug	drug	NN	B-NP
concentration	concentration	NN	I-NP
dose	dose	NN	I-NP
response	response	NN	I-NP
curve	curve	NN	I-NP
for	for	IN	0
the	the	DT	0
most	most	RBS	0
potent	potent	JJ	0
glucocorticoid	glucocorticoid	NN	B-NP
,	,	,	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
and	and	CC	0
fluticasone	fluticasone	JJ	B-NP
propionate	propionate	NN	I-NP
,	,	,	0
beginning	beginning	VBG	0
as	as	IN	0
low	low	JJ	0
as	as	IN	0
10	10	CD	0
12	12	CD	0
M	M	NNP	0
(	(	-LRB-	0
picomolar	picomolar	LS	B-NP
)	)	-RRB-	0
and	and	CC	0
transcriptional	transcriptional	JJ	B-NP
response	response	NN	I-NP
ec50	ec50	NN	I-NP
level	level	JJ	I-NP
at	at	IN	0
10	10	CD	0
10	10	CD	0
M	M	NNP	0
(	(	-LRB-	0
100	100	CD	0
picomolar	picomolar	NN	B-NP
;	;	:	0
maximal	maximal	JJ	B-NP
transcriptional	transcriptional	JJ	I-NP
response	response	NN	I-NP
was	was	VBD	0
seen	seen	VBN	0
in	in	IN	0
most	most	JJS	0
cases	cases	NNS	0
by	by	IN	0
10	10	CD	0
9	9	CD	0
M	M	NNP	0
(	(	-LRB-	0
nanomolar	nanomolar	LS	B-NP
)	)	-RRB-	0
drug	drug	NN	B-NP
concentration	concentration	NN	I-NP
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
in	in	IN	0
vitro	vitro	JJ	B-NP
model	model	NN	I-NP
have	have	VBP	0
been	been	VBN	0
accepted	accepted	VBN	0
as	as	IN	0
equivalent	equivalent	JJ	0
to	to	TO	0
and	and	CC	0
highly	highly	RB	0
correlated	correlated	VBN	0
with	with	IN	0
in	in	IN	0
vivo	vivo	JJ	B-NP
model	model	NN	I-NP
of	of	IN	0
efficacy	efficacy	NNS	0
(	(	-LRB-	0
Romestan	Romestan	NNP	B-NP
C.	C.	NNP	I-NP
et	et	FW	0
al	al	FW	0
Fluticasone	Fluticasone	NNP	B-NP
Propionate	Propionate	NNP	I-NP
and	and	CC	0
Mometasone	Mometasone	NNP	B-NP
Furoate	Furoate	NNP	I-NP
Have	Have	NNP	0
equivalent	equivalent	JJ	B-NP
transcriptional	transcriptional	NN	I-NP
potency	potency	NN	I-NP
,	,	,	0
Clin	Clin	NNP	B-NP
Exp	Exp	NNP	I-NP
Allergy	Allergy	NNP	I-NP
2003	2003	CD	0
;	;	:	0
33	33	CD	0
:	:	:	0
895-901	895-901	CD	0
)	)	-RRB-	0
.	.	.	0
All	All	DT	0
publication	publication	NN	B-NP
,	,	,	0
patents	patents	NNS	0
,	,	,	0
and	and	CC	0
patent	patent	NN	0
application	application	NN	B-NP
cited	cited	VBD	0
herein	herein	NNS	0
are	are	VBP	0
hereby	hereby	VBN	0
incorporated	incorporated	VBN	0
by	by	IN	0
reference	reference	NN	0
in	in	IN	0
their	their	PRP$	0
entirety	entirety	NN	0
for	for	IN	0
all	all	DT	0
purposes	purposes	NNS	0
to	to	TO	0
the	the	DT	0
same	same	JJ	0
extent	extent	NN	0
as	as	IN	0
if	if	IN	0
each	each	DT	0
individual	individual	JJ	0
publication	publication	NN	0
,	,	,	0
patent	patent	NN	0
,	,	,	0
or	or	CC	0
patent	patent	NN	0
application	application	NN	0
were	were	VBD	0
specifically	specifically	RB	0
and	and	CC	0
individually	individually	RB	0
indicated	indicated	VBN	0
to	to	TO	0
be	be	VB	0
so	so	RB	0
incorporated	incorporated	VBN	0
by	by	IN	0
reference	reference	NN	0
.	.	.	0
Although	Although	IN	0
the	the	DT	0
foregoing	foregoing	JJ	0
invention	invention	NN	0
has	has	VBZ	0
been	been	VBN	0
described	described	VBN	0
in	in	IN	0
some	some	DT	0
detail	detail	NN	0
by	by	IN	0
way	way	NN	0
of	of	IN	0
illustration	illustration	NN	B-NP
and	and	CC	0
example	example	NN	0
for	for	IN	0
purposes	purposes	NNS	0
of	of	IN	0
clarity	clarity	NN	0
of	of	IN	0
understanding	understanding	NN	0
,	,	,	0
it	it	PRP	0
will	will	MD	0
be	be	VB	0
readily	readily	RB	0
apparent	apparent	JJ	0
to	to	TO	0
those	those	DT	0
of	of	IN	0
ordinary	ordinary	JJ	B-NP
skill	skill	NN	I-NP
in	in	IN	0
the	the	DT	0
art	art	NN	0
in	in	IN	0
light	light	NN	0
of	of	IN	0
the	the	DT	0
teachings	teachings	NN	0
of	of	IN	0
this	this	DT	0
invention	invention	NN	0
that	that	IN	0
certain	certain	JJ	0
changes	changes	NNS	0
and	and	CC	0
modification	modification	NN	B-NP
may	may	MD	0
be	be	VB	0
made	made	VBN	0
thereto	thereto	VBN	0
without	without	IN	0
departing	departing	VBG	0
from	from	IN	0
the	the	DT	0
spirit	spirit	NN	0
and	and	CC	0
scope	scope	NN	0
of	of	IN	0
the	the	DT	0
appended	appended	JJ	0
claims	claims	NNS	0
.	.	.	0
What	What	WP	0
is	is	VBZ	0
claimed	claimed	VBN	0
as	as	IN	0
new	new	JJ	0
and	and	CC	0
desired	desired	VBN	0
to	to	TO	0
be	be	VB	0
protected	protected	VBN	0
by	by	IN	0
Letters	Letters	NNP	0
Patent	Patent	NNP	0
of	of	IN	0
the	the	DT	0
united	united	JJ	B-NP
state	state	NN	I-NP
is	is	VBZ	0
:	:	:	0
1	1	LS	0
.	.	.	0
A	A	DT	0
device	device	NN	0
for	for	IN	0
treating	treating	VBG	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
comprising	comprising	VBG	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
and	and	CC	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agent	agent	NN	B-NP
for	for	IN	0
sustained	sustained	JJ	0
release.	release.	CD	0
2	2	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
has	has	VBZ	0
a	a	DT	0
first	first	JJ	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
that	that	WDT	0
permits	permits	VBZ	0
the	the	DT	0
device	device	NN	0
to	to	TO	0
pass	pass	VB	0
through	through	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
or	or	CC	0
surgically	surgically	RB	0
created	created	VBN	B-NP
fenestration	fenestration	NN	I-NP
and	and	CC	0
a	a	DT	0
second	second	JJ	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
after	after	IN	0
placement	placement	NN	0
into	into	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
cavity.	cavity.	CD	I-NP
3	3	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
2	2	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
in	in	IN	0
the	the	DT	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
has	has	VBZ	0
a	a	DT	0
surface	surface	NN	0
area	area	NN	0
to	to	TO	0
volume	volume	NN	B-NP
ratio	ratio	NN	I-NP
that	that	WDT	0
is	is	VBZ	0
substantially	substantially	RB	0
unchanged	unchanged	JJ	0
from	from	IN	0
that	that	DT	0
of	of	IN	0
the	the	DT	0
collapsed	collapsed	JJ	0
configuration.	configuration.	CD	B-NP
4	4	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
2	2	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
in	in	IN	0
the	the	DT	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
substantially	substantially	RB	0
contacts	contacts	VB	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
mucosal	mucosal	JJ	I-NP
surface	surface	NN	I-NP
5	5	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
are	are	VBP	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member.	member.	CD	0
6	6	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
are	are	VBP	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion.	portion.	CD	I-NP
7	7	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
are	are	VBP	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
and	and	CC	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion.	portion.	CD	I-NP
8	8	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
further	further	JJ	0
comprising	comprising	VBG	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member.	member.	CD	I-NP
9	9	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
8	8	CD	0
wherein	wherein	CD	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
maintain	maintain	VB	0
patency	patency	VBN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
ostium.	ostium.	CD	I-NP
10	10	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
8	8	CD	0
wherein	wherein	CD	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
comprises	comprises	VBZ	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
pliable	pliable	JJ	0
filaments	filaments	JJ	0
configured	configured	NN	0
to	to	TO	0
anchor	anchor	VB	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
within	within	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity.	cavity.	CD	I-NP
11	11	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
8	8	CD	0
wherein	wherein	CD	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
sheet-like	sheet-like	JJ	B-NP
material	material	NN	I-NP
configured	configured	NN	I-NP
to	to	TO	0
anchor	anchor	VB	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
within	within	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity.	cavity.	CD	I-NP
12	12	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
8	8	CD	0
wherein	wherein	CD	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
are	are	VBP	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member.	member.	CD	I-NP
13	13	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
8	8	CD	0
wherein	wherein	CD	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
are	are	VBP	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
and	and	CC	0
the	the	DT	0
cavity	cavity	JJ	0
member.	member.	CD	0
14	14	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
8	8	CD	0
wherein	wherein	CD	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
are	are	VBP	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
and	and	CC	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion.	portion.	CD	I-NP
15	15	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
comprises	comprises	VBZ	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
pliable	pliable	JJ	0
filaments	filaments	JJ	0
configured	configured	NN	0
to	to	TO	0
anchor	anchor	VB	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
within	within	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity.	cavity.	CD	I-NP
16	16	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
comprises	comprises	VBZ	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
pliable	pliable	JJ	0
filaments	filaments	JJ	0
configured	configured	NN	0
to	to	TO	0
prevent	prevent	VB	0
displacement	displacement	VBN	B-NP
of	of	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
from	from	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity.	cavity.	CD	I-NP
17	17	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
comprises	comprises	VBZ	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
pliable	pliable	JJ	0
filaments	filaments	JJ	0
configured	configured	NN	0
to	to	TO	0
anchor	anchor	VB	0
the	the	DT	0
ostial	ostial	JJ	B-NP
portion.	portion.	CD	I-NP
18	18	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
8	8	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
and	and	CC	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
comprise	comprise	VBP	0
a	a	DT	0
biocompatible	biocompatible	JJ	B-NP
material.	material.	CD	I-NP
19	19	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
18	18	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
and	and	CC	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
comprise	comprise	VBP	0
the	the	DT	0
same	same	JJ	0
biocompatible	biocompatible	NN	B-NP
material.	material.	CD	I-NP
20	20	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
18	18	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
and	and	CC	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
comprise	comprise	VBP	0
different	different	JJ	0
biocompatible	biocompatible	NN	B-NP
material	material	JJ	I-NP
21	21	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
18	18	CD	0
wherein	wherein	CD	0
the	the	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
,	,	,	0
a	a	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
a	a	DT	0
metal	metal	NN	0
,	,	,	0
or	or	CC	0
a	a	DT	0
combination	combination	NN	0
thereof.	thereof.	CD	0
22	22	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
21	21	CD	0
wherein	wherein	CD	0
the	the	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer.	polymer.	CD	B-NP
23	23	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
22	22	CD	0
wherein	wherein	CD	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolide	glycolide	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolic	glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid-co-glycolic	acid-co-glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolide	glycolide	LS	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
glycolic	glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid-co-glycolic	acid-co-glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
caprolactone	caprolactone	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
caprolactone	caprolactone	LS	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(ethylene	poly(ethylene	NN	B-NP
glycol)	glycol)	NN	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
orthoester	orthoester	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
phosphazene	phosphazene	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
hydroxybutyrate	hydroxybutyrate	LS	I-NP
)	)	-RRB-	I-NP
or	or	CC	0
a	a	DT	0
copolymer	copolymer	NN	B-NP
including	including	VBG	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
hydroxybutyrate	hydroxybutyrate	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide-co-caprolactone	lactide-co-caprolactone	NNP	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
polycarbonate	polycarbonate	NN	0
;	;	:	0
a	a	DT	0
polyesteramide	polyesteramide	NN	B-NP
;	;	:	0
a	a	DT	0
polyanhidride	polyanhidride	NN	B-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
dioxanone	dioxanone	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
alkylene	alkylene	NN	I-NP
alkylate	alkylate	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
copolymer	copolymer	NN	B-NP
of	of	IN	0
polyethylene	polyethylene	NN	0
glycol	glycol	NNS	0
and	and	CC	0
a	a	DT	0
polyorthoester	polyorthoester	NN	B-NP
;	;	:	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polyurethane	polyurethane	NN	B-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
amino	amino	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
;	;	:	0
a	a	DT	0
polyetherester	polyetherester	NN	B-NP
;	;	:	0
a	a	DT	0
polyacetal	polyacetal	NN	0
;	;	:	0
a	a	DT	0
polycyanoacrylate	polycyanoacrylate	NN	B-NP
;	;	:	0
a	a	DT	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
oxyethylene	oxyethylene	LS	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
oxypropylene	oxypropylene	LS	I-NP
)	)	-RRB-	I-NP
copolymer	copolymer	NN	I-NP
;	;	:	0
and	and	CC	0
blends	blends	NNS	0
or	or	CC	0
copolymers	copolymers	CD	0
thereof.	thereof.	CD	0
24	24	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
23	23	CD	0
wherein	wherein	CD	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
comprises	comprises	VBZ	0
a	a	DT	0
lactide	lactide	JJ	B-NP
/	/	CD	I-NP
glycolide	glycolide	CD	I-NP
polymer.	polymer.	CD	I-NP
25	25	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
18	18	CD	0
wherein	wherein	CD	0
the	the	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer.	polymer.	CD	I-NP
26	26	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
25	25	CD	0
wherein	wherein	CD	0
the	the	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
ethylene	ethylene	NN	I-NP
vinyl	vinyl	NN	I-NP
acetate	acetate	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
vinyl	vinyl	NN	I-NP
acetate	acetate	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
silicone	silicone	JJ	0
polymers	polymers	NNS	0
,	,	,	0
polyurethanes	polyurethanes	NN	0
,	,	,	0
polysaccharides	polysaccharides	JJ	0
such	such	JJ	0
as	as	IN	0
a	a	DT	0
cellulosic	cellulosic	JJ	B-NP
polymer	polymer	NN	I-NP
and	and	CC	0
cellulose	cellulose	JJ	B-NP
derivative	derivative	JJ	I-NP
,	,	,	0
acyl	acyl	NN	B-NP
substituted	substituted	FW	0
cellulose	cellulose	FW	0
acetates	acetates	FW	0
and	and	CC	0
derivatives	derivatives	NNS	0
thereof	thereof	RB	0
,	,	,	0
copolymers	copolymers	VBG	0
of	of	IN	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
ethylene	ethylene	NN	I-NP
glycol	glycol	NN	I-NP
)	)	-RRB-	I-NP
and	and	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
butylene	butylene	NN	I-NP
terephthalate	terephthalate	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
polystyrenes	polystyrenes	NN	0
,	,	,	0
polyvinyl	polyvinyl	JJ	B-NP
chloride	chloride	NN	I-NP
,	,	,	0
polyvinyl	polyvinyl	JJ	B-NP
fluoride	fluoride	NN	I-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
vinyl	vinyl	NN	I-NP
imidazole	imidazole	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
chorosulphonated	chorosulphonated	JJ	B-NP
polyolefin	polyolefin	NN	I-NP
,	,	,	0
polyethylene	polyethylene	NN	B-NP
oxide	oxide	NN	I-NP
,	,	,	0
and	and	CC	0
copolymers	copolymers	NNS	0
and	and	CC	0
blends	blends	CD	0
thereof.	thereof.	CD	0
27	27	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
18	18	CD	0
wherein	wherein	CD	0
the	the	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
metal.	metal.	CD	0
28	28	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
27	27	CD	0
wherein	wherein	CD	0
the	the	DT	0
metal	metal	NN	0
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
cobalt	cobalt	NN	0
,	,	,	0
chromium	chromium	NN	0
,	,	,	0
nickel	nickel	NN	0
,	,	,	0
platinum	platinum	NN	0
,	,	,	0
stainless	stainless	JJ	0
steel	steel	NN	0
,	,	,	0
titanium	titanium	NN	B-NP
,	,	,	0
tantalum	tantalum	NN	0
,	,	,	0
nickel-titanium	nickel-titanium	NNP	B-NP
,	,	,	0
and	and	CC	0
alloys	alloys	NNS	0
and	and	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
29	29	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
or	or	CC	0
8	8	CD	0
wherein	wherein	CD	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
are	are	VBP	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
anticholinergic	anticholinergic	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antihistamine	antihistamine	NN	B-NP
,	,	,	0
anti-infective	anti-infective	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antiscarring	antiscarring	NN	B-NP
or	or	CC	0
antiproliferative	antiproliferative	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
chemotherapeutic	chemotherapeutic	NN	B-NP
or	or	CC	0
antineoplastic	antineoplastic	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
cytokine	cytokine	NN	B-NP
,	,	,	0
decongestant	decongestant	NN	B-NP
,	,	,	0
healing	healing	VBG	B-NP
promotion	promotion	NN	I-NP
agent	agent	NN	I-NP
and	and	CC	0
vitamins	vitamins	NN	0
,	,	,	0
hyperosmolar	hyperosmolar	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
immunomodulator	immunomodulator	NN	B-NP
or	or	CC	0
immunosuppressive	immunosuppressive	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
leukotriene	leukotriene	JJ	B-NP
modifier	modifier	NN	I-NP
,	,	,	0
mucolytic	mucolytic	NN	B-NP
,	,	,	0
narcotic	narcotic	JJ	B-NP
analgesic	analgesic	NN	I-NP
,	,	,	0
small	small	JJ	0
molecules	molecules	NNS	0
,	,	,	0
tyrosine	tyrosine	NN	B-NP
kinase	kinase	NN	I-NP
inhibitor	inhibitor	NN	I-NP
,	,	,	0
peptide	peptide	NN	B-NP
,	,	,	0
proteins	proteins	NNS	0
,	,	,	0
nucleic	nucleic	JJ	B-NP
acid	acid	JJ	I-NP
,	,	,	0
vasoconstrictor	vasoconstrictor	NN	B-NP
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
30	30	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
29	29	CD	0
wherein	wherein	CD	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
comprises	comprises	VBZ	0
an	an	DT	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
agent.	agent.	CD	I-NP
31	31	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
30	30	CD	0
wherein	wherein	CD	0
the	the	DT	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
agent	agent	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent.	agent.	CD	I-NP
32	32	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
31	31	CD	0
wherein	wherein	CD	0
the	the	DT	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
21-acetoxypregnenolone	21-acetoxypregnenolone	NNP	0
,	,	,	0
alclometasone	alclometasone	NN	B-NP
,	,	,	0
algestone	algestone	NN	B-NP
,	,	,	0
amcinonide	amcinonide	NN	B-NP
,	,	,	0
beclomethasone	beclomethasone	NN	B-NP
,	,	,	0
betamethasone	betamethasone	NN	B-NP
,	,	,	0
budesonide	budesonide	NN	B-NP
,	,	,	0
chloroprednisone	chloroprednisone	NN	B-NP
,	,	,	0
clobetasol	clobetasol	NN	B-NP
,	,	,	0
clobetasone	clobetasone	NN	B-NP
,	,	,	0
clocortolone	clocortolone	NN	B-NP
,	,	,	0
cloprednol	cloprednol	NN	B-NP
,	,	,	0
corticosterone	corticosterone	NN	B-NP
,	,	,	0
cortisone	cortisone	NN	B-NP
,	,	,	0
cortivazol	cortivazol	NN	B-NP
,	,	,	0
deflazacort	deflazacort	NN	B-NP
,	,	,	0
desonide	desonide	NN	B-NP
,	,	,	0
desoximetasone	desoximetasone	NN	B-NP
,	,	,	0
dexamethasone	dexamethasone	NN	B-NP
,	,	,	0
diflorasone	diflorasone	NN	B-NP
,	,	,	0
diflucortolone	diflucortolone	NN	B-NP
,	,	,	0
difluprednate	difluprednate	NN	B-NP
,	,	,	0
enoxolone	enoxolone	NN	B-NP
,	,	,	0
fluazacort	fluazacort	NN	B-NP
,	,	,	0
flucloronide	flucloronide	NN	B-NP
,	,	,	0
flumethasone	flumethasone	NN	B-NP
,	,	,	0
flunisolide	flunisolide	NN	B-NP
,	,	,	0
fluocinolone	fluocinolone	JJ	B-NP
acetonide	acetonide	NN	I-NP
,	,	,	0
fluocinonide	fluocinonide	NN	B-NP
,	,	,	0
fluocortin	fluocortin	JJ	B-NP
butyl	butyl	NN	I-NP
,	,	,	0
fluocortolone	fluocortolone	NN	B-NP
,	,	,	0
fluorometholone	fluorometholone	NN	B-NP
,	,	,	0
fluperolone	fluperolone	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
fluprednidene	fluprednidene	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
fluprednisolone	fluprednisolone	NN	B-NP
,	,	,	0
flurandrenolide	flurandrenolide	NN	B-NP
,	,	,	0
fluticasone	fluticasone	JJ	B-NP
propionate	propionate	NN	I-NP
,	,	,	0
formocortal	formocortal	NN	B-NP
,	,	,	0
halcinonide	halcinonide	NN	B-NP
,	,	,	0
halobetasol	halobetasol	JJ	B-NP
propionate	propionate	NN	I-NP
,	,	,	0
halometasone	halometasone	NN	B-NP
,	,	,	0
halopredone	halopredone	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
hydrocortamate	hydrocortamate	NN	B-NP
,	,	,	0
hydrocortisone	hydrocortisone	NN	B-NP
,	,	,	0
loteprednol	loteprednol	JJ	B-NP
etabonate	etabonate	NN	I-NP
,	,	,	0
mazipredone	mazipredone	NN	B-NP
,	,	,	0
medrysone	medrysone	NN	B-NP
,	,	,	0
meprednisone	meprednisone	NN	B-NP
,	,	,	0
methylprednisolone	methylprednisolone	NN	B-NP
,	,	,	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
,	,	,	0
paramethasone	paramethasone	NN	B-NP
,	,	,	0
prednicarbate	prednicarbate	NN	B-NP
,	,	,	0
prednisolone	prednisolone	NN	B-NP
,	,	,	0
prednisolone	prednisolone	CD	0
25-diethylamino-acetate	25-diethylamino-acetate	CD	0
,	,	,	0
prednisolone	prednisolone	NN	B-NP
sodium	sodium	NN	I-NP
phosphate	phosphate	NN	I-NP
,	,	,	0
prednisone	prednisone	NN	B-NP
,	,	,	0
prednival	prednival	NN	B-NP
,	,	,	0
prednylidene	prednylidene	NN	B-NP
,	,	,	0
rimexolone	rimexolone	NN	B-NP
,	,	,	0
tixocortol	tixocortol	NN	B-NP
,	,	,	0
triamcinolone	triamcinolone	NN	B-NP
,	,	,	0
triamcinolone	triamcinolone	JJ	B-NP
acetonide	acetonide	NN	I-NP
,	,	,	0
triamcinolone	triamcinolone	JJ	B-NP
benetonide	benetonide	NN	I-NP
,	,	,	0
triamcinolone	triamcinolone	JJ	B-NP
hexacetonide	hexacetonide	NN	I-NP
,	,	,	0
and	and	CC	0
derivatives	derivatives	NNS	0
and	and	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
33	33	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
32	32	CD	0
wherein	wherein	CD	0
the	the	DT	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
agent	agent	NN	I-NP
comprises	comprises	VBZ	0
mometasone	mometasone	CD	B-NP
furoate.	furoate.	CD	I-NP
34	34	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
29	29	CD	0
wherein	wherein	CD	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
comprises	comprises	VBZ	0
an	an	DT	0
anti-infective	anti-infective	JJ	B-NP
agent.	agent.	CD	I-NP
35	35	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
34	34	CD	0
wherein	wherein	CD	0
the	the	DT	0
anti-infective	anti-infective	JJ	B-NP
agent	agent	NN	I-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
antibacterial	antibacterial	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antifungal	antifungal	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antiparasitic	antiparasitic	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antiviral	antiviral	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antiseptics	antiseptics	NN	0
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
36	36	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
35	35	CD	0
wherein	wherein	CD	0
the	the	DT	0
anti-infective	anti-infective	JJ	B-NP
agent	agent	NN	I-NP
comprises	comprises	VBZ	0
an	an	DT	0
antibacterial	antibacterial	JJ	B-NP
agent.	agent.	CD	I-NP
37	37	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
36	36	CD	0
wherein	wherein	CD	0
the	the	DT	0
antibacterial	antibacterial	JJ	B-NP
agent	agent	NN	I-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
aminoglycoside	aminoglycoside	NN	B-NP
,	,	,	0
amphenicol	amphenicol	NN	B-NP
,	,	,	0
ansamycin	ansamycin	NN	B-NP
,	,	,	0
-lactams	-lactams	NNP	0
,	,	,	0
lincosamide	lincosamide	NN	B-NP
,	,	,	0
macrolide	macrolide	NN	B-NP
,	,	,	0
nitrofuran	nitrofuran	NN	B-NP
,	,	,	0
quinolone	quinolone	NN	B-NP
,	,	,	0
sulfonamide	sulfonamide	NN	B-NP
,	,	,	0
sulfone	sulfone	NN	B-NP
,	,	,	0
tetracycline	tetracycline	NN	B-NP
,	,	,	0
vancomycin	vancomycin	NN	B-NP
,	,	,	0
and	and	CC	0
any	any	DT	0
derivatives	derivatives	NNS	0
and	and	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
38	38	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
device	device	NN	0
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
differentially	differentially	VB	0
release	release	VB	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents.	agents.	CD	0
39	39	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
included	included	VBN	0
in	in	IN	0
a	a	DT	0
coating	coating	NN	0
on	on	IN	0
the	the	DT	0
device.	device.	CD	0
40	40	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
39	39	CD	0
wherein	wherein	CD	0
the	the	DT	0
coating	coating	NN	0
further	further	RB	0
comprises	comprises	VBZ	0
a	a	DT	0
polymer.	polymer.	CD	B-NP
41	41	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
40	40	CD	0
wherein	wherein	CD	0
the	the	DT	0
polymer	polymer	NN	B-NP
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer.	polymer.	CD	B-NP
42	42	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
or	or	CC	0
8	8	CD	0
comprising	comprising	NN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
40	40	CD	0
%	%	NN	0
of	of	IN	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
by	by	IN	0
weight.	weight.	CD	0
43	43	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
or	or	CC	0
8	8	CD	0
comprising	comprising	NN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
30	30	CD	0
%	%	NN	0
of	of	IN	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
by	by	IN	0
weight.	weight.	CD	0
44	44	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
or	or	CC	0
8	8	CD	0
comprising	comprising	NN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
20	20	CD	0
%	%	NN	0
of	of	IN	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
by	by	IN	0
weight.	weight.	CD	0
45	45	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
or	or	CC	0
8	8	CD	0
comprising	comprising	NN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
10	10	CD	0
%	%	NN	0
of	of	IN	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
by	by	IN	0
weight.	weight.	CD	0
46	46	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
or	or	CC	0
8	8	CD	0
comprising	comprising	NN	0
about	about	IN	0
0.01	0.01	CD	0
%	%	NN	0
to	to	TO	0
about	about	RB	0
1	1	CD	0
%	%	NN	0
of	of	IN	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
active	active	JJ	0
agents	agents	NNS	0
by	by	IN	0
weight.	weight.	CD	0
47	47	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
sinus	sinus	JJ	B-NP
inflammation	inflammation	JJ	I-NP
due	due	JJ	0
to	to	TO	0
functional	functional	VB	B-NP
endoscopic	endoscopic	JJ	I-NP
sinus	sinus	JJ	I-NP
surgery	surgery	NN	I-NP
(	(	-LRB-	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
)	)	-RRB-	0
;	;	:	0
acute	acute	JJ	0
sinusitis	sinusitis	NN	0
;	;	:	0
chronic	chronic	JJ	B-NP
sinusitis	sinusitis	NN	I-NP
;	;	:	0
allergic	allergic	JJ	B-NP
rhiniti	rhiniti	NN	I-NP
;	;	:	0
rhinosinusiti	rhinosinusiti	NN	B-NP
;	;	:	0
sinusitis	sinusitis	NN	0
that	that	IN	0
recurs	recurs	NN	0
after	after	IN	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
;	;	:	0
upper	upper	JJ	0
respiratory	respiratory	JJ	B-NP
tract	tract	NN	I-NP
infection	infection	NN	I-NP
;	;	:	0
otitis	otitis	JJ	B-NP
medium	medium	JJ	I-NP
;	;	:	0
bronchitis	bronchitis	CD	0
;	;	:	0
bronchioliti	bronchioliti	NN	B-NP
;	;	:	0
asthma	asthma	NN	B-NP
;	;	:	0
tonsillitis	tonsillitis	NNS	0
and	and	CC	0
other	other	JJ	0
chronic	chronic	JJ	B-NP
disease	disease	NN	I-NP
of	of	IN	0
the	the	DT	0
tonsils	tonsils	NN	0
and	and	CC	0
adenoid	adenoid	NN	B-NP
;	;	:	0
laryngitis	laryngitis	CD	0
;	;	:	0
tracheiti	tracheiti	NN	B-NP
;	;	:	0
nasal	nasal	NN	B-NP
and	and	CC	0
sinus	sinus	JJ	B-NP
polyposi	polyposi	NN	I-NP
;	;	:	0
neoplasms	neoplasms	NN	0
of	of	IN	0
the	the	DT	0
large	large	JJ	0
and	and	CC	0
small	small	JJ	0
airway	airway	NN	B-NP
;	;	:	0
and	and	CC	0
nasal	nasal	NN	B-NP
,	,	,	0
sinus	sinus	NN	B-NP
,	,	,	0
and	and	CC	0
nasopharynx	nasopharynx	CD	B-NP
tumor	tumor	NN	I-NP
48	48	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
47	47	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
is	is	VBZ	0
sinus	sinus	JJ	B-NP
inflammation	inflammation	JJ	I-NP
due	due	JJ	0
to	to	TO	0
functional	functional	VB	B-NP
endoscopic	endoscopic	JJ	I-NP
sinus	sinus	JJ	I-NP
surgery	surgery	NN	I-NP
(	(	-LRB-	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
)	)	-RRB-	0
.	.	.	0
49	49	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
47	47	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
is	is	VBZ	0
rhinosinusiti	rhinosinusiti	NN	B-NP
50	50	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
further	further	JJ	0
comprising	comprising	VBG	0
a	a	DT	0
substance	substance	NN	0
that	that	WDT	0
prevents	prevents	VBZ	0
biofilm	biofilm	CD	B-NP
formation.	formation.	CD	I-NP
51	51	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
50	50	CD	0
wherein	wherein	CD	0
the	the	DT	0
substance	substance	NN	0
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
alcohol	alcohol	NN	B-NP
,	,	,	0
chlorhexidine	chlorhexidine	NN	B-NP
,	,	,	0
iodine	iodine	NN	0
,	,	,	0
triclosan	triclosan	NN	B-NP
,	,	,	0
hexachlorophene	hexachlorophene	NN	B-NP
,	,	,	0
silver-based	silver-based	JJ	0
agents	agents	NNS	0
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
52	52	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
wherein	wherein	CD	0
the	the	DT	0
surface	surface	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
has	has	VBZ	0
been	been	VBN	0
treated	treated	VBN	0
by	by	IN	0
a	a	DT	0
process	process	NN	0
altering	altering	VBG	0
the	the	DT	0
physical	physical	JJ	B-NP
property	property	NN	I-NP
of	of	IN	0
the	the	DT	0
surface	surface	NN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
in	in	IN	0
order	order	NN	0
to	to	TO	0
prevent	prevent	VB	0
biofilm	biofilm	CD	B-NP
formation.	formation.	CD	I-NP
53	53	CD	0
.	.	.	0
A	A	DT	0
device	device	NN	0
for	for	IN	0
treating	treating	VBG	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
comprising	comprising	NNS	0
:	:	:	0
a	a	LS	0
)	)	-RRB-	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
having	having	VBG	0
a	a	DT	0
proximal	proximal	JJ	B-NP
end	end	NN	I-NP
and	and	CC	0
a	a	DT	0
distal	distal	JJ	B-NP
end	end	NN	I-NP
;	;	:	0
b	b	LS	0
)	)	-RRB-	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
attached	attached	VBN	0
to	to	TO	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
distal	distal	NN	I-NP
end	end	NN	I-NP
;	;	:	0
c	c	LS	0
)	)	-RRB-	0
optionally	optionally	NN	0
,	,	,	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
attached	attached	VBN	0
to	to	TO	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
proximal	proximal	NN	I-NP
end	end	NN	I-NP
;	;	:	0
and	and	CC	0
d	d	LS	0
)	)	-RRB-	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
for	for	IN	0
sustained	sustained	JJ	0
release	release	NN	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
optional	optional	JJ	B-NP
nasal	nasal	JJ	I-NP
portion	portion	NN	I-NP
comprise	comprise	VBP	0
a	a	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
and	and	CC	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
or	or	CC	0
any	any	DT	0
combination	combination	NN	0
thereof	thereof	RB	0
,	,	,	0
to	to	TO	0
treat	treat	VB	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
condition.	condition.	CD	I-NP
54	54	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
,	,	,	0
a	a	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
a	a	DT	0
metal	metal	NN	0
,	,	,	0
or	or	CC	0
a	a	DT	0
combination	combination	NN	0
thereof.	thereof.	CD	0
55	55	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
54	54	CD	0
wherein	wherein	CD	0
the	the	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer.	polymer.	CD	B-NP
56	56	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
55	55	CD	0
wherein	wherein	CD	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
lactide	lactide	LS	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
glycolide	glycolide	LS	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
lactide-co-glycolide	lactide-co-glycolide	NNP	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
glycolic	glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
lactic	lactic	JJ	I-NP
acid-co-glycolic	acid-co-glycolic	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
caprolactone	caprolactone	LS	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
orthoester	orthoester	LS	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
phosphazene	phosphazene	LS	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
hydroxybutyrate	hydroxybutyrate	LS	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
or	or	CC	0
copolymers	copolymers	VBP	0
including	including	VBG	B-NP
poly	poly	NN	I-NP
(	(	-LRB-	I-NP
hydroxybutyrate	hydroxybutyrate	LS	I-NP
)	)	-RRB-	I-NP
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
lactide-co-caprolactone	lactide-co-caprolactone	NNP	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
polycarbonates	polycarbonates	CD	0
;	;	:	0
polyesteramide	polyesteramide	NN	B-NP
;	;	:	0
polyanhidride	polyanhidride	NN	B-NP
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
dioxanone	dioxanone	LS	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
alkylene	alkylene	NN	I-NP
alkylate	alkylate	NN	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
copolymers	copolymers	NN	0
of	of	IN	0
polyethylene	polyethylene	NN	0
glycol	glycol	NNS	0
and	and	CC	0
a	a	DT	0
polyorthoester	polyorthoester	NN	B-NP
;	;	:	0
biodegradable	biodegradable	JJ	0
polyurethanes	polyurethanes	NN	0
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
amino	amino	JJ	I-NP
acid	acid	NN	I-NP
)	)	-RRB-	I-NP
s	s	VBZ	0
;	;	:	0
polyetherester	polyetherester	NN	B-NP
;	;	:	0
polyacetals	polyacetals	CD	0
;	;	:	0
polycyanoacrylate	polycyanoacrylate	NN	B-NP
;	;	:	0
poly	poly	CD	B-NP
(	(	-LRB-	I-NP
oxyethylene	oxyethylene	LS	I-NP
)	)	-RRB-	I-NP
/	/	FW	0
poly(oxypropylene)	poly(oxypropylene)	NN	B-NP
copolymer	copolymer	NN	I-NP
,	,	,	0
and	and	CC	0
blends	blends	NNS	0
and	and	CC	0
copolymers	copolymers	CD	0
thereof.	thereof.	CD	0
57	57	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
56	56	CD	0
wherein	wherein	CD	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
comprises	comprises	VBZ	0
a	a	DT	0
lactide	lactide	JJ	B-NP
/	/	CD	I-NP
glycolide	glycolide	CD	I-NP
polymer.	polymer.	CD	I-NP
58	58	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
54	54	CD	0
wherein	wherein	CD	0
the	the	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer.	polymer.	CD	I-NP
59	59	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
58	58	CD	0
wherein	wherein	CD	0
the	the	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
ethylene	ethylene	NN	I-NP
vinyl	vinyl	NN	I-NP
acetate	acetate	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
vinyl	vinyl	NN	I-NP
acetate	acetate	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
silicone	silicone	JJ	0
polymers	polymers	NNS	0
,	,	,	0
polyurethanes	polyurethanes	NN	0
,	,	,	0
polysaccharides	polysaccharides	JJ	0
such	such	JJ	0
as	as	IN	0
a	a	DT	0
cellulosic	cellulosic	JJ	B-NP
polymer	polymer	NN	I-NP
and	and	CC	0
cellulose	cellulose	JJ	B-NP
derivative	derivative	JJ	I-NP
,	,	,	0
acyl	acyl	NN	B-NP
substituted	substituted	FW	0
cellulose	cellulose	FW	0
acetates	acetates	FW	0
and	and	CC	0
derivatives	derivatives	NNS	0
thereof	thereof	RB	0
,	,	,	0
copolymers	copolymers	VBG	0
of	of	IN	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
ethylene	ethylene	NN	I-NP
glycol	glycol	NN	I-NP
)	)	-RRB-	I-NP
and	and	CC	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
butylene	butylene	NN	I-NP
terephthalate	terephthalate	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
polystyrenes	polystyrenes	NN	0
,	,	,	0
polyvinyl	polyvinyl	JJ	B-NP
chloride	chloride	NN	I-NP
,	,	,	0
polyvinyl	polyvinyl	JJ	B-NP
fluoride	fluoride	NN	I-NP
,	,	,	0
poly	poly	NN	B-NP
(	(	-LRB-	I-NP
vinyl	vinyl	NN	I-NP
imidazole	imidazole	NN	I-NP
)	)	-RRB-	I-NP
,	,	,	0
chorosulphonated	chorosulphonated	JJ	B-NP
polyolefin	polyolefin	NN	I-NP
,	,	,	0
polyethylene	polyethylene	NN	B-NP
oxide	oxide	NN	I-NP
,	,	,	0
and	and	CC	0
copolymers	copolymers	NNS	0
and	and	CC	0
blends	blends	CD	0
thereof.	thereof.	CD	0
60	60	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
54	54	CD	0
wherein	wherein	CD	0
the	the	DT	0
biocompatible	biocompatible	JJ	B-NP
material	material	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
metal.	metal.	CD	0
61	61	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
60	60	CD	0
wherein	wherein	CD	0
the	the	DT	0
metal	metal	NN	0
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
cobalt	cobalt	NN	0
,	,	,	0
chromium	chromium	NN	0
,	,	,	0
nickel	nickel	NN	0
,	,	,	0
platinum	platinum	NN	0
,	,	,	0
stainless	stainless	JJ	0
steel	steel	NN	0
,	,	,	0
titanium	titanium	NN	B-NP
,	,	,	0
tantalum	tantalum	NN	0
,	,	,	0
nickel-titanium	nickel-titanium	NNP	B-NP
,	,	,	0
and	and	CC	0
any	any	DT	0
alloy	alloy	NN	0
or	or	CC	0
combination	combination	NN	0
thereof.	thereof.	CD	0
62	62	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
anticholinergic	anticholinergic	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antihistamine	antihistamine	NN	B-NP
,	,	,	0
anti-infective	anti-infective	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
antiscarring	antiscarring	NN	B-NP
or	or	CC	0
antiproliferative	antiproliferative	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
chemotherapeutic	chemotherapeutic	NN	B-NP
or	or	CC	0
antineoplastic	antineoplastic	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
cytokine	cytokine	NN	B-NP
,	,	,	0
decongestant	decongestant	NN	B-NP
,	,	,	0
healing	healing	VBG	B-NP
promotion	promotion	NN	I-NP
agent	agent	NN	I-NP
and	and	CC	0
vitamins	vitamins	NN	0
,	,	,	0
hyperosmolar	hyperosmolar	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
immunomodulator	immunomodulator	NN	B-NP
or	or	CC	0
immunosuppressive	immunosuppressive	JJ	B-NP
agent	agent	NN	I-NP
,	,	,	0
leukotriene	leukotriene	JJ	B-NP
modifier	modifier	NN	I-NP
,	,	,	0
mucolytic	mucolytic	NN	B-NP
,	,	,	0
narcotic	narcotic	JJ	B-NP
analgesic	analgesic	NN	I-NP
,	,	,	0
small	small	JJ	0
molecules	molecules	NNS	0
,	,	,	0
tyrosine	tyrosine	NN	B-NP
kinase	kinase	NN	I-NP
inhibitor	inhibitor	NN	I-NP
,	,	,	0
peptide	peptide	NN	B-NP
,	,	,	0
proteins	proteins	NNS	0
,	,	,	0
nucleic	nucleic	JJ	B-NP
acid	acid	JJ	I-NP
,	,	,	0
vasoconstrictor	vasoconstrictor	NN	B-NP
,	,	,	0
and	and	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
63	63	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
62	62	CD	0
wherein	wherein	CD	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
comprises	comprises	VBZ	0
an	an	DT	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
agent.	agent.	CD	I-NP
64	64	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
63	63	CD	0
wherein	wherein	CD	0
the	the	DT	0
anti-inflammatory	anti-inflammatory	JJ	B-NP
agent	agent	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent.	agent.	CD	I-NP
65	65	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
64	64	CD	0
wherein	wherein	CD	0
the	the	DT	0
steroidal	steroidal	JJ	B-NP
anti-inflammatory	anti-inflammatory	JJ	I-NP
agent	agent	NN	I-NP
is	is	VBZ	0
selected	selected	VBN	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
21-acetoxypregnenolone	21-acetoxypregnenolone	NNP	0
,	,	,	0
alclometasone	alclometasone	NN	B-NP
,	,	,	0
algestone	algestone	NN	B-NP
,	,	,	0
amcinonide	amcinonide	NN	B-NP
,	,	,	0
beclomethasone	beclomethasone	NN	B-NP
,	,	,	0
betamethasone	betamethasone	NN	B-NP
,	,	,	0
budesonide	budesonide	NN	B-NP
,	,	,	0
chloroprednisone	chloroprednisone	NN	B-NP
,	,	,	0
clobetasol	clobetasol	NN	B-NP
,	,	,	0
clobetasone	clobetasone	NN	B-NP
,	,	,	0
clocortolone	clocortolone	NN	B-NP
,	,	,	0
cloprednol	cloprednol	NN	B-NP
,	,	,	0
corticosterone	corticosterone	NN	B-NP
,	,	,	0
cortisone	cortisone	NN	B-NP
,	,	,	0
cortivazol	cortivazol	NN	B-NP
,	,	,	0
deflazacort	deflazacort	NN	B-NP
,	,	,	0
desonide	desonide	NN	B-NP
,	,	,	0
desoximetasone	desoximetasone	NN	B-NP
,	,	,	0
dexamethasone	dexamethasone	NN	B-NP
,	,	,	0
diflorasone	diflorasone	NN	B-NP
,	,	,	0
diflucortolone	diflucortolone	NN	B-NP
,	,	,	0
difluprednate	difluprednate	NN	B-NP
,	,	,	0
enoxolone	enoxolone	NN	B-NP
,	,	,	0
fluazacort	fluazacort	NN	B-NP
,	,	,	0
flucloronide	flucloronide	NN	B-NP
,	,	,	0
flumethasone	flumethasone	NN	B-NP
,	,	,	0
flunisolide	flunisolide	NN	B-NP
,	,	,	0
fluocinolone	fluocinolone	JJ	B-NP
acetonide	acetonide	NN	I-NP
,	,	,	0
fluocinonide	fluocinonide	NN	B-NP
,	,	,	0
fluocortin	fluocortin	JJ	B-NP
butyl	butyl	NN	I-NP
,	,	,	0
fluocortolone	fluocortolone	NN	B-NP
,	,	,	0
fluorometholone	fluorometholone	NN	B-NP
,	,	,	0
fluperolone	fluperolone	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
fluprednidene	fluprednidene	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
fluprednisolone	fluprednisolone	NN	B-NP
,	,	,	0
flurandrenolide	flurandrenolide	NN	B-NP
,	,	,	0
fluticasone	fluticasone	JJ	B-NP
propionate	propionate	NN	I-NP
,	,	,	0
formocortal	formocortal	NN	B-NP
,	,	,	0
halcinonide	halcinonide	NN	B-NP
,	,	,	0
halobetasol	halobetasol	JJ	B-NP
propionate	propionate	NN	I-NP
,	,	,	0
halometasone	halometasone	NN	B-NP
,	,	,	0
halopredone	halopredone	JJ	B-NP
acetate	acetate	NN	I-NP
,	,	,	0
hydrocortamate	hydrocortamate	NN	B-NP
,	,	,	0
hydrocortisone	hydrocortisone	NN	B-NP
,	,	,	0
loteprednol	loteprednol	JJ	B-NP
etabonate	etabonate	NN	I-NP
,	,	,	0
mazipredone	mazipredone	NN	B-NP
,	,	,	0
medrysone	medrysone	NN	B-NP
,	,	,	0
meprednisone	meprednisone	NN	B-NP
,	,	,	0
methylprednisolone	methylprednisolone	NN	B-NP
,	,	,	0
mometasone	mometasone	JJ	B-NP
furoate	furoate	NN	I-NP
,	,	,	0
paramethasone	paramethasone	NN	B-NP
,	,	,	0
prednicarbate	prednicarbate	NN	B-NP
,	,	,	0
prednisolone	prednisolone	NN	B-NP
,	,	,	0
prednisolone	prednisolone	CD	0
25-diethylamino-acetate	25-diethylamino-acetate	CD	0
,	,	,	0
prednisolone	prednisolone	NN	B-NP
sodium	sodium	NN	I-NP
phosphate	phosphate	NN	I-NP
,	,	,	0
prednisone	prednisone	NN	B-NP
,	,	,	0
prednival	prednival	NN	B-NP
,	,	,	0
prednylidene	prednylidene	NN	B-NP
,	,	,	0
rimexolone	rimexolone	NN	B-NP
,	,	,	0
tixocortol	tixocortol	NN	B-NP
,	,	,	0
triamcinolone	triamcinolone	NN	B-NP
,	,	,	0
triamcinolone	triamcinolone	JJ	B-NP
acetonide	acetonide	NN	I-NP
,	,	,	0
triamcinolone	triamcinolone	JJ	B-NP
benetonide	benetonide	NN	I-NP
,	,	,	0
triamcinolone	triamcinolone	JJ	B-NP
hexacetonide	hexacetonide	NN	I-NP
,	,	,	0
and	and	CC	0
derivatives	derivatives	NNS	0
and	and	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
66	66	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
65	65	CD	0
wherein	wherein	CD	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
comprises	comprises	VBZ	0
mometasone	mometasone	CD	B-NP
furoate.	furoate.	CD	I-NP
67	67	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
51	51	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
has	has	VBZ	0
a	a	DT	0
first	first	JJ	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
that	that	WDT	0
permits	permits	VBZ	0
it	it	PRP	0
to	to	TO	0
pass	pass	VB	0
through	through	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
or	or	CC	0
surgically	surgically	RB	0
created	created	VBN	B-NP
fenestration	fenestration	NN	I-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
second	second	JJ	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
after	after	IN	0
placement	placement	NN	0
into	into	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
cavity.	cavity.	CD	I-NP
68	68	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
67	67	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
at	at	IN	0
least	least	JJS	0
partially	partially	RB	0
conforms	conforms	VBZ	0
to	to	TO	0
the	the	DT	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
and	and	CC	0
substantially	substantially	RB	0
contacts	contacts	VB	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
mucosal	mucosal	JJ	I-NP
surface	surface	NN	I-NP
in	in	IN	0
the	the	DT	0
expanded	expanded	JJ	0
configuration.	configuration.	CD	B-NP
69	69	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
51	51	CD	0
wherein	wherein	CD	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member.	member.	CD	0
70	70	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
,	,	,	0
a	a	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
a	a	DT	0
metal	metal	NN	0
,	,	,	0
or	or	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
71	71	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
70	70	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer.	polymer.	CD	B-NP
72	72	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
71	71	CD	0
wherein	wherein	CD	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
comprises	comprises	VBZ	0
a	a	DT	0
lactide	lactide	JJ	B-NP
/	/	CD	I-NP
glycolide	glycolide	CD	I-NP
polymer.	polymer.	CD	I-NP
73	73	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
comprises	comprises	VBZ	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
pliable	pliable	JJ	0
filaments.	filaments.	CD	0
74	74	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
73	73	CD	0
wherein	wherein	CD	0
the	the	DT	0
one	one	NN	0
or	or	CC	0
more	more	RBR	0
pliable	pliable	JJ	0
filaments	filaments	NNS	0
are	are	VBP	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
a	a	DT	0
multi-looped	multi-looped	JJ	B-NP
structure.	structure.	CD	I-NP
75	75	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
74	74	CD	0
wherein	wherein	CD	0
the	the	DT	0
multiple	multiple	JJ	0
loops	loops	NNS	0
are	are	VBP	0
concentric	concentric	VBN	0
to	to	TO	0
one	one	CD	0
another.	another.	CD	0
76	76	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
self-expands.	self-expands.	CD	0
77	77	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
expands	expands	VBZ	0
by	by	IN	0
exertion	exertion	NN	0
of	of	IN	0
an	an	DT	0
expansive	expansive	JJ	B-NP
force.	force.	CD	I-NP
78	78	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
77	77	CD	0
wherein	wherein	CD	0
the	the	DT	0
expansive	expansive	JJ	B-NP
force	force	NN	I-NP
is	is	VBZ	0
provided	provided	VBN	0
by	by	IN	0
expansion	expansion	NN	0
of	of	IN	0
a	a	DT	0
balloon.	balloon.	CD	0
79	79	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
prevent	prevent	VB	0
migration	migration	VBN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
out	out	RP	0
of	of	IN	0
a	a	DT	0
sinus.	sinus.	CD	B-NP
80	80	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
,	,	,	0
a	a	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
a	a	DT	0
metal	metal	NN	0
,	,	,	0
or	or	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
81	81	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
80	80	CD	0
wherein	wherein	CD	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer.	polymer.	CD	B-NP
82	82	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
81	81	CD	0
wherein	wherein	CD	0
the	the	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
comprises	comprises	VBZ	0
a	a	DT	0
lactide	lactide	JJ	B-NP
/	/	CD	I-NP
glycolide	glycolide	CD	I-NP
polymer.	polymer.	CD	I-NP
83	83	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
form	form	VB	0
a	a	DT	0
tubular	tubular	JJ	B-NP
structure.	structure.	CD	I-NP
84	84	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
prevent	prevent	VB	0
migration	migration	VBN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
out	out	RP	0
of	of	IN	0
a	a	DT	0
sinus.	sinus.	CD	B-NP
85	85	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
maintain	maintain	VB	0
patency	patency	VBN	0
of	of	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium.	ostium.	CD	I-NP
86	86	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
released	released	VBN	0
from	from	IN	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion.	portion.	CD	I-NP
87	87	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	NN	B-NP
,	,	,	0
a	a	DT	0
nonbiodegradable	nonbiodegradable	JJ	B-NP
polymer	polymer	NN	I-NP
,	,	,	0
a	a	DT	0
metal	metal	NN	0
,	,	,	0
or	or	CC	0
combination	combination	NN	B-NP
thereof.	thereof.	CD	0
88	88	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
87	87	CD	0
wherein	wherein	CD	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer.	polymer.	CD	B-NP
89	89	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
88	88	CD	0
wherein	wherein	CD	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
lactide	lactide	JJ	B-NP
/	/	CD	I-NP
glycolide	glycolide	CD	I-NP
polymer.	polymer.	CD	I-NP
90	90	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
is	is	VBZ	0
configured	configured	VBN	0
as	as	IN	0
a	a	DT	0
plurality	plurality	NN	0
of	of	IN	0
spokes.	spokes.	CD	0
91	91	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
53	53	CD	0
wherein	wherein	CD	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
prevent	prevent	VB	0
migration	migration	VBN	0
of	of	IN	0
the	the	DT	0
device	device	NN	0
out	out	RP	0
of	of	IN	0
a	a	DT	0
sinus.	sinus.	CD	B-NP
92	92	CD	0
.	.	.	0
A	A	DT	0
system	system	NN	0
for	for	IN	0
treating	treating	VBG	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
comprising	comprising	NNS	0
:	:	:	0
a	a	LS	0
)	)	-RRB-	0
a	a	DT	0
sinus	sinus	JJ	B-NP
inserter	inserter	NN	I-NP
comprising	comprising	VBG	0
a	a	DT	0
conduit	conduit	NN	0
having	having	VBG	0
a	a	DT	0
lumen	lumen	NN	B-NP
and	and	CC	0
a	a	DT	0
distal	distal	JJ	B-NP
portion	portion	NN	I-NP
;	;	:	0
b	b	LS	0
)	)	-RRB-	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
within	within	IN	0
the	the	DT	0
lumen	lumen	NN	B-NP
or	or	CC	0
releasably	releasably	VB	0
secured	secured	VBN	0
to	to	TO	0
the	the	DT	0
sinus	sinus	JJ	B-NP
inserter	inserter	NN	I-NP
distal	distal	JJ	I-NP
portion	portion	NN	I-NP
,	,	,	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
comprising	comprising	VBG	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
a	a	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
optionally	optionally	VBG	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
has	has	VBZ	0
a	a	DT	0
first	first	JJ	0
collapsed	collapsed	JJ	0
configuration	configuration	NN	B-NP
that	that	WDT	0
permits	permits	VBZ	0
the	the	DT	0
device	device	NN	0
to	to	TO	0
pass	pass	VB	0
through	through	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
ostium	ostium	NN	I-NP
or	or	CC	0
surgically	surgically	RB	0
created	created	VBN	B-NP
fenestration	fenestration	NN	I-NP
and	and	CC	0
a	a	DT	0
second	second	JJ	0
expanded	expanded	JJ	0
configuration	configuration	NN	B-NP
after	after	IN	0
placement	placement	NN	0
into	into	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
cavity.	cavity.	CD	I-NP
93	93	CD	0
.	.	.	0
The	The	DT	0
system	system	NN	0
of	of	IN	0
claim	claim	NN	0
92	92	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
is	is	VBZ	0
delivered	delivered	VBN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
by	by	IN	0
advancing	advancing	VBG	0
a	a	DT	0
pusher	pusher	NN	0
through	through	IN	0
the	the	DT	0
conduit	conduit	NN	B-NP
lumen.	lumen.	CD	I-NP
94	94	CD	0
.	.	.	0
The	The	DT	0
system	system	NN	0
of	of	IN	0
claim	claim	NN	0
92	92	CD	0
further	further	JJ	0
comprising	comprising	VBG	0
a	a	DT	0
sheath.	sheath.	CD	0
95	95	CD	0
.	.	.	0
The	The	DT	0
system	system	NN	0
of	of	IN	0
claim	claim	NN	0
94	94	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
is	is	VBZ	0
delivered	delivered	VBN	0
into	into	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
by	by	IN	0
retracting	retracting	VBG	0
the	the	DT	0
sheath	sheath	NN	0
to	to	TO	0
deploy	deploy	VB	0
the	the	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
and	and	CC	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
and	and	CC	0
expand	expand	VB	0
the	the	DT	0
cavity	cavity	JJ	0
member.	member.	CD	0
96	96	CD	0
.	.	.	0
The	The	DT	0
system	system	NN	0
of	of	IN	0
claim	claim	NN	0
92	92	CD	0
wherein	wherein	CD	0
the	the	DT	0
sinus	sinus	JJ	B-NP
inserter	inserter	NN	I-NP
is	is	VBZ	0
preloaded	preloaded	VBN	0
with	with	IN	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
device.	device.	CD	I-NP
97	97	CD	0
.	.	.	0
The	The	DT	0
system	system	NN	0
of	of	IN	0
claim	claim	NN	0
92	92	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
is	is	VBZ	0
sinus	sinus	JJ	B-NP
inflammation	inflammation	JJ	I-NP
due	due	JJ	0
to	to	TO	0
functional	functional	VB	B-NP
endoscopic	endoscopic	JJ	I-NP
sinus	sinus	JJ	I-NP
surgery	surgery	NN	I-NP
(	(	-LRB-	0
functional	functional	JJ	B-NP
endoscopic	endoscopic	NN	I-NP
sinus	sinus	NN	I-NP
surgery	surgery	NN	I-NP
)	)	-RRB-	0
.	.	.	0
98	98	CD	0
.	.	.	0
A	A	DT	0
method	method	NN	0
for	for	IN	0
treating	treating	VBG	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
comprising	comprising	NNS	0
:	:	:	0
a	a	LS	0
)	)	-RRB-	0
providing	providing	VBG	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
comprising	comprising	VBG	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
a	a	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
optionally	optionally	VBG	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
within	within	IN	0
or	or	CC	0
on	on	IN	0
a	a	DT	0
sinus	sinus	JJ	B-NP
inserter	inserter	NN	I-NP
;	;	:	0
b	b	LS	0
)	)	-RRB-	0
accessing	accessing	VBZ	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
with	with	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
inserter	inserter	NN	I-NP
;	;	:	0
c	c	LS	0
)	)	-RRB-	0
deploying	deploying	VBZ	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
so	so	RB	0
that	that	IN	0
the	the	DT	0
cavity	cavity	JJ	0
member	member	NN	0
substantially	substantially	RB	0
contacts	contacts	VB	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	NN	I-NP
mucosal	mucosal	JJ	I-NP
surface	surface	NN	I-NP
after	after	IN	0
expansion.	expansion.	CD	0
99	99	CD	0
.	.	.	0
The	The	DT	0
method	method	NN	0
of	of	IN	0
claim	claim	NN	0
98	98	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
releases	releases	VBZ	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
to	to	TO	0
treat	treat	VB	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
for	for	IN	0
about	about	IN	0
one	one	CD	0
week.	week.	CD	B-NP
100	100	CD	0
.	.	.	0
The	The	DT	0
method	method	NN	0
of	of	IN	0
claim	claim	NN	0
98	98	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
releases	releases	VBZ	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
to	to	TO	0
treat	treat	VB	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
for	for	IN	0
about	about	IN	0
two	two	CD	0
weeks.	weeks.	CD	0
101	101	CD	0
.	.	.	0
The	The	DT	0
method	method	NN	0
of	of	IN	0
claim	claim	NN	0
98	98	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
releases	releases	VBZ	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
to	to	TO	0
treat	treat	VB	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
for	for	IN	0
about	about	IN	0
three	three	CD	0
weeks.	weeks.	CD	0
102	102	CD	0
.	.	.	0
The	The	DT	0
method	method	NN	0
of	of	IN	0
claim	claim	NN	0
98	98	CD	0
wherein	wherein	CD	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
device	device	NN	I-NP
releases	releases	VBZ	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
to	to	TO	0
treat	treat	VB	0
the	the	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
for	for	IN	0
about	about	IN	0
one	one	CD	0
month.	month.	CD	0
103	103	CD	0
.	.	.	0
A	A	DT	0
device	device	NN	B-NP
configured	configured	NN	I-NP
to	to	TO	0
deliver	deliver	VB	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
and	and	CC	0
to	to	TO	0
prevent	prevent	VB	0
lateralization	lateralization	VBN	0
of	of	IN	0
the	the	DT	0
middle	middle	JJ	B-NP
turbinate.	turbinate.	CD	I-NP
104	104	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
103	103	CD	0
wherein	wherein	CD	0
the	the	DT	0
device	device	NN	0
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
deliver	deliver	VB	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
in	in	IN	0
a	a	DT	0
sustained	sustained	JJ	0
release	release	NN	B-NP
fashion.	fashion.	CD	I-NP
105	105	CD	0
.	.	.	0
A	A	DT	0
device	device	NN	B-NP
configured	configured	NN	I-NP
to	to	TO	0
deliver	deliver	VB	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
and	and	CC	0
to	to	TO	0
prevent	prevent	VB	0
tissue	tissue	NN	0
adhesions	adhesions	NN	0
in	in	IN	0
the	the	DT	0
area	area	NN	0
proximate	proximate	VBD	0
a	a	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
or	or	CC	0
proximate	proximate	VBG	0
an	an	DT	0
area	area	NN	0
or	or	CC	0
an	an	DT	0
excised	excised	JJ	0
sinus	sinus	NN	B-NP
cavity.	cavity.	CD	I-NP
106	106	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
105	105	CD	0
wherein	wherein	CD	0
the	the	DT	0
device	device	NN	0
is	is	VBZ	0
configured	configured	VBN	0
to	to	TO	0
deliver	deliver	VB	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
in	in	IN	0
a	a	DT	0
sustained	sustained	JJ	0
release	release	NN	B-NP
fashion.	fashion.	CD	I-NP
107	107	CD	0
.	.	.	0
A	A	DT	0
device	device	NN	0
for	for	IN	0
treating	treating	VBG	0
a	a	DT	0
paranasal	paranasal	JJ	B-NP
sinus	sinus	JJ	I-NP
condition	condition	NN	I-NP
comprising	comprising	VBG	0
an	an	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
dispersed	dispersed	NN	I-NP
within	within	IN	0
a	a	DT	0
biodegradable	biodegradable	JJ	0
polymer	polymer	JJ	B-NP
matrix	matrix	NN	I-NP
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
device	device	NN	0
comprises	comprises	VBZ	0
a	a	DT	0
cavity	cavity	JJ	0
member	member	NN	0
,	,	,	0
an	an	DT	0
ostial	ostial	JJ	B-NP
member	member	NN	I-NP
,	,	,	0
and	and	CC	0
optionally	optionally	VBG	0
a	a	DT	0
nasal	nasal	JJ	B-NP
portion	portion	NN	I-NP
,	,	,	0
and	and	CC	0
exhibits	exhibits	VBZ	0
an	an	DT	0
in	in	IN	0
vivo	vivo	JJ	B-NP
cumulative	cumulative	JJ	I-NP
release	release	NN	I-NP
profile	profile	NN	I-NP
in	in	IN	0
which	which	WDT	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
amount	amount	NN	0
of	of	IN	0
said	said	VBD	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
maintained	maintained	VBN	0
in	in	IN	0
a	a	DT	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
for	for	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
35	35	CD	0
days	days	NNS	0
after	after	IN	0
implantation	implantation	NN	B-NP
of	of	IN	0
the	the	DT	0
device.	device.	CD	0
108	108	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
107	107	CD	0
in	in	IN	0
which	which	WDT	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
amount	amount	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
maintained	maintained	VBN	0
in	in	IN	0
the	the	DT	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
for	for	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
25	25	CD	0
days	days	NNS	0
after	after	IN	0
implantation	implantation	NN	B-NP
of	of	IN	0
the	the	DT	0
device.	device.	CD	0
109	109	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
107	107	CD	0
in	in	IN	0
which	which	WDT	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
amount	amount	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
maintained	maintained	VBN	0
in	in	IN	0
the	the	DT	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
for	for	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
14	14	CD	0
days	days	NNS	0
after	after	IN	0
implantation	implantation	VBG	0
the	the	DT	0
device.	device.	CD	0
110	110	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
107	107	CD	0
in	in	IN	0
which	which	WDT	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
amount	amount	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
maintained	maintained	VBN	0
in	in	IN	0
the	the	DT	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
for	for	IN	0
at	at	IN	0
least	least	JJS	0
about	about	IN	0
four	four	CD	0
days	days	NNS	0
after	after	IN	0
implantation	implantation	VBG	0
the	the	DT	0
device.	device.	CD	0
111	111	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
107	107	CD	0
with	with	IN	0
a	a	DT	0
kinetic	kinetic	NN	B-NP
profile	profile	NN	I-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
which	which	WDT	0
achieves	achieves	VBZ	0
at	at	IN	0
least	least	JJS	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
level	level	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
in	in	IN	0
the	the	DT	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
within	within	IN	0
4	4	CD	0
days	days	NNS	0
after	after	IN	0
implantation.	implantation.	CD	B-NP
112	112	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
107	107	CD	0
with	with	IN	0
a	a	DT	0
kinetic	kinetic	NN	B-NP
profile	profile	NN	I-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
which	which	WDT	0
sustains	sustains	VBZ	0
at	at	IN	0
least	least	JJS	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
level	level	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
in	in	IN	0
the	the	DT	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
from	from	IN	0
day	day	NN	0
4	4	CD	0
through	through	IN	0
day	day	NN	0
35	35	CD	0
after	after	IN	0
implantation.	implantation.	CD	B-NP
113	113	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
107	107	CD	0
with	with	IN	0
a	a	DT	0
kinetic	kinetic	NN	B-NP
profile	profile	NN	I-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
which	which	WDT	0
is	is	VBZ	0
substantially	substantially	RB	0
proportional	proportional	JJ	0
and	and	CC	0
contemporaneous	contemporaneous	NN	0
with	with	IN	0
the	the	DT	0
biodegradation	biodegradation	NN	B-NP
and	and	CC	0
mass	mass	JJ	B-NP
clearance	clearance	NN	I-NP
of	of	IN	0
the	the	DT	0
device	device	NN	0
from	from	IN	0
the	the	DT	0
sinus	sinus	JJ	B-NP
cavity	cavity	NN	I-NP
and	and	CC	0
sustains	sustains	VBZ	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
level	level	NN	0
of	of	IN	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
in	in	IN	0
the	the	DT	0
sinus	sinus	JJ	0
tissue	tissue	NN	0
up	up	RP	0
until	until	IN	0
clearance	clearance	NN	0
of	of	IN	0
the	the	DT	0
device.	device.	CD	0
114	114	CD	0
.	.	.	0
The	The	DT	0
device	device	NN	0
of	of	IN	0
claim	claim	NN	0
107	107	CD	0
wherein	wherein	CD	0
the	the	DT	0
active	active	JJ	0
agent	agent	NN	B-NP
is	is	VBZ	0
released	released	VBN	0
with	with	IN	0
a	a	DT	0
kinetic	kinetic	NN	B-NP
profile	profile	NN	I-NP
drug	drug	NN	I-NP
release	release	NN	I-NP
combining	combining	VBG	0
two	two	CD	0
or	or	CC	0
more	more	JJR	0
of	of	IN	0
the	the	DT	0
profiles	profiles	NN	0
of	of	IN	0
claims	claims	NNS	0
111	111	CD	0
,	,	,	0
112	112	CD	0
,	,	,	0
and	and	CC	0
113	113	CD	0
.	.	.	0
